

# Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



#### Overview for Request cder\_mpl2r\_wp016

#### Request ID: cder\_mpl2r\_wp016

**Request Description:** In this request, we assessed the risk of angioedema associated with sacubitril/valsartan (SV) compared to angiotensin-converting enzyme inhibitors (ACEI) or to angiotensin II receptor blockers (ARBs, excluding SV) among heart failure patients in the Sentinel Distributed Database (SDD).

**Sentinel Modular Program Tool:** Cohort Identification and Descriptive Analysis (CIDA) and Propensity Score Analysis (PSA) tools, version 9.7.0

**Data Source:** The study period spanned from July 7, 2015 to February 29, 2020. We distributed the analytic package to seven Data Partners (DP) on November 13, 2020. This report contains aggregated data from five Data Partners for which the propensity score estimation models converged across all comparisons. See Appendix A for a list of the latest dates of available data for each DP included in this report.

**Study Design:** We identified individuals with incident use of SV, ACEI, and ARBs who were 18 years or older with a history of heart failure and evaluated the occurrence of angioedema and serious angioedema during exposure episodes. We then conducted a PSA comparing the SV users to the ACEI or ARB users, matching and stratifying on propensity score. This is a Type 2 analysis using the Propensity Score Analysis module in the Query Request Package (QRP) documentation.

**Exposure and Comparator:** We defined exposures of interest as new use of SV, ACEI, and ARBs. The exposure drugs were defined using National Drug Codes (NDCs). For a list of generic and brand names of medical products used to define the exposure and comparator drugs, please see Appendix B.

**Outcomes of Interest:** We defined our main outcome of interest, angioedema, as an angioedema diagnosis code recorded in any diagnostic position of an inpatient, emergency department, or outpatient encounter. We defined our secondary outcome of interest, serious angioedema, as an angioedema diagnosis recorded in any diagnostic position of an inpatient or emergency department encounter with evidence of an intensive care unit admission, intubation, tracheostomy, or laryngoscopy occurring within two days of the hospital admission or emergency department visit. We defined our outcomes using International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System, Level II (HCPCS). For a list of codes used to define outcomes, please see Appendix C.

**Cohort Eligibility Criteria:** We required patients 18 years or older to be enrolled in plans with both medical and drug coverage for at least 183 days before index dispensing, during which gaps in coverage of up to 45 days were allowed and treated as continuous enrollment. New use was defined as no use of SV, ACEI, or ARBs in the 183 days preceding the index dispensing. We included patients with evidence of heart failure in the 183 days preceding and including index date. We excluded patients from the cohort if they had evidence of a dispensing for the other two exposures on their index date. Incidence, inclusion, and exclusion criteria were defined using NDCs, ICD-9-CM, and ICD-10-CM. For a list of generic and brand names of medical products and specific codes used to define cohort eligibility, please see Appendices D and E.

**Follow-up:** We determined follow-up time based on the length of the exposure episodes and censored upon prespecified criteria. We created exposure episodes using outpatient pharmacy dispensing data. We bridged together exposure episodes less than 14 days apart and added 14 days at the end of each exposure episodes to create continuous treatment episodes. Sensitivity analyses shortened the episode gap and episode extension to 7 days. Follow-up began on the day of exposure initiation and continued until the earliest of any of the following: 1) outcome occurrence; 2) requester-defined censoring criteria -- initiation of any of the other two study drugs or after 365 days of continuous exposure; 3) disenrollment; 4) recorded death; 5) end of exposure episode; 6) end of query period; or 7) end of available data. Only the first valid exposure episode that occurred during the study period was included per patient.

**Baseline Covariates:** Please refer to Appendices F, G, and I for a list of covariates, codes, and evaluation windows used to defined covariates.



#### Overview for Request cder\_mpl2r\_wp016

**Propensity Score Estimation:** For each comparison, we fit a logistic regression model to estimate the propensity score (PS) based on potential confounders outlined in Appendix J. The matching ratio for the PS was 1:1 and the matching caliper was 0.05. Patients in the exposed and comparator cohorts were nearest neighbor matched without replacement, meaning that each comparator patient was matched one time, at most, to an exposed patient. We also used PS stratification (deciles) for our main analyses comparing SV to ACEI and ARBs and risk of angioedema. For each comparison, we used risk set-based approach to estimate the adjusted hazard ratio and 95% confidence intervals for the unadjusted analyses, unconditional and conditional matched analyses, and PS stratified analyses. Subgroup analyses for effect estimation included angioedema diagnosis in 183 days prior to index date and separately, in entire enrollment history prior to index date; serious allergies diagnosis in the 183 days prior to index date; sex; age group; race; *and follow-up time*.

#### See Appendices H and I for the specifications of parameters used in the analyses for this request.

**Limitations:** As with all observational studies, this evaluation was limited in its ability to control for all sources of potential bias. Algorithms used to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

<u>Notes:</u> Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-queryingtooldocumentation/browse).



	Table of Contents
<b>CIDA Glossary</b>	List of terms and their definitions found in this report pertaining to Sentinel's Cohort Identification and
	Descriptive Analysis (CIDA) Tool
PSA Glossary	List of terms and their definitions found in this report pertaining to Sentinel's Propensity Score Analysis (PSA)
Table 1a	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-
	Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated)
Table 1b	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-
	Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05
<u>Table 1c</u>	Weighted Baseline Characteristics of Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-
	Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database
	(SDD) between July 7, 2015 and February 29, 2020 (Propensity Score (PS) Stratified, Aggregated), Percentiles: 10
Table 1d	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap,
	and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	(Unadjusted, Aggregated)
<u>Table 1e</u>	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap,
	and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05
Table 1f	Weighted Baseline Characteristics of Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II
	Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD)
	between July 7, 2015 and February 29, 2020 (Propensity Score (PS) Stratified, Aggregated), Percentiles: 10
Table 1g	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day
<u></u> a	Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29,
	2020 (Unadjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05
Table 1h	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day
	Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29,
	2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05
<u>Table 1i</u>	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap,
	and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
Table 4	(Unadjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05
Table 1	Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	(Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05
Table 2	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap,
<u></u>	and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	by Analysis Type
Table 3	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap,
	and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	by Analysis Type and Follow-up Time
<u>Table 4</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap,
	and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	by Analysis Type and Angioedema (-183, -1)
<u>Table 5</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap,
	and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183 -1) and Follow-up Time
	by Analysis Type and Angioedema (-183, -1) and Follow-up Time



	Table of Contents
<u>Table 6</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (ever, -1)
<u>Table 7</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Serious Allergies
<u>Table 8</u>	Effect Estimates for Risk of Angioedema Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI) 14-Day Gap in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type, Sex and Follow-up Time
<u>Table 9</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Age Group
<u>Table 10</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type, Age Group and Follow-up Time
<u>Table 11</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race
<u>Table 12</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type, Race and Follow-up Time
<u>Table 13</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type
<u>Table 14</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Follow-up Time
<u>Table 15</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183, -1)
<u>Table 16</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183, -1) and Follow-up Time
<u>Table 17</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (ever, -1)
<u>Table 18</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Serious Allergies
<u>Table 19</u>	Effect Estimates for Risk of Angioedema Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARB) 14 Day Gap in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type, Sex and Follow-up Time
<u>Table 20</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Age Group



	Table of Contents
<u>Table 21</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type, Age Group and Follow-up Time
<u>Table 22</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race
<u>Table 23</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type, Race and Follow-up Time
<u>Table 24</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type
<u>Table 25</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type
<u>Table 26</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type
<u>Table 27</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183, -1)
<u>Table 28</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (ever, -1)
<u>Table 29</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Serious Allergies
<u>Table 30</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Sex
<u>Table 31</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Age Group
<u>Table 32</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race
<u>Table 33</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type
<u>Table 34</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183, -1)
<u>Table 35</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (ever, -1)



	Table of Contents
<u>Table 36</u>	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk
	of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	by Analysis Type and Serious Allergies
Table 37	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk
	of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	by Analysis Type and Sex
Table 38	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk
	of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
Table 20	by Analysis Type and Age Group
Table 39	Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020
	by Analysis Type and Race
Figuros 1a	
Figures 1a	Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, Aggregated
Figures 1h	
Figures 1b	Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin-Converting Enzyme Inhibitors
	(ACEI), 14-Day Gap
	Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use
Figures 2a	of Angiotensin II Receptor Blockers (ARBs), 14-day gap, Aggregated
Figures 2b	Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution
<u>Figures 20</u>	Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin II Receptor Blockers (ARBs), 14-
	Day Gap
	Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use
Figures 3a	of Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, Aggregated
Figures 3b	Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution
<u>rigules su</u>	Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin-Converting Enzyme Inhibitors
	(ACEI), 7-Day Gap
Figures 4a	Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use
<u>ngures <del>q</del>u</u>	of Angiotensin II Receptor Blockers (ARBs), 7-day gap, Aggregated
Figures 4b	Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution
<u>1 igures 40</u>	Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin II Receptor Blockers (ARBs), 7-Day
	Gap
Figure 5	Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI),
<u>inguic s</u>	14-Day Gap, and Risk of Angioedema
Figure 6	Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day
<u> </u>	Gap, and Risk of Angioedema
Figure 7	Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI),
	7-Day Gap, and Risk of Angioedema
Figure 8	Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day
_	Gap, and Risk of Angioedema
Figure 9	Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI),
	14-Day Gap, and Risk of Serious Angioedema
Figure 10	Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day
	Gap, and Risk of Serious Angioedema
Figure 11	Kaplan Meier Survival Curves for Risk of Angioedema, Sacubitril/Valsartan (SV) (14-day gap) and Angiotensin-
	Converting Enzyme Inhibitors (ACEI) (14-day gap)



	Table of Contents
Figure 12	Kaplan Meier Survival Curves for Risk of Angioedema, Sacubitril/Valsartan (SV) (14-day gap) and
	Angiotensin II Receptor Blockers (ARBs) (14-day gap)
<u>Appendix A</u>	Start and End Dates for Each Data Partner up to Request End Date (09/30/2020)
<u>Appendix B</u>	Generic and Brand Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International
	Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of
	Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), Current Procedural Terminology, Fourth
	Edition (CPT-4), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Outcome in this Request
<u>Appendix D</u>	Generic and Brand Names of Medical Products Used to Define Exposure Incidence and Exclusion Criteria in this
	Request
<u>Appendix E</u>	International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International
	Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request
Appendix F	International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International
	Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Healthcare Common Procedure
	Coding System, Level II (HCPCS) Codes Used to Define Covariates in this Request
<u>Appendix G</u>	Generic and Brand Names of Medical Products Used to Define Covariates in this Request
<u>Appendix H</u>	Specifications Defining Parameters for this Request
<u>Appendix I</u>	Specifications Defining Parameters for Baseline Covariate Groups in this Request



### Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module\*

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. **Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

**Ambulatory Visit (AV)** - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

**Emergency Department (ED)** - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

**Inpatient Hospital Stay (IP)** - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

**Non-Acute Institutional Stay (IS)** - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

**Other Ambulatory Visit (OA)** - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

**Charlson/Elixhauser Combined Comorbidity Score** - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

**Code Days** - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

**Cohort Definition (drug/exposure)** - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

**Computed Start Marketing Date** - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Event Deduplication** - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time." **Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.



**Lookback Period** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Maximum Episode Duration** - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Member-Years** - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

**Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

**Switch Gap Inclusion Indicator - i**ndicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

**Switch Pattern Cohort Inclusion Date** - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

**Switch Pattern Cohort Inclusion Strategy** - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

**Treatment Episode Truncation Indicator** - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event

(procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

\*all terms may not be used in this report



## Glossary of Terms for Analyses Using Propensity Score Analysis (PSA) Tool\*

**Covariate** - requester defined binary variable to include in the propensity score estimation model (e.g., diabetes, heart failure, etc.) during requester-defined lookback period. Requester may also choose to add any of the following categorical, continuous, or count

- 1. Age (continuous)
- 2. Sex
- 3. Time period (i.e., monitoring period for sequential analyses)
- 4. Year of exposure
- 5. Comorbidity score
- 6. Medical utilization number of inpatient stays
- 7. Medical utilization number of institutional stays
- 8. Medical utilization number of emergency department visits
- 9. Medical utilization number of outpatient visits
- 10. Health care utilization number of other ambulatory encounters (e.g., telemedicine, email consults)
- 11. Drug utilization number of dispensings
- 12. Drug utilization number of unique generics dispensed
- 13. Drug Utilization number of unique drug classes dispensed

**Covariate Evaluation Window** - specified number of days relative to index date to evaluate the occurrence of covariates of interest. Note: members are required to have continuous enrollment during the covariate evaluation window, regardless of the value **Individual Level Data Return** - program may return individual-level, de-identified datasets to the Sentinel Operations Center (SOC). While the datasets contain a single row per patient for each specified analysis, patient identifiers such as a patient ID are not included in the output. Individual-level datasets are returned to the SOC, aggregated, and used to calculate effect estimates via Cox

Mahalanobis Distance - provides a measure of balance across all variables while accounting for their correlation.

**Matching Caliper** - maximum allowed difference in propensity scores between treatment and control patients. Requester may select any caliper (e.g., 0.01, 0.025, and 0.05).

Matching Ratio - patients in exposed and comparator groups are nearest neighbor matched by a 1:1 or 1:n (up to 10) matching

**Matched Conditional and Unconditional Analysis** - in a conditional matched analysis, a Cox model, stratified by Data Partner site and matched set, is run on the matched population. This can be done for both the both 1:1 and 1:n matched cohorts. In an unconditional analysis, a Cox model, stratified by Data Partner site only, is run on the matched population. This can be done for the

**Propensity Score Stratification** - option to stratify propensity scores based on requester-defined percentiles in the unmatched population. In a stratified analysis, a Cox model, stratified by Data Partner site, is run on the stratified population. Note that all

**PSM Tool** - performs effect estimation by comparing exposure propensity-score matched parallel new user cohorts. Propensity score estimation and matching are conducted within each Sentinel Data Partner site via distributed programming code; data are

**Risk-set Level Data Return** - alternative to the patient-level data return approach. In this approach, the PSM tool will produce deidentified, risk-set level datasets instead of or in addition to individual-level output. Whereas each observation in the patient-level datasets represents one patient in the cohort, each observation in the risk set dataset represents one event. Risk sets are created at the Data Partner site, returned to the SOC, aggregated, and used to calculate effect estimates via case-centered logistic regression.

**Subgroup Analysis** - may be conducted using any requester-defined covariates. Subgroup analyses may be performed in the **Zero Cell Correction** - indicator for whether to screen variables with a zero correction added to each cell in the confounder/outcome 2x2 table. Recommended when the number of exposed outcomes is fewer than 150.

\*all terms may not be used in this report



Table 1a. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-DayGap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020(Unadjusted, Aggregated)

	Medical Product				Covaria	Covariate Balance		
	SV (14-day gap) ACE			-day gap)				
					Absolute	Standardized		
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Difference	Difference		
Patients (Number)	41,998	100.0%	695,012	100.0%	-	-		
		Standard		Standard				
Demographics	Mean	Deviation	Mean	Deviation				
Mean age, years	71.6	11.8	72.7	12.5	-1.108	-0.091		
Age	Number	Percent	Number	Percent				
18-44 years	1,538	3.7%	21,594	3.1%	0.555	0.031		
45-54 years	2,863	6.8%	45,064	6.5%	0.333	0.013		
55-64 years	5,807	13.8%	97,267	14.0%	-0.168	-0.005		
≥65 years	31,790	75.7%	531,087	76.4%	-0.720	-0.017		
Sex								
Female	14,867	35.4%	341,886	49.2%	-13.792	-0.282		
Male	27,131	64.6%	353,126	50.8%	13.792	0.282		
Race								
American Indian or Alaska Native	132	0.3%	4,529	0.7%	-0.337	-0.049		
Asian	519	1.2%	7,874	1.1%	0.103	0.010		
Black or African American	5,566	13.3%	92,129	13.3%	-0.003	-0.000		
Native Hawaiian or Other Pacific Islander	46	0.1%	741	0.1%	0.003	0.001		
Unknown	7,029	16.7%	99,645	14.3%	2.399	0.066		
White	28,706	68.4%	490,094	70.5%	-2.165	-0.047		
Hispanic Origin	708	1.7%	15,586	2.2%	-0.557	-0.040		
Year								
2015	430	1.0%	87,092	12.5%	-11.507	-0.470		
2016	4,087	9.7%	172,883	24.9%	-15.143	-0.409		
2017	8,846	21.1%	156,612	22.5%	-1.471	-0.036		
2018	11,912	28.4%	143,025	20.6%	7.784	0.182		
2019	16,392	39.0%	133,649	19.2%	19.801	0.447		
2020	331	5.8%	1,751	2.4%	3.366	0.170		
		Standard		Standard				
Recorded History of:	Mean	Deviation	Mean	Deviation				
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.8	3.0	-0.259	-0.089		
Score <sup>3</sup>								
	Number	Percent	Number	Percent				
Ambulatory allergies or allergy treatment	20,540	48.9%	320,744	46.1%	2.758	0.055		
Ambulatory allergies or treatment and not	16,919	40.3%	253,012	36.4%	3.881	0.080		

Ambulatory allergies or treatment and not	16,919	40.3%	253,012	36.4%	3.881	0.080
serious allergies						
Angioedema (-183, -1)	57	0.1%	864	0.1%	0.011	0.003
Angioedema (ever, -1)	571	1.4%	7,320	1.1%	0.306	0.028
Diabetes	19,570	46.6%	326,116	46.9%	-0.325	-0.007
Ischemic heart disease	31,758	75.6%	433,085	62.3%	13.305	0.291
Renal disorders	18,574	44.2%	289,803	41.7%	2.528	0.051
Serious allergies	5,684	13.5%	110,980	16.0%	-2.434	-0.069



Table 1a. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated)

	Medical Product				Covariate Balance	
	SV (14-	day gap)	ACEI (14-day gap)			
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
History of Use:						
Diuretics (thiazides, potassium sparing, loop diuretics)	33,728	80.3%	458,232	65.9%	14.377	0.329
Everolimus	12	0.0%	183	0.0%	0.002	0.001
Nonsteroidal anti-inflammatory drugs (NSAIDs)	4,213	10.0%	88,980	12.8%	-2.771	-0.087
Sirolimus	****	****	208	0.0%	-0.006	-0.004
		Standard		Standard		
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation		
Mean number of ambulatory encounters	18.2	17.0	17.3	19.7	0.886	0.048
Mean number of emergency room encounters	0.6	1.3	0.9	1.8	-0.205	-0.129
Mean number of inpatient hospital encounters	0.8	1.1	1.0	1.2	-0.212	-0.190
Mean number of non-acute institutional encounters	0.3	0.9	0.4	1.1	-0.163	-0.168
Mean number of other ambulatory encounters	9.2	14.1	12.8	18.0	-3.641	-0.226
Mean number of filled prescriptions	26.5	20.5	26.9	23.0	-0.349	-0.016
Mean number of generics	11.6	5.4	11.5	5.7	0.106	0.019
Mean number of unique drug classes	11.0	4.9	10.8	5.0	0.195	0.039

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1b. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-DayGap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020(Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covaria	Covariate Balance	
	SV (14-	SV (14-day gap) ACI		-day gap)			
					Absolute	Standardized	
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Difference	Difference	
Patients (Number)	41,998	100.0%	41,998	6.0%	-	-	
		Standard		Standard			
Demographics	Mean	Deviation	Mean	Deviation			
Mean age, years	71.6	11.8	71.6	12.1	0.033	0.003	
Age	Number	Percent	Number	Percent			
18-44 years	1,538	3.7%	1,462	3.5%	0.181	0.010	
45-54 years	2,863	6.8%	2,925	7.0%	-0.148	-0.006	
55-64 years	5,807	13.8%	6,460	15.4%	-1.555	-0.045	
≥65 years	31,790	75.7%	31,151	74.2%	1.522	0.038	
Sex							
Female	14,867	35.4%	15,072	35.9%	-0.488	-0.010	
Male	27,131	64.6%	26,926	64.1%	0.488	0.010	
Race							
American Indian or Alaska Native	132	0.3%	132	0.3%	0.000	0.000	
Asian	519	1.2%	536	1.3%	-0.040	-0.004	
Black or African American	5,566	13.3%	5,557	13.2%	0.021	0.001	
Native Hawaiian or Other Pacific Islander	46	0.1%	41	0.1%	0.012	0.004	
Unknown	7,029	16.7%	7,058	16.8%	-0.069	-0.003	
White	28,706	68.4%	28,674	68.3%	0.076	0.002	
Hispanic Origin	708	1.7%	843	2.0%	-0.321	-0.024	
Year							
2015	430	1.0%	378	0.9%	0.124	0.013	
2016	4,087	9.7%	4,104	9.8%	-0.040	-0.001	
2017	8,846	21.1%	8,931	21.3%	-0.202	-0.005	
2018	11,912	28.4%	11,867	28.3%	0.107	0.002	
2019	16,392	39.0%	16,366	39.0%	0.062	0.001	
2020	331	5.8%	352	6.1%	-0.367	-0.016	
		Standard		Standard			
Recorded History of:	Mean	Deviation	Mean	Deviation			
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.6	2.8	0.006	0.002	
Score <sup>3</sup>							
	Number	Percent	Number	Percent			
Ambulatory allergies or allergy treatment	20,540	48.9%	20,437	48.7%	0.245	0.005	
Ambulatory allergies or treatment and not	16,919	40.3%	16,914	40.3%	0.012	0.000	
sarious allergies	_0,0 10		_0,0		0.016	0.000	

Ambulatory allergies or treatment and not	16,919	40.3%	16,914	40.3%	0.012	0.000	
serious allergies							
Angioedema (-183, -1)	57	0.1%	53	0.1%	0.010	0.003	
Angioedema (ever, -1)	571	1.4%	448	1.1%	0.293	0.027	
Diabetes	19,570	46.6%	19,715	46.9%	-0.345	-0.007	
Ischemic heart disease	31,758	75.6%	31,645	75.3%	0.269	0.006	
Renal disorders	18,574	44.2%	18,577	44.2%	-0.007	-0.000	
Serious allergies	5,684	13.5%	5,702	13.6%	-0.043	-0.001	



Table 1b. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

	Medical Product				Covariate Balance	
	SV (14-	day gap)	ACEI (14-day gap)			
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
History of Use:						
Diuretics (thiazides, potassium sparing, loop diuretics)	33,728	80.3%	33,786	80.4%	-0.138	-0.003
Everolimus	12	0.0%	13	0.0%	-0.002	-0.001
Nonsteroidal anti-inflammatory drugs (NSAIDs)	4,213	10.0%	4,192	10.0%	0.050	0.002
Sirolimus	****	****	****	****	0.000	0.000
		Standard		Standard		
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation		
Mean number of ambulatory encounters	18.2	17.0	18.2	21.5	-0.011	-0.001
Mean number of emergency room encounters	0.6	1.3	0.6	1.1	0.002	0.002
Mean number of inpatient hospital encounters	0.8	1.1	0.8	0.9	0.002	0.002
Mean number of non-acute institutional encounters	0.3	0.9	0.3	0.8	-0.001	-0.002
Mean number of other ambulatory encounters	9.2	14.1	9.2	12.8	-0.024	-0.002
Mean number of filled prescriptions	26.5	20.5	26.7	22.3	-0.208	-0.010
Mean number of generics	11.6	5.4	11.7	5.5	-0.035	-0.006
Mean number of unique drug classes	11.0	4.9	11.0	4.9	0.014	0.003

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1c. Weighted Baseline Characteristics of Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) betweenJuly 7, 2015 and February 29, 2020 (Propensity Score (PS) Stratified, Aggregated), Percentiles: 10

		Medical	Covariate Balance			
	SV (14-	SV (14-day gap)		ACEI (14-day gap)		
122					Absolute	Standardized
Characteristic <sup>1,2,3</sup>	Number	Percent	Number	Percent	Difference	Difference
Patients (Number)	41,998	100.0%	695,012	100.0%	-	-
		Standard		Standard		
Demographics	Mean	Deviation	Mean	Deviation		
Mean age, years	72.3	12.2	72.7	12.5	-0.418	-0.034
Age	Number	Percent	Number	Percent		
18-44 years	1,456	3.5%	21,633	3.1%	0.355	0.020
45-54 years	2,752	6.6%	45,109	6.5%	0.062	0.003
55-64 years	5,690	13.5%	97,451	14.0%	-0.473	-0.014
≥65 years	32,100	76.4%	530,819	76.4%	0.057	0.001
Sex						
Female	19,800	47.1%	336,959	48.5%	-1.338	-0.027
Male	22,198	52.9%	358,053	51.5%	1.338	0.027
Race						
American Indian or Alaska Native	235	0.6%	4,407	0.6%	-0.075	-0.010
Asian	489	1.2%	7,914	1.1%	0.025	0.002
Black or African American	5,426	12.9%	92,228	13.3%	-0.351	-0.010
Native Hawaiian or Other Pacific Islander	34	0.1%	744	0.1%	-0.026	-0.009
Unknown	7,013	16.7%	99,598	14.3%	2.369	0.110
White	28,802	68.6%	490,120	70.5%	-1.941	-0.050
Hispanic Origin	703	1.7%	15,517	2.2%	-0.558	-0.040
Year						
2015	4,956	11.8%	82,533	11.9%	-0.074	-0.002
2016	9,386	22.3%	166,944	24.0%	-1.672	-0.040
2017	9,299	22.1%	156,252	22.5%	-0.339	-0.008
2018	9,003	21.4%	146,432	21.1%	0.368	0.009
2019	9,192	21.9%	140,943	20.3%	1.607	0.039
2020	162	2.8%	1,909	2.6%	0.199	0.012
		Standard		Standard		
Recorded History of:	Mean	Deviation	Mean	Deviation		
Charlson/Elixhauser Combined Comorbidity	5.9	3.1	5.8	3.0	0.103	0.034
Score <sup>4</sup>						
	Number	Percent	Number	Percent		
Ambulatory allergies or allergy treatment	20,161	48.0%	321,762	46.3%	1.709	0.034
	•		•			

Ambulatory allergies or allergy treatment	20,161	48.0%	321,762	46.3%	1.709	0.034
Ambulatory allergies or treatment and not	15,900	37.9%	254,456	36.6%	1.246	0.026
serious allergies						
Angioedema (-183, -1)	56	0.1%	866	0.1%	0.008	0.002
Angioedema (ever, -1)	532	1.3%	7,325	1.1%	0.214	0.020
Diabetes	19,849	47.3%	326,148	46.9%	0.334	0.007
Ischemic heart disease	27,212	64.8%	438,289	63.1%	1.731	0.036
Renal disorders	18,387	43.8%	290,929	41.9%	1.921	0.039
Serious allergies	6,765	16.1%	110,244	15.9%	0.245	0.007



Table 1c. Weighted Baseline Characteristics of Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Propensity Score (PS) Stratified, Aggregated), Percentiles: 10

	Medical Product				Covariate Balance		
	SV (14-	day gap)	ACEI (14-day gap)				
	_				Absolute	Standardized	
Characteristic <sup>1,2,3</sup>	Number	Percent	Number	Percent	Difference	Difference	
History of Use:							
Diuretics (thiazides, potassium sparing, loop	29,007	69.1%	463,884	66.7%	2.322	0.050	
diuretics)							
Everolimus	* * * * *	* * * * *	184	0.0%	-0.008	-0.005	
Nonsteroidal anti-inflammatory drugs	5,321	12.7%	87,959	12.7%	0.013	0.000	
(NSAIDs)							
Sirolimus	16	0.0%	205	0.0%	0.008	0.004	
		Standard		Standard			
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation			
Mean number of ambulatory encounters	18.6	16.7	17.4	19.8	1.218	0.067	
Mean number of emergency room	1.0	2.9	0.8	1.8	0.181	0.076	
encounters							
Mean number of inpatient hospital	1.1	1.7	1.0	1.1	0.121	0.084	
encounters							
Mean number of non-acute institutional	0.4	1.2	0.4	1.0	0.022	0.019	
encounters							
Mean number of other ambulatory	13.2	20.4	12.6	17.8	0.598	0.031	
encounters							
Mean number of filled prescriptions	27.6	22.1	26.9	23.0	0.685	0.030	
Mean number of generics	11.7	5.9	11.5	5.7	0.223	0.039	
Mean number of unique drug classes	11.0	5.3	10.8	5.0	0.256	0.050	

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>Weighted patient characteristics tables facilitate the assessment of covariate balance after PS stratification. Treated/control patients are weigh ted by the proportion of the total patient population included in their PS stratum

divided by the proportion of the total treated/control patient population included in their PS stratum.

<sup>4</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1d. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated)

		Medical	Product		Covariate Balance		
	SV (14-	day gap)	ARBs (14	1-day gap)			
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference	
Patients (Number)	43,777	100.0%	337,157	100.0%	-	-	
Demographics	Mean	Standard Deviation	Mean	Standard Deviation			
Mean age, years	71.5	11.9	73.8	12.0	-2.285	-0.191	
Age	Number	Percent	Number	Percent			
18-44 years	1,634	3.7%	8,500	2.5%	1.211	0.070	
45-54 years	3,068	7.0%	18,297	5.4%	1.581	0.066	
55-64 years	6,120	14.0%	40,556	12.0%	1.951	0.058	
≥65 years	32,955	75.3%	269,804	80.0%	-4.744	-0.114	
Sex							
Female	15,466	35.3%	187,905	55.7%	-20.403	-0.419	
Male	28,311	64.7%	149,252	44.3%	20.403	0.419	
Race							
American Indian or Alaska Native	143	0.3%	1,947	0.6%	-0.251	-0.037	
Asian	511	1.2%	7,817	2.3%	-1.151	-0.088	
Black or African American	5,853	13.4%	55,815	16.6%	-3.185	-0.089	
Native Hawaiian or Other Pacific Islander	46	0.1%	478	0.1%	-0.037	-0.010	
Unknown	7,289	16.7%	47,812	14.2%	2.469	0.068	
White	29,935	68.4%	223,288	66.2%	2.154	0.046	
Hispanic Origin	751	1.7%	9,038	2.7%	-0.965	-0.066	
Year							
2015	430	1.0%	32,231	9.6%	-8.577	-0.391	
2016	4,168	9.5%	70,705	21.0%	-11.450	-0.323	
2017	9,173	21.0%	73,808	21.9%	-0.937	-0.023	
2018	12,488	28.5%	81,684	24.2%	4.299	0.098	
2019	17,167	39.2%	77,624	23.0%	16.192	0.355	
2020	351	5.9%	1,105	3.2%	2.670	0.128	
		Standard		Standard			
Recorded History of:	Mean	Deviation	Mean	Deviation			
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.8	3.0	-0.171	-0.059	
Score <sup>3</sup>							
	Number	Percent	Number	Percent			
Ambulatory allergies or allergy treatment	21,349	48.8%	169,542	50.3%	-1.518	-0.030	
Ambulatory allergies or treatment and not serious allergies	17,590	40.2%	134,478	39.9%	0.295	0.006	
Angioedema (-183, -1)	60	0.1%	825	0.2%	-0.108	-0.025	
Anaioedema (ever1)	599	1.4%	7.359	2.2%	-0.814	-0.062	

, inglocacina ( 100), 1,	00	011/0	025	0.2/0	0.100	0.025	
Angioedema (ever, -1)	599	1.4%	7,359	2.2%	-0.814	-0.062	
Diabetes	20,372	46.5%	173,558	51.5%	-4.941	-0.099	
Ischemic heart disease	33,124	75.7%	203,999	60.5%	15.160	0.330	
Renal disorders	19,390	44.3%	154,663	45.9%	-1.580	-0.032	
Serious allergies	5,930	13.5%	54,432	16.1%	-2.598	-0.073	



Table 1d. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated)

		Medical	Covariate Balance			
	SV (14-	day gap)	ARBs (14	-day gap)		
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
History of Use:						
Diuretics (thiazides, potassium sparing, loop diuretics)	35,208	80.4%	222,934	66.1%	14.304	0.328
Everolimus	12	0.0%	98	0.0%	-0.002	-0.001
Nonsteroidal anti-inflammatory drugs (NSAIDs)	4,405	10.1%	44,187	13.1%	-3.043	-0.095
Sirolimus	****	****	142	0.0%	-0.022	-0.012
		Standard		Standard		
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation		
Mean number of ambulatory encounters	18.2	17.1	20.4	22.5	-2.205	-0.110
Mean number of emergency room encounters	0.7	1.4	0.8	1.7	-0.114	-0.075
Mean number of inpatient hospital encounters	0.8	1.1	0.8	1.1	-0.047	-0.042
Mean number of non-acute institutional encounters	0.3	0.9	0.4	1.0	-0.112	-0.116
Mean number of other ambulatory encounters	9.2	14.0	11.7	17.4	-2.490	-0.157
Mean number of filled prescriptions	26.6	20.7	27.8	22.3	-1.120	-0.052
Mean number of generics	11.6	5.5	12.0	5.8	-0.342	-0.061
Mean number of unique drug classes	11.0	4.9	11.2	5.1	-0.221	-0.044

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1e. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical		Covariate Balance			
	SV (14-	day gap)	ARBs (14	I-day gap)			
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference	
Patients (Number)	43,755	99.9%	43,755	13.0%	-	-	
		Standard		Standard			
Demographics	Mean	Deviation	Mean	Deviation			
Mean age, years	71.5	11.9	71.6	11.9	-0.033	-0.003	
Age	Number	Percent	Number	Percent			
18-44 years	1,623	3.7%	1,517	3.5%	0.242	0.013	
45-54 years	3,059	7.0%	3,067	7.0%	-0.018	-0.001	
55-64 years	6,118	14.0%	6,380	14.6%	-0.599	-0.018	
≥65 years	32,955	75.3%	32,791	74.9%	0.375	0.009	
Sex							
Female	15,466	35.3%	15,554	35.5%	-0.201	-0.004	
Male	28,289	64.7%	28,201	64.5%	0.201	0.004	
Race							
American Indian or Alaska Native	143	0.3%	155	0.4%	-0.027	-0.005	
Asian	511	1.2%	506	1.2%	0.011	0.001	
Black or African American	5,852	13.4%	5,880	13.4%	-0.064	-0.002	
Native Hawaiian or Other Pacific Islander	46	0.1%	35	0.1%	0.025	0.008	
Unknown	7,271	16.6%	7,265	16.6%	0.014	0.001	
White	29,932	68.4%	29,914	68.4%	0.041	0.001	
Hispanic Origin	751	1.7%	833	1.9%	-0.187	-0.014	
Year							
2015	430	1.0%	400	0.9%	0.069	0.007	
2016	4,168	9.5%	4,044	9.2%	0.283	0.010	
2017	9,173	21.0%	9,222	21.1%	-0.112	-0.003	
2018	12,486	28.5%	12,664	28.9%	-0.407	-0.009	
2019	17,148	39.2%	17,038	38.9%	0.251	0.005	
2020	350	5.9%	387	6.5%	-0.625	-0.026	
		Standard		Standard			
Recorded History of:	Mean	Deviation	Mean	Deviation			
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.6	2.9	-0.030	-0.011	
Score <sup>3</sup>							
	Number	Percent	Number	Percent			
Ambulatory allergies or allergy treatment	21,340	48.8%	21,523	49.2%	-0.418	-0.008	
Ambulatory allergies or treatment and not serious allergies	17,582	40.2%	17,679	40.4%	-0.222	-0.005	

serious allergies						
Angioedema (-183, -1)	60	0.1%	58	0.1%	0.005	0.001
Angioedema (ever, -1)	598	1.4%	916	2.1%	-0.727	-0.056
Diabetes	20,371	46.6%	20,282	46.4%	0.203	0.004
Ischemic heart disease	33,103	75.7%	33,062	75.6%	0.094	0.002
Renal disorders	19,388	44.3%	19,531	44.6%	-0.327	-0.007
Serious allergies	5,928	13.5%	5,967	13.6%	-0.089	-0.003



Table 1e. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Covariate Balance			
	SV (14-	day gap)	ARBs (14	-day gap)		
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
History of Use:						
Diuretics (thiazides, potassium sparing, loop diuretics)	35,186	80.4%	35,179	80.4%	0.016	0.000
Everolimus	12	0.0%	16	0.0%	-0.009	-0.005
Nonsteroidal anti-inflammatory drugs	4,405	10.1%	4,394	10.0%	0.025	0.001
(NSAIDs) Sirolimus	****	****	****	****	0.000	0.000
		Standard		Standard		
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation		
Mean number of ambulatory encounters	18.2	17.1	18.3	19.0	-0.087	-0.005
Mean number of emergency room encounters	0.7	1.4	0.7	1.3	0.007	0.005
Mean number of inpatient hospital encounters	0.8	1.1	0.8	1.1	-0.015	-0.014
Mean number of non-acute institutional encounters	0.3	0.9	0.3	0.9	-0.008	-0.010
Mean number of other ambulatory encounters	9.2	14.0	9.4	13.8	-0.153	-0.011
Mean number of filled prescriptions	26.6	20.7	26.2	20.5	0.441	0.021
Mean number of generics	11.6	5.5	11.7	5.5	-0.085	-0.016
Mean number of unique drug classes	11.0	4.9	11.0	4.8	-0.025	-0.005

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1f. Weighted Baseline Characteristics of Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin IIReceptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7,2015 and February 29, 2020 (Propensity Score (PS) Stratified, Aggregated), Percentiles: 10

		Medical	Product		Covaria	te Balance
	SV (14-	day gap)	ARBs (14	I-day gap)		
Characteristic <sup>1,2,3</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Patients (Number)	43,777	100.0%	337,157	100.0%		
Patients (Number)	45,777	Standard	557,157	Standard	-	-
Demographics	Mean	Deviation	Mean	Deviation		
Mean age, years	73.2	12.0	73.6	12.0	-0.382	-0.032
Age	Number	Percent	Number	Percent		
18-44 years	1,249	2.9%	8,753	2.6%	0.258	0.016
45-54 years	2,559	5.8%	18,681	5.5%	0.306	0.013
55-64 years	5,585	12.8%	41,057	12.2%	0.579	0.018
≥65 years	34,384	78.5%	268,666	79.7%	-1.143	-0.030
Sex						
Female	22,862	52.2%	180,403	53.5%	-1.282	-0.026
Male	20,915	47.8%	156,754	46.5%	1.282	0.026
Race						
American Indian or Alaska Native	201	0.5%	1,862	0.6%	-0.092	-0.013
Asian	887	2.0%	7,405	2.2%	-0.170	-0.012
Black or African American	6,822	15.6%	54,823	16.3%	-0.677	-0.019
Native Hawaiian or Other Pacific Islander	46	0.1%	466	0.1%	-0.032	-0.009
Unknown	7,504	17.1%	47,484	14.1%	3.058	0.134
White	28,316	64.7%	225,116	66.8%	-2.086	-0.050
Hispanic Origin	944	2.2%	8,771	2.6%	-0.446	-0.029
Year						
2015	3,661	8.4%	28,920	8.6%	-0.214	-0.008
2016	8,426	19.2%	66,279	19.7%	-0.410	-0.010
2017	9,453	21.6%	73,686	21.9%	-0.262	-0.006
2018	10,758	24.6%	83,656	24.8%	-0.237	-0.005
2019	11,261	25.7%	83,387	24.7%	0.991	0.023
2020	217	3.7%	1,230	3.6%	0.054	0.003
		Standard		Standard		
Recorded History of:	Mean	Deviation	Mean	Deviation		
Charlson/Elixhauser Combined Comorbidity	5.7	2.9	5.8	3.0	-0.010	-0.003
Score <sup>4</sup>						
	Number	Percent	Number	Percent		
Ambulatory allergies or allergy treatment	22,289	50.9%	169,231	50.2%	0.722	0.014
Ambulatory allergies or treatment and not	17,968	41.0%	134,696	40.0%	1.093	0.022

Ambulatory allergies or treatment and not	17,968	41.0%	134,696	40.0%	1.093	0.022
serious allergies						
Angioedema (-183, -1)	134	0.3%	784	0.2%	0.074	0.014
Angioedema (ever, -1)	675	1.5%	7,308	2.2%	-0.626	-0.046
Diabetes	21,885	50.0%	172,051	51.0%	-1.037	-0.021
Ischemic heart disease	27,492	62.8%	209,958	62.3%	0.526	0.011
Renal disorders	20,094	45.9%	154,462	45.8%	0.088	0.002
Serious allergies	6,724	15.4%	53,664	15.9%	-0.556	-0.015



Table 1f. Weighted Baseline Characteristics of Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin IIReceptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7,2015 and February 29, 2020 (Propensity Score (PS) Stratified, Aggregated), Percentiles: 10

	Medical Product				Covariate Balance		
	SV (14-	day gap)	ARBs (14-day gap)				
Characteristic <sup>1,2,3</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference	
History of Use:							
Diuretics (thiazides, potassium sparing, loop diuretics)	30,349	69.3%	228,471	67.8%	1.563	0.034	
Everolimus	****	****	97	0.0%	-0.009	-0.006	
Nonsteroidal anti-inflammatory drugs (NSAIDs)	5,657	12.9%	43,061	12.8%	0.151	0.005	
Sirolimus	12	0.0%	133	0.0%	-0.012	-0.006	
		Standard		Standard			
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation			
Mean number of ambulatory encounters	20.2	20.3	20.2	22.2	0.017	0.001	
Mean number of emergency room encounters	0.8	1.9	0.8	1.6	0.029	0.016	
Mean number of inpatient hospital encounters	0.8	1.2	0.8	1.1	-0.007	-0.006	
Mean number of non-acute institutional encounters	0.4	1.1	0.4	1.0	-0.005	-0.004	
Mean number of other ambulatory encounters	11.2	17.6	11.5	17.1	-0.317	-0.018	
Mean number of filled prescriptions	28.6	22.8	27.6	22.2	0.984	0.044	
Mean number of generics	12.0	5.8	12.0	5.8	0.043	0.007	
Mean number of unique drug classes	11.3	5.2	11.2	5.1	0.106	0.020	

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>Weighted patient characteristics tables facilitate the assessment of covariate balance after PS stratification. Treated/control patients are weigh ted by the proportion of the total patient population included in their PS stratum

divided by the proportion of the total treated/control patient population included in their PS stratum.

<sup>4</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1g. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covariate Balance		
	SV (7-0	lay gap)	ACEI (7-	-day gap)			
					Absolute	Standardized	
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Difference	Difference	
Patients (Number)	41,998	100.0%	695,012	100.0%	-	-	
		Standard		Standard			
Demographics	Mean	Deviation	Mean	Deviation			
Mean age, years	71.6	11.8	72.7	12.5	-1.108	-0.091	
Age	Number	Percent	Number	Percent			
18-44 years	1,538	3.7%	21,594	3.1%	0.555	0.031	
45-54 years	2,863	6.8%	45,064	6.5%	0.333	0.013	
55-64 years	5,807	13.8%	97,267	14.0%	-0.168	-0.005	
≥65 years	31,790	75.7%	531,087	76.4%	-0.720	-0.017	
Sex							
Female)	14,867	35.4%	341,886	49.2%	-13.792	-0.282	
Male	27,131	64.6%	353,126	50.8%	13.792	0.282	
Race							
American Indian or Alaska Native	132	0.3%	4,529	0.7%	-0.337	-0.049	
Asian	519	1.2%	7,874	1.1%	0.103	0.010	
Black or African American	5,566	13.3%	92,129	13.3%	-0.003	-0.000	
Native Hawaiian or Other Pacific Islander	46	0.1%	741	0.1%	0.003	0.001	
Unknown	7,029	16.7%	99,645	14.3%	2.399	0.066	
White	28,706	68.4%	490,094	70.5%	-2.165	-0.047	
Hispanic Origin	708	1.7%	15,586	2.2%	-0.557	-0.040	
Year							
2015	430	1.0%	87,092	12.5%	-11.507	-0.470	
2016	4,087	9.7%	172,883	24.9%	-15.143	-0.409	
2017	8,846	21.1%	156,612	22.5%	-1.471	-0.036	
2018	11,912	28.4%	143,025	20.6%	7.784	0.182	
2019	16,392	39.0%	133,649	19.2%	19.801	0.447	
2020	331	5.8%	1,751	2.4%	3.366	0.170	
		Standard		Standard			
Recorded History of:	Mean	Deviation	Mean	Deviation			
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.8	3.0	-0.259	-0.089	
Score <sup>3</sup>							
	Number	Percent	Number	Percent			
Ambulatory allergies or allergy treatment	20,540	48.9%	320,744	46.1%	2.758	0.055	
Ambulatory allergies or treatment and not	16,919	40.3%	253,012	36.4%	3.881	0.080	
, , ,	,		,				

Ambulatory allergies or treatment and not	16,919	40.3%	253,012	36.4%	3.881	0.080	
serious allergies							
Angioedema (-183, -1)	57	0.1%	864	0.1%	0.011	0.003	
Angioedema (ever, -1)	571	1.4%	7,320	1.1%	0.306	0.028	
Diabetes	19,570	46.6%	326,116	46.9%	-0.325	-0.007	
Ischemic heart disease	31,758	75.6%	433,085	62.3%	13.305	0.291	
Renal disorders	18,574	44.2%	289,803	41.7%	2.528	0.051	
Serious allergies	5,684	13.5%	110,980	16.0%	-2.434	-0.069	



Table 1g. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covaria	te Balance
	SV (7-d	lay gap)	ACEI (7-	day gap)		
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
History of Use:						
Diuretics (thiazides, potassium sparing, loop diuretics)	33,728	80.3%	458,232	65.9%	14.377	0.329
Everolimus	12	0.0%	183	0.0%	0.002	0.001
Nonsteroidal anti-inflammatory drugs (NSAIDs)	4,213	10.0%	88,980	12.8%	-2.771	-0.087
Sirolimus	****	****	208	0.0%	-0.006	-0.004
		Standard		Standard		
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation		
Mean number of ambulatory encounters	18.2	17.0	17.3	19.7	0.886	0.048
Mean number of emergency room encounters	0.6	1.3	0.9	1.8	-0.205	-0.129
Mean number of inpatient hospital encounters	0.8	1.1	1.0	1.2	-0.212	-0.190
Mean number of non-acute institutional encounters	0.3	0.9	0.4	1.1	-0.163	-0.168
Mean number of other ambulatory encounters	9.2	14.1	12.8	18.0	-3.641	-0.226
Mean number of filled prescriptions	26.5	20.5	26.9	23.0	-0.349	-0.016
Mean number of generics	11.6	5.4	11.5	5.7	0.106	0.019
Mean number of unique drug classes	11.0	4.9	10.8	5.0	0.195	0.039

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1h. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical		Covaria	te Balance		
	SV (7-d	lay gap)	ACEI (7-	day gap)			
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference	
Patients (Number)	41,998	100.0%	41,998	6.0%		-	
	41,550	Standard	41,550	Standard	-	_	
Demographics	Mean	Deviation	Mean	Deviation			
Mean age, years	71.6	11.8	71.6	12.1	0.033	0.003	
Age	Number	Percent	Number	Percent			
18-44 years	1,538	3.7%	1,462	3.5%	0.181	0.010	
45-54 years	2,863	6.8%	2,925	7.0%	-0.148	-0.006	
55-64 years	5,807	13.8%	6,460	15.4%	-1.555	-0.045	
≥65 years	31,790	75.7%	31,151	74.2%	1.522	0.038	
Sex							
Female	14,867	35.4%	15,072	35.9%	-0.488	-0.010	
Male	27,131	64.6%	26,926	64.1%	0.488	0.010	
Race							
American Indian or Alaska Native	132	0.3%	132	0.3%	0.000	0.000	
Asian	519	1.2%	536	1.3%	-0.040	-0.004	
Black or African American	5,566	13.3%	5,557	13.2%	0.021	0.001	
Native Hawaiian or Other Pacific Islander	46	0.1%	41	0.1%	0.012	0.004	
Unknown	7,029	16.7%	7,058	16.8%	-0.069	-0.003	
White	28,706	68.4%	28,674	68.3%	0.076	0.002	
Hispanic Origin	708	1.7%	843	2.0%	-0.321	-0.024	
Year							
2015	430	1.0%	378	0.9%	0.124	0.013	
2016	4,087	9.7%	4,104	9.8%	-0.040	-0.001	
2017	8,846	21.1%	8,931	21.3%	-0.202	-0.005	
2018	11,912	28.4%	11,867	28.3%	0.107	0.002	
2019	16,392	39.0%	16,366	39.0%	0.062	0.001	
2020	331	5.8%	352	6.1%	-0.367	-0.016	
		Standard		Standard			
Recorded History of:	Mean	Deviation	Mean	Deviation			
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.6	2.8	0.006	0.002	
Score <sup>3</sup>							
	Number	Percent	Number	Percent			
Ambulatory allergies or allergy treatment	20,540	48.9%	20,437	48.7%	0.245	0.005	
Ambulatory allergies or treatment and not	16,919	40.3%	16,914	40.3%	0.012	0.000	
serious allergies	,		,				
5	<b>F7</b>	57	0.1%	52		0.1% 0.010	0 003
Angioedema (-183, -1)	57	0.1%	53	0.1%	0.010	0.003	



Table 1h. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covaria	Covariate Balance		
	SV (7-d	lay gap)	ACEI (7-	day gap)				
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference		
History of Use:								
Diuretics (thiazides, potassium sparing, loop diuretics)	33,728	80.3%	33,786	80.4%	-0.138	-0.003		
Everolimus	12	0.0%	13	0.0%	-0.002	-0.001		
Nonsteroidal anti-inflammatory drugs (NSAIDs)	4,213	10.0%	4,192	10.0%	0.050	0.002		
Sirolimus	****	****	****	****	0.000	0.000		
		Standard		Standard				
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation				
Mean number of ambulatory encounters	18.2	17.0	18.2	21.5	-0.011	-0.001		
Mean number of emergency room encounters	0.6	1.3	0.6	1.1	0.002	0.002		
Mean number of inpatient hospital encounters	0.8	1.1	0.8	0.9	0.002	0.002		
Mean number of non-acute institutional encounters	0.3	0.9	0.3	0.8	-0.001	-0.002		
Mean number of other ambulatory encounters	9.2	14.1	9.2	12.8	-0.024	-0.002		
Mean number of filled prescriptions	26.5	20.5	26.7	22.3	-0.208	-0.010		
Mean number of generics	11.6	5.4	11.7	5.5	-0.035	-0.006		
Mean number of unique drug classes	11.0	4.9	11.0	4.9	0.014	0.003		

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1i. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covariate Balance		
	SV (7-c	lay gap)	ARBs (7	-day gap)			
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference	
Patients (Number)	43,777	100.0%	337,157	100.0%	-	-	
		Standard		Standard			
Demographics	Mean	Deviation	Mean	Deviation			
Mean age, years	71.5	11.9	73.8	12.0	-2.285	-0.191	
Age	Number	Percent	Number	Percent			
18-44 years	1,634	3.7%	8,500	2.5%	1.211	0.070	
45-54 years	3,068	7.0%	18,297	5.4%	1.581	0.066	
55-64 years	6,120	14.0%	40,556	12.0%	1.951	0.058	
≥65 years	32,955	75.3%	269,804	80.0%	-4.744	-0.114	
Sex							
Female	15,466	35.3%	187,905	55.7%	-20.403	-0.419	
Male	28,311	64.7%	149,252	44.3%	20.403	0.419	
Race							
American Indian or Alaska Native	143	0.3%	1,947	0.6%	-0.251	-0.037	
Asian	511	1.2%	7,817	2.3%	-1.151	-0.088	
Black or African American	5,853	13.4%	55,815	16.6%	-3.185	-0.089	
Native Hawaiian or Other Pacific Islander	46	0.1%	478	0.1%	-0.037	-0.010	
Unknown	7,289	16.7%	47,812	14.2%	2.469	0.068	
White	29,935	68.4%	223,288	66.2%	2.154	0.046	
Hispanic Origin	751	1.7%	9,038	2.7%	-0.965	-0.066	
Year							
2015	430	1.0%	32,231	9.6%	-8.577	-0.391	
2016	4,168	9.5%	70,705	21.0%	-11.450	-0.323	
2017	9,173	21.0%	73,808	21.9%	-0.937	-0.023	
2018	12,488	28.5%	81,684	24.2%	4.299	0.098	
2019	17,167	39.2%	77,624	23.0%	16.192	0.355	
2020	351	5.9%	1,105	3.2%	2.670	0.128	
		Standard		Standard			
Recorded History of:	Mean	Deviation	Mean	Deviation			
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.8	3.0	-0.171	-0.059	
Score <sup>3</sup>							
	Number	Percent	Number	Percent			
Ambulatory allergies or allergy treatment	21,349	48.8%	169,542	50.3%	-1.518	-0.030	
Ambulatory allergies or treatment and not	17,590	40.2%	134,478	39.9%	0.295	0.006	
serious allergies			,				
0							
Angioedema (-183, -1)	60	0.1%	825	0.2%	-0.108	-0.025	



Table 1i. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Unadjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covaria	Covariate Balance		
	SV (7-d	lay gap)	ARBs (7-	day gap)				
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference		
History of Use:								
Diuretics (thiazides, potassium sparing, loop diuretics)	35,208	80.4%	222,934	66.1%	14.304	0.328		
Everolimus	12	0.0%	98	0.0%	-0.002	-0.001		
Nonsteroidal anti-inflammatory drugs (NSAIDs)	4,405	10.1%	44,187	13.1%	-3.043	-0.095		
Sirolimus	****	****	142	0.0%	-0.022	-0.012		
		Standard		Standard				
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation				
Mean number of ambulatory encounters	18.2	17.1	20.4	22.5	-2.205	-0.110		
Mean number of emergency room encounters	0.7	1.4	0.8	1.7	-0.114	-0.075		
Mean number of inpatient hospital encounters	0.8	1.1	0.8	1.1	-0.047	-0.042		
Mean number of non-acute institutional encounters	0.3	0.9	0.4	1.0	-0.112	-0.116		
Mean number of other ambulatory encounters	9.2	14.0	11.7	17.4	-2.490	-0.157		
Mean number of filled prescriptions	26.6	20.7	27.8	22.3	-1.120	-0.052		
Mean number of generics	11.6	5.5	12.0	5.8	-0.342	-0.061		
Mean number of unique drug classes	11.0	4.9	11.2	5.1	-0.221	-0.044		

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 1j. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covariate Balance		
	SV (7-0	lay gap)	ARBs (7	-day gap)			
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference	
Patients (Number)	43,755	99.9%	43,755	13.0%	-	-	
		Standard		Standard			
Demographics	Mean	Deviation	Mean	Deviation			
Mean age, years	71.5	11.9	71.6	11.9	-0.033	-0.003	
Age	Number	Percent	Number	Percent			
18-44 years	1,623	3.7%	1,517	3.5%	0.242	0.013	
45-54 years	3,059	7.0%	3,067	7.0%	-0.018	-0.001	
55-64 years	6,118	14.0%	6,380	14.6%	-0.599	-0.018	
≥65 years	32,955	75.3%	32,791	74.9%	0.375	0.009	
Sex							
Female	15,466	35.3%	15,554	35.5%	-0.201	-0.004	
Male	28,289	64.7%	28,201	64.5%	0.201	0.004	
Race							
American Indian or Alaska Native	143	0.3%	155	0.4%	-0.027	-0.005	
Asian	511	1.2%	506	1.2%	0.011	0.001	
Black or African American	5,852	13.4%	5,880	13.4%	-0.064	-0.002	
Native Hawaiian or Other Pacific Islander	46	0.1%	35	0.1%	0.025	0.008	
Unknown	7,271	16.6%	7,265	16.6%	0.014	0.001	
White	29,932	68.4%	29,914	68.4%	0.041	0.001	
Hispanic Origin	751	1.7%	833	1.9%	-0.187	-0.014	
Year							
2015	430	1.0%	400	0.9%	0.069	0.007	
2016	4,168	9.5%	4,044	9.2%	0.283	0.010	
2017	9,173	21.0%	9,222	21.1%	-0.112	-0.003	
2018	12,486	28.5%	12,664	28.9%	-0.407	-0.009	
2019	17,148	39.2%	17,038	38.9%	0.251	0.005	
2020	350	5.9%	387	6.5%	-0.625	-0.026	
		Standard		Standard			
Recorded History of:	Mean	Deviation	Mean	Deviation			
Charlson/Elixhauser Combined Comorbidity	5.6	2.8	5.6	2.9	-0.030	-0.011	
Score <sup>3</sup>							
	Number	Percent	Number	Percent			
Ambulatory allergies or allergy treatment	21,340	48.8%	21,523	49.2%	-0.418	-0.008	
Ambulatory allergies or treatment and not	17,582	40.2%	17,679	40.4%	-0.222	-0.005	
serious allergies	17,502	40.270	17,075	-070	0.222	0.000	
Angioedema (-183, -1)	60	0.1%	58	0.1%	0.005	0.001	

6							
Angioedema (-183, -1)	60	0.1%	58	0.1%	0.005	0.001	
Angioedema (ever, -1)	598	1.4%	916	2.1%	-0.727	-0.056	
Diabetes	20,371	46.6%	20,282	46.4%	0.203	0.004	
Ischemic heart disease	33,103	75.7%	33,062	75.6%	0.094	0.002	
Renal disorders	19,388	44.3%	19,531	44.6%	-0.327	-0.007	
Serious allergies	5,928	13.5%	5,967	13.6%	-0.089	-0.003	



Table 1j. Cohort of New Initiators of Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 (Adjusted, Aggregated), Fixed Ratio 1:1, Caliper: 0.05

		Medical	Product		Covaria	te Balance
	SV (7-d	lay gap)	ARBs (7-	day gap)		
Characteristic <sup>1,2</sup>	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
History of Use:						
Diuretics (thiazides, potassium sparing, loop diuretics)	35,186	80.4%	35,179	80.4%	0.016	0.000
Everolimus	12	0.0%	16	0.0%	-0.009	-0.005
Nonsteroidal anti-inflammatory drugs	4,405	10.1%	4,394	10.0%	0.025	0.001
(NSAIDs) Sirolimus	* * * * *	****	****	****	0.000	0.000
		Standard		Standard		
Health Service Utilization Intensity:	Mean	Deviation	Mean	Deviation		
Mean number of ambulatory encounters	18.2	17.1	18.3	19.0	-0.087	-0.005
Mean number of emergency room encounters	0.7	1.4	0.7	1.3	0.007	0.005
Mean number of inpatient hospital encounters	0.8	1.1	0.8	1.1	-0.015	-0.014
Mean number of non-acute institutional encounters	0.3	0.9	0.3	0.9	-0.008	-0.010
Mean number of other ambulatory encounters	9.2	14.0	9.4	13.8	-0.153	-0.011
Mean number of filled prescriptions	26.6	20.7	26.2	20.5	0.441	0.021
Mean number of generics	11.6	5.5	11.7	5.5	-0.085	-0.016
Mean number of unique drug classes	11.0	4.9	11.0	4.8	-0.025	-0.005

<sup>1</sup>Covariates in italics were not included in the propensity score logistic regression model

<sup>2</sup>Covariates in blue show a standardized difference greater than 0.1

<sup>3</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 2. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analy	sis										
SV	41,998	****	****	****	****	1.33	****	Γ 4	****	0.10 (0.12 0.20)	-0.001
ACEI	695,012	****	****	****	****	6.73	****	-5.4	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.19 (0.12, 0.29)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	41,998	****	****	****	****	1.59	****	0.07	****	0.45 (0.00, 0.26)	-0.001
ACEI	41,998	****	****	****	****	10.66	****	-9.07	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.15 (0.08, 0.26)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	41,998	****	****	****	****	1.33	****	F 0.4	****	0.40 (0.44 0.20)	-0.001
ACEI	41,998	****	****	****	****	7.17	****	-5.84	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.18 (0.11, 0.29)	<0.001
Propensity Score Ad	ljusted Stratified	Analysis; I	Percentiles=	10 <sup>1</sup>							
SV	41,998	****	****	****	****	1.33	****	Γ 4	****	0.40 (0.42 0.20)	-0.001
ACEI	695,012	****	****	****	****	6.73	* * * * *	-5.4	ጥ ጥ ጥ ጥ ጥ	0.18 (0.12, 0.29)	<0.001

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 3. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Follow-up Time

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
	-					Overall					
Site-Adjusted Analysi SV (14-day gap)	s 41,998	****	****	****	****	1.33	****				
ACEI (14-day gap)	41,998 695,012	****	****	****	****	6.73	****	-5.4	****	0.19 ( 0.12, 0.29)	< 0.001
Fixed Ratio 1:1 Prope	,					0.75					
		*****		****	****	1.59	****				
SV (14-day gap) ACEI (14-day gap)	41,998 41,998	****	****	****	****	1.59	****	-9.07	****	0.15 ( 0.08, 0.26)	<0.001
Fixed Ratio 1:1 Prope	,					10.00					
SV (14-day gap)	41,998	****	****	*****	****	1.33	****				
ACEI (14-day gap)	41,998	****	****	****	****	7.17	****	-5.84	****	0.18 ( 0.11, 0.29)	<0.001
/(cli(14 ddy 5dp)	41,550				0	- 30 Days					
Site-Adjusted Analysi	s	-	-	-			-		-		-
SV (14-day gap)	41,998	****	****	****	****	0.9	****				
ACEI (14-day gap)	695,012	****	****	****	****	15.33	****	-14.43	****	0.06 ( 0.02, 0.18)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	41,998	****	****	****	****	0.94	****			/	
ACEI (14-day gap)	41,998	****	****	****	****	18.76	****	-17.83	****	0.05 ( 0.02, 0.16)	<0.001
ixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	41,998	****	****	****	****	0.9	****	47.22	****		-0.001
ACEI (14-day gap)	41,998	****	****	****	****	18.12	****	-17.22		0.05 ( 0.02, 0.16)	<0.001
					31	- 60 Days					
ite-Adjusted Analysi	S										
SV (14-day gap)	38,241	****	****	****	****	1.55	****	-4.49	****	0.26 ( 0.10, 0.69)	0.007
ACEI (14-day gap)	638,495	****	****	****	****	6.05	****	-4.43		0.20 ( 0.10, 0.09)	0.007
ixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Anal	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	34,662	****	****	****	****	1.95	****	-3.89	****	0.33 ( 0.11, 1.03)	0.057
ACEI (14-day gap)	34,662	****	****	****	****	5.84	****	-3.03		0.33 (0.11, 1.03)	0.057



Table 3. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Follow-up Time

Medical Product Fixed Ratio 1:1 Prope	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
SV (14-day gap)	38,241	****	****	****	****	1.55	****				
ACEI (14-day gap)	38,053	****	****	****	****	4.84	****	-3.29	****	0.32 (0.10, 0.98)	0.047
					61	- 90 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	25,273	****	****	****	****	2.11	****	-3.67	****	0.37 ( 0.14, 0.99)	0.047
ACEI (14-day gap)	463,109	****	****	****	****	5.78	****	-3.07		0.37 (0.14, 0.99)	0.047
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	16,757	****	****	****	****	3.4	****	-0.85	****	0.80 ( 0.21 - 2.08)	0.739
ACEI (14-day gap)	16,757	****	****	****	****	4.25	****	-0.85		0.80 (0.21, 2.98)	0.739
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	25,273	****	****	****	****	2.11	****	-3.05	****	0.41 ( 0.13, 1.29)	0.128
ACEI (14-day gap)	27,895	****	****	****	****	5.16	****	-3.05		0.41 ( 0.13, 1.29)	0.128
					91 -	- 180 Days					
Site-Adjusted Analysi											
SV (14-day gap)	20,547	****	****	****	****	1.66	****	-2.73	****	0.38 ( 0.17, 0.85)	0.019
ACEI (14-day gap)	397,838	****	****	****	****	4.39	****				
Fixed Ratio 1:1 Prope											
SV (14-day gap)	11,738	****	****	****	****	1.94	****	-5.18	****	0.27 ( 0.08, 0.98)	0.046
ACEI (14-day gap)	11,738	****	****	****	****	7.12	****	5.10		0.27 (0.00, 0.00)	0.040
Fixed Ratio 1:1 Prope	-				-						
SV (14-day gap)	20,547	****	****	****	****	1.66	****	-2.81	****	0.37 ( 0.15, 0.92)	0.033
ACEI (14-day gap)	23,945	****	****	****	****	4.47	****				
					181	- 270 Days					
Site-Adjusted Analysi		ale ale ale ale al	ale ale ale ale al	ale ale ale ale al	ate ate ate ate ate		ate ate ate ate ate				
SV (14-day gap)	11,098	****	****	****	****	0.93	****	-3.19	****	0.23 ( 0.06, 0.91)	0.037
ACEI (14-day gap)	235,612	****	****	****	****	4.12	****	-		· · · / · · · · · · · · /	



Table 3. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Follow-up Time

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	3,606	****	****	****	****	0	****	6.07	****	-	-
ACEI (14-day gap)	3,606	****	****	****	****	6.97	****	-6.97			
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	11,098	****	****	****	****	0.93	****	4.24	****	0.18 ( 0.04, 0.80)	0.024
ACEI (14-day gap)	13,550	****	****	****	****	5.28	****	-4.34			
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	6,937	****	****	****	****	0.68	****	-2.87	****	0.19 ( 0.03, 1.33)	0.094
ACEI (14-day gap)	164,817	****	****	****	****	3.54	****				
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	1,512	****	****	****	****	0	****	-7.46	****	-	-
ACEI (14-day gap)	1,512	****	****	****	****	7.46	****				
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	6,937	****	****	****	****	0.68	****	1 40	****	0.33 ( 0.04, 2.97)	0.323
ACEI (14-day gap)	8,796	****	****	****	****	2.16	****	-1.48			

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



 Table 4. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema in the Sentinel

 Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183, -1)

							-				
		Person	Average Person	Average Person	Number of	Incidence Rate per 1,000	Risk per	Incidence Rate Difference	Difference in Risk per	Hazard Ratio	Wald
	Number of										
Medical Product	New Users	Years at Risk	Days at Risk	Years at Risk	Events	Person Years	1,000 Now Usors	per 1,000 Person Years	1,000 New Users	(95% Confidence Interval)	P-Value
					Events	Tears	New Osers	Person rears	Users	liiteivaij	F-Value
No Angioedema (-18	, ,							_	_		
SV SV	41,941	****	****	****	****	1.07	****				
ACEI	41,941 694,148	****	****	****	****	6.47	****	-5.41	****	0.15 (0.09, 0.25)	<0.001
	,					0.47					
Fixed Ratio 1:1 Prop		*****		****	r= 0.05 ****		****				
SV	41,930	****	****	****	****	1.14	****	-9.43	****	0.11 (0.06, 0.21)	<0.001
ACEI	41,930					10.56	* * * *				
Fixed Ratio 1:1 Prop	-				-						
SV	41,930	****	****	****	****	1.07	****	-5.99	****	0.15 (0.09, 0.24)	<0.001
ACEI	41,930	****	****	****	****	7.06	****				
Angioedema (-183, -	-1)										
Site-Adjusted Analy	sis										
SV	57	****	****	****	****	193.8	****	-74.4	****	0.75 (0.27, 2.07)	0.584
ACEI	864	****	****	****	****	268.2	****	-74.4			
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	42	****	****	****	****	355.03	****	118.34	****	1.50 (0.25, 8.98)	0 657
ACEI	42	****	****	****	****	236.69	****				0.657
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	42	****	****	****	****	195.82	****	81.21	****	1.97 (0.33, 11.91)	0.46
ACEI	42	****	****	****	****	114.61	****				0.46

<sup>1</sup>Conditional analysis accounts for informative events and person-time.


Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
No Angioedema (-183	8, -1)										
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	41,941	****	****	****	****	1.07	****	-5.41	****		<0.001
ACEI (14-day gap)	694,148	****	****	****	****	6.47	****	-5.41		0.15 (0.09, 0.25)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	41,930	****	****	****	****	1.14	****	0.40	****		
ACEI (14-day gap)	41,930	****	****	****	****	10.56	****	-9.43	* * * * *	0.11 (0.06, 0.21)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	41,930	****	****	****	****	1.07	****	5.00	****	0.45 ( 0.00 . 0.04)	.0.004
ACEI (14-day gap)	41,930	****	****	****	****	7.06	****	-5.99	ጥ ጥ ጥ ጥ	0.15 (0.09, 0.24)	<0.001
					0 -	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	41,941	****	****	****	****	0.3	****	1110	****	0.02 ( 0.00 . 0.45)	-0.001
ACEI (14-day gap)	694,148	****	****	****	****	14.46	****	-14.16	ጥ ጥ ጥ ጥ	0.02 (0.00, 0.15)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	41,930	****	****	****	****	0.31	****	10.17	****		0.05÷
ACEI (14-day gap)	41,930	****	****	****	****	18.48	****	-18.17	<u> </u>	0.02 (0.00, 0.12)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	41,930	****	****	****	****	0.3	****	47.55	****	0.02/0.02.0.12)	.0.001
ACEI (14-day gap)	41,930	****	****	****	****	17.85	****	-17.55	* * * * *	0.02 (0.00, 0.12)	<0.001
					31	- 60 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	38,191	****	****	****	****	1.55	****	4.10	****	0.27/0.10 0.72)	
ACEI (14-day gap)	637,749	****	****	****	****	5.74	****	-4.19	-1111-	0.27 (0.10, 0.73)	0.01



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	vsis; Calipe	r= 0.05 <sup>1</sup>					-	
SV (14-day gap)	34,610	****	****	****	****	1.95	****				
ACEI (14-day gap)	34,610	****	****	****	****	5.84	****	-3.9	****	0.33 (0.11, 1.03)	0.057
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	38,182	****	****	****	****	1.55	****		****		
ACEI (14-day gap)	37,993	****	****	****	****	4.85	****	-3.3	* * * * *	0.32 (0.10, 0.98)	0.047
					61	- 90 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	25,238	****	****	****	****	1.58	****	1.0.5	****		
ACEI (14-day gap)	462,621	****	****	****	****	5.65	****	-4.06	* * * * *	0.28 (0.09, 0.88)	0.03
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	16,735	****	****	****	****	2.55	****			/	
ACEI (14-day gap)	16,735	****	****	****	****	4.25	****	-1.7	****	0.60 (0.14, 2.51)	0.484
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	25,233	****	****	****	****	1.58	****	2.50	****		
ACEI (14-day gap)	27,852	****	****	****	****	5.16	****	-3.58	* * * * *	0.31 (0.09, 1.10)	0.07
					91	- 180 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	20,519	****	****	****	****	1.39	****	2.04	****	0.00 ( 0.40 , 0.70)	0.010
ACEI (14-day gap)	397,439	****	****	****	****	4.32	****	-2.94	ጥ ጥ ጥ ጥ	0.32 (0.13, 0.78)	0.012
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	11,721	****	****	****	****	1.3	****		ale ale ale ale ale		
ACEI (14-day gap)	11,721	****	****	****	****	7.13	****	-5.84	****	0.18 (0.04, 0.82)	0.027
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	20,515	****	****	****	****	1.39	****	2.00	<u>بل</u> ە بلە بلە بلە	0.04 / 0.44 . 0.55	
ACEI (14-day gap)	23,905	* * * * *	****	****	****	4.48	****	-3.09	****	0.31 (0.11, 0.82)	0.018



	<u> </u>	1 1		1 .	<u> </u>	71	<u> </u>	<u> </u>			
						Incidence		Incidence	5.11		
		-	Average	Average		Rate per	<b>D</b> <sup>1</sup>	Rate	Difference	Hazard Ratio	
	Number of	Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	(95% Confidence	Wald
	Number of	Years	Days	Years	of Events	Person	1,000	per 1,000	1,000 New	Interval) <sup>2</sup>	P-Value
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval)	P-value
ov					181	- 270 Days					
Site-Adjusted Analysi		****	****	****	****		****				
SV (14-day gap)	11,083	****	****	****	****	0.93	****	-3.15	****	0.23 ( 0.06, 0.92)	0.038
ACEI (14-day gap)	235,412					4.08	****			. , ,	
Fixed Ratio 1:1 Prope											
SV (14-day gap)	3,599	****	****	****	****	0	****	-6.98	* * * * *	-	-
ACEI (14-day gap)	3,599	****	****	****	****	6.98	****	0.50			
Fixed Ratio 1:1 Prope	•				•						
SV (14-day gap)	11,082	****	****	****	****	0.93	****	-3.97	****	0.20 ( 0.04, 0.87)	0.032
ACEI (14-day gap)	13,529	****	****	****	****	4.91	****	-3.57		0.20 ( 0.04, 0.07)	0.032
					271	- 365 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	6,928	****	****	****	****	0.68	****	-2.78	* * * * *	0.19 ( 0.03, 1.36)	0.099
ACEI (14-day gap)	164,674	****	****	****	****	3.46	****	-2.78		0.19 ( 0.05, 1.50)	0.099
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,509	****	****	****	****	0	****	7.45	****		
ACEI (14-day gap)	1,509	****	****	****	****	7.45	****	-7.45		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Uncc	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	6,927	****	****	****	****	0.68	****		****	0.00 ( 0.04 . 0.07)	
ACEI (14-day gap)	8,783	****	****	****	****	2.17	****	-1.49	ጥ ጥ ጥ ጥ	0.33 (0.04, 2.97)	0.323
Angioedema (-183, -1	)										
					(	Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	57	****	****	****	****	193.8	****				
								-74.4	****	0.75 ( 0.27, 2.07)	0.584



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	42	****	****	****	****	355.03	****		****	4 50 ( 0 05 0 00)	0.057
ACEI (14-day gap)	42	****	****	****	****	236.69	****	118.34	ጥ ጥ ጥ ጥ ጥ	1.50 ( 0.25, 8.98)	0.657
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	42	****	****	****	****	195.82	****	01.21	****	4 07 ( 0 22 44 04)	0.40
ACEI (14-day gap)	42	****	****	****	****	114.61	****	81.21		1.97 ( 0.33, 11.91)	0.46
					0	- 30 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	453	****	****	****	****	301.66	****	4.46.72	****	0.57 ( 0.4.4 . 0.2.4)	0 422
ACEI (14-day gap)	8,744	****	****	****	****	448.39	****	-146.73		0.57 (0.14, 2.34)	0.432
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	630	****	****	****	****	40	****	•	****		
ACEI (14-day gap)	630	****	****	****	****	40	****	0	<b>ጥ ጥ ጥ ጥ</b>	1.00 ( 0.06, 15.99)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	4,023	****	****	****	****	6.84	****	4 74	****	4 0 4 ( 0 0 7 4 6 6 7 )	0.076
ACEI (14-day gap)	5,300	****	****	****	****	5.12	****	1.71	ጥ ጥ ጥ ጥ ጥ	1.04 ( 0.07, 16.67)	0.976
					31	- 60 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	50	****	****	****	****	0	****	276 46	****		
ACEI (14-day gap)	749	****	****	****	****	276.46	****	-276.46	ቁ የ የ የ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	95	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	95	****	****	****	****	0	****	0	* * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	371	****	****	****	*****	0	****		ماد ماد ماد ماد		
ACEI (14-day gap)	536	****	****	****	****	0	****	0	****	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					61	- 90 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	35	****	****	****	****	387.6	****	253.22	* * * * *	3.57 ( 0.42, 30.57)	0.245
ACEI (14-day gap)	497	****	****	****	****	134.37	****	233.22		5.57 (0.42, 50.57)	0.245
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	91	****	****	****	****	162.07	****	462.07	****		
ACEI (14-day gap)	91	****	****	****	****	0	****	162.07		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	360	****	****	****	****	34.19	****	24.40	****		
ACEI (14-day gap)	524	****	****	****	****	0	****	34.19		-	-
					91	- 180 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	28	****	****	****	****	190.84	****	447 42	****	2.02 ( 0.22.25.76)	0.225
ACEI (14-day gap)	408	****	****	****	****	73.72	****	117.12	<b>ጥ ጥ ጥ ጥ</b>	2.92 ( 0.33, 25.76)	0.335
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	70	****	****	****	****	242.13	****	242.42	****		
ACEI (14-day gap)	70	****	****	****	****	0	****	242.13	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	352	****	****	****	****	63.49	****	62.40	****		
ACEI (14-day gap)	521	****	****	****	****	0	****	63.49	<b>ጥ ጥ ጥ ጥ</b>	-	-
					181	- 270 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	18	****	****	****	****	0	****	40.22	****		
ACEI (14-day gap)	202	****	****	****	****	48.23	****	-48.23	-ተ ተ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	662.25	****		
ACEI (14-day gap)	****	****	****	****	****	662.25	****	-662.25	ዝ ዝ ጥ ጥ	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	14	****	****	****	****	0	****	200 75	****		
ACEI (14-day gap)	15	****	****	****	****	306.75	****	-306.75		-	-
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	12	****	****	****	****	0	****	04.4	* * * * *		
ACEI (14-day gap)	145	****	****	****	****	94.4	****	-94.4		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	<u> </u>	****		
ACEI (14-day gap)	****	****	****	****	****	0	****	0	ተ ተ የ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	****	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	11	****	****	****	****	0	****	0	······	-	-

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



			Average	Average		Incidence Rate per		Incidence Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Davs	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	,	Person Years	Users	Interval)	P-Value
No Angioedema (ev	er, -1)										
Site-Adjusted Analy	sis										
SV	41,427	****	****	****	****	1.01	****	4.06	****	0.46 (0.40, 0.27)	.0.004
ACEI	687,692	****	****	****	****	5.87	****	-4.86	* * * * *	0.16 (0.10, 0.27)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	41,416	****	****	****	****	1.04	****	-8.4	* * * * *	0.11/0.06 0.22)	<0.001
ACEI	41,416	****	****	****	****	9.43	****	-8.4		0.11 (0.06, 0.22)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco		nalysis; Cali	per= 0.05						
SV	41,416	****	****	****	****	1.01	****	-5.41	* * * * *	0.15 (0.09, 0.26)	<0.001
ACEI	41,416	****	****	****	****	6.43	****	-5.41		0.15 (0.09, 0.20)	<0.001
Angioedema (ever,	-1)										
Site-Adjusted Analy	sis										
SV	571	****	****	****	****	24.05	****	-73.01	* * * * *	0.24 (0.10, 0.59)	0.002
ACEI	7,320	****	****	****	****	97.06	****	-73.01		0.24 (0.10, 0.39)	0.002
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	437	****	****	****	****	47.03	****	-58.79	****	0 44 (0 14 1 44)	0.177
ACEI	437	****	****	****	****	105.82	****	-58.79		0.44 (0.14, 1.44)	0.177
Fixed Ratio 1:1 Prop	ensity Score Ma			1 .	•						
SV	437	****	****	****	****	31.92	****	-50.6	* * * * *	0.38 (0.14, 1.07)	0.067
ACEI	437	****	****	****	****	82.51	****	-20.0		0.36 (0.14, 1.07)	0.007

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
No Serious Allergies	5										
Site-Adjusted Analy	sis										
SV	36,314	****	****	****	****	1.14	****	F 22	****	0 17 (0 10 0 27)	-0.001
ACEI	584,032	****	****	****	****	6.47	****	-5.33		0.17 (0.10, 0.27)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	36,159	****	****	****	****	1.42	****	8.01	****	0.14/0.07 0.20	-0.001
ACEI	36,159	****	****	****	****	10.34	****	-8.91		0.14 (0.07, 0.26)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	36,159	****	****	****	****	1.14	****	F 77	****	0.16 (0.00 0.0.27)	-0.001
ACEI	36,159	****	****	****	****	6.92	****	-5.77		0.16 (0.09, 0.27)	<0.001
Serious Allergies											
Site-Adjusted Analy	sis										
SV	5,684	****	****	****	****	2.67	****	-5.62	****		0.000
ACEI	110,980	****	****	****	****	8.29	****	-5.02		0.31 (0.13, 0.75)	0.009
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,545	****	****	****	****	1.92	****	0.65	****	0.40 (0.04 0.02)	0.027
ACEI	5,545	****	****	****	****	10.58	****	-8.65	-14141414-	0.18 (0.04, 0.82)	0.027
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	5,545	****	****	****	****	2.73	****	6.64	****	0.20 (0.11 0.70)	0.015
ACEI	5,545	****	****	****	****	9.37	****	-6.64		0.29 (0.11, 0.79)	0.015

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



	Number of	Person Imber of Years Iw Users at Risk	Average Person Days	Average Person Years	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Rate Difference per 1,000 Person	Difference in Risk per 1,000	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Medical Product	New Users		at Risk	at Risk	Events	Years	New Users	Years	New Users	Interval)	P-value
Sex: Male	_			_	_	Overall	_	_	_		
Site-Adjusted Analysi	<u> </u>					Overall					
SV (14-Day Gap)	27,131	****	****	****	****	0.93	****				
ACEI (14-Day Gap)	353,126	****	****	****	****	5.98	****	-5.05	* * * * *	0.14 ( 0.07, 0.28)	<0.001
Fixed Ratio 1:1 Prope	-	tched Conc	litional Ana	lycic: Calina	$r = 0.05^{1}$	5.50					
SV (14-Day Gap)	26,865	****	****	*****	****	1.23	****				
ACEI (14-Day Gap)	26,865	****	****	****	****	1.25	****	-9.13	****	0.12 ( 0.05, 0.26)	<0.001
Fixed Ratio 1:1 Prope	,		nditional A			10.30					
SV (14-Day Gap)	26,865	****	*****	****	*****	0.94	****				
ACEI (14-Day Gap)	26,865	****	****	****	****	7.06	****	-6.13	* * * * *	0.13 ( 0.06, 0.25)	<0.001
ACLI (14-Day Gap)	20,805				0	- 30 Days					
Site-Adjusted Analysi	5				0	50 Days					
SV (14-Day Gap)	27,131	****	****	****	****	0.46	****				
ACEI (14-Day Gap)	353,126	****	****	****	****	14.6	****	-14.14	****	0.03 ( 0.00, 0.23)	<0.001
Fixed Ratio 1:1 Prope	,	tched Conc	litional Ana	lysis: Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	26,865	****	****	****	****	0.49	****				
ACEI (14-Day Gap)	26,865	****	****	****	****	20.97	****	-20.49	****	0.02 ( 0.00, 0.17)	<0.001
Fixed Ratio 1:1 Prope	-	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	26,865	****	****	****	****	0.47	****				
ACEI (14-Day Gap)	26,865	****	****	****	****	20.28	****	-19.81	****	0.02 ( 0.00, 0.17)	<0.001
. , 17	-				31	- 60 Days					
Site-Adjusted Analysi	s										
SV (14-Day Gap)	24,802	****	****	****	****	1.8	****	2.0	****	0.00/0.40 4.01	1) 0.052
ACEI (14-Day Gap)	325,651	****	****	****	****	5.59	****	-3.8	<u> </u>	0.32 (0.10, 1.01)	0.052



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope											
SV (14-Day Gap)	22,346	****	****	****	****	2.26	****	-1.51	****	0.60 ( 0.14, 2.51)	0.484
ACEI (14-Day Gap)	22,346	****	****	****	****	3.76	****	-1.51		0.00 ( 0.14, 2.31)	0.404
ixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-Day Gap)	24,557	****	****	****	****	1.81	****	2.24	****	0.45 (0.12, 1.72)	0.241
ACEI (14-Day Gap)	24,423	****	****	****	****	4.05	****	-2.24		0.45 (0.12, 1.72)	0.241
					61	- 90 Days					
Site-Adjusted Analysi	S										
SV (14-Day Gap)	16,352	****	****	****	****	0.81	****	2.02	****	0.47 ( 0.02 4.25)	0.000
ACEI (14-Day Gap)	236,828	****	****	****	****	4.74	****	-3.92	<b>ጥ ጥ ጥ ጥ</b>	0.17 (0.02, 1.25)	0.082
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	10,859	****	****	****	****	1.31	****				
ACEI (14-Day Gap)	10,859	****	****	****	****	5.23	****	-3.92	****	0.25 ( 0.03, 2.24)	0.215
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-Day Gap)	16,184	****	****	****	****	0.82	****				
ACEI (14-Day Gap)	18,020	****	****	****	****	6.52	****	-5.7	****	0.13 ( 0.02, 1.00)	0.05
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysi	5										
SV (14-Day Gap)	13,315	****	****	****	****	0.86	****				
ACEI (14-Day Gap)	203,967	****	****	****	****	3.5	****	-2.64	****	0.25 ( 0.06, 1.00)	0.05
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	7,652	****	****	****	****	2.01	****				
ACEI (14-Day Gap)	7,652	****	****	****	****	2.01	****	0	****	1.00 ( 0.14, 7.10)	1
Fixed Ratio 1:1 Prope	-	tched Unco	onditional A	nalysis; Cali	per= 0.05	-					
SV (14-Day Gap)	13,180	****	****	****	****	0.87	****				
ACEI (14-Day Gap)	15,521	****	****	****	****	2.92	****	-2.05	****	0.30 ( 0.06, 1.39)	0.123
	10,021					- 270 Days					



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
SV (14-Day Gap)	7,179	****	****	****	****	0.72	****	-2.68	****	0.21 ( 0.03, 1.51)	0.121
ACEI (14-Day Gap)	120,304	****	****	****	****	3.4	****	2.00		0.22 (0.00) 2.02)	0.222
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	2,354	****	****	****	****	0	****	10 56	* * * * *		
ACEI (14-Day Gap)	2,354	****	****	****	****	10.56	****	-10.56		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	7,102	****	****	****	****	0.73	****	4.40	****		0.067
ACEI (14-Day Gap)	8,784	****	****	****	****	5.21	****	-4.48	<b>ጥ ጥ ጥ ጥ</b>	0.14 (0.02, 1.14)	0.067
					271	- 365 Days					
Site-Adjusted Analysis	S										
SV (14-Day Gap)	4,493	****	****	****	****	1.06	****	4.05	****	0.05 ( 0.05	0.005
ACEI (14-Day Gap)	84,166	****	****	****	****	2.91	****	-1.85	* * * * *	0.35 (0.05, 2.52)	0.295
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	1,015	****	****	****	****	0	****		ala ala ala ala ala		
ACEI (14-Day Gap)	1,015	****	****	****	****	5.59	****	-5.59	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	4,445	****	****	****	****	1.07	****				
ACEI (14-Day Gap)	5,717	****	****	****	****	0.83	****	0.23	****	1.32 ( 0.08, 21.08)	0.845
Sex: Female											
						Overall					
Site-Adjusted Analysis	S										
SV (14-Day Gap)	14,867	****	****	****	****	2.07	****		****		0.00 <i>i</i>
ACEI (14-Day Gap)	341,886	****	****	****	****	7.52	****	-5.45	<u> </u>	0.26 (0.14, 0.47)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	14,820	****	****	****	****	1.62	****				
ACEI (14-Day Gap)	14,820	****	****	****	****	10.04	****	-8.42	****	0.16 (0.06, 0.41)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	14,820	****	****	****	****	2.07	****	-5 75	****	0 7 2 <i>(</i> 0 1 <i>1</i> 0 5 <i>1</i> )	<u>~0 001</u>



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
ACEI (14-Day Gap)	14,820	****	****	****	****	7.32	****			( - , ,	
					0	- 30 Days					
Site-Adjusted Analysis		****	****	****	****		****				
SV (14-Day Gap)	14,867	****	****	****	****	1.7	****	-14.39	* * * * *	0.11 (0.03, 0.42)	0.001
ACEI (14-Day Gap)	341,886					16.09	<u>ጥ ጥ ጥ ጥ</u>				
Fixed Ratio 1:1 Prope											
SV (14-Day Gap)	14,820	****	****	****	****	0.89	****	-14.23	* * * * *	0.06 ( 0.01, 0.44)	0.006
ACEI (14-Day Gap)	14,820	****	****	****	****	15.12	****				
Fixed Ratio 1:1 Prope	•				-						
SV (14-Day Gap)	14,820	****	****	* * * * *	****	1.71	****	-12.86	* * * * *	0.12 ( 0.03, 0.51)	0.004
ACEI (14-Day Gap)	14,820	****	****	****	****	14.57	****			0.000, 0.000,	
					31	- 60 Days					
Site-Adjusted Analysis											
SV (14-Day Gap)	13,439	****	****	****	****	1.1	****	-5.42	****	0.17 ( 0.02, 1.22)	0.078
ACEI (14-Day Gap)	312,844	****	****	****	****	6.52	****	0		0.27 (0.02) 2.22)	0.070
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	12,080	****	****	****	****	0	****	-6.99	* * * * *		
ACEI (14-Day Gap)	12,080	****	****	****	****	6.99	****	-0.99		-	-
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Unco		nalysis; Cali	per= 0.05						
SV (14-Day Gap)	13,397	****	****	****	****	1.1	****	-5.29	* * * * *	0.17 ( 0.02, 1.45)	0.106
ACEI (14-Day Gap)	13,360	****	****	****	****	6.4	****	-3.29		0.17 (0.02, 1.43)	0.100
					61	- 90 Days					
Site-Adjusted Analysis	5										
SV (14-Day Gap)	8,921	****	****	****	****	4.49	****	-2.39	****	0.65 ( 0.21, 2.03)	0.456
ACEI (14-Day Gap)	226,281	****	****	****	****	6.88	****	-2.39		0.05 ( 0.21, 2.03)	0.456
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	5,806	****	****	****	****	7.38	****	4.02	****	2.00/0.21.20.04	0.244
ACEI (14-Day Gap)	5,806	****	****	****	****	2.46	****	4.92	4.4.4.4.4.	3.00 ( 0.31, 28.84)	0.341



				, ,			•				
			Average	Average		Incidence Rate per		Rate Difference	Difference in		
		Person	Person	Person	Number	1,000	Risk per	per 1,000	Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	Person	1,000	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Years	New Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	8,894	****	****	****	****	4.5	****	1 70	****	1 60 / 0 28 10 10)	0 5 6 7
ACEI (14-Day Gap)	9,686	****	****	****	****	2.71	****	1.79		1.69 ( 0.28, 10.10)	0.567
					91	- 180 Days					
Site-Adjusted Analysis	5										
SV (14-Day Gap)	7,232	****	****	****	****	3.12	****	2.10	****		0 277
ACEI (14-Day Gap)	193,871	****	****	****	****	5.31	****	-2.19		0.58 (0.21, 1.55)	0.277
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	4,049	****	****	****	****	0	****		****		
ACEI (14-Day Gap)	4,049	****	****	****	****	12.91	****	-12.91	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	7,208	****	****	****	****	3.13	****	4.24	****	0 42 ( 0 42 4 24 )	0 4 2 4
ACEI (14-Day Gap)	8,263	****	****	****	****	7.45	****	-4.31		0.42 (0.13, 1.31)	0.134
					181	- 270 Days					
Site-Adjusted Analysis	5										
SV (14-Day Gap)	3,919	****	****	****	****	1.32	****	2.54	****	0.28 ( 0.04 . 1.07)	0 100
ACEI (14-Day Gap)	115,308	****	****	****	****	4.86	****	-3.54		0.28 (0.04, 1.97)	0.199
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	1,256	****	****	****	****	4.98	****	0	****	4 00 ( 0 00 45 00)	4
ACEI (14-Day Gap)	1,256	****	****	****	****	4.98	****	0	ጥ ጥ ጥ ጥ	1.00 ( 0.06, 15.99)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	3,911	****	****	****	****	1.32	****	-3.06	****	0.31 ( 0.03, 2.74)	0.289



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					271	- 365 Days					
Site-Adjusted Analysi	S										
SV (14-Day Gap)	2,444	****	****	****	****	0	****	4.24	****		
ACEI (14-Day Gap)	80,651	****	****	****	****	4.21	****	-4.21	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	538	****	****	****	****	0	****		****		
ACEI (14-Day Gap)	538	****	****	****	****	0	* * * * *	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-Day Gap)	2,441	****	****	****	****	0	****	1.60	****		
ACEI (14-Day Gap)	3,036	****	****	****	****	4.69	****	-4.69	<u>ጥ ጥ ች ች ች</u>	-	-

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



		•					• •				
	Number of	Person Years	Average Person Days	Average Person Years	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years		Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Age Group: 18-44 ye	ears										
Site-Adjusted Analy	sis										
SV	1,538	****	*****	****	****	1.95	****	7.0	****		0.4.42
ACEI	21,594	****	****	****	****	9.15	****	-7.2	<b>ጥ ጥ ጥ ጥ</b>	0.23 (0.03, 1.65)	0.143
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV	1,408	****	****	****	****	3.99	****	0	****	1 00 (0 00 45 00)	4
ACEI	1,408	****	****	****	****	3.99	****	0	<b>ጥ ጥ ጥ ጥ</b>	1.00 (0.06, 15.99)	1
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV	1,408	****	****	****	****	2.11	****	2.42	****		0.001
ACEI	1,408	****	****	****	****	4.24	****	-2.13		0.53 (0.05, 5.85)	0.601
Age Group: 45-54 ye	ears										
Site-Adjusted Analy	sis										
SV	2,863	****	****	****	****	1.01	****	0.27	****	0.10 (0.01 0.00)	0.02
ACEI	45,064	****	****	****	****	10.28	****	-9.27		0.10 (0.01, 0.69)	0.02
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV	2,789	****	****	****	****	0	****	20.20	****		
ACEI	2,789	****	****	****	****	20.26	****	-20.26		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV	2,789	****	****	****	****	1.04	****	11 12	****	0.00 (0.01 0.02)	0.015
ACEI	2,789	****	****	****	****	12.47	****	-11.43		0.08 (0.01, 0.62)	0.015
Age Group: 55-64 ye	ears										
Site-Adjusted Analy	sis										
SV	5,807	****	****	****	****	1.97	****	6.04	****		0.002
ACEI	97,267	****	****	****	****	8.91	****	-6.94	-1111- -1111-	0.22 (0.08, 0.59)	0.003
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Con	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV	5,692	****	****	****	****	2.64	****	-10.55	****		0.011
ACEI	5,692	****	****	****	****	13.19	****	-10.22		0.20 (0.06, 0.69)	0.011



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,692	****	****	****	****	2.01	****	7.02	****	0.21 (0.07 0.02)	0.004
ACEI	5,692	****	****	****	****	9.63	****	-7.62		0.21 (0.07, 0.62)	0.004
Age Group: ≥65 year	s										
Site-Adjusted Analys	sis										
SV	31,790	****	****	****	****	1.22	****	4.04	****	0.40 (0.44 0.22)	10,001
ACEI	531,087	****	****	****	****	6.03	****	-4.81		0.19 (0.11, 0.32)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV	31,082	****	****	****	****	1.5	****	0.00	****	0.46 (0.00, 0.20)	
ACEI	31,082	****	****	****	****	9.59	****	-8.09	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.16 (0.08, 0.30)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	31,082	****	****	****	****	1.24	****	F 4 6	****	0.40 (0.40 0.22)	-0.001
ACEI	31,082	****	****	****	****	6.4	****	-5.16	***** 0.18 (0.10, 0.33	0.18 (0.10, 0.33)	3) <0.001

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Age Group: 18-44	_	_	_	_	_	Overall	_	_	_		_
Site-Adjusted Analysi	ic .					Overall					
SV (14-day gap)	1,538	****	****	****	****	1.95	****				
ACEI (14-day gap)	21,594	****	****	****	****	9.15	****	-7.2	****	0.23 ( 0.03, 1.65)	0.143
Fixed Ratio 1:1 Prope	-	tched Conc	litional Ana	lysis: Caline	$r = 0.05^{1}$	5.15					
SV (14-day gap)	1,408	****	****	****	****	3.99	****				
ACEI (14-day gap)	1,408	****	****	****	****	3.99	****	0	****	1.00 ( 0.06, 15.99)	1
Fixed Ratio 1:1 Prope		tched Unco	onditional A	nalvsis: Cali	iper= 0.05	0.00					
SV (14-day gap)	1,408	****	****	****	****	2.11	****				
ACEI (14-day gap)	1,408	****	****	****	****	4.24	****	-2.13	****	0.53 (0.05, 5.85)	0.601
					0	- 30 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	1,538	****	****	****	****	0	****	10.00	****		
ACEI (14-day gap)	21,594	****	****	****	****	18.03	****	-18.03	-1111-	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	1,396	****	****	****	****	0	****	0.47	****		
ACEI (14-day gap)	1,396	****	****	****	****	9.47	****	-9.47		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	1,406	****	****	****	****	0	****	-9.06	****	_	_
ACEI (14-day gap)	1,469	****	****	****	****	9.06	****	-9.00			
					31	- 60 Days					
Site-Adjusted Analysi											
SV (14-day gap)	1,414	****	****	****	****	0	****	-8.33	****	-	-
ACEI (14-day gap)	20,001	****	****	****	****	8.33	****	0.00			
Fixed Ratio 1:1 Prope											
SV (14-day gap)	1,158	****	****	****	****	0	****	0	****	-	-
ACEI (14-day gap)	1,158	****	****	****	****	0	****	Ū			



	<u> </u>				1 1	11 / 0	•	•			
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
Fixed Ratio 1:1 Prope	-				•						
SV (14-day gap)	1,293	****	****	****	****	0	****	0	****	-	-
ACEI (14-day gap)	1,256	****	****	****	****	0	****	0			
					61	- 90 Days					
Site-Adjusted Analysi											
SV (14-day gap)	891	****	****	****	****	0	****	-7.41	****	-	_
ACEI (14-day gap)	12,616	****	****	****	****	7.41	****	-7.41		_	_
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	485	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	485	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	824	****	****	****	****	0	****	_	****		
ACEI (14-day gap)	817	****	****	****	****	0	****	0	* * * * *	-	-
					91 -	180 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	673	****	****	****	****	8.49	****	2.65	****		
ACEI (14-day gap)	10,173	****	****	****	****	5.84	****	2.65	* * * * *	1.82 ( 0.23, 14.38)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	294	****	****	****	****	28.34	****				
ACEI (14-day gap)	294	****	****	****	****	0	****	28.34	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	624	****	****	****	****	9.12	****	_	4.4.4.4.4		
ACEI (14-day gap)	659	****	****	****	****	8.99	****	0.13	****	1.10 ( 0.07, 17.82)	0.947
- ( / 0- / /					181	- 270 Days					
Site-Adjusted Analysi	S					1-					
	362	****	****	****	****	0	****				
SV (14-day gap)	302							-7.89	****		



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope											
SV (14-day gap)	71	****	****	****	****	0	****	0	****	_	_
ACEI (14-day gap)	71	****	****	****	****	0	****	Ũ			
Fixed Ratio 1:1 Prope	nsity Score Ma				per= 0.05						
SV (14-day gap)	338	****	****	****	****	0	****	0	* * * * *		
ACEI (14-day gap)	335	****	****	****	****	0	****	0		-	-
					271	- 365 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	214	****	****	****	****	0	****	1.20	****		
ACEI (14-day gap)	3,345	****	****	****	****	1.38	****	-1.38	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	26	****	****	****	****	0	****				
ACEI (14-day gap)	26	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	205	****	****	****	****	0	****				
ACEI (14-day gap)	202	****	****	****	****	0	****	0	****	-	-
Age Group: 45-54											
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	2,863	****	****	****	****	1.01	****		ala ala ala ala ala		
ACEI (14-day gap)	45,064	****	****	****	****	10.28	****	-9.27	****	0.10 (0.01, 0.69)	0.02
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,789	****	****	****	****	0	****				
ACEI (14-day gap)	2,789	****	****	****	****	20.26	****	-20.26	****	-	-
Fixed Ratio 1:1 Prope	<i>i</i>	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,789	****	****	****	****	1.04	****		4.4.4.1.1		_
ACEI (14-day gap)	2,789	****	****	****	****	12.47	****	-11.43	****	0.08 (0.01, 0.62)	0.015



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					0 -	- 30 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	2,863	****	****	****	****	0	****	-23.69	****		
ACEI (14-day gap)	45,064	****	****	****	****	23.69	****	-25.09		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,789	****	****	****	****	0	****	-28.18	****		
ACEI (14-day gap)	2,789	****	****	****	****	28.18	****	-28.18		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,789	****	****	****	****	0	****	27.2	****		
ACEI (14-day gap)	2,789	****	****	****	****	27.3	****	-27.3		-	-
					31	- 60 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	2,623	****	****	****	****	0	****	-9.2	****		
ACEI (14-day gap)	41,772	****	****	****	****	9.2	****	-9.2		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,337	****	****	****	****	0	****	22.42	****		
ACEI (14-day gap)	2,337	****	****	****	****	22.42	****	-22.42		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,566	****	****	****	****	0	****	22.00	****		
ACEI (14-day gap)	2,531	****	****	****	****	22.88	****	-22.88		-	-
					61	- 90 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	1,674	****	****	****	****	0	****	0.54	****		
ACEI (14-day gap)	27,866	****	****	****	****	9.51	****	-9.51		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,024	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	1,024	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b>	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma			nalysis; Cali	per= 0.05						
SV (14-day gap)	1,630	****	****	****	****	0	****	0	****	_	_
ACEI (14-day gap)	1,771	****	****	****	****	0	****	0		-	_
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	1,324	****	****	****	****	0	****	-5.25	****		_
ACEI (14-day gap)	22,994	****	****	****	****	5.25	****	-3.25		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	663	****	****	****	****	0	****	11.10	****		
ACEI (14-day gap)	663	****	****	****	****	11.49	****	-11.49		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,291	****	****	****	****	0	****	7.07	****		
ACEI (14-day gap)	1,459	****	****	****	****	7.87	****	-7.87	ጥ ጥ ጥ ጥ	-	-
					181	- 270 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	706	****	****	****	****	7.31	****	2.90	****	1 02 ( 0 22 14 20)	0 5 6 0
ACEI (14-day gap)	12,537	****	****	****	****	4.42	****	2.89		1.82 ( 0.23, 14.29)	0.569
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	194	****	****	****	****	0	****	22.02	****		
ACEI (14-day gap)	194	****	****	****	****	32.92	****	-32.92	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	691	****	****	****	****	7.46	****	1	****	1 10 / 0 07 10 00	0.000
ACEI (14-day gap)	789	****	****	****	****	6.45	****	1	·*· ·*· ·*· ·*· ·*·	1.18 ( 0.07, 19.00)	0.906
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	449	****	****	****	****	0	****	F 47	****		
ACEI (14-day gap)	8,412	****	****	****	****	5.47	****	-5.47	··· ·· ጥ ጥ	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	82	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	82	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Mat	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	444	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	514	****	****	****	****	0	****	0		-	-
Age Group: 55-64											
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	5,807	****	****	****	****	1.97	****	6.04	****	0.00 ( 0.00 0.00)	0.000
ACEI (14-day gap)	97,267	****	****	****	****	8.91	****	-6.94		0.22 ( 0.08, 0.59)	0.003
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,692	****	****	****	****	2.64	****			/	
ACEI (14-day gap)	5,692	****	****	****	****	13.19	****	-10.55	****	0.20 ( 0.06, 0.69)	0.011
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,692	****	****	****	****	2.01	****		ala ala ala ala ala		
ACEI (14-day gap)	5,692	****	****	****	****	9.63	****	-7.62	****	0.21(0.07, 0.62)	0.004
					0	- 30 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	5,807	****	****	****	****	2.18	****	45.04	****	0.40.40.00	
ACEI (14-day gap)	97,267	****	****	****	****	17.19	****	-15.01	* * * * *	0.13 ( 0.02, 0.92)	0.041
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,692	****	****	****	****	2.31	****				
ACEI (14-day gap)	5,692	****	****	****	****	23.11	****	-20.8	****	0.10 ( 0.01, 0.78)	0.028
Fixed Ratio 1:1 Prope	-	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,692	****	****	****	****	2.22	****				
	- /		****	****	****	22.27	****	-20.05	****	0.10(0.01, 0.78)	0.028



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					31	- 60 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	5,279	****	****	****	****	0	****	-7.74	* * * * *	_	_
ACEI (14-day gap)	89,870	****	****	****	****	7.74	****	-7.74		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	4,725	****	****	****	****	0	****	7.20	****		
ACEI (14-day gap)	4,725	****	****	****	****	7.29	****	-7.29		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,177	****	****	****	****	0	****	<b>F F 4</b>	****		
ACEI (14-day gap)	5,184	****	****	****	****	5.54	****	-5.54		-	-
					61	- 90 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	3,449	****	****	****	****	7.76	****	0.42	****	1 10 / 0 20 4 01	0.040
ACEI (14-day gap)	62,809	****	****	****	****	7.33	****	0.43		1.16 (0.28, 4.81)	0.843
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,151	****	****	****	****	13.46	****	6 70	****		0.574
ACEI (14-day gap)	2,151	****	****	****	****	6.73	****	6.73	ጥ ጥ ጥ ጥ	2.00 ( 0.18, 22.06)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	3,385	****	****	****	****	7.91	****	0.70	****	4.45/0.45 0.24	0.000
ACEI (14-day gap)	3,696	****	****	****	****	7.12	****	0.79		1.16 ( 0.16, 8.24)	0.882
					<b>91</b> ·	180 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	2,776	****	****	****	****	2.07	****	4.22	****		0.270
ACEI (14-day gap)	52,867	****	****	****	****	6.39	****	-4.32	ቁ ቁ ጥ ጥ	0.33 ( 0.05, 2.42)	0.278
ixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,452	****	****	****	****	0	****	40.65	****		
ACEI (14-day gap)	1,452	****	****	****	****	10.65	****	-10.65	<u>ት</u> ት ት ት	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	-				•						
SV (14-day gap)	2,728	****	****	****	****	2.11	****	-3.39	****	0.39 ( 0.04, 3.81)	0.422
ACEI (14-day gap)	3,127	****	****	****	****	5.5	****	5.55		0.00 ( 0.04, 0.01)	0.422
					181	- 270 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	1,462	****	****	****	****	0	****	-6.55	* * * * *	_	_
ACEI (14-day gap)	29,794	****	****	****	****	6.55	****	-0.55		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	414	****	****	****	****	0	****		****		
ACEI (14-day gap)	414	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,431	****	****	****	****	0	****	0.40	****		
ACEI (14-day gap)	1,689	****	****	****	****	9.19	****	-9.19	* * * * *	-	-
					271	- 365 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	919	****	****	****	****	0	****		****		
ACEI (14-day gap)	20,223	****	****	****	****	6.32	****	-6.32	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	173	****	****	****	****	0	****				
ACEI (14-day gap)	173	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	898	****	****	****	****	0	****		****		
ACEI (14-day gap)	1,058	****	****	****	****	4.57	****	-4.57	* * * *	-	-
Age Group: 65+											
						Overall					
Site-Adjusted Analysis	S										
SV (14-day gap)	31,790	****	****	****	****	1.22	****	4.04	****	0.40/0.44_0.22	-0.001
ACEI (14-day gap)	531,087	****	****	****	****	6.03	****	-4.81	* * * * *	0.19(0.11, 0.32)	<0.001



	Number of	Person Years	Average Person Days	Average Person Years	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	31,082	****	****	****	****	1.5	****	0.00	****		.0.004
ACEI (14-day gap)	31,082	****	****	****	****	9.59	****	-8.09	ጥ ጥ ጥ ጥ	0.16 (0.08, 0.30)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	31,082	****	****	****	****	1.24	****	F 4.C	****	0.40 ( 0.40 . 0.22)	-0.001
ACEI (14-day gap)	31,082	****	****	****	****	6.4	****	-5.16		0.18 (0.10, 0.33)	<0.001
					0	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	31,790	****	****	****	****	0.79	****	12.20	****	0.06 ( 0.01 0.02)	.0.004
ACEI (14-day gap)	531,087	****	****	****	****	14.17	****	-13.38	ጥ ጥ ጥ ጥ	0.06 (0.01, 0.22)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	30,993	****	****	****	****	0.84	****	16 47	****	0.05 ( 0.01 . 0.20)	.0.004
ACEI (14-day gap)	30,993	****	****	****	****	17.32	****	-16.47	ጥ ጥ ጥ ጥ	0.05 (0.01, 0.20)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	31,034	****	****	****	****	0.81	****	45.00	****	0.05 ( 0.01 . 0.20)	-0.001
ACEI (14-day gap)	31,041	****	****	****	****	16.73	****	-15.92		0.05 (0.01, 0.20)	<0.001
					31	- 60 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	28,925	****	****	****	****	2.04	****	2.25	****	0.20 ( 0.14, 1.02)	0.055
ACEI (14-day gap)	486,852	****	****	****	****	5.4	****	-3.35		0.38 (0.14, 1.02)	0.055
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	25,639	****	****	****	****	2.6	****	4.05	****	0.57 ( 0.47 ( 0.5)	0.070
ACEI (14-day gap)	25,639	****	****	****	****	4.56	****	-1.95	<u> </u>	0.57 (0.17, 1.95)	0.372
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	28,289	****	****	****	****	2.09	****		****	0.00/0.47 0.01	0.444
ACEI (14-day gap)	28,148	****	****	****	****	3.5	****	-1.41	<u>ት ት ት ት</u>	0.60 ( 0.17, 2.04)	0.411



Nedical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					61	- 90 Days					
Site-Adjusted Analysi		****	****	****	ale ale ale ale ale		****				
SV (14-day gap)	19,259				****	1.38		-3.79	****	0.27 (0.07, 1.08)	0.064
ACEI (14-day gap)	359,818	****	****	****	****	5.17	****			- (,,	
Fixed Ratio 1:1 Prope											
SV (14-day gap)	12,705	****	****	****	****	2.23	****	-2.23	****	0.50 ( 0.09, 2.73)	0.423
ACEI (14-day gap)	12,705	****	****	****	****	4.45	****	2.25		0.50 ( 0.05, 2.75)	0.425
Fixed Ratio 1:1 Prope	nsity Score Ma			1 .	•						
SV (14-day gap)	18,847	****	****	****	****	1.41	* * * * *	-4.18	****	0.25 ( 0.05, 1.16)	0.077
ACEI (14-day gap)	20,968	****	****	****	****	5.59	****	-4.10		0.25 (0.05, 1.10)	0.077
					<b>91</b> ·	180 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	15,774	****	****	****	****	1.44	****	2.54	****	0.07/0.11 0.00)	0.047
ACEI (14-day gap)	311,804	****	****	****	****	3.96	****	-2.51		0.37 (0.14, 0.99)	0.047
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	9,047	****	****	****	****	1.66	****		****		
ACEI (14-day gap)	9,047	****	****	****	****	6.66	****	-4.99	* * * * *	0.25 (0.05, 1.18)	0.08
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	15,448	****	****	****	****	1.47	****		ala ala ala ala ala		
ACEI (14-day gap)	18,166	****	****	****	****	3.7	****	-2.23	****	0.40 (0.13, 1.23)	0.108
					181	- 270 Days					
Site-Adjusted Analysi	s					-					
SV (14-day gap)	8,568	****	****	****	****	0.6	****	_	4.4.4.1.1		_
ACEI (14-day gap)	188,096	****	****	****	****	3.62	****	-3.02	****	0.17 (0.02, 1.20)	0.075
Fixed Ratio 1:1 Prope	,	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,837	****	****	****	****	0	****				
ACEI (14-day gap)	2,837	****	****	****	****	6.61	****	-6.61	****	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	8,387	****	****	****	****	0.62	****	4.25	****	0.12 ( 0.02 . 0.00)	0.040
ACEI (14-day gap)	10,439	****	****	****	****	4.87	****	-4.25		0.13 ( 0.02, 0.99)	0.049
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	5,355	****	****	****	****	0.87	****	2.10	****	0.20 ( 0.04 . 2.05 )	0 212
ACEI (14-day gap)	132,840	****	****	****	****	3.06	****	-2.19		0.29 ( 0.04, 2.05)	0.212
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,212	****	****	****	****	0	****	4.50	****		
ACEI (14-day gap)	1,212	****	****	****	****	4.52	****	-4.52	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	5,241	****	****	****	****	0.89	****	1 1 0	****	0.42 ( 0.04 .4.45)	0.467
ACEI (14-day gap)	6,850	****	****	****	****	2.08	****	-1.18	<u>ጉ</u> ጉጥጥጥ	***** 0.43 (0.04, 4.15)	0.467

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Race: Unknown											
Site-Adjusted Analy	sis										
SV	7,029	****	****	****	****	0.77	****	-6	* * * * *	0.11 (0.03, 0.44)	0.002
ACEI	99,645	****	****	****	****	6.76	****	-0		0.11 (0.03, 0.44)	0.002
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	6,992	****	****	****	****	0	****	-8.33	* * * * *		
ACEI	6,992	****	****	****	****	8.33	****	-8.33		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	6,992	****	****	****	****	0.77	****	C 49	****	0 11 (0 02 0 47)	0.002
ACEI	6,992	****	****	****	****	7.25	****	-6.48		0.11 (0.03, 0.47)	0.003
Race: American Indi	ian										
Site-Adjusted Analy	sis										
SV	132	****	****	****	****	0	****	2.20	****		
ACEI	4,529	****	****	****	****	2.38	****	-2.38		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	123	****	****	****	****	0	****	0	****		
ACEI	123	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	123	****	****	****	****	0	****	0	****		
ACEI	123	****	****	****	****	0	****	0		-	-
Race: Asian											
Site-Adjusted Analy	sis										
SV	519	****	****	****	****	0	****	2.62	****		
ACEI	7,874	****	****	****	****	2.63	****	-2.63	-11111-	-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	495	****	****	****	****	0	****	10.40	****		
ACEI	495	****	****	****	****	10.49	* * * * *	-10.49	ጥ ጥ ጥ ጥ	-	-



	· · /			1 1	, ,						
	Number of edical Product New Users	Person Person Years Days	n Person Numl s Years of	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald	
Medical Product	New Users		at Risk	at Risk	Events	Years		Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	495	****	****	****	****	0	****	5.6	****		
ACEI	495	****	****	****	****	5.6	****	-5.6		-	-
Race: Black											
Site-Adjusted Analy	sis										
SV	5,566	****	****	****	****	4.18	****	-18.39	****	0.17 (0.08, 0.36)	<0.001
ACEI	92,129	****	****	****	****	22.57	****	-18.59		0.17 (0.08, 0.50)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,479	****	****	****	****	4.08	****	-30.58	****	0.12 (0.04, 0.33)	<0.001
ACEI	5,479	****	****	****	****	34.66	****	-50.56		0.12 (0.04, 0.55)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,479	****	****	****	****	4.25	****	-20.53	****	0.16 (0.07, 0.36)	<0.001
ACEI	5,479	****	****	****	****	24.79	****	-20.55		0.10 (0.07, 0.30)	<0.001
Race: Pacific Islande	er										
Site-Adjusted Analy	sis										
SV	46	****	****	****	****	0	****	-14.36	* * * * *	_	_
ACEI	741	****	****	****	****	14.36	****	-14.50			_
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	39	****	****	****	****	0	****	0	* * * * *		
ACEI	39	****	****	****	****	0	****	0		-	_
Fixed Ratio 1:1 Prop	ensity Score Ma				-						
SV	39	****	****	****	****	0	****	0	* * * * *	_	_
ACEI	39	****	****	****	****	0	****			-	_
Race: White											
Site-Adjusted Analy											
SV	28,706	****	****	****	****	1.05	****	-3.29	****	0.23 (0.13, 0.41)	) <0.001
ACEI	490,094	****	****	****	****	4.34	****	5.25		0.20 (0.10, 0.41)	-0.001



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	28,638	****	****	****	****	1.43	****	4.04	****	0.22 (0.11 0.40)	(0.001
ACEI	28,638	****	****	****	****	6.37	****	-4.94		0.23 (0.11, 0.46)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	28,638	****	****	****	****	1.05	****	2.20	****	*** 0.23 (0.12, 0.44)	-0.001
ACEI	28,638	****	****	****	****	4.33	****	-3.28	****		<0.001

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Medical Product Race: Unknown	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Race: Unknown											
						Overall					
Site-Adjusted Analysi	is										
SV (14-day gap)	7,029	****	****	****	****	0.77	****	-6	****	0.11 ( 0.02 . 0.44)	0.002
ACEI (14-day gap)	99,645	****	****	****	****	6.76	****	-0		0.11(0.03, 0.44)	0.002
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	6,992	****	****	****	****	0	****	0.00	****		
ACEI (14-day gap)	6,992	****	****	****	****	8.33	****	-8.33	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	6,992	****	****	****	****	0.77	****	C 49	****	0.11 ( 0.02 0.47)	0.000
ACEI (14-day gap)	6,992	****	****	****	****	7.25	****	-6.48		0.11(0.03, 0.47)	0.003
					0	- 30 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	7,029	****	****	****	****	0	****	15.00	****		
ACEI (14-day gap)	99,645	****	****	****	****	15.99	****	-15.99		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	6,992	****	****	****	****	0	****	20.00	****		
ACEI (14-day gap)	6,992	****	****	****	****	20.99	****	-20.99	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	6,992	****	****	****	****	0	****	20.15	****		
ACEI (14-day gap)	6,992	****	****	****	****	20.15	****	-20.15	-8888-	-	-
					31	- 60 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	6,335	****	****	****	****	0	****	-5.05	****		
ACEI (14-day gap)	91,186	****	****	****	****	5.05	****	-5.05		-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,635	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	5,635	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	6,307	****	****	****	****	0	****	2.24	****		
ACEI (14-day gap)	6,232	****	****	****	****	2.31	****	-2.31		-	-
					61	- 90 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	4,314	****	****	****	****	3.09	****	2.22	****	0.50 ( 0.00 ( 0.27)	0.000
ACEI (14-day gap)	64,654	****	****	****	****	5.32	****	-2.23	ጥ ጥ ጥ ጥ	0.59 (0.08, 4.37)	0.608
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,742	****	****	****	****	0	****	_	****		
ACEI (14-day gap)	2,742	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	4,296	****	****	****	****	3.1	****	0.44	****		0.067
ACEI (14-day gap)	4,422	****	****	****	****	3	****	0.11	* * * * *	1.06 ( 0.07, 16.95)	0.967
					91	- 180 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	3,500	****	****	****	****	1.57	****	2.02	****		0.0
ACEI (14-day gap)	53,831	****	****	****	****	4.5	****	-2.93	ጥ ጥ ጥ ጥ	0.35 (0.05, 2.55)	0.3
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,845	****	****	****	****	0	****		ale ale ale ale ale		
ACEI (14-day gap)	1,845	****	****	****	****	3.91	****	-3.91	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	3,487	****	****	****	****	1.57	****				
ACEI (14-day gap)	3,656	****	****	****	****	6.09	****	-4.51	****	0.26 ( 0.03, 2.32)	0.227



Nedical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					181	- 270 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	1,996	****	****	****	****	0	****	-3.81	****		
ACEI (14-day gap)	31,204	****	****	****	****	3.81	****	-3.81		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	584	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	584	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,990	****	****	****	****	0	****	F 10	****		
ACEI (14-day gap)	2,022	****	****	****	****	5.12	****	-5.12		-	-
					271	- 365 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	1,269	****	****	****	****	0	****	-3.8	****		
ACEI (14-day gap)	21,471	****	****	****	****	3.8	****	-3.0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	253	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	253	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,264	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	1,259	****	****	****	****	0	****	0		-	-
Race: American India	n										
						Overall					
Site-Adjusted Analysi	is										
SV (14-day gap)	132	****	****	****	****	0	****	-2.38	****	_	
ACEI (14-day gap)	4,529	****	****	****	****	2.38	****	-2.50		-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis: Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	123	****	****	****	****	0	****				
ACEI (14-day gap)	123	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	123	****	****	****	****	0	****		di di di di di		
ACEI (14-day gap)	123	****	****	****	****	0	****	0	****	-	-
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					0	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	192	****	****	****	****	0	****				
ACEI (14-day gap)	5,667	****	****	****	****	5.35	****	-5.35	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	125	****	****	****	****	0	****				
ACEI (14-day gap)	125	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	193	****	****	****	****	0	****	<u> </u>	****		
ACEI (14-day gap)	214	****	****	****	****	0	****	0	* * * * *	-	-
					31	- 60 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	117	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	4,188	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	101	****	****	****	****	0	****		****		
ACEI (14-day gap)	101	****	****	****	****	0	****	0	<u> </u>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	179	****	****	****	****	0	****		****		
ACEI (14-day gap)	204	****	****	****	****	0	****	0	* * * * *	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					61	- 90 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	73	****	****	****	****	0	****	0	* * * * *	_	_
ACEI (14-day gap)	2,743	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	49	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	49	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	72	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	79	****	****	****	****	0	****	0		-	-
					91 -	180 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	59	****	****	****	****	0	****	F	****		
ACEI (14-day gap)	2,256	****	****	****	****	5	****	-5		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	33	****	****	****	****	0	****		****		
ACEI (14-day gap)	33	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	59	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	65	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-
					181	- 270 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	30	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	1,258	****	****	****	****	0	****	0	· · · · · · · · · · · · · · · · · · ·	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	****	****	****	****	****	0	****	0		-	-



	· /					11 1					
			Average	Average		Incidence Rate per		Incidence Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	31	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	37	****	****	****	****	0	****	U		-	-
					271	- 365 Days					
Site-Adjusted Analysi	is										
SV (14-day gap)	17	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	838	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	â	****		
ACEI (14-day gap)	****	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	18	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	25	****	****	****	****	0	****	0		-	-
Race: Asian											
						Overall					
Site-Adjusted Analysi	is										
SV (14-day gap)	519	****	****	****	****	0	****	2.62	****		
ACEI (14-day gap)	7,874	****	****	****	****	2.63	****	-2.63		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	495	****	****	****	****	0	****	10.40	****		
ACEI (14-day gap)	495	****	****	****	****	10.49	****	-10.49	ጥ ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	495	****	****	****	****	0	****	5.6	****		
ACEI (14-day gap)	495	****	****	****	****	5.6	****	-5.6	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-


Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					0 -	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	519	****	****	****	****	0	****	-4.83	* * * * *		
ACEI (14-day gap)	7,874	****	****	****	****	4.83	****	-4.05		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	479	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	479	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	488	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	485	****	****	****	****	0	****	0		-	-
					31	- 60 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	479	****	****	****	****	0	****	6.01	****		
ACEI (14-day gap)	7,151	****	****	****	****	6.01	****	-6.01	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	417	****	****	****	****	0	****	26 70	****		
ACEI (14-day gap)	417	****	****	****	****	36.79	****	-36.79	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	458	****	****	****	****	0	****	20.02	****		
ACEI (14-day gap)	449	****	****	****	****	30.83	****	-30.83		-	-
					61	- 90 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	326	****	****	****	****	0	****		****		
ACEI (14-day gap)	5,094	****	****	****	****	5.15	****	-5.15	-8191919-	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	217	****	****	****	****	0	****	6	****		
ACEI (14-day gap)	217	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-



	. ,	1		1 .	, ,	<i>// /</i>		•			
		Person	Average Person	Average Person	Number	Incidence Rate per 1,000	Risk per	Incidence Rate Difference	Difference in Risk per	Hazard Ratio (95% Confidence	Wald
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	•	
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope				-	-						
SV (14-day gap)	320	****	****	****	****	0	****	0	****	_	_
ACEI (14-day gap)	327	****	****	****	****	0	****	0			
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysi											
SV (14-day gap)	249	****	****	****	****	0	****	0	****	_	_
ACEI (14-day gap)	4,335	****	****	****	****	0	****	0		-	
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	125	****	****	****	****	0	****		****		
ACEI (14-day gap)	125	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	240	****	****	****	****	0	****		****		
ACEI (14-day gap)	261	****	****	****	****	0	****	0	* * * * *	-	-
					181	- 270 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	131	****	****	****	****	0	****	_	****		
ACEI (14-day gap)	2,369	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	31	****	****	****	****	0	****				
ACEI (14-day gap)	31	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope		tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	127	****	****	****	****	0	****	_	d d d d d		
ACEI (14-day gap)	130	****	****	****	****	0	****	0	****	-	-
					271	- 365 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	82	****	****	****	****	0	****				
						-		0	****		



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope											
SV (14-day gap)	12	*****	****	*****	****	0	****				
ACEI (14-day gap)	12	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope		tched Unco	onditional A	nalysis; Cali	per= 0.05	-					
SV (14-day gap)	82	****	****	****	****	0	****				
ACEI (14-day gap)	88	****	****	****	****	0	****	0	****	-	-
Race: Black											
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	5,566	****	****	****	****	4.18	****	40.00	****	0.47 ( 0.00 . 0.00)	.0.001
ACEI (14-day gap)	92,129	****	****	****	****	22.57	****	-18.39	* * * * *	0.17 (0.08, 0.36)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,479	****	****	****	****	4.08	****	20.50	****		0.004
ACEI (14-day gap)	5,479	****	****	****	****	34.66	****	-30.58	* * * * *	0.12 (0.04, 0.33)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,479	****	****	****	****	4.25	****	20.52	****	0.46 ( 0.07, 0.26)	-0.001
ACEI (14-day gap)	5,479	****	****	****	****	24.79	****	-20.53		0.16 ( 0.07, 0.36)	<0.001
					0	- 30 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	5,566	****	****	****	****	2.27	****	-46.47	****	0.05 ( 0.01, 0.33)	0.002
ACEI (14-day gap)	92,129	****	****	****	****	48.74	****	-40.47		0.05 (0.01, 0.33)	0.002
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,479	****	****	****	****	2.39	****	F0 70	****	0.04/0.04 0.20	0.004
ACEI (14-day gap)	5,479	****	****	****	****	62.18	****	-59.79	··· ·· ጥ ጥ	0.04 (0.01, 0.28)	0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,479	****	****	****	****	2.3	****	F7 76	****	0.04/0.01 0.28	0.001
ACEI (14-day gap)	5,479	****	****	****	****	60.06	****	-57.76	1911 1911 1917 1917 1917	0.04 (0.01, 0.28)	0.001



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					31	- 60 Days					
Site-Adjusted Analysi		****	****	****	****	2.00	****				
SV (14-day gap)	5,059	****	****	****	****	3.08	****	-14.89	* * * * *	0.17 ( 0.02, 1.21)	0.076
ACEI (14-day gap)	84,701					17.97	* * * * *			,	
Fixed Ratio 1:1 Prope											
SV (14-day gap)	4,542	****	****	****	****	3.95	****	-15.82	****	0.20(0.02, 1.71)	0.142
ACEI (14-day gap)	4,542	****	****	****	****	19.77	****	10.02		0.20 ( 0.02, 1.71)	0.1.12
Fixed Ratio 1:1 Prope	•			1 .	•						
SV (14-day gap)	4,982	****	****	****	****	3.13	****	-11.52	****	0.22 ( 0.03, 1.85)	0.161
ACEI (14-day gap)	4,995	****	****	****	****	14.65	****	-11.52		0.22 ( 0.03, 1.85)	0.101
					61	- 90 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	2,977	****	****	****	****	4.58	****	1.4.1	****		0.167
ACEI (14-day gap)	56,538	****	****	****	****	18.67	****	-14.1		0.25 (0.03, 1.79)	0.167
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,834	****	****	****	****	0	****		****		
ACEI (14-day gap)	1,834	****	****	****	****	15.97	****	-15.97	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,927	****	****	****	****	4.66	****			/	
ACEI (14-day gap)	3,425	****	****	****	****	11.5	****	-6.85	****	0.40 ( 0.04, 3.85)	0.428
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysi	S					-					
SV (14-day gap)	2,268	****	****	****	****	5.54	****				
ACEI (14-day gap)	47,224	****	****	****	****	14.6	****	-9.05	****	0.38 (0.09, 1.54)	0.176
ixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,181	****	****	****	****	7.74	****	_	di di di di di		
ACEI (14-day gap)	1,181	****	****	****	****	7.74	****	0	****	1.00 ( 0.06, 15.99)	1



								-			
			Average	Average		Incidence Rate per		Incidence Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,231	****	****	****	****	5.64	****	11 12	****		0.10
ACEI (14-day gap)	2,902	****	****	****	****	17.06	****	-11.42		0.33 (0.07, 1.55)	0.16
					181	- 270 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	1,029	****	****	****	****	10.3	****	4.05	****	0.02 ( 0.20 . 2.44)	0 700
ACEI (14-day gap)	24,192	****	****	****	****	12.15	****	-1.85		0.83 (0.20, 3.41)	0.799
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	253	****	****	****	****	25.37	****		****		
ACEI (14-day gap)	253	****	****	****	****	0	****	25.37	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,012	****	****	****	****	10.47	****	0.6	****	0.54 ( 0.40, 0.70)	0.455
ACEI (14-day gap)	1,401	****	****	****	****	19.06	****	-8.6	ጥ ጥ ጥ ጥ	0.54 (0.10, 2.76)	0.455
					271	- 365 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	631	****	****	****	****	0	****	11 50	****		
ACEI (14-day gap)	15,675	****	****	****	****	11.59	****	-11.59		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	106	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	106	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	623	****	****	****	****	0	****	-5.85	****		
Sv (14-uay gap)											



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Race: Pacific Islander											
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	46	****	****	****	****	0	****	-14.36	* * * * *	_	_
ACEI (14-day gap)	741	****	****	****	****	14.36	****	-14.50		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	39	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	39	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	39	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	39	****	****	****	****	0	****	0		-	-
					0	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	66	****	****	****	****	0	****	-33.11	****		
ACEI (14-day gap)	1,001	****	****	****	****	33.11	****	-33.11		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	39	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	39	****	****	****	****	0	****	0	"" "" ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	63	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	106	****	****	****	****	0	****	0	-8191919-	-	-
					31	- 60 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	43	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	652	****	****	****	****	0	****	U		-	-



						Incidence		Incidence			
			Average	Average		Rate per		Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	32	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	32	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	37	****	****	****	****	0	****	0	* * * * *		
ACEI (14-day gap)	32	****	****	****	****	0	****	0		-	-
					61	- 90 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	28	****	****	****	****	0	****	-26.53	* * * * *		
ACEI (14-day gap)	490	****	****	****	****	26.53	****	-20.53		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	17	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	17	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	25	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	27	****	****	****	****	0	****	0		-	-
					91	- 180 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	24	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	424	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	11	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	11	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	21	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	21	****	****	****	****	0	****	0	<u> </u>	-	-



	· /										
						Incidence		Incidence			
			Average	Average		Rate per		Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value
					181	- 270 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	14	****	****	****	****	0	****	-24.49	* * * * *	_	_
ACEI (14-day gap)	208	****	****	****	****	24.49	****	-24.49		-	_
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	****	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	12	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	****	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	****	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	138	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	****	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	****	****	****	****	****	0	****	0	****		
ACEI (14-day gap)	****	****	****	****	****	0	****	0		-	-
Race: White											
						Overall					
Site-Adjusted Analysi	S										
	28,706	****	****	****	****	1.05	****				
SV (14-day gap)	28,700					1.05		-3.29	****	0.23 (0.13, 0.41)	< 0.001



	· /	1 1		1 ,	, ,	71 7		•			
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis: Caline	or= 0.05 <sup>1</sup>					•	
SV (14-day gap)	28,638	****	****	****	****	1.43	****				
ACEI (14-day gap)	28,638	****	****	****	****	6.37	****	-4.94	****	0.23 (0.11, 0.46)	<0.001
Fixed Ratio 1:1 Prope	-	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	28,638	****	****	****	****	1.05	****				
ACEI (14-day gap)	28,638	****	****	****	****	4.33	****	-3.28	****	0.23 (0.12, 0.44)	<0.001
, , , , , , , , , , , , , , , , , , , ,	,				0	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	28,706	****	****	****	****	0.88	****		****		
ACEI (14-day gap)	490,094	****	****	****	****	9.15	****	-8.27	* * * * *	0.10 ( 0.02, 0.39)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	28,638	****	****	****	****	0.91	****		****		
ACEI (14-day gap)	28,638	****	****	****	****	10.05	****	-9.14	* * * * *	0.09 (0.02, 0.39)	0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	28,638	****	****	****	****	0.88	****	0.04	****	0.00 ( 0.02 . 0.20)	0.001
ACEI (14-day gap)	28,638	****	****	****	****	9.72	****	-8.84		0.09 ( 0.02, 0.39)	0.001
					31	- 60 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	26,209	****	****	****	****	1.69	****	-2.48	****	0.41 ( 0.13, 1.28)	0.125
ACEI (14-day gap)	450,620	****	****	****	****	4.16	****	-2.48		0.41 (0.13, 1.28)	0.125
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	23,776	****	****	****	****	2.1	****	1.4	****	0.60 ( 0.14 - 0.54)	0.494
ACEI (14-day gap)	23,776	****	****	****	****	3.5	****	-1.4		0.60 ( 0.14, 2.51)	0.484
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	26,150	****	****	****	****	1.69	****	-1.54	****	0.52 ( 0.13, 2.08)	0.357
ACEI (14-day gap)	26,026	****	****	****	****	3.24	****	-1.34		0.52 (0.15, 2.08)	0.557
ACEI (14-day gap)	26,026	* * * * *	* * * * *	* * * * *	* * * * *	3.24	* * * * *				



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					61	- 90 Days					
Site-Adjusted Analysi											
SV (14-day gap)	17,556	****	****	****	****	1.51	****	-2.23	* * * * *	0.40 ( 0.10, 1.63)	0.203
ACEI (14-day gap)	333,594	****	****	****	****	3.74	****				
Fixed Ratio 1:1 Prope		tched Conc		lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	11,888	****	****	****	****	2.37	****	0	****	1.00 ( 0.14, 7.10)	1
ACEI (14-day gap)	11,888	****	****	****	****	2.37	****	0		1.00 ( 0.14, 7.10)	-
Fixed Ratio 1:1 Prope	nsity Score Ma				iper= 0.05						
SV (14-day gap)	17,513	****	****	****	****	1.51	****	-3.16	* * * * *	0.32 ( 0.07, 1.54)	0.156
ACEI (14-day gap)	19,475	****	****	****	****	4.68	****	-5.10		0.32 (0.07, 1.34)	0.150
					91 -	- 180 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	14,448	****	****	****	****	1.18	****	1 75	****	0 41 / 0 12 1 27)	0 1 2 1
ACEI (14-day gap)	289,770	****	****	****	****	2.92	****	-1.75		0.41(0.13, 1.27)	0.121
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	8,587	****	****	****	****	1.74	****		****		0.440
ACEI (14-day gap)	8,587	****	****	****	****	6.08	****	-4.34	* * * * *	0.29 (0.06, 1.38)	0.118
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	14,411	****	****	****	****	1.18	****	4.42	****	0.54 / 0.42 / 0.0	0.001
ACEI (14-day gap)	16,921	****	****	****	****	2.3	****	-1.12	ጥ ጥ ጥ ጥ ጥ	0.51(0.13, 1.96)	0.324
					181	- 270 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	7,898	****	****	****	****	0	****	2.4.2	****		
ACEI (14-day gap)	176,393	****	****	****	****	3.19	****	-3.19	<u> </u>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,800	****	****	****	****	0	****	6.60	<b></b>		
ACEI (14-day gap)	2,800	****	****	****	****	6.69	****	-6.69	****	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	7,872	****	****	****	****	0	****	2 5 9	****		
ACEI (14-day gap)	9,890	****	****	****	****	3.58	****	-3.58		-	-
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	4,930	****	****	****	****	0.96	****	1.64	****		0 221
ACEI (14-day gap)	125,154	****	****	****	****	2.59	****	-1.64		0.37 (0.05, 2.65)	0.321
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,178	****	****	****	****	0	****	4.62	****		
ACEI (14-day gap)	1,178	****	****	****	****	4.62	****	-4.62	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	4,916	****	****	****	****	0.96	****	1.2	****		0.470
ACEI (14-day gap)	6,552	****	****	****	****	2.16	****	-1.2	an an stranger and	**** 0.44 (0.05, 4.25)	0.479

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analy	sis										
SV	43,777	****	****	****	****	1.35	****	4.67	****	0.40.(0.07.0.05)	.0.004
ARBs	337,157	****	****	****	****	3.01	****	-1.67	ጥ ጥ ጥ ጥ	0.42 (0.27, 0.65)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	43,755	****	****	****	****	1.36	****	0.04	****	0.62 (0.24 . 4.24)	0.474
ARBs	43,755	****	****	****	****	2.2	****	-0.84		0.62 (0.31, 1.24)	0.174
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	43,755	****	****	****	****	1.35	****	0.07	****	0.50 (0.25 4.04)	0.050
ARBs	43,755	****	****	****	****	2.21	****	-0.87		0.59 (0.35, 1.01)	0.053
Propensity Score Ad	ljusted Stratified	Analysis; I	Percentiles=	10 <sup>1</sup>							
SV	43,777	****	****	****	****	1.35	****	4.67	****	0.50 (0.22, 0.70)	0.002
ARBs	337,157	****	****	****	****	3.01	****	-1.67	ጥ ጥ <b>ጥ ጥ</b> ጥ	** 0.50 (0.32, 0.79)	) 0.003

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
						Overall					
Site-Adjusted Analys	is										
SV (14-day gap)	43,777	****	****	****	****	1.35	****	-1.67	****	0.42 ( 0.27, 0.65)	<0.001
ARBs (14-day gap)	337,157	****	****	****	****	3.01	****	-1.07		0.42 (0.27, 0.65)	<0.001
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	43,755	****	****	****	****	1.36	****	0.04	****	0.62 ( 0.21 . 1.24)	0 174
ARBs (14-day gap)	43,755	****	****	****	****	2.2	****	-0.84		0.62 (0.31, 1.24)	0.174
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	43,755	****	****	****	****	1.35	****	0.07	****	0.50 ( 0.05 . 4.04 )	0.052
ARBs (14-day gap)	43,755	****	****	****	****	2.21	****	-0.87		0.59 (0.35, 1.01)	0.053
					0	- 30 Days					
Site-Adjusted Analys	is										
SV (14-day gap)	43,777	****	****	****	****	1.15	****	4.04	****	0.20 ( 0.07, 0.52)	0.001
ARBs (14-day gap)	337,157	****	****	****	****	5.96	****	-4.81		0.20(0.07,0.53)	0.001
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	43,755	****	****	****	****	1.19	****	2.20	****	0.00 (0.11.1.00)	0.057
ARBs (14-day gap)	43,755	****	****	****	****	3.57	****	-2.38	* * * * *	0.33 (0.11, 1.03)	0.057
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	43,755	****	****	****	****	1.15	****	2.20	****	0.00 (0.11.1.0.0)	0.050
ARBs (14-day gap)	43,755	****	****	****	****	3.45	****	-2.29	* * * * *	0.33 (0.11, 1.04)	0.058
					31	- 60 Days					
Site-Adjusted Analys	is										
SV (14-day gap)	39,842	****	****	****	****	1.49	****	4.02	****		0.446
ARBs (14-day gap)	316,299	****	****	****	****	3.42	****	-1.92	ጥ ጥ ጥ ጥ	0.45 (0.16, 1.22)	0.116
ANDS (14-uay gap)					1						
, , , , , , , , , , , , , , , , , , , ,	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
Fixed Ratio 1:1 Prope SV (14-day gap)	ensity Score Ma 36,865	tched Conc ****	litional Ana ****	lysis; Calipe ****	r= 0.05 <sup>1</sup> ****	1.35	****	0	****	1.00 ( 0.20, 4.95)	1



. ,					/1	•					
		_	Average	Average		Incidence Rate per		Incidence Rate	Difference	Hazard Ratio	
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	(95% Confidence	Wald
<b>.</b>	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	•	
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	-				-						
SV (14-day gap)	39,822	****	****	****	****	1.49	****	-1.25	* * * * *	0.55 ( 0.17, 1.84)	0.333
ARBs (14-day gap)	40,510	****	****	****	****	2.74	****	0			
					61	- 90 Days					
Site-Adjusted Analysis											
SV (14-day gap)	26,195	****	****	****	****	2.04	****	-0.77	****	0.77 ( 0.28, 2.11)	0.606
ARBs (14-day gap)	243,513	****	****	****	****	2.81	****	0.77		0.77 (0.20, 2.11)	0.000
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	18,508	****	****	****	****	3.07	****	0	****	1.00 ( 0.25 . 4.00)	1
ARBs (14-day gap)	18,508	****	****	****	****	3.07	****	0		1.00 (0.25, 4.00)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	26,181	****	****	****	****	2.04	****	0.00	****		0.000
ARBs (14-day gap)	30,964	****	****	****	****	2.1	****	-0.06	<b>ጥ ጥ ጥ ጥ</b>	0.99 ( 0.26, 3.67)	0.982
					91	- 180 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	21,286	****	****	****	****	1.61	****	0.64	****	0.70 ( 0.24 . 4.64 )	0.400
ARBs (14-day gap)	214,289	****	****	****	****	2.25	****	-0.64		0.70(0.31, 1.61)	0.406
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	13,070	****	****	****	****	1.17	****	_	****		
ARBs (14-day gap)	13,070	****	****	****	****	1.17	****	0	* * * * *	1.00 ( 0.14, 7.10)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	21,278	****	****	****	****	1.61	****			/	
ARBs (14-day gap)	26,917	****	****	****	****	2.08	****	-0.47	****	0.77 (0.28, 2.13)	0.62
, , , , , , , , , , , , , , , , , , , ,					181	- 270 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	11,464	****	****	****	****	0.9	****	-1.17	****	0.44 ( 0.11, 1.80)	
SV (14-uay gap)											0.252



	-		=			=					
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	4,037	****	****	****	****	0	****		****		
ARBs (14-day gap)	4,037	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	11,461	****	****	****	****	0.9	****	0.7	****		0 5 1 0
ARBs (14-day gap)	15,621	****	****	****	****	1.6	****	-0.7		0.58 (0.11, 3.00)	0.518
					271	365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	7,161	****	****	****	****	0.66	****	0.0	****	0.42 ( 0.06 2.10)	0.412
ARBs (14-day gap)	92,668	****	****	****	****	1.56	****	-0.9		0.43 (0.06, 3.19)	0.412
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	1,737	****	****	****	****	0	****		****		
ARBs (14-day gap)	1,737	****	****	****	****	0	****	0	· · · · · · · · · · · · · · · · · · ·	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	7,159	****	****	****	****	0.66	****	0.22	****		0 0 20
ARBs (14-day gap)	10,561	****	****	****	****	0.89	****	-0.23	***** 0.78(0.07,	0.78 (0.07, 8.60)	0.839

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



						-					
		_	Average	Average		Incidence Rate per		Incidence Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval)	P-Value
No Angioedema (-18											
Site-Adjusted Analys											
SV	43,717	****	****	****	****	1.09	****	-1.34	****	0.43 (0.27, 0.70)	<0.001
ARBs	336,332	****	****	****	****	2.43	****	1.54		0.43 (0.27, 0.70)	10.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	43,685	****	****	****	****	1.05	****	-0.94	* * * * *		0.1
ARBs	43,685	****	****	****	****	1.99	****	-0.94		0.53 (0.24, 1.13)	0.1
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	43,685	****	****	****	****	1.09	****	0.01	****		0 0 2 2
ARBs	43,685	****	****	****	****	2.01	****	-0.91		0.53 (0.30, 0.95)	0.032
Angioedema (-183, -	-1)										
Site-Adjusted Analys	sis										
SV	60	****	****	****	****	174.67	****	06.06	****	0 50 (0 24 4 50)	0.20
ARBs	825	****	****	****	****	271.63	****	-96.96		0.58 (0.21, 1.59)	0.29
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	48	****	****	****	****	215.52	****	107.70	****		
ARBs	48	****	****	****	****	323.28	****	-107.76	<u> </u>	0.67 (0.11, 3.99)	0.657
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	48	****	****	****	****	209.86	****		****		
ARBs	48	****	****	****	****	174.52	****	35.34	* * * * *	1.36 (0.30, 6.09)	0.686

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Medical Product    New Users    at Risk							Incidence		Incidence			
Overall      Overall      Site Adjusted Analysis      SV (14-day gap)    43,717    ******    1.09    ******    1.34    ******    0.43 (0.27, 0.70) <d< td="">      Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05<sup>1</sup>    5    5    5    5    1.05    ******    1.05    ******    0.94    *****    0.53 (0.24, 1.13)    0      Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05    5    5    5    5    5    0.53 (0.24, 1.13)    0      Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05    5    5    5    5    0.53 (0.30, 0.95)    0      SV (14-day gap)    43,685    *****    1.09    *****    0.91    *****    0.53 (0.30, 0.95)    0      ARBs (14-day gap)    43,685    *****    1.09    *****    0.91    *****    0.53 (0.30, 0.95)    0      Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05<sup>1</sup>    5    0.14 (0.04, 0.58)    0    0    1.40 (0.04, 0.58)</d<>	Medical Product		Years	Person Days	Person Years	of	1,000 Person	1,000	Difference per 1,000	in Risk per 1,000 New	(95% Confidence	Wald P-Value <sup>2</sup>
Site-Adjusted Analysis    SV (14-day gap)  43,717  *****  1.09  *****  1.34  *****  0.43 (0.27, 0.70)  <0	No Angioedema (-183	3, -1)										
SV (14-day gap)  43,717  *****  *****  1.09  ******  -1.34  ******  0.43 ( 0.27, 0.70)  <0							Overall					
ABS (14-day gap)  336,332  ******  ******  2.43  ******  0.43 ( 0.27, 0.70)  <0	Site-Adjusted Analysi											
ARBS (14-day gap)  336,32  *****  *****  2,43  ******  ******    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> ******  ******  0.53 (0.24, 1.13)  0    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  ******  0.94  ******  0.53 (0.24, 1.13)  0    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  ******  0.91  ******  0.53 (0.30, 0.95)  0.    ARBs (14-day gap)  43,685  ******  ******  2.01  ******  0.91  ******  0.53 (0.30, 0.95)  0.    ARBs (14-day gap)  43,685  ******  ******  2.01  ******  0.91  ******  0.53 (0.30, 0.95)  0.    SV (14-day gap)  43,685  ******  ******  0.58  ******  0.91  ******  0.53 (0.30, 0.95)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> SV (14-day gap)  43,685  ******  ******  0.66  ******  2.38  ******  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Cali	SV (14-day gap)	43,717	****	****	****	****	1.09		-1 3/	****	0/13/027 070)	<0.001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	ARBs (14-day gap)	336,332	****	****	****	****	2.43	****	-1.54		0.43 (0.27, 0.70)	<0.001
1.0.3  1.0.3  -0.94  *****  0.53 (0.24, 1.13)  0    ARBs (14-day gap)  43,685  *****  *****  1.99  *****  0.53 (0.24, 1.13)  0    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  *****  0.94  *****  0.53 (0.30, 0.95)  0.    SV (14-day gap)  43,685  *****  *****  1.09  ******  -0.91  ******  0.53 (0.30, 0.95)  0.    SV (14-day gap)  43,685  *****  *****  2.01  ******  -0.91  ******  0.53 (0.30, 0.95)  0.    SV (14-day gap)  43,717  *****  *****  0.58  *****  -3.51  ******  0.14 (0.04, 0.58)  0.    SV (14-day gap)  43,685  *****  *****  0.6  ******  -2.38  ******  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  ******  2.98  ******  -2.38  ******  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  ******  2.88  ******  2.	Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
ARBs (14-day gap)  43,685  *****  *****  1.99  *****  0.54  0.55 (0.24, 1.15)  0.55    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper=0.05  -0.91  *****  0.53 (0.30, 0.95)  0.    ARBs (14-day gap)  43,685  *****  *****  1.09  *****  -0.91  *****  0.53 (0.30, 0.95)  0.    SV (14-day gap)  43,685  *****  *****  1.09  *****  -0.91  *****  0.53 (0.30, 0.95)  0.    SV (14-day gap)  43,717  *****  *****  0.58  *****  -3.51  *****  0.14 (0.04, 0.58)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  -2.38  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  SV (14-day gap)  43,685  *****  *****	SV (14-day gap)	43,685	****	****	****	****	1.05	****	0.04	****	0 5 2 / 0 2 4 1 1 2 )	0.1
SV (14-day gap)  43,685  ******  ******  1.09  ******  -0.91  ******  0.53 (0.30, 0.95)  0.    O - 30 Days    Site-Adjusted Analysis    Site-Adjusted Analysis    SV (14-day gap)  43,717  ******  ******  0.58  ******  0.14 (0.04, 0.58)  0.    Site-Adjusted Analysis    Site-Adjusted Analysis    Site-Adjusted Analysis    Site-Adjusted Conditional Analysis; Caliper 0.05 <sup>1</sup> SV (14-day gap)  43,685  *****  *****  0.6  *****  -2.38  ******  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis; Caliper = 0.05    SV (14-day gap)  43,685  *****  *****  0.58  *****  -2.38  ******  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis; Caliper= 0.05    SV (14-day gap)  43,685  *****  *****  0.58  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis    Site-Adjusgap)  43,685	ARBs (14-day gap)	43,685	****	****	****	****	1.99	****	-0.94		0.53 (0.24, 1.13)	0.1
ARBs (14-day gap)  43,685  *****  *****  0.53 (0.30, 0.95)  0.    ARBs (14-day gap)  43,685  *****  *****  0.30 Days    Site-Adjusted Analysis  -0.91  *****  0.53 (0.30, 0.95)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> *****  -3.51  *****  0.14 (0.04, 0.58)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  *****  2.98  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  2.98  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  ******  -2.3  ******	Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
ARBs (14-day gap)  43,685  *****  *****  2.01  ******  *0.91  0.33 (0.30, 0.93)  0.    Site-Adjusted Analysis  -0.30 Days  -0.30 Days  -0.40 Page  -0.51  0.35 (0.30, 0.93)  0.    Site-Adjusted Analysis  -0.30 Days  -0.30 Days  -0.52  -0.51  *****  0.14 (0.04, 0.58)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper = 0.05 <sup>1</sup> -2.38  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05 <sup>1</sup> -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  -2.38  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  2.98  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91) </td <td>SV (14-day gap)</td> <td>43,685</td> <td>****</td> <td>****</td> <td>****</td> <td>****</td> <td>1.09</td> <td>****</td> <td>0.01</td> <td>* * * * *</td> <td></td> <td>0.022</td>	SV (14-day gap)	43,685	****	****	****	****	1.09	****	0.01	* * * * *		0.022
Site-Adjusted Analysis    SV (14-day gap)  43,717  *****  *****  0.58  *****  -3.51  *****  0.14 (0.04, 0.58)  0.    ARBs (14-day gap)  336,332  *****  *****  4.08  *****  -3.51  *****  0.14 (0.04, 0.58)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> 5V  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  *****  2.98  *****  -2.38  ******  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  5V  14-day gap)  43,685  *****  *****  0.58  *****  -2.38  ******  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  5  -2.3  ******  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis  *****  *****  2.88  ******  -2.3  ******  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis  Site-Adjusted Analysis  *****  2.88  ******  -2.3	ARBs (14-day gap)	43,685	****	****	****	****	2.01	****	-0.91		0.53 ( 0.30, 0.95)	0.032
SV (14-day gap)  43,717  *****  *****  0.58  *****  -3.51  *****  0.14 (0.04, 0.58)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> *****  0.6  *****  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05 <sup>1</sup> *****  0.6  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05   *****  2.98  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05   *****  0.58  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  1.49  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis  Site-Adjusted Analysis  *****  1.49  *****  -1.49 <t< td=""><td></td><td></td><td></td><td></td><td></td><td>0</td><td>- 30 Days</td><td></td><td></td><td></td><td></td><td></td></t<>						0	- 30 Days					
35 (14-day gap)  43,717  0.53  -3.51  *****  0.14 (0.04, 0.58)  0.    ARBs (14-day gap)  336,332  *****  *****  4.08  *****  -3.51  *****  0.14 (0.04, 0.58)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> 5V (14-day gap)  43,685  *****  *****  0.6  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  5V (14-day gap)  43,685  *****  *****  0.58  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  5V (14-day gap)  43,685  *****  *****  0.58  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    Stie-Adjusted Analysis  5  *****  2.98  *****  -1.49  *****  0.51 (0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup>	Site-Adjusted Analysi	s										
ARBs (14-day gap)  336,332  *****  *****  4.08  ******  5.31  0.14 (0.04, 0.05)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper = 0.05 <sup>1</sup> 5V (14-day gap)  43,685  *****  *****  0.6  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper = 0.05   *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper = 0.05   *****  0.58  *****  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper = 0.05    -2.3  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis  *****  *****  2.88  ******  -2.3  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper = 0.05 <sup>1</sup> ******  1.49  *****  -1.49  *****  0.51 (0.19, 1.4	SV (14-day gap)	43,717	****	****	****	****	0.58	****	2 5 1	****		0.007
SV (14-day gap)  43,685  *****  *****  0.6  *****    ARBs (14-day gap)  43,685  *****  *****  2.98  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  5  *****  0.58  *****  -2.38  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis     31 - 60 Days   -2.3  *****  0.51 (0.19, 1.41)  0.    SV (14-day gap)  39,788  *****  *****  2.98  *****  -1.49  *****  0.51 (0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> /	ARBs (14-day gap)	336,332	****	****	****	****	4.08	****	-3.51		0.14 ( 0.04, 0.58)	0.007
SV (14-day gap)  43,685  *****  *****  0.20 (0.04, 0.91)  0.    ARBs (14-day gap)  43,685  *****  *****  2.98  ******  -2.38  ******  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  5  5  5  7  7  *****  0.20 (0.04, 0.91)  0.    ARBs (14-day gap)  43,685  *****  *****  0.58  *****  -2.38  ******  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  -2.3  ******  0.20 (0.04, 0.91)  0.    ARBs (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  ******  0.20 (0.04, 0.91)  0.    Ste-Adjusted Analysis  -  -  -2.3  ******  0.20 (0.04, 0.91)  0.    SV (14-day gap)  39,788  ******  ******  1.49  *****  -1.49  *****  0.51 (0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> -  -  ******	Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
ARBs (14-day gap)  43,685  *****  *****  2.98  ******  *2.38  0.20 (0.04, 0.91)  0.    Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper= 0.05  5V (14-day gap)  43,685  *****  *****  0.58  *****  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  *****  0.20 (0.04, 0.91)  0.    SV (14-day gap)  43,685  *****  *****  0.58  *****  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis  *****  *****  2.88  ******  -2.3  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis  Sol (14-day gap)  39,788  *****  *****  1.49  *****  -2.3  *****  0.51 (0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05^1  String (14-day gap)  36,810  ******  ******  1.35  ******  0.00 (0.20, 4.95)	SV (14-day gap)	43,685	****	****	****	****	0.6	****	2.20	* * * * *		0.020
SV (14-day gap)  43,685  *****  *****  0.58  *****    ARBs (14-day gap)  43,685  *****  *****  0.58  *****    ARBs (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis	ARBs (14-day gap)	43,685	****	****	****	****	2.98	****	-2.38	<b>ጥ ጥ ጥ ጥ</b>	0.20(0.04, 0.91)	0.038
ARBs (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    ARBs (14-day gap)  43,685  *****  *****  2.88  *****  -2.3  *****  0.20 (0.04, 0.91)  0.    Site-Adjusted Analysis    Site-Adjusted Analysis    SV (14-day gap)  39,788  *****  *****  1.49  *****  -1.49  *****  0.51 (0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> SV (14-day gap)  36,810  *****  *****  1.35  *****  1.00 (0.20, 4.95)  4.95)	Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
ARBs (14-day gap)  43,685  *****  *****  2.88  *****  *****  0.20 (0.04, 0.91)  0.40    Site-Adjusted Analysis    Site-Adjusted Analysis    SV (14-day gap)  39,788  *****  *****  1.49  *****  -1.49  *****  0.51 (0.19, 1.41)  0.5 (0.19, 1.41)	SV (14-day gap)	43,685	****	****	****	****	0.58	****	2.2	* * * * *	0.20 / 0.04 . 0.04)	0.020
Site-Adjusted Analysis    SV (14-day gap)  39,788  *****  *****  1.49  *****    ARBs (14-day gap)  315,576  *****  *****  2.98  *****  -1.49  *****  0.51 ( 0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> 5V (14-day gap)  36,810  *****  *****  1.35  *****  1.00 ( 0.20, 4.95)	ARBs (14-day gap)	43,685	****	****	****	****	2.88	****	-2.3		0.20(0.04, 0.91)	0.038
SV (14-day gap)  39,788  *****  *****  1.49  *****    ARBs (14-day gap)  315,576  *****  *****  2.98  *****  -1.49  *****  0.51 ( 0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> -  -						31	L - 60 Days					
SV (14-bay gap)  39,788  1.49  -1.49  *****  0.51 (0.19, 1.41)  0.    ARBs (14-bay gap)  315,576  *****  *****  2.98  *****  -1.49  *****  0.51 (0.19, 1.41)  0.    Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> 5V (14-bay gap)  36,810  *****  *****  1.35  *****  1.00 (0.20, 4.95)	Site-Adjusted Analysi	s										
ARBs (14-day gap)  315,576  *****  *****  2.98  *****  *1.49  0.51 (0.19, 1.41)  0.51 (0	SV (14-day gap)	39,788	****	****	****	****	1.49	*****	1 40	****		0 10 4
SV (14-day gap) 36,810 ***** ***** ***** 1.35 ***** 0 ***** 1.00 ( 0.20 4.95)	ARBs (14-day gap)	315,576	****	****	****	****	2.98	****	-1.49		0.51 (0.19, 1.41)	0.194
SV (14-day gap) 36,810 ***** ***** ***** 1.35 ***** 0 ***** 1.00 ( 0.20 4.95)	Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
	SV (14-day gap)	36,810	****	****	****	****	1.35	****	0	****	1.00/0.20 4.05	1
	ARBs (14-day gap)	36,810	****	****	****	****	1.35	****	U		1.00 ( 0.20, 4.95)	1



	-		-			-		-			
		Person	Average Person	Average Person	Number	Incidence Rate per 1,000	Risk per	Incidence Rate Difference	Difference in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	39,758	****	****	****	****	1.5	****	-1.25	****		0.333
ARBs (14-day gap)	40,450	****	****	****	****	2.75	****	-1.25		0.55 (0.17, 1.84)	0.333
					61	- 90 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	26,157	****	****	****	****	1.53	****	-0.7	* * * * *	0.72 ( 0.22, 2.33)	0.586
ARBs (14-day gap)	242,996	****	****	****	****	2.23	****	-0.7		0.72 (0.22, 2.33)	0.580
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	18,487	****	****	****	****	2.3	****	0.77	****		0 706
ARBs (14-day gap)	18,487	****	****	****	****	3.07	****	-0.77		0.75 (0.17, 3.35)	0.706
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	26,139	****	****	****	****	1.53	****	0.15	****	0.01 ( 0.20 . 4.00)	0.007
ARBs (14-day gap)	30,921	****	****	****	****	1.68	****	-0.15		0.91(0.20, 4.09)	0.907
					91	- 180 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	21,255	****	****	****	****	1.34	****	0.66	****		0 202
ARBs (14-day gap)	213,845	****	****	****	****	2	****	-0.66		0.67 (0.27, 1.65)	0.382
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	13,057	****	****	****	****	1.17	****	0	****	1.00/0.14 7.10)	1
ARBs (14-day gap)	13,057	****	****	****	****	1.17	****	0		1.00 ( 0.14, 7.10)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	21,245	****	****	****	****	1.34	****	-0.74	****	0 64 ( 0 22 1 80)	0 422
ARBs (14-day gap)	26,883	****	****	****	****	2.08	****	-0.74		0.64 (0.22, 1.89)	0.422
					181	- 270 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	11,447	****	****	****	****	0.9	****	-0.94	****	0.49 ( 0.12, 2.01)	0.319
ARBs (14-day gap)	129,815	****	****	****	****	1.85	****	-0.94		0.49 ( 0.12, 2.01)	0.519



						Incidence		Incidence			
		_	Average	Average		Rate per		Rate	Difference	Useerd Datia	
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	اما ما
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Proper	nsity Score Ma										
SV (14-day gap)	4,033	****	****	****	****	0	****	0	* * * * *	_	_
ARBs (14-day gap)	4,033	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	11,442	****	****	****	****	0.9	****	-0.38	****	0.72 ( 0.13, 3.92)	0.701
ARBs (14-day gap)	15,602	****	****	****	****	1.28	****	-0.58		0.72 (0.15, 5.92)	0.701
					271	- 365 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	7,150	****	****	****	****	0.66	****	0.75	****	0.40(0.07, 0.57)	0 477
ARBs (14-day gap)	92,474	****	****	****	****	1.41	****	-0.75		0.48 (0.07, 3.57)	0.477
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,736	****	****	****	****	0	****	_	****		
ARBs (14-day gap)	1,736	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	7,147	****	****	****	****	0.66	****		****		
ARBs (14-day gap)	10,551	****	****	****	****	0.89	****	-0.23	* * * * *	0.78(0.07, 8.61)	0.84
Angioedema (-183, -1)											
	-					Overall					
Site-Adjusted Analysis	5										
SV (14-day gap)	60	****	****	****	****	174.67	****		****		
ARBs (14-day gap)	825	****	****	****	****	271.63	****	-96.96	* * * * *	0.58 ( 0.21, 1.59)	0.29
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= <b>0.05</b> <sup>1</sup>						
SV (14-day gap)	48	****	****	****	****	215.52	****				
ARBs (14-day gap)	48	****	****	****	****	323.28	****	-107.76	****	0.67 (0.11, 3.99)	0.657
Fixed Ratio 1:1 Proper		tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	48	****	****	****	****	209.86	****	35.34	****		
3V (14-uav gab)										1.36 ( 0.30, 6.09)	0.686



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					0	- 30 Days					
Site-Adjusted Analysis											
SV (14-day gap)	681	****	****	****	****	49.13	****	-86.01	****	0.49 ( 0.12, 2.01)	0.322
ARBs (14-day gap)	5,694	****	****	****	****	135.14	****	-80.01		0.49 (0.12, 2.01)	0.522
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	785	****	****	****	****	90.29	****	0	****	1.00 ( 0.14, 7.10)	1
ARBs (14-day gap)	785	****	****	****	****	90.29	****	0		1.00(0.14, 7.10)	T
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	4,532	****	****	****	****	16.52	****	F 1F	****		0.005
ARBs (14-day gap)	6,990	****	****	****	****	11.37	****	5.15		1.01 (0.14, 7.15)	0.995
					31	- 60 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	54	****	****	****	****	0	****	105.01	****		
ARBs (14-day gap)	725	****	****	****	****	195.01	****	-195.01	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	98	****	****	****	****	0	****		****		
ARBs (14-day gap)	98	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	455	****	****	****	****	0	****		****		
ARBs (14-day gap)	519	****	****	****	****	0	****	0	* * * * *	-	-
					61	- 90 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	38	****	****	****	****	354.61	****	70.57	****		0.745
ARBs (14-day gap)	522	****	****	****	****	276.04	****	78.57	<u> </u>	1.41 ( 0.18, 10.92)	0.743
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Anal	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	23	****	****	****	****	0	****		ale ale ale ale ale		
ARBs (14-day gap)	23	****	****	****	****	666.67	****	-666.67	****	-	-



	Number of	Person Years	Person Days	Person Years	Number of	1,000 Person	Risk per 1,000	Difference per 1,000	in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	-			nalysis; Cali	-		di di di di di				
SV (14-day gap)	32	****	****		****	420.17	****	35.55	****	1.14 ( 0.07, 18.31)	0.924
ARBs (14-day gap)	34	****	****	****	****	384.62	****				
<u></u>					91	- 180 Days					
Site-Adjusted Analysi		****	****	****	****	470.04	****				
SV (14-day gap)	31					173.31		54.52	****	1.48 ( 0.19, 11.65)	0.711
ARBs (14-day gap)	449	****	****	****	****	118.79	****				
Fixed Ratio 1:1 Prope											
SV (14-day gap)	14	****	****	****	****	0	****	0	****	-	-
ARBs (14-day gap)	14	****	****	****	****	0	****	Ũ			
Fixed Ratio 1:1 Prope	nsity Score Ma				-						
SV (14-day gap)	26	****	****	****	****	191.2	****	191.2	* * * * *		
ARBs (14-day gap)	29	****	****	****	****	0	****	191.2		-	-
					181	- 270 Days					
Site-Adjusted Analysi											
SV (14-day gap)	19	****	****	****	****	0	****	-106.5	* * * * *		
ARBs (14-day gap)	285	****	****	****	****	106.5	****	-100.5		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	****	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	18	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	15	****	****	****	****	0	****	0	100 AU AU AU AU	-	-
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	12	****	****	****	****	0	****	(7.2)	****		
ARBs (14-day gap)	197	****	****	****	****	67.2	****	-67.2	ጥ ጥ ጥ ጥ	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	0	* * * * *		
ARBs (14-day gap)	****	****	****	****	****	0	****	U		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	11	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	****	****	****	****	****	0	****		-	-	

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



						-					
		Demonstra	Average	Average	N	Incidence Rate per	Disk a sa	Incidence Rate	Difference		
	Number of	Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	Malal
Mardian Duradurat	Number of New Users	Years at Risk	Days at Risk	Years at Risk	of Events	Person Years	1,000	per 1,000 Person Years	1,000 New Users	(95% Confidence Interval)	Wald P-Value
Medical Product				dt KISK	Events	rears	New Users	Person rears	Users	Intervalj	P-Value
No Angioedema (ev	•	_	_	_	_	_	_	_	_		_
Site-Adjusted Analys		****	****	****	****		****				
SV	43,178					0.98		-1.05	****	0.46 (0.28, 0.78)	0.004
ARBs	329,798	****	****	****	****	2.03	****			( , ,	
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe							
SV	42,832	****	****	****	****	0.96	****	-0.75	* * * * *	0.56 (0.25, 1.27)	0.167
ARBs	42,832	****	****	****	****	1.71	****	-0.75		0.50 (0.25, 1.27)	0.107
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	42,832	****	****	****	****	0.98	****	0.74	****		0.000
ARBs	42,832	****	****	****	****	1.72	****	-0.74		0.56 (0.30, 1.04)	0.066
Angioedema (ever, -	-1)										
Site-Adjusted Analys	sis										
SV	599	****	****	****	****	27.13	****	22.24	****		
ARBs	7,359	****	****	****	****	47.94	****	-20.81	* * * * *	0.51 (0.22, 1.15)	0.104
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	591	****	****	****	****	36.79	****	_			
ARBs	591	****	****	****	****	36.79	****	0	****	1.00 (0.29, 3.45)	1
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV .	591	****	****	****	*****	27.53	****			• ·	
ARBs	591	****	****	****	****	30.3	****	-2.77	****	0.85 (0.30, 2.47)	0.772

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



· /					<i>,</i> .		0				
	Number of	Person Years	Average Person Days	Average Person Years	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	,	Person Years		Interval)	P-Value
No Serious Allergies	•									•	
Site-Adjusted Analy	sis										
SV	37,847	****	****	****	****	1.17	****		****		
ARBs	282,725	****	****	****	****	2.59	****	-1.41	* * * * *	0.43 (0.26, 0.71)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	37,637	****	****	****	****	1.07	****	0.72	****	0.00 (0.00 1.07)	0.220
ARBs	37,637	****	****	****	****	1.79	****	-0.72		0.60 (0.26, 1.37)	0.226
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	37,637	****	****	****	****	1.18	****	-0.94	* * * * *		0.045
ARBs	37,637	****	****	****	****	2.12	****	-0.94		0.54 (0.30, 0.99)	0.045
Serious Allergies											
Site-Adjusted Analy	sis										
SV	5,930	****	****	****	****	2.56	****	-2.93	* * * * *	0.43 (0.18, 1.06)	0.068
ARBs	54,432	****	****	****	****	5.5	****	-2.95		0.43 (0.18, 1.00)	0.008
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,774	****	****	****	****	2.65	****	-1.77	****		0.484
ARBs	5,774	****	****	****	****	4.42	****	-1.//		0.60 (0.14, 2.51)	0.484
Fixed Ratio 1:1 Prop	ensity Score Ma				-						
SV	5,774	****	****	****	****	2.64	****	-0.41	* * * * *	0.86 (0.27, 2.73)	0.801
ARBs	5,774	****	****	****	****	3.05	****	-0.41		0.00 (0.27, 2.73)	0.001

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



				<u>, ,, ,</u>		•					
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
Sex: Male											
						Overall					
Site-Adjusted Analysi	S										
SV (14-Day Gap)	28,311	****	****	****	****	0.99	****	1.0	****	0.22 / 0.17 0.02)	-0.001
ARB (14-Day Gap)	149,252	****	****	****	****	2.9	****	-1.9		0.33 (0.17, 0.62)	<0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-Day Gap)	27,999	****	****	****	****	0.82	****	4.40	****	0.00 ( 0.40, 0.00)	
ARB (14-Day Gap)	27,999	****	****	****	****	2.3	****	-1.48	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.36 (0.13, 0.99)	0.048
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-Day Gap)	27,999	****	****	****	****	1.01	****	4 7 4	****	0.26 / 0.40 0.72)	0.005
ARB (14-Day Gap)	27,999	****	****	****	****	2.74	****	-1.74		0.36 (0.18, 0.73)	0.005
					0	- 30 Days					
Site-Adjusted Analysi	S										
SV (14-Day Gap)	28,311	****	****	****	****	0.89	****	4.12	****	0.10 ( 0.04 0.72)	0.010
ARB (14-Day Gap)	149,252	****	****	****	****	5.02	****	-4.13		0.18 ( 0.04, 0.73)	0.016
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-Day Gap)	27,999	****	****	****	****	0.93	****	2.25	****	0.00 ( 0.05 ( 0.00)	0.054
ARB (14-Day Gap)	27,999	****	****	****	****	4.18	****	-3.25	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.22 (0.05, 1.03)	0.054
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cal	iper= 0.05						
SV (14-Day Gap)	27,999	****	****	****	****	0.9	****	2.14	****	0.22/0.05 1.02)	
ARB (14-Day Gap)	27,999	****	****	****	****	4.04	****	-3.14	and the standard	0.22 (0.05, 1.03)	0.055
					31	- 60 Days					
Site-Adjusted Analysi	s										
SV (14-Day Gap)	25,869	****	****	****	****	1.73	****	-1.15	****	0.62 ( 0.19, 2.03)	3) 0.427
ARB (14-Day Gap)	139,781	****	****	****	****	2.88	****	-1.15		0.02 (0.19, 2.03)	0.427



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	23,643	****	****	****	****	1.41	****		****		
ARB (14-Day Gap)	23,643	****	****	****	****	0	****	1.41	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	25,578	****	****	****	****	1.75	****	0.04	****		0.500
ARB (14-Day Gap)	25,890	****	****	****	****	2.69	****	-0.94	<b>ጥ ጥ ጥ ጥ</b>	0.66 ( 0.16, 2.76)	0.569
					61	- 90 Days					
Site-Adjusted Analysi	S										
SV (14-Day Gap)	16,938	****	****	****	****	0.79	****	4.62	****		
ARB (14-Day Gap)	107,343	****	****	****	****	2.41	****	-1.62	* * * * *	0.34 (0.05, 2.54)	0.294
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	11,771	****	****	****	****	1.2	****		ate ale ale ale ale		
ARB (14-Day Gap)	11,771	****	****	****	****	2.41	* * * * *	-1.2	****	0.50 (0.05, 5.51)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	16,736	****	****	****	****	0.8	****	4.4.9	****		
ARB (14-Day Gap)	19,728	****	****	****	****	1.98	****	-1.18	* * * * *	0.40 ( 0.04, 3.87)	0.431
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysi	S										
SV (14-Day Gap)	13,783	****	****	****	****	0.83	****	4.00	****	0.00/0.07 4.04	0.00
ARB (14-Day Gap)	94,209	****	****	****	****	2.76	****	-1.93	<b>ጥ ጥ ጥ ጥ</b>	0.29 (0.07, 1.21)	0.09
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	8,328	****	****	****	****	0	****		ale ale strate ale		
ARB (14-Day Gap)	8,328	****	****	****	****	2.79	****	-2.79	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	13,619	****	****	****	****	0.84	****	2.44	****	0.00 ( 0.00 ( 1.10)	0.000
ARB (14-Day Gap)	17,120	****	****	****	****	3.29	****	-2.44	* * * * *	0.26 ( 0.06, 1.19)	0.083



				, <u>,</u> , ,		•					
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
					181	- 270 Days				•	
Site-Adjusted Analysi	S				-	1-					
SV (14-Day Gap)	7,405	****	****	****	****	0.7	****				
ARB (14-Day Gap)	56,410	****	****	****	****	1.83	****	-1.13	****	0.38 ( 0.05, 2.83)	0.345
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	2,559	****	****	****	****	0	****				
ARB (14-Day Gap)	2,559	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-Day Gap)	7,315	****	****	****	****	0.71	****	4.00	****		
ARB (14-Day Gap)	9,864	****	****	****	****	2.54	****	-1.83	* * * * *	0.29 (0.03, 2.48)	0.258
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-Day Gap)	4,632	****	****	****	****	1.03	****	1 1 2	****		0.464
ARB (14-Day Gap)	39,969	****	****	****	****	2.15	****	-1.13		0.47 (0.06, 3.53)	0.464
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	1,127	****	****	****	****	0	****	0	****		
ARB (14-Day Gap)	1,127	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-Day Gap)	4,575	****	****	****	****	1.04	****	0.33	****		0.764
ARB (14-Day Gap)	6,649	****	****	****	****	0.71	****	0.55		1.53 ( 0.10, 24.43)	0.764
Sex: Female											
						Overall					
Site-Adjusted Analysi	s										
SV (14-Day Gap)	15,466	****	****	****	****	2	****	-1.11	****	0.60 ( 0.33, 1.09)	0.096
ARB (14-Day Gap)	187,905	****	****	****	****	3.1	****	-1.11		0.00 ( 0.35, 1.09)	0.090



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	15,267	****	****	****	****	1.77	****		****		0 700
ARB (14-Day Gap)	15,267	****	****	****	****	2.06	****	-0.29	* * * * *	0.86 ( 0.29, 2.55)	0.782
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	15,267	****	****	****	****	2.02	****	0.00	****		
ARB (14-Day Gap)	15,267	****	****	****	****	1.34	****	0.68	* * * * *	1.45 (0.60, 3.50)	0.41
					0	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-Day Gap)	15,466	****	****	****	****	1.64	****		****		
ARB (14-Day Gap)	187,905	****	****	****	****	6.71	****	-5.07	* * * * *	0.25 (0.06, 1.01)	0.051
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	15,267	****	****	****	****	1.71	****			/	
ARB (14-Day Gap)	15,267	****	****	****	****	2.56	****	-0.85	****	0.67 (0.11, 3.99)	0.657
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	15,267	****	****	****	****	1.66	****		****		
ARB (14-Day Gap)	15,267	****	****	****	****	2.47	****	-0.81	* * * * *	0.67 (0.11, 3.99)	0.657
					31	- 60 Days					
Site-Adjusted Analysi	s										
SV (14-Day Gap)	13,973	****	****	****	****	1.06	****	2 70	****	0.00 ( 0.04 . 0.00)	0.000
ARB (14-Day Gap)	176,518	****	****	****	****	3.84	****	-2.78	ጥ ጥ ጥ ጥ	0.28 (0.04, 2.00)	0.202
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	12,817	****	****	****	****	1.29	****				
ARB (14-Day Gap)	12,817	****	****	****	****	3.86	****	-2.57	****	0.33 ( 0.03, 3.20)	0.341
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	13,795	****	****	****	*****	1.07	****	4.00	عله عله عله عله		0.000
ARB (14-Day Gap)	14,173	****	****	****	****	2.93	****	-1.86	****	0.37 ( 0.04, 3.58)	0.392



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Site-Adjusted Analysis	<u> </u>				61	- 90 Days					
SV (14-Day Gap)	9,257	****	****	****	****	4.33	****				
ARB (14-Day Gap)	136,170	****	****	****	****	3.13	****	1.2	****	1.47 (0.45, 4.80)	0.522
Fixed Ratio 1:1 Prope	-	tched Cond	litional Anal	lysis; Calipe	r= 0.05 <sup>1</sup>	0.20					
SV (14-Day Gap)	6,544	****	****	****	****	4.32	****				
ARB (14-Day Gap)	6,544	****	****	****	****	2.16	****	2.16	****	2.00 ( 0.18, 22.06)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	9,145	****	****	****	****	4.38	****	2	****	4 00 ( 0 04 44 00)	0.400
ARB (14-Day Gap)	10,897	****	****	****	****	2.38	****	2	* * * * *	1.88 ( 0.31, 11.28)	0.488
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysis	s										
SV (14-Day Gap)	7,503	****	****	****	****	3.02	****	1 16	****	1.66 ( 0.59, 4.63)	0 220
ARB (14-Day Gap)	120,080	****	****	****	****	1.86	****	1.16		1.00 (0.59, 4.03)	0.338
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-Day Gap)	4,666	****	****	****	****	1.61	****	1.01	****		
ARB (14-Day Gap)	4,666	****	****	****	****	0	****	1.61		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-Day Gap)	7,419	****	****	****	****	3.05	****	2.05	* * * * *		
ARB (14-Day Gap)	9,505	****	****	****	****	0	****	3.05		-	-
					181	- 270 Days					
Site-Adjusted Analysis	S										
SV (14-Day Gap)	4,060	****	****	****	****	1.28	****	-0.98	****	0.57 ( 0.08, 4.19)	0.582
ARB (14-Day Gap)	73,690	****	****	****	****	2.25	****	-0.98		0.57 (0.08, 4.19)	0.582
Fixed Ratio 1:1 Prope											
SV (14-Day Gap)	1,493	****	****	****	****	0	****	0	****		_
ARB (14-Day Gap)	1,493	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
SV (14-Day Gap)	4,020	****	****	****	****	1.29	****	4.20	****		
ARB (14-Day Gap)	5,591	****	****	****	****	0	****	1.29		-	-
					271	- 365 Days					
Site-Adjusted Analysi	S										
SV (14-Day Gap)	2,529	****	****	****	****	0	****	1 1 1	****		
ARB (14-Day Gap)	52,699	****	****	****	****	1.11	****	-1.11		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-Day Gap)	646	****	****	****	****	0	****	<u> </u>	****		
ARB (14-Day Gap)	646	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-Day Gap)	2,505	****	****	****	****	0	****	1 22	* * * * *		
ARB (14-Day Gap)	3,802	****	****	****	****	1.22	****	**** - <b>1.</b> 22 *****	-88888-	-	-

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Age Group: 18-44 ye	ears										
Site-Adjusted Analy	sis										
SV	1,634	****	****	****	****	1.87	****	-6.02	****	0.27 (0.04, 2.05)	0.207
ARBs	8,500	****	****	****	****	7.89	****	-0.02		0.27 (0.04, 2.03)	0.207
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	1,448	****	****	****	****	3.8	****	3.8	* * * * *		
ARBs	1,448	****	****	****	****	0	****	5.0		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	1,448	****	****	****	****	2.11	****	-0.02	****	1.00 (0.06, 16.19)	0.009
ARBs	1,448	****	****	****	****	2.13	****	-0.02		1.00 (0.06, 16.19)	0.998
Age Group: 45-54 ye	ears										
Site-Adjusted Analy	sis										
SV	3,068	****	****	****	****	0.95	****	2.26	****	0.22 (0.02 1.70)	0.149
ARBs	18,297	****	****	****	****	4.32	****	-3.36		0.23 (0.03, 1.70)	0.149
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	2,938	****	****	****	****	1.72	****	4 70	****		0.574
ARBs	2,938	****	****	****	****	3.43	****	-1.72		0.50 (0.05, 5.51)	0.571
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	2,938	****	****	****	****	0.99	****	4.0	****	0.07 (0.04. 0.57)	0.00
ARBs	2,938	****	****	****	****	2.8	****	-1.8		0.37 (0.04, 3.57)	0.39
Age Group: 55-64 ye	ears										
Site-Adjusted Analy	sis										
SV	6,120	****	****	****	****	1.88	****	2.42	****	0.40 (0.17 4.24)	0.452
ARBs	40,556	****	****	****	****	4	****	-2.12	·r· ·r· የ ጥ ጥ	0.48 (0.17, 1.31)	0.152
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,994	****	****	****	****	2.43	****	0	****	1.00 (0.20	1
ARBs	5,994	****	****	****	****	2.43	****	0	ጥ ጥ ኆ ጥ ጥ	1.00 (0.20, 4.95)	1



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,994	****	****	****	****	1.91	****	0.10	****	0.02 (0.25 . 2.42)	0.000
ARBs	5,994	****	****	****	****	2.1	****	-0.18		0.92 (0.25, 3.43)	0.899
Age Group: ≥65 yeaı	rs										
Site-Adjusted Analys	sis										
SV	32,955	****	****	****	****	1.26	****		****	0.42 (0.20, 0.72)	0.001
ARBs	269,804	****	****	****	****	2.71	****	-1.44		0.43 (0.26, 0.72)	0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	32,649	****	****	****	****	1.22	****	0.01	****	0.00 (0.00 4.07)	0.000
ARBs	32,649	****	****	****	****	2.03	****	-0.81	ጥ ጥ ጥ ጥ ጥ	0.60 (0.26, 1.37)	0.226
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	32,649	****	****	****	****	1.19	****	0.01	****	0.55 (0.20, 4.02)	0.000
ARBs	32,649	****	****	****	****	2.1	****	-0.91	ት ተ ሶ ጥ ጥ	0.55 (0.29, 1.03)	0.062

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



					<i></i>	•					
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
Age Group: 18-44											
						Overall					
Site-Adjusted Analysis	S										
SV (14-day gap)	1,634	****	****	****	****	1.87	****	6.02	****	0.07/0.04.0.05	0.207
ARBs (14-day gap)	8,500	****	****	****	****	7.89	****	-6.02	-1111-	0.27 (0.04, 2.05)	0.207
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,448	****	****	****	****	3.8	****		****		
ARBs (14-day gap)	1,448	****	****	****	****	0	****	3.8	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	1,448	****	****	****	****	2.11	****		****		
ARBs (14-day gap)	1,448	****	****	****	****	2.13	****	-0.02	* * * * *	1.00 ( 0.06, 16.19)	0.998
					0 -	- 30 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	1,788	****	****	****	****	0	****	5.04	****		
ARBs (14-day gap)	10,999	****	****	****	****	5.84	****	-5.84	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,422	****	****	****	****	0	****	_	****		
ARBs (14-day gap)	1,422	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	1,605	****	****	****	****	0	****		****		
ARBs (14-day gap)	1,760	****	****	****	****	0	****	0	<u>ት ት ት ት ት</u>	-	-
					31	- 60 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	1,497	****	****	****	****	0	****	7.65	****		
ARBs (14-day gap)	7,924	****	****	****	****	7.65	****	-7.65	·1· ·1· ·1· ·1·	-	-



. ,	• •					•	•				
						Incidence		Incidence			
			Average	Average	_	Rate per		Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	14/-1-1
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,211	****	****	****	****	0	****	0	* * * * *		
ARBs (14-day gap)	1,211	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,331	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1,314	****	****	****	****	0	****	0		-	-
					61	- 90 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	933	****	****	****	****	0	****	5.00	****		
ARBs (14-day gap)	5,002	****	****	****	****	5.33	****	-5.33	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	492	****	****	****	****	0	****	_	****		
ARBs (14-day gap)	492	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	830	****	****	****	****	0	****	45.00	****		
ARBs (14-day gap)	854	****	****	****	****	15.86	****	-15.86	ጥ ጥ ጥ ጥ	-	-
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	704	****	****	****	****	8.2	****	0.24	****		0.00
ARBs (14-day gap)	4,048	****	****	****	****	16.52	****	-8.31		0.63 (0.08, 4.94)	0.66
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	288	****	****	****	****	28.03	****		****		
ARBs (14-day gap)	288	****	****	****	****	0	****	28.03	<u> </u>	-	-
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	625	****	****	****	****	9.19	****	0.10	ماد ماد ماد بله بله		
ARBs (14-day gap)	662	****	****	****	****	0	****	9.19	****	-	-



					<i></i>	•	•				
						Incidence		Incidence			
			Average	Average		Rate per		Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value
					181	- 270 Days					
Site-Adjusted Analysis											
SV (14-day gap)	371	****	****	****	****	0	****	-5.1	* * * * *	_	_
ARBs (14-day gap)	1,995	****	****	****	****	5.1	****	-5.1		-	_
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	77	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	77	****	****	****	****	0	****	U		-	-
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	335	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	296	****	****	****	****	0	****	0		-	-
					271	- 365 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	223	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1,317	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	42	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	42	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Proper	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	200	****	****	****	****	0	****		****		
ARBs (14-day gap)	199	****	****	****	****	0	****	0	* * * * *	-	-
Age Group: 45-54											
					(	Overall					
Site-Adjusted Analysis	5										
SV (14-day gap)	3,068	****	****	****	****	0.95	****	2.25	****		0.1.15
ARBs (14-day gap)	18,297	****	****	****	****	4.32	****	-3.36	* * * * *	0.23 ( 0.03, 1.70)	0.149



		Person	Average Person	Average Person	Number	Rate per 1,000	Risk per	Rate Difference	Difference in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,938	****	****	****	****	1.72	****	4 70	****		0.574
ARBs (14-day gap)	2,938	****	****	****	****	3.43	****	-1.72	ጥ ጥ ጥ ጥ	0.50(0.05, 5.51)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,938	****	****	****	****	0.99	****	4.0	****	0.07 ( 0.04 . 0.57)	0.20
ARBs (14-day gap)	2,938	****	****	****	****	2.8	****	-1.8	ጥ ጥ ጥ ጥ	0.37 (0.04, 3.57)	0.39
					0 -	30 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	3,068	****	****	****	****	0	****	40.07	****		
ARBs (14-day gap)	18,297	****	****	****	****	10.27	****	-10.27	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,938	****	****	****	****	0	****	4.45	****		
ARBs (14-day gap)	2,938	****	****	****	****	4.45	****	-4.45	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,938	****	****	****	****	0	****	4.2	****		
ARBs (14-day gap)	2,938	****	****	****	****	4.3	****	-4.3		-	-
					31	- 60 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	2,806	****	****	****	****	0	****	4.20	****		
ARBs (14-day gap)	17,086	****	****	****	****	4.29	****	-4.29		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,467	****	****	****	****	0	****	6.96	****		
ARBs (14-day gap)	2,467	****	****	****	****	6.86	****	-6.86	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,693	****	****	****	****	0	****	5.42	****		
ARBs (14-day gap)	2,684	****	****	****	****	5.42	****	-5.42	<b>ጥ ጥ ጥ ጥ</b>	-	-


Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					61	- 90 Days					
Site-Adjusted Analysi		****	****	****	****		****				
SV (14-day gap)	1,779	****	****	****	****	0	****	0	****	-	-
ARBs (14-day gap)	11,645					0	* * * * *				
Fixed Ratio 1:1 Prope											
SV (14-day gap)	1,093	****	****	****	****	0	****	0	* * * * *	-	-
ARBs (14-day gap)	1,093	****	****	****	****	0	****	Ũ			
Fixed Ratio 1:1 Prope	,			1 .	•						
SV (14-day gap)	1,711	****	****	****	****	0	****	0	* * * * *	_	_
ARBs (14-day gap)	1,863	****	****	****	****	0	****	0		-	-
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	1,412	****	****	****	****	0	****	2.0	****		
ARBs (14-day gap)	9,740	****	****	****	****	3.6	****	-3.6		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	729	****	****	****	****	0	****		****		
ARBs (14-day gap)	729	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,357	****	****	****	****	0	****		****		
ARBs (14-day gap)	1,544	****	****	****	****	3.83	****	-3.83	* * * * *	-	-
					181	- 270 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	744	****	****	****	****	6.99	****		ala ala al- de de		
ARBs (14-day gap)	5,203	****	****	****	****	1.94	****	5.05	****	3.89 ( 0.34, 44.69)	0.275
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	211	****	****	****	****	29.15	****		ale ale ale ale ale		
ARBs (14-day gap)	211	****	****	****	****	0	****	29.15	****	-	-



	-					-	•				
						Incidence		Incidence			
			Average	Average		Rate per		Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	721	****	****	****	****	7.19	****	7.19	****		
ARBs (14-day gap)	782	****	****	****	****	0	****	7.19		-	-
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	468	****	****	****	****	0	****	2.60	****		
ARBs (14-day gap)	3,437	****	****	****	****	2.69	****	-2.69		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	88	****	****	****	****	0	****	2	****		
ARBs (14-day gap)	88	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	454	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	496	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Age Group: 55-64											
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	6,120	****	****	****	****	1.88	****	2.12	****	0.40/0.17 1.21	0 1 5 2
ARBs (14-day gap)	40,556	****	****	****	****	4	****	-2.12		0.48 (0.17, 1.31)	0.152
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,994	****	****	****	****	2.43	****	<u>^</u>	****	1.00 ( 0.00	
ARBs (14-day gap)	5,994	****	****	****	****	2.43	****	0	ጥ ጥ ጥ ጥ	1.00 ( 0.20, 4.95)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,994	****	****	****	****	1.91	****	0.10	****	0.02 ( 0.25 . 2.42)	0.000
ARBs (14-day gap)	5,994	****	****	****	****	2.1	****	-0.18	* * * * *	0.92 ( 0.25, 3.43)	0.899



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					0	- 30 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	6,120	****	****	****	****	2.07	****	-5.95	****	0.25 ( 0.03, 1.84)	0.173
ARBs (14-day gap)	40,556	****	****	****	****	8.01	****	-5.55		0.25 (0.05, 1.04)	0.175
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,994	****	****	****	****	2.18	****	-4.36	****	0.33 ( 0.03, 3.20)	0.341
ARBs (14-day gap)	5,994	****	****	****	****	6.54	****	-4.30		0.33 (0.03, 3.20)	0.341
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,994	****	****	****	****	2.11	****	4.10	****	0.22 ( 0.02 . 2.20)	0.241
ARBs (14-day gap)	5,994	****	****	****	****	6.3	****	-4.19		0.33 ( 0.03, 3.20)	0.341
					31	- 60 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	5,561	****	****	****	****	0	****	2.25	****		
ARBs (14-day gap)	37,960	****	****	****	****	2.25	****	-2.25		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,036	****	****	****	****	0	****		****		
ARBs (14-day gap)	5 <i>,</i> 036	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,453	****	****	****	****	0	****		****		
ARBs (14-day gap)	5,536	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-
					61	- 90 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	3,609	****	****	****	****	7.43	****	F 04	****		0.424
ARBs (14-day gap)	27,418	****	****	****	****	2.38	****	5.04	ጥ ጥ ጥ ጥ	3.55 ( 0.68, 18.41)	0.131
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,358	****	****	****	****	6.08	****	6.00	****		
ARBs (14-day gap)	2,358	****	****	****	****	0	****	6.08	<u>ጥ ጥ ጥ ጥ</u> ጥ	-	-



	-		•			-					
		Demonstra	Average	Average	N	Incidence Rate per		Incidence Rate	Difference	Hazard Ratio	
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	(95% Confidence	Wald
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	•	P-Value <sup>2</sup>
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-value
Fixed Ratio 1:1 Prope	-				•						
SV (14-day gap)	3,547	****	****	****	****	7.57	****	7.57	****	-	-
ARBs (14-day gap)	4,002	****	****	****	****	0	****				
					<b>91</b> ·	- 180 Days					
Site-Adjusted Analysi											
SV (14-day gap)	2,898	****	****	****	****	1.98	****	-1.4	****	0.61 (0.08, 4.69)	0.637
ARBs (14-day gap)	23,333	****	****	****	****	3.39	****	-1.4		0.01 ( 0.08, 4.05)	0.057
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,619	****	****	****	****	4.79	****	4.70	****		
ARBs (14-day gap)	1,619	****	****	****	****	0	****	4.79	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,846	****	****	****	****	2.02	****		****		
ARBs (14-day gap)	3,362	****	****	****	****	1.69	****	0.33	* * * * *	1.31 ( 0.08, 20.90)	0.85
					181	- 270 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	1,528	****	****	****	****	0	****		****		
ARBs (14-day gap)	13,310	****	****	****	****	3.39	****	-3.39	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	483	****	****	****	****	0	****				
ARBs (14-day gap)	483	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,507	****	****	****	****	0	****				
ARBs (14-day gap)	1,880	****	****	****	****	2.73	****	-2.73	****	-	-
	_,				271	- 365 Days					
Site-Adjusted Analysi	S										
		****	****	****	****	0	****				
SV (14-day gap)	958	* * * * *	* * * * *		de de de de de	0		-3.54	****		



	1 .		1 .	<u>, ,</u>	<i>// i</i>	•	•				
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con		lysis: Caline	$r = 0.05^{1}$					•	
SV (14-day gap)	203	****	*****	****	****	0	****				
ARBs (14-day gap)	203	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prope		tched Unc	onditional A	nalysis: Cali	per= 0.05	<u> </u>					
SV (14-day gap)	946	****	****	****	*****	0	****				
ARBs (14-day gap)	1,209	****	****	****	****	0	****	0	****	-	-
Age Group: 65+	,					-					
						Overall					
Site-Adjusted Analysi	S										
SV (14-day gap)	32,955	****	****	****	****	1.26	****				
ARBs (14-day gap)	269,804	****	****	****	****	2.71	****	-1.44	****	0.43 ( 0.26, 0.72)	0.001
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lvsis: Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	32,649	****	****	****	****	1.22	****				
ARBs (14-day gap)	32,649	****	****	****	****	2.03	****	-0.81	****	0.60 ( 0.26, 1.37)	0.226
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	32,649	****	****	****	****	1.19	****			/	
ARBs (14-day gap)	32,649	****	****	****	****	2.1	****	-0.91	****	0.55 ( 0.29, 1.03)	0.062
					0	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	32,955	****	****	****	****	1.15	****	4.22	****	0.00 (0.07, 0.00)	0.000
ARBs (14-day gap)	269,804	****	****	****	****	5.36	****	-4.22	ጥ ጥ ጥ ጥ	0.22 (0.07, 0.68)	0.009
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	32,556	****	****	****	****	1.19	****		* * * * *		• · · ·=
ARBs (14-day gap)	32,556	****	****	****	****	3.18	****	-1.99	* * * * *	0.38 (0.10, 1.41)	0.147
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	32,600	****	****	****	****	1.16	****	4.00	****		6.15
ARBs (14-day gap)	32,605	****	****	****	****	3.07	****	-1.92	<b>* * * *</b>	0.38 (0.10, 1.42)	0.15



. ,	• •					•	•				
	Number of	Person Years	Average Person Days	Average Person Years	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
					31	- 60 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	29,979	****	****	****	****	1.98	****	-1.43	****	0.58 ( 0.21, 1.59)	0.291
ARBs (14-day gap)	253,331	****	****	****	****	3.41	****	-1.45		0.38 ( 0.21, 1.39)	0.291
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	27,574	****	****	****	****	1.78	****	0	****	4.00/0.20 4.05	4
ARBs (14-day gap)	27,574	****	****	****	****	1.78	****	0		1.00 ( 0.20, 4.95)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	29,701	****	****	****	****	1.99	****	4 4 7	****	0.64/0.40, 0.40	0 474
ARBs (14-day gap)	30,313	****	****	****	****	3.17	****	-1.17	<b>ጥ ጥ ጥ ጥ</b>	0.64 (0.19, 2.18)	0.474
					61	- 90 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	19,875	****	****	****	****	1.34	****	4.62	****	0.46 / 0.44 . 4.00	0.070
ARBs (14-day gap)	199,450	****	****	****	****	2.97	****	-1.63	ጥ ጥ ጥ ጥ	0.46 (0.11, 1.88)	0.278
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	14,351	****	****	****	****	0.98	****		****		
ARBs (14-day gap)	14,351	****	****	****	****	2.95	****	-1.96	* * * * *	0.33 ( 0.03, 3.20)	0.341
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	19,699	****	****	****	****	0.67	****		****		
ARBs (14-day gap)	23,789	****	****	****	****	2.17	****	-1.5	* * * * *	0.31 (0.03, 2.79)	0.298
					91	- 180 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	16,273	****	****	****	****	1.4	****	0.55	ماد ماد مار بله بله		
ARBs (14-day gap)	177,174	****	****	****	****	1.75	****	-0.35	****	0.81 (0.29, 2.24)	0.687
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	10,320	****	****	****	****	0.73	****	_	ste ste ste ste ste		
ARBs (14-day gap)	10,320	****	****	****	****	0.73	****	0	****	1.00 ( 0.06, 15.99)	1
, , , , , , , , , , , , , , , , , , , ,	,										



						Incidence		Incidence			
			Average	Average				Rate	Difference		
		Person	Average Person	Average Person	Number	Rate per 1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000		1,000 New	(95% Confidence	Wald
Madical Duaduct	New Users	at Risk	at Risk	at Risk	Events	Years	•	per 1,000 Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Medical Product						Tears	New Osers	Person fears	Users	interval)	P-value
Fixed Ratio 1:1 Prope	,			1 1							
SV (14-day gap)	16,124	****	****	****	****	1.41	****	-0.17	* * * * *	0.90 ( 0.25, 3.18)	0.867
ARBs (14-day gap)	20,952	****	****	****	****	1.59	****	0.27			
					181	- 270 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	8,822	****	****	****	****	0.59	****	-1.28	****	0.32 ( 0.04, 2.30)	0.256
ARBs (14-day gap)	109,601	****	****	****	****	1.87	****	-1.20		0.32 (0.04, 2.30)	0.230
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	3,325	****	****	****	****	1.87	****	4.07	****		
ARBs (14-day gap)	3,325	****	****	****	****	0	****	1.87	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	8,739	****	****	****	****	0.59	****		****		
ARBs (14-day gap)	12,445	****	****	****	****	1.6	****	-1.01	* * * * *	0.38 ( 0.04, 3.38)	0.384
					271	- 365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	5,512	****	****	****	****	0.85	****	0.46	****		0.000
ARBs (14-day gap)	78,866	****	****	****	****	1.31	****	-0.46	* * * * *	0.67 (0.09, 4.94)	0.693
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,436	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1,436	****	****	****	****	0	****	0	<u>ት ት ት ት</u>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	5,458	****	****	****	****	0.86	****	0.24	****	0.70 ( 0.07, 0.75)	0.05
ARBs (14-day gap)	8,510	****	****	****	****	1.1	****	-0.24	<u>ት ት ት ት</u>	0.79 ( 0.07, 8.75)	0.85
	0,510					1.1					

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Race: Unknown											
Site-Adjusted Analy	sis										
SV	7,289	****	****	****	****	0.75	****	-1.77	* * * * *	0.30 (0.07, 1.22)	0.092
ARBs	47,812	****	****	****	****	2.51	****	-1.77		0.30 (0.07, 1.22)	0.092
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	7,159	****	****	****	****	0.65	****	-1.31	****	0.22 (0.02, 2.20)	0.341
ARBs	7,159	****	****	****	****	1.96	****	-1.31		0.33 (0.03, 3.20)	0.341
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	7,159	****	****	****	****	0.76	****	1 22	****	0.20 (0.00 1.07)	0.232
ARBs	7,159	****	****	****	****	2.08	****	-1.32		0.38 (0.08, 1.87)	0.232
Race: American Ind	ian										
Site-Adjusted Analy	sis										
SV	143	****	****	****	****	0	****	-1.36	****		
ARBs	1,947	****	****	****	****	1.36	****	-1.30		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	138	****	****	****	****	0	****	0	****		
ARBs	138	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	138	****	****	****	****	0	****	0	****		
ARBs	138	****	****	****	****	0	****	0		-	-
Race: Asian											
Site-Adjusted Analy	sis										
SV	511	****	****	****	****	0	****	0.04	****		
ARBs	7,817	****	****	****	****	0.81	****	-0.81	-11111-	-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	484	****	****	****	****	0	****	0	****		
ARBs	484	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	-	tched Unco	nditional A	nalysis; Cali	per= 0.05		****				
SV	484	****	****	****	****	0	****	0	****	-	-
ARBs	484	* * * * *	* * * * *	* * * *	* * * * *	0	* * * *		_		_
Race: Black	-1-										
SV	5,853	****	****	****	****	4.01	****				
SV ARBs		****	****	****	****	6.8	****	-2.79	****	0.54 (0.25, 1.15)	0.11
	55,815					0.8					
Fixed Ratio 1:1 Prop				iysis; Callpe ****	r= 0.05 ****	2.70	****				
SV ARBs	5,765 5,765	****	****	****	****	3.76 3.76	****	0	****	1.00 (0.25, 4.00)	1
Fixed Ratio 1:1 Prop	,					3.76					
SV	5,765	*****		****	per= 0.05	4.06	****				
SV ARBs	5,765	****	****	****	****	4.06	****	0.36	****	1.08 (0.39, 3.00)	0.879
Race: Pacific Islande	,					5.7					
Site-Adjusted Analy									_		
SV	46	****	****	****	****	0	****				
ARBs	478	****	****	****	****	8.97	****	-8.97	****	-	-
Fixed Ratio 1:1 Prop		tched Conc	litional Ana	lysis: Caline	$r = 0.05^{1}$	0.57					
SV	31	****	****	****	****	0	****				
ARBs	31	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Prop		tched Unco	nditional A	nalvsis: Cali	per= 0.05						
SV	31	****	****	****	****	0	****				
ARBs	31	****	****	****	****	0	****	0	* * * * *	-	-
Race: White						Ŭ					
Site-Adjusted Analy	sis										
SV	29,935	****	****	****	****	1.1	****	-1.3	****	0.42 (0.24, 0.76)	0.004



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	29,757	****	****	****	****	1.03	****	1.10	****		0.000
ARBs	29,757	****	****	****	****	2.21	****	-1.18		0.47 (0.19, 1.14)	0.096
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	29,757	****	****	****	****	1.11	****	0.07	****		0.051
ARBs	29,757	****	****	****	****	2.08	****	-0.97	-0.97 ****	0.51 (0.26, 1.00)	0.051

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



· · ·	1 '				11 /		-				
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Race: Unknown										•	
						Overall					
Site-Adjusted Analys	is										
SV (14-day gap)	7,289	****	****	****	****	0.75	****				
ARBs (14-day gap)	47,812	****	****	****	****	2.51	****	-1.77	****	0.30 ( 0.07, 1.22)	0.092
Fixed Ratio 1:1 Prope		tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	7,159	****	****	****	****	0.65	****				
ARBs (14-day gap)	7,159	****	****	****	****	1.96	****	-1.31	****	0.33 ( 0.03, 3.20)	0.341
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	7,159	****	****	****	****	0.76	****		ale ale ale ale ale		
ARBs (14-day gap)	7,159	****	****	****	****	2.08	****	-1.32	****	0.38 (0.08, 1.87)	0.232
					0	- 30 Days					
Site-Adjusted Analys	is										
SV (14-day gap)	7,289	****	****	****	****	0	****	2.44	****		
ARBs (14-day gap)	47,812	****	****	****	****	3.41	****	-3.41		-	-
Fixed Ratio 1:1 Prope	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	7,125	****	****	****	****	0	****	4.05	****		
ARBs (14-day gap)	7,125	****	****	****	****	1.85	****	-1.85	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	7,209	****	****	****	****	0	****	-1.77	****		
ARBs (14-day gap)	7,398	****	****	****	****	1.77	****	-1.//			-
					31	- 60 Days					
Site-Adjusted Analys											
SV (14-day gap)	6,560	****	****	****	****	0	****	-2.52	* * * * *		
	44,564	****	****	****	****	2.52	****				



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,874	****	****	****	****	0	****		****		
ARBs (14-day gap)	5,874	****	****	****	****	2.82	****	-2.82	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	6,446	****	****	****	****	0	****		****		
ARBs (14-day gap)	6,520	****	****	****	****	4.33	****	-4.33	* * * * *	-	-
					61	- 90 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	4,440	****	****	****	****	3.01	****		****	2 00 ( 0 24 25 42)	0.00
ARBs (14-day gap)	33,271	****	****	****	****	1.57	****	1.44	ጥ ጥ ጥ ጥ	2.80 ( 0.31, 25.43)	0.36
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,963	****	****	****	****	0	****	_	****		
ARBs (14-day gap)	2,963	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	4,367	****	****	****	****	3.06	****	2.05	****		
ARBs (14-day gap)	4,816	****	****	****	****	0	****	3.06	* * * * *	-	-
					91	- 180 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	3,591	****	****	****	****	1.53	****	4.70	****	0.47 ( 0.06 - 0.52)	0.40
ARBs (14-day gap)	28,540	****	****	****	****	3.29	****	-1.76		0.47 (0.06, 3.53)	0.46
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Anal	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	2,019	****	****	****	****	3.63	****		****		
ARBs (14-day gap)	2,019	****	****	****	****	3.63	****	0	<u> </u>	1.00 ( 0.06, 15.99)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	3,541	****	****	****	****	1.55	****	1.21	****		0.612
ARBs (14-day gap)	4,059	****	****	****	****	2.76	****	-1.21	ጥ ጥ ጥ ጥ	0.54 ( 0.05, 5.93)	0.612



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					181	- 270 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	2,040	****	****	****	****	0	****	2.00	****		
ARBs (14-day gap)	16,763	****	****	****	****	2.06	****	-2.06		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	657	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	657	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,021	****	****	****	****	0	****	2.24	****		
ARBs (14-day gap)	2,273	****	****	****	****	2.21	****	-2.21		-	-
					271	- 365 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	1,297	****	****	****	****	0	****	1.10	****		
ARBs (14-day gap)	11,721	****	****	****	****	1.16	****	-1.16		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	292	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	292	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,284	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1,522	****	****	****	****	0	****	0	-8191919-	-	-
Race: American India	n										
						Overall					
Site-Adjusted Analysi	S										
SV (14-day gap)	143	****	****	****	****	0	****	-1.36	****		
ARBs (14-day gap)	1,947	****	****	****	****	1.36	****	-1.50		-	-



· · ·	1 ,		1 1	<u>, , ,</u>	<u>,                                    </u>						
		Person	Average Person	Average Person	Number	Incidence Rate per 1,000	Risk per	Incidence Rate Difference	Difference in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	•	Person Years	Users	Interval) <sup>2</sup>	P-Value
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	138	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	138	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	138	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	138	****	****	****	****	0	****	0		-	-
					0	- 30 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	211	****	****	****	****	0	****	5.6	****		
ARBs (14-day gap)	2,647	****	****	****	****	5.6	****	-5.6		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	143	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	143	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	205	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	237	****	****	****	****	0	****	0		-	-
					31	- 60 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	126	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1,839	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	115	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	115	****	****	****	****	0	****	0	ቁ ቁ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	122	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	131	****	****	****	****	0	****	0	4. 4. 4. 4. 4.	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					61	- 90 Days					
Site-Adjusted Analysi		****	****	****	****	-	****				
SV (14-day gap)	78	****	****	****	****	0	****	0	****	-	-
ARBs (14-day gap)	1,234					0	* * * *				
Fixed Ratio 1:1 Prope											
SV (14-day gap)	57	****	****	****	****	0	****	0	****	-	-
ARBs (14-day gap)	57	****	****	****	****	0	****	Ũ			
Fixed Ratio 1:1 Prope	-			1 .							
SV (14-day gap)	77	****	****	****	****	0	****	0	****	-	_
ARBs (14-day gap)	93	****	****	****	****	0	****	0			_
					91 -	180 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	63	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1,023	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	40	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	40	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	62	****	****	****	****	0	****		****		
ARBs (14-day gap)	81	****	****	****	****	0	****	0	* * * * *	-	-
					181	- 270 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	32	****	****	****	****	0	****	6	****		
ARBs (14-day gap)	551	****	****	****	****	0	****	0	<u> </u>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	15	****	****	****	****	0	****		****		
ARBs (14-day gap)	15	****	****	****	****	0	****	0	* * * * *	-	-



· · ·							•				
			A	Average		Incidence		Incidence Rate	Difference		
		Person	Average Person	Average Person	Number	Rate per	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years		Years	of	1,000 Person	1.000		1,000 New	(95% Confidence	Wald
Mardia al Dua du at	Number of	at Risk	Days at Risk	at Risk	Events	Years		per 1,000 Person Years	Users	Interval) <sup>2</sup>	P-Value
Medical Product						rears	New Users	Person rears	Users	interval)	P-value
Fixed Ratio 1:1 Prope	,				•						
SV (14-day gap)	33	****	****	****	****	0	****	0	* * * * *	-	-
ARBs (14-day gap)	47	****	****	****	****	0	****	5			
					271	365 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	18	****	****	****	****	0	****	0	* * * * *		
ARBs (14-day gap)	370	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	****	****	****	****	****	0	****	-	****		
ARBs (14-day gap)	****	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	19	****	****	****	****	0	****	-	****		
ARBs (14-day gap)	31	****	****	****	****	0	****	0	* * * * *	-	-
Race: Asian											
						Overall					
Site-Adjusted Analysi	S										
SV (14-day gap)	511	****	****	****	****	0	****	0.01	****		
ARBs (14-day gap)	7,817	****	****	****	****	0.81	****	-0.81		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	484	****	****	****	****	0	****	<u> </u>	****		
ARBs (14-day gap)	484	****	****	****	****	0	****	0	<u>ት ት ት ት</u>	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	484	****	****	****	****	0	****	-	ala ala ala ala ala		
ARBs (14-day gap)	484	****	****	****	****	0	****	0	****	-	-
- ( / 3/	-					-					



Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
				0	- 30 Days					
					-		0	* * * * *	-	-
,					0	****				
nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
437	****	****	****	****	0	****	0	* * * * *	_	_
437	****	****	****	****	0	****	0		-	_
nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
448	****	****	****	****	0	****	0	****		
453	****	****	****	****	0	****	0		-	-
				31	- 60 Days					
S										
472	****	****	****	****	0	****	0	* * * * *		
7,373	****	****	****	****	0	****	0		-	-
nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
405	****	****	****	****	0	****				
405	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b>	-	-
nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
432	****	****	****	****	0	****				
442	****	****	****	****	0	****	0	* * * * *	-	-
				61	- 90 Days					
S										
325	****	****	****	****	0	****	2.4.6	****		
5,973	****	****	****	****	2.16	****	-2.16	ጥ ጥ ጥ ጥ ጥ	-	-
nsity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
251	****	****	****	****	0	****	0	*****		
251	****	****	****	****	0	****	U	····· ·· ·· ··	-	-
	New Users   s   509   7,782   nsity Score Mar   437   437   437   437   437   437   437   437   437   437   437   437   437   5   472   7,373   nsity Score Mar   405   405   405   405   405   325   5,973   nsity Score Mar   325   5,973	Number of New Users   Years at Risk     509   *****     509   *****     7,782   *****     nsity Score   Matched Cond     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     437   *****     448   *****     453   *****     453   *****     405   *****     405   *****     405   *****     432   *****     432   *****     325   *****     325   *****     5,973   *****     251   *****	Number of New Users   Person 3 t Risk   Person Days at Risk     509   *****   *****     509   *****   *****     7,782   *****   *****     nsity Score Matched Conditional Ana 437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     s   *****   *****     453   *****   *****     453   *****   *****     453   *****   *****     453   *****   *****     405   *****   *****     405   *****   *****     405   *****   *****     432   *****   *****     442   *****   *****     325   *****   *****     5,973   *****   ***** <td>Person Number of New Users   Person at Risk   Person Days at Risk   Person Years at Risk     s   509   *****   *****     7,782   *****   *****     nsity Score Matched Conditional Analysis; Calipe 437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     433   *****   *****     5  </td> <td>Number of New Users   Person at Risk   Person Days at Risk   Person at Risk   Number of at Risk     509   ******   ******   ******   ******   ******     509   *****   ******   ******   ******   ******     7,782   ******   ******   ******   ******   ******     nsity Score Matched Conditional Analysis; Caliper= 0.05<sup>1</sup>   437   ******   ******   ******     437   ******   ******   ******   ******   ******     437   ******   ******   ******   ******   ******     437   ******   ******   ******   ******     437   ******   ******   ******     437   ******   ******   ******     437   ******   ******   ******     sity Score Matched Unconditional Analysis; Caliper= 0.05<sup>1</sup>   405   ******   ******     405   ******   ******   ******   ******     432   ******   ******</td> <td>Number of New Users   Person at Risk   Average Person Days at Risk   Number Person Number of Person at Risk   Number of Person Person at Risk   Rate per 1,000     Number of New Users   Years at Risk   Days at Risk   Number of Person at Risk   O     So   *****   *****   *****   *****   0     509   *****   *****   *****   0     7,782   *****   *****   *****   0     A37   *****   *****   *****   0     437   *****   *****   *****   0     433   *****   *****   *****   0     433   *****   *****   *****   0     433   *****   *****   *****   0     448   *****   *****   *****   0     453   *****   *****   0   0     7,373   *****   *****   0   0     noticy Score Mat-ter Uncontional Analysis; Caliperiods   0   0     472   <td< td=""><td>Average Person Number of New UsersAverage Person Person Days at RiskAverage Person Person Number Number Number of Person Person Person Person Person New UsersRisk per Risk per 1,000 New Userss<math>0 - 30</math> Days<math>0 - 30</math> Dayss<math>0 - 30</math> Days<math>0 - 30</math>s<math>0 - 30</math><math>0 - </math></td><td>Number of Number of Number of Number of Years at Risk at Risk at Risk</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></td><td>Number of Number of Number of Number of YearsAverage Person DaysAverage Person Years at RiskRate per 1,000 PersonRisk per 1,000 New UsersRate per per 1,000 New UsersRisk per per 1,000 New UsersDifference in Risk per 1,000 New Userss<math>0 - 30</math> Days**********<math>0 - 30</math> Days*****<math>0 - 30</math> Days******<math>0 - 30</math> Days******</td><td>Number of Number of Number of Number of Number of New UsersAverage Person DaysAverage Person of of of of of of of Person Number Person Number of Number of NumbersRate Person Difference pers0,000 Numbers Pers000Difference Difference Numbers Pers000Difference Difference Numbers Pers000Difference Difference NumbersDifference Numbers NumbersDifference Difference NumbersDi</td></td<></td>	Person Number of New Users   Person at Risk   Person Days at Risk   Person Years at Risk     s   509   *****   *****     7,782   *****   *****     nsity Score Matched Conditional Analysis; Calipe 437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     437   *****   *****     433   *****   *****     5	Number of New Users   Person at Risk   Person Days at Risk   Person at Risk   Number of at Risk     509   ******   ******   ******   ******   ******     509   *****   ******   ******   ******   ******     7,782   ******   ******   ******   ******   ******     nsity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> 437   ******   ******   ******     437   ******   ******   ******   ******   ******     437   ******   ******   ******   ******   ******     437   ******   ******   ******   ******     437   ******   ******   ******     437   ******   ******   ******     437   ******   ******   ******     sity Score Matched Unconditional Analysis; Caliper= 0.05 <sup>1</sup> 405   ******   ******     405   ******   ******   ******   ******     432   ******   ******	Number of New Users   Person at Risk   Average Person Days at Risk   Number Person Number of Person at Risk   Number of Person Person at Risk   Rate per 1,000     Number of New Users   Years at Risk   Days at Risk   Number of Person at Risk   O     So   *****   *****   *****   *****   0     509   *****   *****   *****   0     7,782   *****   *****   *****   0     A37   *****   *****   *****   0     437   *****   *****   *****   0     433   *****   *****   *****   0     433   *****   *****   *****   0     433   *****   *****   *****   0     448   *****   *****   *****   0     453   *****   *****   0   0     7,373   *****   *****   0   0     noticy Score Mat-ter Uncontional Analysis; Caliperiods   0   0     472 <td< td=""><td>Average Person Number of New UsersAverage Person Person Days at RiskAverage Person Person Number Number Number of Person Person Person Person Person New UsersRisk per Risk per 1,000 New Userss<math>0 - 30</math> Days<math>0 - 30</math> Dayss<math>0 - 30</math> Days<math>0 - 30</math>s<math>0 - 30</math><math>0 - </math></td><td>Number of Number of Number of Number of Years at Risk at Risk at Risk</br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></br></td><td>Number of Number of Number of Number of YearsAverage Person DaysAverage Person Years at RiskRate per 1,000 PersonRisk per 1,000 New UsersRate per per 1,000 New UsersRisk per per 1,000 New UsersDifference in Risk per 1,000 New Userss<math>0 - 30</math> Days**********<math>0 - 30</math> Days*****<math>0 - 30</math> Days******<math>0 - 30</math> Days******</td><td>Number of Number of Number of Number of Number of New UsersAverage Person DaysAverage Person of of of of of of of Person Number Person Number of Number of NumbersRate Person Difference pers0,000 Numbers Pers000Difference Difference Numbers Pers000Difference Difference Numbers Pers000Difference Difference NumbersDifference Numbers NumbersDifference Difference NumbersDi</td></td<>	Average Person Number of New UsersAverage Person Person Days at RiskAverage Person Person Number Number Number of Person Person Person Person Person New UsersRisk per Risk per 1,000 New Userss $0 - 30$ Days $0 - 30$ Dayss $0 - 30$ Days $0 - 30$ s $0 - 30$ $0 - $	Number of Number of Number of Number of Years at Risk at Risk 	Number of Number of Number of Number of YearsAverage Person DaysAverage Person Years at RiskRate per 1,000 PersonRisk per 1,000 New UsersRate per per 1,000 New UsersRisk per per 1,000 New UsersDifference in Risk per 1,000 New Userss $0 - 30$ Days********** $0 - 30$ Days***** $0 - 30$ Days******	Number of Number of Number of Number of Number of New UsersAverage Person DaysAverage Person of of of of of of of Person Number Person Number of Number of NumbersRate Person Difference pers0,000 Numbers Pers000Difference Difference Numbers Pers000Difference Difference Numbers Pers000Difference Difference NumbersDifference Numbers NumbersDifference Difference NumbersDi



· · ·	1 1				11 2		•				
		Person	Average Person	Average Person	Number	Incidence Rate per 1,000	Risk per	Incidence Rate Difference	Difference in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	316	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	376	****	****	****	****	0	****	0		-	-
					91	- 180 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	247	****	****	****	****	0	****	-1.04	****		
ARBs (14-day gap)	5,297	****	****	****	****	1.04	****	-1.04		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	158	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	158	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	235	****	****	****	*****	0	****	0	****		
ARBs (14-day gap)	326	****	****	****	****	0	****	0		-	-
					181	- 270 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	135	****	****	****	****	0	****	1 55	****		
ARBs (14-day gap)	3,218	****	****	****	****	1.55	****	-1.55		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	60	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	60	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	128	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	177	****	****	****	****	0	****	U		-	-
					271	- 365 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	87	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	2,249	****	****	****	****	0	****	0		-	-



							•				
						Incidence		Incidence			
			Average	Average		Rate per		Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV (14-day gap)	31	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	31	****	****	****	****	0	****	U		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	83	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	115	****	****	****	****	0	****	0		-	-
Race: Black											
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	5,853	****	****	****	****	4.01	****	2 70	****		0.11
ARBs (14-day gap)	55,815	****	****	****	****	6.8	****	-2.79		0.54 (0.25, 1.15)	0.11
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,765	****	****	****	****	3.76	****		****	4.00 ( 0.05 . 4.00)	
ARBs (14-day gap)	5,765	****	****	****	****	3.76	****	0	<b>ጥ ጥ ጥ ጥ</b>	1.00 ( 0.25, 4.00)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	5,765	****	****	****	****	4.06	****	0.00	****	4 00 ( 0 00 - 0 00)	0.070
ARBs (14-day gap)	5,765	****	****	****	****	3.7	****	0.36	ጥ ጥ ጥ ጥ	1.08 (0.39, 3.00)	0.879
					0	- 30 Days					
Site-Adjusted Analysi	s										
SV (14-day gap)	5,853	****	****	****	****	2.16	****	11.10	****	0.46 ( 0.02 . 4.4.4)	0.007
ARBs (14-day gap)	55,815	****	****	****	****	13.65	****	-11.49	-1111-	0.16 ( 0.02, 1.14)	0.067
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	5,765	****	****	****	****	2.26	****		ale ale ale ale ale		
ARBs (14-day gap)	5,765	****	****	****	****	4.52	****	-2.26	****	0.50 (0.05, 5.51)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cal	iper= 0.05						
SV (14-day gap)	5,765	****	****	****	****	2.19	****	0.47	* * * * *		0.565
ARBs (14-day gap)	5,765	****	****	****	****	4.36	****	-2.17	<b>* * * *</b>	0.50 ( 0.04, 5.46)	0.566
, ,,,,,											



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					31	- 60 Days					
Site-Adjusted Analysis			de de de de de	de de de de de			****				
SV (14-day gap)	5,322	****	****	****	****	2.94		-4.46	****	0.40 ( 0.05, 2.93)	0.366
ARBs (14-day gap)	52,284	****	****	****	****	7.4	****	_		( , ,	
Fixed Ratio 1:1 Prope	nsity Score Ma										
SV (14-day gap)	4,860	****	****	****	****	3.66	****	-3.66	****	0.50 ( 0.05, 5.51)	0.571
ARBs (14-day gap)	4,860	****	****	****	****	7.32	****	5.00		0.50 ( 0.05, 5.51)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma			nalysis; Cali	per= 0.05						
SV (14-day gap)	5,243	****	****	****	****	2.98	****	-2.41	* * * * *	0.54 ( 0.05, 5.99)	0.618
ARBs (14-day gap)	5,333	****	****	****	****	5.39	****	-2.41		0.54 (0.05, 5.99)	0.018
					61	- 90 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	3,101	****	****	****	****	4.4	****	2.24	****		0 707
ARBs (14-day gap)	37,460	****	****	****	****	6.61	****	-2.21		0.68 ( 0.09, 5.08)	0.707
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Ana	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,993	****	****	****	****	7.33	****	=	****		
ARBs (14-day gap)	1,993	****	****	****	****	0	****	7.33	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	3,058	****	****	****	****	4.46	****	2.42	****		0.000
ARBs (14-day gap)	3,789	****	****	****	****	6.93	****	-2.48	* * * * *	0.62 (0.06, 6.83)	0.696
					<b>91</b> ·	180 Days					
Site-Adjusted Analysis	s										
SV (14-day gap)	2,361	****	****	****	****	5.3	****	4.07	****		0 70 /
ARBs (14-day gap)	32,147	****	****	****	****	4.23	****	1.07	ጥ ጥ ጥ ጥ ጥ	1.29 ( 0.30, 5.45)	0.734
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	litional Anal	ysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,289	****	****	****	****	6.83	****	6.02	****		
ARBs (14-day gap)	1,289	****	****	****	****	0	****	6.83	<u>ት ት ት ት ት</u>	-	-



					= =						
			Average	Average		Incidence Rate per		Incidence Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	2,333	****	****	****	****	5.37	****		****	2 22 ( 2 2 2 2 2 2 2 2 2	
ARBs (14-day gap)	3,196	****	****	****	****	1.88	****	3.49	* * * * *	2.88 ( 0.26, 31.78)	0.388
					181	- 270 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	1,072	****	****	****	****	9.93	****	F 70	****	2 26 / 0 54 40 27)	0.257
ARBs (14-day gap)	17,235	****	****	****	****	4.18	****	5.76		2.36 ( 0.54, 10.37)	0.257
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	303	****	****	****	****	0	****		****		
ARBs (14-day gap)	303	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	1,058	****	****	****	****	10.05	****	6.84	****	2.02 ( 0.27.22.45)	0.265
ARBs (14-day gap)	1,640	****	****	****	****	3.21	****	6.84		3.03 ( 0.27, 33.45)	0.365
					271	- 365 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	650	****	****	****	****	0	****	-2.9	****		
ARBs (14-day gap)	11,241	****	****	****	****	2.9	****	-2.9		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	115	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	115	****	****	****	****	0	****	0	ne ne ne ne ne	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	643	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1.001	****	****	****	****	0	****	0		-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Race: Pacific Islander											
						Overall					
Site-Adjusted Analysi	s										
SV (14-day gap)	46	****	****	****	****	0	****	-8.97	* * * * *		
ARBs (14-day gap)	478	****	****	****	****	8.97	****	-0.97		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	31	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	31	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	31	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	31	****	****	****	****	0	****	0		-	-
					0	- 30 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	69	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	1,590	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	29	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	29	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	65	****	****	****	****	0	****	6	****		
ARBs (14-day gap)	111	****	****	****	****	0	****	0	* * * * *	-	-
					31	- 60 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	43	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	446	****	****	****	****	0	****	0	·*· ·*· ·*· ·*· ·*·	-	-



			1 .		<u> </u>						
			Average	Average		Incidence Rate per		Incidence Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Davs	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	•	Person Years	Users	Interval) <sup>2</sup>	P-Value
Fixed Ratio 1:1 Proper											
SV (14-day gap)	28	****	****	****	****	0	****				
ARBs (14-day gap)	28	****	****	****	****	0	****	0	****	-	-
Fixed Ratio 1:1 Proper	-	tched Unco	nditional A	nalysis <sup>.</sup> Cali	ner= 0.05						
SV (14-day gap)	29	****	****	****	****	0	****				
ARBs (14-day gap)	30	****	****	****	****	0	****	0	****	-	-
ANDS (14 ddy gdp)	50				61	- 90 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	30	****	****	****	****	0	****				
ARBs (14-day gap)	359	****	****	****	****	34.86	****	-34.86	****	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	13	****	****	****	****	0	****	_	****		
ARBs (14-day gap)	13	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	18	****	****	****	****	0	****		****		
ARBs (14-day gap)	23	****	****	****	****	0	****	0	* * * * *	-	-
					91	- 180 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	27	****	****	****	****	0	****	17 55	****		
ARBs (14-day gap)	335	****	****	****	****	17.55	****	-17.55		-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	12	****	****	****	****	0	****	0	****		
ARBs (14-day gap)	12	****	****	****	****	0	****	0	ቁ ቁ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	17	****	****	****	****	0	****		****		
ARBs (14-day gap)	21	****	****	****	****	0	****	0		-	-



						•				
					Incidence		Incidence	5.11		
	Davaava	-	-	Number	-	Dielemen			Hazard Ratio	
Number of					-	-		-		Wald
		,		•••			• •	,	•	P-Value
New Users	at Risk	at Risk	at RISK			New Users	Person Years	Users	Interval)	P-value
				181	- 270 Days					
	ala ala ala ala ala	ale ale ale ale ale	ala ala ala ala ala	ale ale ale ale ale		ala ala ala ala ala				
-					•		0	****	-	-
					0	****	_			
****	****	****	****	****	0	****	0	****	_	_
****	****	****	****	****	0	****	0		_	_
nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
12	****	****	****	****	0	****	0	* * * * *		
14	****	****	****	****	0	****	0		-	-
				271	- 365 Days					
S										
****	****	****	****	****	0	****	0	* * * * *		
138	****	****	****	****	0	****	0		-	-
nsity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
****	****	****	****	****	0	****	_	ala ala ala ala ala		
****	****	****	****	****	0	****	0	* * * * *	-	-
nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
****	****	****	****	****	0	****	_			
12	****	****	****	****	0	****	0	* * * * *	-	-
					Overall					
S										
3										
29,935	****	****	****	****	1.1	****	-1.3	****	0.42 ( 0.24, 0.76)	0.004
	***** nsity Score Mat 12 14 s ***** 138 nsity Score Mat ***** nsity Score Mat ***** 12	New Users   at Risk     s   15   *****     194   *****     nsity Score Matched Conc   *****     *****   *****     nsity Score Matched Uncc   12     12   *****     14   *****     ss   *****     nsity Score Matched Uncc   12     *****   *****     138   *****     nsity Score Matched Conc   *****     *****   *****     138   *****     nsity Score Matched Conc   *****     *****   *****     12   *****     138   *****     12   *****     12   *****	Number of New Users   Years at Risk   Days at Risk     15   *****   *****     15   *****   *****     194   *****   *****     nsity Score Matched Conditional Anal *****   *****   *****     nsity Score Matched Unconditional Anal *****   *****   *****     nsity Score Matched Unconditional Anal 12   *****   *****     14   *****   *****     138   *****   *****     nsity Score Matched Conditional Anal *****   *****     nsity Score Matched Conditional Anal *****   *****     138   *****   *****     nsity Score Matched Unconditional Anal *****   *****     12   *****   *****     12   *****   *****	Person Number of New UsersPerson Years at RiskPerson Days at RiskPerson Years at Risk15***************194***************194***************nsity Score Matched Conditional Analysis; Calipe ***************nsity Score Matched Unconditional Analysis; Calipe 12**********12***************138***************nsity Score Matched Conditional Analysis; Calipe ***************138***************nsity Score Matched Conditional Analysis; Calipe ***************138***************nsity Score Matched Conditional Analysis; Calipe ***************12***************	Person   Person   Person   Person   Number of years   of of stress     Number of New Users   at Risk   at Risk   at Risk   at Risk   at Risk   at Risk   by years   of     15   *****   *****   *****   *****   *****   *****     194   *****   *****   *****   *****   *****     194   *****   *****   *****   *****     194   *****   *****   *****   *****     nsity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> *****   *****   *****     12   *****   *****   *****   *****     12   *****   *****   *****     14   *****   *****   *****     138   *****   *****   *****     138   *****   *****   *****     138   *****   *****   *****     138   *****   *****   *****     *****   *****   ****	Average Person New Users   Average Person at Risk   Average Person bays   Number Person years   Rate per 1,000     Number of New Users   Years at Risk   O   Person at Risk   Number years   1,000     Number of New Users   at Risk   at Risk   Events   Years     15   *****   *****   *****   0     194   *****   *****   0     194   *****   *****   0     194   *****   *****   0     nisity Score Matched Conditional Analysis; Caliper= 0.05 <sup>1</sup> *****   0     12   *****   *****   0     12   *****   *****   0     12   *****   *****   0     138   *****   *****   0     138   *****   *****   0     *****   *****   *****   0     138   *****   *****   0     *****   *****   *****   0     *****   *****   ****<	Average Person Number of New Users   Average Person at Risk   Average Person person at Risk   Rate per Number of Person New Users     Number of New Users   Years at Risk   Number of Person New Users   1,000 New Users     15   *****   *****   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     194   *****   *****   0   *****     nsity Score Matched Unconditional Analysis; Caliper= 0.05   *****   0   ******     12   *****   *****   0   ******     138   *****   *****   0   ******	Number of New UsersAverage Person At RiskAverage Person Person At RiskRate per Person of Ferson VearsRate per Risk per Person Person New UsersRate Difference per 1,000 New UsersRate Difference per 1,000 New UsersRate Person Person Years15***************0*****015***************0*****0194***************0*****0194***************0*****0194***************0*****015***************0*****015***************0*****015***************0*****015***************0*****012***************0*****012***************0*****0138***************0*****0138***************0*****0139***************0*****0139***************0*****0130***************0*****0131***************0*****0<	Average Person Number of New Users   Average Person at Risk at Risk at Risk at Risk   Average Person At Risk at	Number of Number of New UsersAverage Person A failsAverage Person Person Vears DaysAverage Person Vears VearsRate per 1,000 Person Person New UsersRate Difference per 1,000 New UsersDifference in Risk per 1,000 New UsersHazard Ratio (95% Confidence Interval)2s <t< td=""></t<>



	1 :		1 ;	1 1	// /						
		Person	Average Person	Average Person	Number	Incidence Rate per 1,000	Risk per	Incidence Rate Difference	Difference in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years		Person Years	Users	Interval) <sup>2</sup>	P-Value
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	29,757	****	****	****	****	1.03	****	4.40	****	0.47/0.40.4.44	
ARBs (14-day gap)	29,757	****	****	****	****	2.21	****	-1.18	* * * * *	0.47 (0.19, 1.14)	0.096
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	29,757	****	****	****	****	1.11	****	0.07	****	0.54 ( 0.05 - 4.00)	0.054
ARBs (14-day gap)	29,757	****	****	****	****	2.08	****	-0.97		0.51(0.26, 1.00)	0.051
					0	- 30 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	29,935	****	****	****	****	1.26	****	2.54	****		0.022
ARBs (14-day gap)	223,288	****	****	****	****	4.8	****	-3.54		0.26 ( 0.08, 0.83)	0.023
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	29,757	****	****	****	****	1.31	****	2.64	****	0.00 ( 0.00 ( 0.00)	
ARBs (14-day gap)	29,757	****	****	****	****	3.92	****	-2.61	ጥ ጥ ጥ ጥ	0.33 (0.09, 1.23)	0.099
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	29,757	****	****	****	****	1.27	****	2.52	****	0.00 ( 0.00 ( 0.04)	0.101
ARBs (14-day gap)	29,757	****	****	****	****	3.79	****	-2.52		0.33 (0.09, 1.24)	0.101
					31	- 60 Days					
Site-Adjusted Analysi	S										
SV (14-day gap)	27,322	****	****	****	****	1.62	****	1.10	****	0.50 / 0.40 .4.07)	0.20
ARBs (14-day gap)	209,796	****	****	****	****	2.81	****	-1.19		0.58 (0.18, 1.87)	0.36
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Con	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	25,245	****	****	****	****	1.3	****	0.65	****	2 00 / 0 40 00 00	
ARBs (14-day gap)	25,245	****	****	****	****	0.65	****	0.65	ጥ ጥ ጥ ጥ ጥ	2.00 ( 0.18, 22.06)	0.571
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unc	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	27,160	****	****	****	****	1.63	****	0.26	****	0.02 ( 0.10, 2.00)	0 702
ARBs (14-day gap)	27,657	****	****	****	****	1.99	****	-0.36	ጥ ጥ ጥ ጥ	0.82 (0.18, 3.66)	0.792



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
					61	- 90 Days					
Site-Adjusted Analysis											
SV (14-day gap)	18,222	****	****	****	****	1.46	****	-0.72	****	0.68 ( 0.16, 2.84)	0.592
ARBs (14-day gap)	165,220	****	****	****	****	2.18	****	-0.72		0.00 ( 0.10, 2.04)	0.352
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	13,131	****	****	****	****	1.07	****	-2.14	* * * * *	0.33 ( 0.03, 3.20)	0.341
ARBs (14-day gap)	13,131	****	****	****	****	3.21	****	-2.14		0.33 (0.03, 3.20)	0.341
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	18,107	****	****	****	****	1.47	****	0.22	****	0.02 ( 0.14 . 4.04)	0.022
ARBs (14-day gap)	21,598	****	****	****	****	1.8	****	-0.33		0.83 (0.14, 4.94)	0.833
					91	- 180 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	14,999	****	****	****	****	1.14	****	0.55	****	0.67 ( 0.21 . 2.46)	0.505
ARBs (14-day gap)	146,951	****	****	****	****	1.69	****	-0.55	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.67 (0.21, 2.16)	0.505
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	9,524	****	****	****	****	0.79	****		****	4 00 ( 0 00 45 00)	
ARBs (14-day gap)	9,524	****	****	****	****	0.79	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	1.00 ( 0.06, 15.99)	1
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV (14-day gap)	14,904	****	****	****	****	1.15	****	0.00	****		0.407
ARBs (14-day gap)	19,006	****	****	****	****	2.03	****	-0.89	* * * * *	0.56 (0.15, 2.18)	0.407
					181	- 270 Days					
Site-Adjusted Analysis	5										
SV (14-day gap)	8,170	****	****	****	****	0	****	4 70	****		
ARBs (14-day gap)	92,144	****	****	****	****	1.73	****	-1.73	* * * * *	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	3,108	****	****	****	****	0	****	4.00	****		
ARBs (14-day gap)	3,108	****	****	****	****	1.99	****	-1.99	<u> </u>	-	-



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	8,117	****	****	****	****	0	****	1 21	****		
ARBs (14-day gap)	11,357	****	****	****	****	1.31	****	-1.31		-	-
					271	- 365 Days					
Site-Adjusted Analysis	S										
SV (14-day gap)	5,100	****	****	****	****	0.93	****	0.54	****		0.671
ARBs (14-day gap)	66,959	****	****	****	****	1.47	****	-0.54		0.65 (0.09, 4.80)	0.671
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV (14-day gap)	1,370	****	****	****	****	0	****	<u> </u>	****		
ARBs (14-day gap)	1,370	****	****	****	****	0	****	0	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prope	nsity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV (14-day gap)	5,063	****	****	****	****	0.93	****	0.36	****	0.00 ( 0.07 . 0.70)	0.050
ARBs (14-day gap)	7,812	****	****	****	****	1.19	****	-0.26	an an an an an an	0.80 (0.07, 8.78)	) 0.852

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Table 24. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, and Risk of Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analys	sis										
SV	41,998	****	****	****	****	1.11	****	5.0	****		.0.001
ACEI	695,012	****	****	****	****	6.91	****	-5.8	ጥ ጥ ጥ ጥ	0.15 (0.09, 0.25)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	41,998	****	****	****	****	1.5	****	0.07	****	0.40 (0.07 0.05)	-0.004
ACEI	41,998	****	****	****	****	11.48	****	-9.97	* * * * *	0.13 (0.07, 0.25)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	41,998	****	****	****	****	1.11	****	6.00	****	0.44 (0.00, 0.25)	-0.001
ACEI	41,998	****	****	****	****	7.2	****	* -6.09	ት ት ጥ ጥ	** 0.14 (0.08, 0.25)	<0.001

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analys	sis										
SV	43,777	****	****	****	****	1.14	****	1.0	****	0.25 (0.24 0.50)	-0.001
ARBs	337,157	****	****	****	****	3.04	****	-1.9		0.35 (0.21, 0.58)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	43,755	****	****	****	****	1.26	****	4.42	****	0.52 (0.24 4.42)	0.1
ARBs	43,755	****	****	****	****	2.39	****	-1.13	ጥ ጥ ጥ ጥ	0.53 (0.24, 1.13)	0.1
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	43,755	****	****	****	****	1.14	****	1.12	****	0.40 (0.27 0.00)	0.017
ARBs	43,755	****	****	****	****	2.27	****	* -1.13	ጥ ጥ ጥ ጥ ጥ	** 0.48 (0.27, 0.88)	0.017

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 26. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analy	sis										
SV	41,998	****	****	****	****	0.6	****		****		.0.001
ACEI	695,012	****	****	****	****	2	****	-1.4	ጥ ጥ ጥ ጥ	0.28 (0.15, 0.54)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	41,998	****	****	****	****	0.68	****	2.04	****	0.25 (0.40, 0.64)	0.000
ACEI	41,998	****	****	****	****	2.72	****	-2.04	* * * * *	0.25 (0.10, 0.61)	0.002
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	41,998	****	****	****	****	0.6	****	4 47	****	0.20 (0.42, 0.50)	.0.001
ACEI	41,998	****	****	****	****	2.07	****	* -1.47	ጥ ጥ ጥ ጥ ጥ	** 0.28 (0.13, 0.58)	< 0.001

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 27. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183, -1)

		•					-	• • •			
	Number of	Person ber of Years	Person Person Years Days	-	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users		at Risk	at Risk	Events	Years	•	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
No Angioedema	(-183, -1)										
Site-Adjusted Anal	ysis										
SV	41,941	****	****	****	****	0.53	****	4.99	مله مله مله مله		
ACEI	694,148	****	****	****	****	1.93	****	-1.39	* * * * *	0.26 (0.13, 0.52)	<0.001
Fixed Ratio 1:1 Pro	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	41,930	****	****	****	****	0.57	****	2.46	****		0.001
ACEI	41,930	****	****	****	****	2.72	****	-2.16		0.21 (0.08, 0.55)	0.001
Fixed Ratio 1:1 Pro	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	41,930	****	****	****	****	0.53	****	-1.54	* * * * *		<0.001
ACEI	41,930	****	****	****	****	2.08	****	-1.54		0.25 (0.11, 0.53)	<0.001
Angioedema (-18	3, -1)										
Site-Adjusted Anal	ysis										
SV	57	****	****	****	****	44.8	****	-30.56	* * * * *	0.74 (0.10, 5.47)	0.767
ACEI	864	****	****	****	****	75.37	****	-50.50		0.74 (0.10, 5.47)	0.707
Fixed Ratio 1:1 Pro	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	42	****	****	****	****	0	****		****		
ACEI	42	****	****	****	****	0	****	0			-
Fixed Ratio 1:1 Pro				nalysis; Cali	per= 0.05						
SV	42	****	****	****	****	0	****	0	* * * * *		
ACEI	42	****	****	****	****	0	****	U		-	-

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Table 28. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (ever, -1)

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
No Angioedema (ev	ver, -1)										
Site-Adjusted Analy	rsis										
SV	41,427	****	****	****	****	0.54	****	1 21	* * * * *		-0.001
ACEI	687,692	****	****	****	****	1.75	****	-1.21		0.29 (0.15, 0.59)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	41,416	****	****	****	****	0.57	****	1.05	* * * * *		0.002
ACEI	41,416	****	****	****	****	2.53	****	-1.95		0.23 (0.09, 0.60)	0.003
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	41,416	****	****	****	****	0.54	****	-1.44	****		<0.001
ACEI	41,416	****	****	****	****	1.98	****	-1.44		0.26 (0.12, 0.57)	<0.001
Angioedema (ever,	-1)										
Site-Adjusted Analy	rsis										
SV	571	****	****	****	****	4.77	****	-23.95	* * * * *	0.17 (0.02, 1.19)	0.074
ACEI	7,320	****	****	****	****	28.72	****	-25.95		0.17 (0.02, 1.19)	0.074
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	437	****	****	****	****	11.58	****	11 50	****		0.574
ACEI	437	****	****	****	****	23.17	****	-11.58		0.50 (0.05, 5.51)	0.571
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	437	****	****	****	****	6.31	****	E 2E	****		0 5 7 2
ACEI	437	****	****	****	****	11.66	****	-5.35		0.50 (0.05, 5.53)	0.573

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 29. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Serious Allergies

	Number of		Years Days	Average Person Years	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval)	P-Value
No Serious Allergies	5										
Site-Adjusted Analy	rsis										
SV	36,314	****	****	****	****	0.38	****	1 47	****	0.10 (0.08 0.46)	<0.001
ACEI	584,032	****	****	****	****	1.85	****	-1.47		0.19 (0.08, 0.46)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	36,159	****	****	****	****	0.52	****	1.04	****	0.21 (0.07 0.62)	0.005
ACEI	36,159	****	****	****	****	2.45	****	-1.94		0.21 (0.07, 0.62)	0.005
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	36,159	****	****	****	****	0.38	****	-1.52	****	0.19 (0.07, 0.49)	<0.001
ACEI	36,159	****	****	****	****	1.9	****	-1.52		0.19 (0.07, 0.49)	<0.001
Serious Allergies											
Site-Adjusted Analy	vsis										
SV	5,684	****	****	****	****	2.14	****	-0.78	****	0.70 (0.26, 1.90)	0.489
ACEI	110,980	****	****	****	****	2.92	****	-0.78		0.70 (0.26, 1.90)	0.469
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,545	****	****	****	****	1.92	****	1.02	****		0 422
ACEI	5,545	****	****	****	****	3.84	****	-1.92		0.50 (0.09, 2.73)	0.423
Fixed Ratio 1:1 Prop	pensity Score Ma			nalysis; Cali	per= 0.05						
SV	5,545	****	****	****	****	2.19	****	1.26	****	0 62 (0 19 2 16)	0.465
ACEI	5,545	****	****	****	****	3.45	****	-1.26		0.63 (0.18, 2.16)	0.465

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 30. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Sex

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Sex: Male											
Site-Adjusted Analy	vsis										
SV	27,131	****	****	****	****	0.31	****	1.26	****	0.40 (0.00 0.073)	0.000
ACEI	353,126	****	****	****	****	1.57	****	-1.26		0.18 (0.06, 0.57)	0.003
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	26,865	****	****	****	****	0.53	****	2.20	****	0.40 (0.05 0.64)	0.000
ACEI	26,865	****	****	****	****	2.81	****	-2.28		0.19 (0.05, 0.64)	0.008
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	26,865	****	****	****	****	0.31	****	-1.52	****		0.003
ACEI	26,865	****	****	****	****	1.83	****	-1.52		0.16 (0.05, 0.54)	0.003
Sex: Female											
Site-Adjusted Analy	rsis										
SV	14,867	****	****	****	****	1.13	****	-1.32	****	0.44 (0.20, 0.98)	0.045
ACEI	341,886	****	****	****	****	2.45	****	-1.52		0.44 (0.20, 0.98)	0.045
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	14,820	****	****	****	****	0.97	****	1.62	****	0.28 (0.10 1.41)	0 1 4 7
ACEI	14,820	****	****	****	****	2.59	****	-1.62		0.38 (0.10, 1.41)	0.147
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	14,820	****	****	****	****	1.13	****	1 25	****	0 47 (0 19 1 21)	0 117
ACEI	14,820	****	****	****	****	2.38	****	-1.25		0.47 (0.18, 1.21)	0.117

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 31. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Age Group: 18-44 ye	ears										
Site-Adjusted Analy	sis										
SV	1,538	****	****	****	****	0	****	-3.36	* * * * *		
ACEI	21,594	****	****	****	****	3.36	****	-5.50		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	1,408	****	****	****	****	0	****	0	****		
ACEI	1,408	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	1,408	****	****	****	****	0	****	0	****		
ACEI	1,408	****	****	****	****	0	****	0		-	-
Age Group: 45-54 ye	ears										
Site-Adjusted Analy	sis										
SV	2,863	****	****	****	****	0	****	2 70	****		
ACEI	45,064	****	****	****	****	2.79	****	-2.79		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	2,789	****	****	****	****	0	****		****		
ACEI	2,789	****	****	****	****	5.52	****	-5.52	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	2,789	****	****	****	****	0	****	2.07	****		
ACEI	2,789	****	****	****	****	2.87	****	-2.87		-	-
Age Group: 55-64 ye	ears										
Site-Adjusted Analy	sis										
SV	5,807	****	****	****	****	1.48	****	4 77	****	0.47 (0.45 4.40)	0.401
ACEI	97,267	****	****	****	****	3.25	****	-1.77	ጥ ጥ ጥ ጥ	0.47 (0.15, 1.46)	0.191
ixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,692	****	****	****	****	1.76	****	2.54	****	0.00 (0.07 . 1.05)	0.470
ACEI	5,692	****	****	****	****	5.27	****	-3.51	<u> </u>	0.33 (0.07, 1.65)	0.178



Table 31. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,692	****	****	****	****	1.51	****	2.07	****	0.00 (0.00 1.10)	0.007
ACEI	5,692	****	****	****	****	4.58	****	-3.07		0.32 (0.09, 1.18)	0.087
Age Group: ≥65 year	s										
Site-Adjusted Analys	sis										
SV	31,790	****	****	****	****	0.52	****	4 4 7	****	0.20 (0.12, 0.64)	0.000
ACEI	531,087	****	****	****	****	1.69	****	-1.17		0.29 (0.13, 0.64)	0.002
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	31,082	****	****	****	****	0.6	****	4.2	****	0.00 (0.44, 4.00)	0.057
ACEI	31,082	****	****	****	****	1.8	****	-1.2	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.33 (0.11, 1.03)	0.057
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	31,082	****	****	****	****	0.53	****	1.02	****	0.00 (0.40, 0.00)	0.017
ACEI	31,082	****	****	****	****	1.56	****	-1.03	·*· ·*· ·*· ·*· ·*·	*** 0.33 (0.13, 0.82)	) 0.017

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.


Table 32. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Race: Unknown											
Site-Adjusted Analy											
SV	7,029	****	****	****	****	0	****	-1.93	****	-	_
ACEI	99,645	****	****	****	****	1.93	****	1.55			
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	6,992	****	****	****	****	0	****	-3.47	* * * * *		
ACEI	6,992	****	****	****	****	3.47	****	-5.47		-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	6,992	****	****	****	****	0	****	2.05	* * * * *		
ACEI	6,992	****	****	****	****	3.05	****	-3.05		-	-
Race: American Ind	ian										
Site-Adjusted Analy	vsis										
SV	132	****	****	****	****	0	****	0	****		
ACEI	4,529	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	123	****	****	****	****	0	****	<u> </u>	****		
ACEI	123	****	****	****	****	0	****	0	* * * * *	-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	123	****	****	****	****	0	****		****		
ACEI	123	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Race: Asian											
Site-Adjusted Analy	vsis										
SV	519	****	****	****	****	0	****	0.00	****		
ACEI	7,874	****	****	****	****	0.98	****	-0.98	ጥ ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	495	****	****	****	****	0	****		****		
ACEI	495	****	****	****	****	0	****	0	ጥ ጥ <i>ጥ</i> ጥ ጥ	-	-



Table 32. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race

		1 '		, ,		11					
Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV.	495	****	****	****	****	0	****	_	****		
ACEI	495	****	****	****	****	0	****	0	* * * * *	-	-
Race: Black											
Site-Adjusted Analy	/sis										
SV	5,566	****	****	****	****	2.99	****	1.25	****	0.20 (0.46 0.02)	0.022
ACEI	92,129	****	****	****	****	7.35	****	-4.36	<b>ጥ ጥ ጥ ጥ</b> ጥ	0.38 (0.16, 0.93)	0.033
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,479	****	****	****	****	2.03	****		****		
ACEI	5,479	****	****	****	****	8.14	****	-6.1	* * * * *	0.25 (0.05, 1.18)	0.08
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,479	****	****	****	****	3.04	****		****		0.455
ACEI	5,479	****	****	****	****	6.18	****	-3.14	* * * * *	0.47 (0.17, 1.34)	0.157
Race: Pacific Islande	er										
Site-Adjusted Analy	/sis										
SV	46	****	****	****	****	0	****	2.50	****		
ACEI	741	****	****	****	****	3.59	****	-3.59		-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	39	****	****	****	****	0	****	0	****		
ACEI	39	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b> ጥ	-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	39	****	****	****	****	0	****	0	****		
ACEI	39	****	****	****	****	0	****	0	ne ne ne ne	-	-
Race: White											
	•										
Site-Adjusted Analy	/SIS									** 0.20 (0.44 0.70)	0.015
SV	28,706	****	****	****	****	0.38	****	-0.83	****	0.29 (0.11, 0.79)	0.015



Table 32. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	28,638	****	****	****	****	0.48	****		****	0.20 (0.00, 1.00)	0.067
ACEI	28,638	****	****	****	****	1.59	****	-1.11	-1111-	0.30 (0.08, 1.09)	0.067
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	28,638	****	****	****	****	0.38	****	0.97	****	0.20 (0.10 0.00)	0.020
ACEI	28,638	****	****	****	****	1.25	****	-0.87	-0.87 *****	0.29 (0.10, 0.88)	0.028

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Table 33. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Site-Adjusted Analy	sis										
SV	43,777	****	****	****	****	0.58	****	0.00	****	0.64 (0.24 4.20)	0.45
ARBs	337,157	****	****	****	****	0.9	****	-0.32	ጥ ጥ ጥ ጥ	0.61 (0.31, 1.20)	0.15
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	43,755	****	****	****	****	0.63	****	<u>.</u>	****		0 700
ARBs	43,755	****	****	****	****	0.73	****	-0.1	ጥ ጥ ጥ ጥ	0.86 (0.29, 2.55)	0.782
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	43,755	****	****	****	****	0.58	****	-0.05 *****	****	** 0.90 (0.38, 2.13)	0.000
ARBs	43,755	****	****	****	****	0.63	****		ጥ ጥ ጥ ጥ ጥ		0.802

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 34. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (-183, -1)

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
No Angioedema (-1	83, -1)										
Site-Adjusted Analy	vsis										
SV	43,717	****	****	****	****	0.51	****	0.26	****	0 (2 (0 24 4 20)	0.200
ARBs	336,332	****	****	****	****	0.78	****	-0.26		0.63 (0.31, 1.29)	0.208
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	43,685	****	****	****	****	0.52	****	0.24	****	0.74 (0.22, 2.25)	0.500
ARBs	43,685	****	****	****	****	0.73	****	-0.21		0.71 (0.23, 2.25)	0.566
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	43,685	****	****	****	****	0.51	****	-0.12	****	0.90 (0.22 1.07)	0.631
ARBs	43,685	****	****	****	****	0.63	****	-0.12		0.80 (0.33, 1.97)	0.631
Angioedema (-183,	-1)										
Site-Adjusted Analy	rsis										
SV	60	****	****	****	****	40.67	****	-11.71	****		0.0
ARBs	825	****	****	****	****	52.37	****	-11./1		0.77 (0.10, 5.77)	0.8
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	48	****	****	****	****	90.09	****	00.00	****		
ARBs	48	****	****	****	****	0	****	90.09	1911 1911 19 <b>1</b> 191	-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	48	****	****	****	****	48.19	****	49.10	* * * * *		
ARBs	48	****	****	****	****	0	****	48.19		-	-

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Table 35. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Angioedema (ever, -1)

	Number of	Person Years	Average Person Days	Average Person Years	Number of	Incidence Rate per 1,000 Person	Risk per 1,000	Incidence Rate Difference per 1,000	Difference in Risk per 1,000 New	Hazard Ratio (95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval)	P-Value
No Angioedema (ev Site-Adjusted Analy	•	_	_	_	_	_	_		_		_
SV	43,178	****	****	****	****	0.52	****				
ARBs	43,178 329,798	****	****	****	****	0.52	****	-0.16	****	0.73 (0.36, 1.51)	0.401
Fixed Ratio 1:1 Prop	,	tched Conc	litional Ana	lysis: Caline	$r = 0.05^{1}$	0.00					
SV	42,832	****	****	****	****	0.53	****				
ARBs	42,832	****	****	****	****	0.53	****	0	****	1.00 (0.29, 3.45)	1
Fixed Ratio 1:1 Prop	,	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	42,832	****	****	****	****	0.52	****		****	/	
ARBs	42,832	****	****	****	****	0.54	****	-0.01	* * * * *	0.97 (0.38, 2.47)	0.954
Angioedema (ever,	-1)										
Site-Adjusted Analy	sis										
SV	599	****	****	****	****	4.46	****	6.24	****		0.244
ARBs	7,359	****	****	****	****	10.71	****	-6.24	-1111-	0.38 (0.05, 2.79)	0.344
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	591	****	****	****	****	7.29	****	0	****	1.00 (0.00 15.00)	1
ARBs	591	****	****	****	****	7.29	****	0	-1111- -1111-	1.00 (0.06, 15.99)	1
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco		nalysis; Cali	•						
SV	591	220.75	****	****	****	****	****	0.77	****		0.065
ARBs	591	266.21	****	****	****	****	****	0.77		1.06 (0.07, 17.03)	0.965

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 36. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Serious Allergies

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
No Serious Allergies	;										
Site-Adjusted Analy	sis										
SV	37,847	****	****	****	****	0.37	****	0.00	****	0.50 (0.20, 4.22)	0.40
ARBs	282,725	****	****	****	****	0.69	****	-0.32	ጥ ጥ ጥ ጥ	0.50 (0.20, 1.23)	0.13
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	37,637	****	****	****	****	0.36	****	0.24	****	0.00/0.14. 2.54)	0.404
ARBs	37,637	****	****	****	****	0.6	****	-0.24	ጥ ጥ ጥ ጥ	0.60 (0.14, 2.51)	0.484
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	37,637	****	****	****	****	0.37	****	-0.24	****		0.225
ARBs	37,637	****	****	****	****	0.6	****	-0.24		0.58 (0.20, 1.71)	0.325
Serious Allergies											
Site-Adjusted Analy	sis										
SV	5,930	****	****	****	****	2.05	****	0.00	****	0 02 (0 24 2 50)	0.004
ARBs	54,432	****	****	****	****	2.11	****	-0.06		0.93 (0.34, 2.59)	0.894
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,774	****	****	****	****	1.77	****	4 77	****		
ARBs	5,774	****	****	****	****	0	****	1.77	ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,774	****	****	****	****	2.11	****	1.24	****		0 201
ARBs	5,774	****	****	****	****	0.87	****	1.24		2.55 (0.47, 13.98)	0.281

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



Table 37. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Sex

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Rate per 1,000 Person Years	Risk per 1,000 New Users	Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Sex: Male											
Site-Adjusted Analy	rsis										
SV	28,311	****	****	****	****	0.3	****	-0.6	* * * * *	0.31 (0.10, 1.00)	0.05
ARBs	149,252	****	****	****	****	0.9	****	-0.8		0.51 (0.10, 1.00)	0.05
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conc	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	27,999	****	****	****	****	0.33	****	0.22	****		0.423
ARBs	27,999	****	****	****	****	0.66	****	-0.33		0.50 (0.09, 2.73)	0.423
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	27,999	****	****	****	****	0.3	****	-0.53	* * * * *	0.26 (0.10 1.21)	0.12
ARBs	27,999	****	****	****	****	0.83	****	-0.53		0.36 (0.10, 1.31)	0.12
Sex: Female											
Site-Adjusted Analy	rsis										
SV	15,466	****	****	****	****	1.09	****	0.2	****		0.74
ARBs	187,905	****	****	****	****	0.89	****	0.2		1.15 (0.50, 2.64)	0.74
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	litional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	15,267	****	****	****	****	0.88	****	0.20	****	4 50 (0 35 0 00)	0.057
ARBs	15,267	****	****	****	****	0.59	****	0.29	ጥ ጥ ጥ ጥ	1.50 (0.25, 8.98)	0.657
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	per= 0.05						
SV	15,267	****	****	****	****	1.1	****	0.0	****		0.12
ARBs	15,267	****	****	****	****	0.3	****	0.8	· · · · · · · · · · · · · · · · · · ·	3.56 (0.72, 17.70)	0.12

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 38. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Age Group

			<b>A</b>	A		Incidence		Incidence	Difference		
		Person	Average Person	Average Person	Number	Rate per 1,000	Risk per	Rate Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	•	Person Years	Users	Interval)	P-Value
Age Group: 18-44 ye		at Misk	at hisk		Events	Tears			03013		I Value
Site-Adjusted Analys		_	_	_	_	_	_				_
SV	1,634	****	****	****	****	0	****				
ARBs	8,500	****	****	****	****	2.74	****	-2.74	****	-	-
		tabad Can				2.74					
Fixed Ratio 1:1 Prop				iysis; Calipe	r= 0.05	0	****				
SV	1,448	****	****	****	*****	U U	*****	0	****	-	-
ARBs	1,448					0	4.4.4.4.4.				
Fixed Ratio 1:1 Prop	-				iper= 0.05	0	****				
SV	1,448	****	****	****	*****	•	****	-2.13	****	-	-
ARBs	1,448	4.4.4.4.	4.4.4.4.4.			2.13	4.4.4.4.4.				_
Age Group: 45-54 ye		_	_	_	_	_	_				_
Site-Adjusted Analys		****	****	****	****		****				
SV	3,068	****	****	****	*****	0	*****	-2.01	* * * * *	-	-
ARBs	18,297					2.01	ጥ ጥ ጥ ጥ				
Fixed Ratio 1:1 Prop		tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>-</sup>		****				
SV	2,938					0		0	****	-	-
ARBs	2,938	****	****	****	****	0	****				
Fixed Ratio 1:1 Prop	-				-						
SV	2,938	****	****	****	****	0	****	-0.93	****	-	-
ARBs	2,938	****	****	****	****	0.93	****				
Age Group: 55-64 ye											
Site-Adjusted Analys											
SV	6,120	****	****	****	****	1.41	****	-0.5	****	0.81 (0.25, 2.66)	0.732
ARBs	40,556	****	****	****	****	1.91	****			0.01 (0.20, 2.00)	0.752
Fixed Ratio 1:1 Prop											
SV	5,994	****	****	****	****	2.43	****	2.43	****		
ARBs	5,994	****	****	****	****	0	****	2.45		-	_



Table 38. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Age Group

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,994	****	****	****	****	1.44	****	1.02	****	2 50 (0 27 24 57)	0.200
ARBs	5,994	****	****	****	****	0.42	****	1.02		3.59 (0.37, 34.57)	0.269
Age Group: ≥65 yea	rs										
Site-Adjusted Analys	sis										
SV	32,955	****	****	****	****	0.51	****	0.16	****	0.00 (0.20, 4.50)	0 277
ARBs	269,804	****	****	****	****	0.66	****	-0.16		0.69 (0.30, 1.58)	0.377
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	32,649	****	****	****	****	0.54	****	0.07	****	0.67 (0.40, 0.06)	0.50
ARBs	32,649	****	****	****	****	0.81	****	-0.27	ጥ ጥ ጥ ጥ	0.67 (0.19, 2.36)	0.53
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	32,649	****	****	****	****	0.43	****	0.10	****		0.454
ARBs	32,649	****	****	****	****	0.61	****	-0.18	"የግም ጥጥ	*** 0.66 (0.22, 1.96)	0.451

<sup>1</sup>Conditional analysis accounts for informative events and person-time.



Table 39. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race

	· /	1 :		1 ,	, ,	/1					
						Incidence		Incidence			
			Average	Average		Rate per		Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	New Users	Person Years	Users	Interval) <sup>2</sup>	P-Value
Race: Unknown											
Site-Adjusted Analy											
SV	7,289	****	****	****	****	0	****	-0.63	* * * * *	-	-
ARBs	47,812	****	****	****	****	0.63	****				
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV	7,159	****	****	****	****	0	****	0	* * * * *	_	_
ARBs	7,159	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	7,159	****	****	****	****	0	****		* * * * *		
ARBs	7,159	****	****	****	****	0	****	0		-	-
Race: American Ind	ian										
Site-Adjusted Analy	vsis										
SV	143	****	****	****	****	0	****	4.26	****		
ARBs	1,947	****	****	****	****	1.36	****	-1.36	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV	138	****	****	****	****	0	****		****		
ARBs	138	****	****	****	****	0	****	0	<b>ጥ ጥ ጥ ጥ</b>	-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	138	****	****	****	****	0	****		****		
ARBs	138	****	****	****	****	0	****	0	* * * * *	-	-
Race: Asian											
Site-Adjusted Analy	rsis										
SV	511	****	****	****	****	0	****		****		
ARBs	7,817	****	****	****	****	0.54	****	-0.54	<u>ጥ</u> ጥ ጥ ጥ ጥ	-	-
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	er= 0.05 <sup>1</sup>						
SV	484	****	****	****	****	0	****	0	****		
30											



Table 39. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race

			Average	Average		Incidence Rate per		Incidence Rate	Difference		
		Person	Person	Person	Number	1,000	Risk per	Difference	in Risk per	Hazard Ratio	
	Number of	Years	Days	Years	of	Person	1,000	per 1,000	1,000 New	(95% Confidence	Wald
Medical Product	New Users	at Risk	at Risk	at Risk	Events	Years	•	Person Years	Users	Interval) <sup>2</sup>	P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalvsis: Cali	iper= 0.05					•	
SV .	484	****	****	****	****	0	****				
ARBs	484	****	****	****	****	0	****	0	****	-	-
Race: Black											
Site-Adjusted Analys	sis										
SV	5,853	****	****	****	****	2.86	****	0.07	****	0.04 (0.20, 2.24)	0.000
ARBs	55,815	****	****	****	****	2.79	****	0.07		0.94 (0.38, 2.34)	0.892
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	5,765	****	****	****	****	3.76	****	2.76	****		
ARBs	5,765	****	****	****	****	0	****	3.76		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	5,765	****	****	****	****	2.9	****	1.00	****	2.00 (0.00, 15.04)	0.10
ARBs	5,765	****	****	****	****	0.92	****	1.98		3.08 (0.60, 15.94)	0.18
Race: Pacific Islande	r										
Site-Adjusted Analys	sis										
SV	46	****	****	****	****	0	****	0	* * * * *		
ARBs	478	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conc	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	31	****	****	****	****	0	****	0	* * * * *		
ARBs	31	****	****	****	****	0	****	0		-	-
Fixed Ratio 1:1 Prop	ensity Score Ma			nalysis; Cali	iper= 0.05						
SV	31	****	****	****	****	0	****	0	****	_	_
ARBs	31	****	****	****	****	0	****	0			-
Race: White											
Site-Adjusted Analys											
SV	29,935	****	****	****	****	0.37	****	-0.2	****	0.60 (0.22, 1.64)	0.316
ARBs	223,288	****	****	****	****	0.57	****	-0.2		0.00(0.22, 1.04)	0.510



Table 39. Effect Estimates for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema in the Sentinel Distributed Database (SDD) between July 7, 2015 and February 29, 2020 by Analysis Type and Race

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person Years	Risk per 1,000 New Users	Incidence Rate Difference per 1,000 Person Years	Difference in Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval) <sup>2</sup>	Wald P-Value <sup>2</sup>
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Cond	ditional Ana	lysis; Calipe	r= 0.05 <sup>1</sup>						
SV	29,757	****	****	****	****	0.29	****	0.44	****		0 272
ARBs	29,757	****	****	****	****	0.74	****	-0.44		0.40 (0.08, 2.06)	0.273
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unco	onditional A	nalysis; Cali	iper= 0.05						
SV	29,757	****	****	****	****	0.37	****	0.27	****		0.209
ARBs	29,757	****	****	****	****	0.74	****	-0.37		0.47 (0.15, 1.51)	0.208

<sup>1</sup>Conditional analysis accounts for informative events and person-time.

<sup>2</sup>Data presented by a dash are unable to be calculated. This table may not use all data representations.



# Figure 1a. Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, Aggregated





Figure 1b. Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap





# Figures 2a. Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin II Receptor Blockers (ARBs), 14-day gap, Aggregated





#### Figure 2b. Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin II Receptor Blockers (ARBs), 14-Day Gap





# Figures 3a. Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, Aggregated





Figure 3b. Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap





Figures 4a. Histograms of Propensity Score (PS) Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin II Receptor Blockers (ARBs), 7-day gap, Aggregated





#### Figure 4b. Histograms of Propensity Score (PS) Fixed Ratio 1:1 Matched Cohort, Matched Caliper = 0.05 Distribution Comparing New Initiators of Sacubitril/Valsartan (SV) with use of Angiotensin II Receptor Blockers (ARBs), 7-Day Gap





## Figure 5. Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Angioedema





### Figure 6. Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Angioedema





#### Figure 7. Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 7-Day Gap, and Risk of Angioedema





## Figure 8. Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 7-Day Gap, and Risk of Angioedema





## Figure 9. Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin-Converting Enzyme Inhibitors (ACEI), 14-Day Gap, and Risk of Serious Angioedema





## Figure 10. Kaplan Meier Survival Curves for Sacubitril/Valsartan (SV) and Angiotensin II Receptor Blockers (ARBs), 14-Day Gap, and Risk of Serious Angioedema





### Figure 11. Kaplan Meier Survival Curves for Risk of Angioedema, Sacubitril/Valsartan (SV) (14-day gap) and Angiotensin-Converting Enzyme Inhibitors (ACEI) (14-day gap)

Kaplan Meier Survival Curves of Events and Followup Time for Risk of Angioedema, Unconditional Propensity Score Adjusted Matched Cohort, No Baseline Angioedema (-183, -1)





## Figure 12. Kaplan Meier Survival Curves for Risk of Angioedema, Sacubitril/Valsartan (SV) (14-day gap) and Angiotensin II Receptor Blockers (ARBs) (14-day gap)

Kaplan Meier Survival Curves of Events and Followup Time for Risk of Angioedema, Unconditional Propensity Score Adjusted Matched Cohort, No Baseline Angioedema (-183, -1)





#### Appendix A: Start and End Dates for Each Data Partner up to Request End Date (02/29/2020)

Masked ID	DP Start Date	DP End Date <sup>1</sup>
DP01	06/01/2007	10/31/2019
DP02	01/01/2008	12/31/2019
DP03	01/01/2010	12/31/2019
DP04	01/01/2008	02/29/2020
DP05	01/01/2006	01/31/2020

<sup>1</sup> End Date represents the earlier of: (1) query end date, or (2) most recent year-month of data for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.



#### Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Constinue	Duran d Nama
Generic Name	Brand Name g Enzyme Inhibitors (ACEI)
AMLODIPINE BESYLATE/BENAZEPRIL HCL	Lotrel
AMLODIPINE BESYLATE/BENAZEPRIL HCL	amlodipine-benazepril
BENAZEPRIL HCL	Lotensin
BENAZEPRIL HCL	benazepril
BENAZEPRIL HCL/HYDROCHLOROTHIAZIDE	Lotensin HCT
BENAZEPRIL HCL/HYDROCHLOROTHIAZIDE	benazepril-hydrochlorothiazide
CAPTOPRIL	captopril
CAPTOPRIL/HYDROCHLOROTHIAZIDE	captopril-hydrochlorothiazide
ENALAPRIL MALEATE	Epaned
ENALAPRIL MALEATE	Vasotec
ENALAPRIL MALEATE	enalapril maleate
ENALAPRIL MALEATE/HYDROCHLOROTHIAZIDE	Vaseretic
ENALAPRIL MALEATE/HYDROCHLOROTHIAZIDE	enalapril-hydrochlorothiazide
FOSINOPRIL SODIUM	fosinopril
FOSINOPRIL SODIUM/HYDROCHLOROTHIAZIDE	fosinopril-hydrochlorothiazide
LISINOPRIL	Prinivil
LISINOPRIL	Qbrelis
LISINOPRIL	Zestril
LISINOPRIL	lisinopril
LISINOPRIL/HYDROCHLOROTHIAZIDE	Zestoretic
LISINOPRIL/HYDROCHLOROTHIAZIDE	lisinopril-hydrochlorothiazide
MOEXIPRIL HCL	Univasc
MOEXIPRIL HCL	moexipril
MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE	Uniretic
MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE	moexipril-hydrochlorothiazide
PERINDOPRIL ARGININE/AMLODIPINE BESYLATE	Prestalia
	Aceon
	perindopril erbumine
QUINAPRIL HCL	Accupril
	quinapril
	Accuretic
QUINAPRIL HCL/HYDROCHLOROTHIAZIDE RAMIPRIL	quinapril-hydrochlorothiazide Altace
RAMIPRIL	ramipril
TRANDOLAPRIL	Mavik
TRANDOLAPRIL	trandolapril
TRANDOLAFRIE TRANDOLAPRIL/VERAPAMIL HCL	Tarka
TRANDOLAPRIL/VERAPAMIL HCL	trandolapril-verapamil
amlodipine besylate/benazepril HCl	amlodipine-benazepril
benazepril HCl	Lotensin
benazepril HCl	benazepril
captopril	captopril
enalapril maleate	enalapril maleate
lisinopril	lisinopril
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
· ·	



#### Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
quinapril HCl	quinapril
ramipril	ramipril
randolapril	trandolapril
Angiotensin II Recept	tor Blockers (ARB)
AMLODIPINE BESYLATE/OLMESARTAN MEDOXOMIL	Azor
AMLODIPINE BESYLATE/OLMESARTAN MEDOXOMIL	amlodipine-olmesartan
AMLODIPINE BESYLATE/VALSARTAN	Exforge
AMLODIPINE BESYLATE/VALSARTAN	amlodipine-valsartan
AMLODIPINE BESYLATE/VALSARTAN /HYDROCHLOROTHIAZIDE	Exforge HCT
AMLODIPINE BESYLATE/VALSARTAN /HYDROCHLOROTHIAZIDE	amlodipine-valsartan-hcthiazid
AZILSARTAN MEDOXOMIL	Edarbi
AZILSARTAN MEDOXOMIL/CHLORTHALIDONE	Edarbyclor
CANDESARTAN CILEXETIL	Atacand
CANDESARTAN CILEXETIL	candesartan
CANDESARTAN CILEXETIL/HYDROCHLOROTHIAZIDE	Atacand HCT
CANDESARTAN CILEXETIL/HYDROCHLOROTHIAZIDE	candesartan-hydrochlorothiazid
EPROSARTAN MESYLATE	Teveten
EPROSARTAN MESYLATE	eprosartan
EPROSARTAN MESYLATE/HYDROCHLOROTHIAZIDE	Teveten HCT
RBESARTAN	Avapro
RBESARTAN	irbesartan
RBESARTAN/HYDROCHLOROTHIAZIDE	Avalide
RBESARTAN/HYDROCHLOROTHIAZIDE	irbesartan-hydrochlorothiazide
OSARTAN POTASSIUM	Cozaar
OSARTAN POTASSIUM	losartan
OSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE	Hyzaar
OSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE	losartan-hydrochlorothiazide
NEBIVOLOL HCL/VALSARTAN	Byvalson
DLMESARTAN MEDOXOMIL	Benicar
DLMESARTAN MEDOXOMIL	olmesartan
DLMESARTAN MEDOXOMIL/AMLODIPINE	
BESYLATE/HYDROCHLOROTHIAZIDE	Tribenzor
DLMESARTAN MEDOXOMIL/AMLODIPINE	
JESYLATE/HYDROCHLOROTHIAZIDE	olmesartan-amlodipin-hcthiazid
OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE	Benicar HCT
DLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE	olmesartan-hydrochlorothiazide
relmisartan	Micardis
relmisartan	telmisartan
relmisartan/amlodipine besylate	Twynsta
relmisartan/amlodipine besylate	telmisartan-amlodipine
relmisartan/hydrochlorothiazide	Micardis HCT
relmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
/ALSARTAN	Diovan
VALSARTAN	valsartan
VALSARTAN/HYDROCHLOROTHIAZIDE	Diovan HCT



#### Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name			
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan			
amlodipine besylate/valsartan	amlodipine-valsartan			
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid			
candesartan cilexetil	Atacand			
candesartan cilexetil	candesartan			
candesartan cilexetil/hydrochlorothiazide	Atacand HCT			
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid			
irbesartan	irbesartan			
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide			
losartan potassium	losartan			
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide			
olmesartan medoxomil	Benicar			
olmesartan medoxomil	olmesartan			
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid			
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT			
telmisartan	telmisartan			
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid			
valsartan	valsartan			
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide			
Sacubitril/Valsartan				
SACUBITRIL/VALSARTAN	Entresto			

cder\_mpl2r\_wp016



Appendix C. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Outcome in this Request

CodeDescriptionCode TypeIntensive Care Unit Admission, Intubation, Tracheostomy, or Laryngocopy09HN782Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS09HN82Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS09HN82Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0811344Bypass Trachea to Cutaneous with Tracheostomy Device, Percutaneous ApproachProcedureICD-10-PCS0811344Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0811244Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0811202Dilation of Trachea, Open ApproachProcedureICD-10-PCS0811202Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS081122Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS081122Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS081122Dilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS081122Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS081122Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS081122Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS081122Dilation of Trachea, Via Nat			Code	
99HN782 Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening Procedure ICD-10-PCS   09HN882 Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS   09HN782 Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS   09H104 Bypass Trachea to Cutaneous, Open Approach Procedure ICD-10-PCS   0811324 Bypass Trachea to Cutaneous, Percutaneous Approach Procedure ICD-10-PCS   081144 Bypass Trachea to Cutaneous, Percutaneous Approach Procedure ICD-10-PCS   081142 Bypass Trachea to Cutaneous, Percutaneous Approach Procedure ICD-10-PCS   081142 Bypass Trachea to Cutaneous, Percutaneous Approach Procedure ICD-10-PCS   081102 Dilation of Trachea, Percutaneous Approach Procedure ICD-10-PCS   081122 Dilation of Trachea, Percutaneous Endoscopic Approach Procedure ICD-10-PCS   081142 Dilation of Trachea, Percutaneous Endoscopic Approach Procedure ICD-10-PCS   0811422 Dilation of Trachea, Via Natural or Artificial Opening Procedure	Code		Category	Code Type
99HN86ZInsertion of Airwa'i nto Nasopharynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS081104Bypass Trachea to Cutaneous, Open ApproachProcedureICD-10-PCS0811124Bypass Trachea to Cutaneous, Open ApproachProcedureICD-10-PCS0811134Bypass Trachea to Cutaneous, Open ApproachProcedureICD-10-PCS0811134Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0811142Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0811142Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0811125Dilation of Trachea, Open ApproachProcedureICD-10-PCS081122Dilation of Trachea, NeproachProcedureICD-10-PCS081122Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS081122Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS081122Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS081122Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS081122Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS081122Dilation of Carina, With Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS081122Dilation of Carina, With Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS081122Dilation of Carina, With Intraluminal Devic				
0B110F4Bypass Trachea to Cutaneous with Tracheostomy Device, Open ApproachProcedureICD-10-PCS0B11024Bypass Trachea to Cutaneous, Open ApproachProcedureICD-10-PCS0B11324Bypass Trachea to Cutaneous with Tracheostomy Device, Percutaneous ApproachProcedureICD-10-PCS0B11324Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0B11344Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0B11254Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0B71022Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Vith Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Vith Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71722Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71822Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B71822Dilation of Carina, Open ApproachProcedureICD-10-PCS0B72022Dilation of Carina, Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B7222Dilation of Carina, Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72322	09HN7BZ		Procedure	ICD-10-PCS
0B11024Bypass Trachea to Cutaneous, Open ApproachProcedureICD-10-PCS0B1134Bypass Trachea to Cutaneous with Tracheostomy Device, Percutaneous ApproachProcedureICD-10-PCS0B11344Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B11444Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B11447Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B11428Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B71022Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B71422Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71422Dilation of Trachea, Vercutaneous ApproachProcedureICD-10-PCS0B71422Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71222Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71222Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B71222Dilation of Carina, Open ApproachProcedureICD-10-PCS0B72222Dilation of Carina, Nith Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B72222Dilation of Carina, Nith Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B72222Dilation of Carina, Nith Intraluminal Device, Percuta			Procedure	ICD-10-PCS
0B113F4Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0B11328Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0B11474Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0B11424Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B71020Dilation of Trachea with Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B71422Dilation of Trachea, Vith Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71222Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71222Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B71222Dilation of Carina, Open ApproachProcedureICD-10-PCS0B72022Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B72022Dilation of Carina, With Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B72222Dilation of Carina, With Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B72322Dilation of Ca	0B110F4	Bypass Trachea to Cutaneous with Tracheostomy Device, Open Approach	Procedure	ICD-10-PCS
0B11324Bypass Trachea to Cutaneous, Percutaneous ApproachProcedureICD-10-PCS0B11445Bypass Trachea to Cutaneous, with Tracheostomy Device, Percutaneous Endoscopic ApproacProcedureICD-10-PCS0B11424Bypass Trachea to Cutaneous, With Tracheostomy Device, Open ApproachProcedureICD-10-PCS0B11020Dilation of Trachea, With Intraluminal Device, Open ApproachProcedureICD-10-PCS0B71022Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71422Dilation of Trachea, Percutaneous ChopcochProcedureICD-10-PCS0B71425Dilation of Trachea, Percutaneous ChopcochProcedureICD-10-PCS0B71425Dilation of Trachea, Vith Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71252Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B71252Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72025Dilation of Carina, Open ApproachProcedureICD-10-PCS0B72025Dilation of Carina, NeproachProcedureICD-10-PCS0B72025Dilation of Carina, NeproachProcedureICD-10-PCS0B72025Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B72252Dilation of Carina, Neth Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B72252Dilation of Carina, Neth Nat	0B110Z4	Bypass Trachea to Cutaneous, Open Approach	Procedure	ICD-10-PCS
0B114F4Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B11424Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B71002Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B71422Dilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B71425Dilation of Trachea, Via Natural Or Artificial OpeningProcedureICD-10-PCS0B71425Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71825Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71825Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B71825Dilation of Carina, With Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72052Dilation of Carina, Open ApproachProcedureICD-10-PCS0B72252Dilation of Carina, Via Natural or Artificial Opening Endoscopic ApproachProcedureICD-10-PCS0B72252Dilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B72252Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72252Dilation of	0B113F4	Bypass Trachea to Cutaneous with Tracheostomy Device, Percutaneous Approach	Procedure	ICD-10-PCS
0B114Z4Bypass Trachea to Cutaneous, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B710D2Dilation of Trachea with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B713D2Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B713D2Dilation of Trachea, Open ApproachProcedureICD-10-PCS0B713D2Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B713D2Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B714D2Dilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B717D2Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B717D2Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720D2Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720D2Dilation of Carina, Open ApproachProcedureICD-10-PCS0B720D2Dilation of Carina, Open ApproachProcedureICD-10-PCS0B720D2Dilation of Carina, With Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B720D2Dilation of Carina with Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B720D2Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B720D2Dilation of Carina with Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B7212D2Dilation of Carina, Nia Natural or Artificial Openi	0B113Z4	Bypass Trachea to Cutaneous, Percutaneous Approach	Procedure	ICD-10-PCS
0B710DDDilation of Trachea with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B710ZDDilation of Trachea, Open ApproachProcedureICD-10-PCS0B713ZDDilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B714ZDDilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B714ZDDilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B714ZDDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B714ZDDilation of Trachea with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B718ZDDilation of Trachea with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B718ZDDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B7202DDilation of Carina with Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B7232DDilation of Carina with Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B7232DDilation of Carina with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B7232DDilation of Carina with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B7232DDilation of Carina with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B7232DDilation of Carina with Intraluminal Device, Via Natural or Artificial OpeningProcedure <t< td=""><td>0B114F4</td><td>Bypass Trachea to Cutaneous with Tracheostomy Device, Percutaneous Endoscopic Approa</td><td>Procedure</td><td>ICD-10-PCS</td></t<>	0B114F4	Bypass Trachea to Cutaneous with Tracheostomy Device, Percutaneous Endoscopic Approa	Procedure	ICD-10-PCS
0B710ZZDilation of Trachea, Open ApproachProcedureICD-10-PCS0B713DZDilation of Trachea, With Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B7132ZDilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B7142ZDilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B7142ZDilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B7142ZDilation of Trachea, Vith Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B712ZDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B718ZZDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B718ZZDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B720DZDilation of Carina with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B723DZDilation of Carina with Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B723DZDilation of Carina with Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B723DZDilation of Carina with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724DZDilation of Carina, Nia Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724DZDilation of Carina, Wia Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724DZDilation of Carina, Via Natural or Artificial Opening Endoscop	0B114Z4	Bypass Trachea to Cutaneous, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0B713DZDilation of Trachea with Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B713ZZDilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B714ZZDilation of Trachea, With Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B717ZZDilation of Trachea, Vith Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B717ZZDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B717ZZDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B712DZDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720DZDilation of Carina with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B720ZZDilation of Carina, Open ApproachProcedureICD-10-PCS0B722ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B722ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B722ZDilation of Carina, With Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B722ZDilation of Carina, With Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B722ZDilation of Carina, With Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B722ZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B722ZDilation of Carina, Via Natural or Artif	0B710DZ	Dilation of Trachea with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0B71322Dilation of Trachea, Percutaneous ApproachProcedureICD-10-PCS0B714D2Dilation of Trachea, Vercutaneous Endoscopic ApproachProcedureICD-10-PCS0B71427Dilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B71727Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71727Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B71727Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B71827Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72027Dilation of Carina, Open ApproachProcedureICD-10-PCS0B72328Dilation of Carina, Open ApproachProcedureICD-10-PCS0B72427Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B72428Dilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B72429Dilation of Carina, Nith Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B72420Dilation of Carina, Nith Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B72427Dilation of Carina, Nith Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72428Dilation of Carina, Nith Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72429Dilation of Carina, Nia Natural or Artificial Opening Endoscopic <td>0B710ZZ</td> <td>Dilation of Trachea, Open Approach</td> <td>Procedure</td> <td>ICD-10-PCS</td>	0B710ZZ	Dilation of Trachea, Open Approach	Procedure	ICD-10-PCS
0B714D2Dilation of Trachea with Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B714D2Dilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B717D2Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B718D2Dilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B718D2Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B718D2Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720D2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720D2Dilation of Carina, Open ApproachProcedureICD-10-PCS0B723D2Dilation of Carina, Open ApproachProcedureICD-10-PCS0B724D2Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724D2Dilation of Carina, With Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724D2Dilation of Carina, With Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724D2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B727D2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72822Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B72825Dilation of Carina, Via Natural or Artificial Opening Endosc	0B713DZ	Dilation of Trachea with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
OB714ZZDilation of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B717DZDilation of Trachea with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B717ZZDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B718ZZDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B718ZZDilation of Carina with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B720ZZDilation of Carina, Open ApproachProcedureICD-10-PCS0B723ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificia	0B713ZZ	Dilation of Trachea, Percutaneous Approach	Procedure	ICD-10-PCS
0B717DZDilation of Trachea with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B717ZZDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B718DZDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B718ZZDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720ZZDilation of Carina, Open ApproachProcedureICD-10-PCS0B723ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B727ZZDil	0B714DZ	Dilation of Trachea with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0B717ZZDilation of Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B718DZDilation of Trachea with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B718ZZDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720DZDilation of Carina with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B723DZDilation of Carina, Open ApproachProcedureICD-10-PCS0B723DZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724DZDilation of Carina, Nercutaneous ApproachProcedureICD-10-PCS0B724DZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724DZDilation of Carina, With Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724DZDilation of Carina, With Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724DZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724DZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724DZDilation of Carina, With Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724DZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724DZDilation of Earina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B17EZInsertion of Endotracheal Airway into Trachea,	0B714ZZ	Dilation of Trachea, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
DB718D2Dilation of Trachea with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B718Z2Dilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720D2Dilation of Carina with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B720Z2Dilation of Carina, Open ApproachProcedureICD-10-PCS0B723D2Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724D2Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724D2Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724D2Dilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724D2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724D2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724D2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B7252Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B7252Dilation of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedure<	0B717DZ	Dilation of Trachea with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
D8718ZZDilation of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B720DZDilation of Carina with Intraluminal Device, Open ApproachProcedureICD-10-PCS0B720ZZDilation of Carina, Open ApproachProcedureICD-10-PCS0B723DZDilation of Carina, Open ApproachProcedureICD-10-PCS0B723ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724ZZDilation of Carina, With Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B724ZZDilation of Carina, With Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B724ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B725ZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B725ZInsertion of Intraluminal Device into Trachea, Via Natural or Artificial Opening Endoscopic <t< td=""><td>0B717ZZ</td><td>Dilation of Trachea, Via Natural or Artificial Opening</td><td>Procedure</td><td>ICD-10-PCS</td></t<>	0B717ZZ	Dilation of Trachea, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
D8720D2Dilation of Carina with Intraluminal Device, Open ApproachProcedureICD-10-PCS08720Z2Dilation of Carina, Open ApproachProcedureICD-10-PCS08723D2Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS08724D2Dilation of Carina, Percutaneous ApproachProcedureICD-10-PCS08724D2Dilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS08724D2Dilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS08727D2Dilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0872722Dilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0872722Dilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0872722Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0872723Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0872724Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0872725Dilation of Endotracheal Airway into Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0811425Insertion of Endotracheal Airway into Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0811425Insertion of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0811425Insertion of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS	0B718DZ	Dilation of Trachea with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0B720ZZDilation of Carina, Open ApproachProcedureICD-10-PCS0B723DZDilation of Carina with Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B723ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B14ZZInsertion of Intraluminal Device into Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B114ZZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B114ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B114ZZInspection of Trachea, Via Natural or Artificial Opening EndoscopicProcedure <td>0B718ZZ</td> <td>Dilation of Trachea, Via Natural or Artificial Opening Endoscopic</td> <td>Procedure</td> <td>ICD-10-PCS</td>	0B718ZZ	Dilation of Trachea, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0B723DZDilation of Carina with Intraluminal Device, Percutaneous ApproachProcedureICD-10-PCS0B723ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724DZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B727DZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728ZZDilation of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial Opening ProcedureICD-10-PCS0B14ZZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B14ZZInspection of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B14ZZInspection of Trachea, Nercutaneous Endoscopic ApproachProcedureICD-10-PCS0B213ZZRepair Trachea, Percutaneou	0B720DZ	Dilation of Carina with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0B723ZZDilation of Carina, Percutaneous ApproachProcedureICD-10-PCS0B724DZDilation of Carina with Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B727DZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B172ZInsertion of Intraluminal Device into Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0B117ZZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B114ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B114ZZInspection of Trachea, Open ApproachProcedureICD-10-PCS0BQ13ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCS0BQ13ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BQ13ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicPr	0B720ZZ	Dilation of Carina, Open Approach	Procedure	ICD-10-PCS
08724DZDilation of Carina with Intraluminal Device, Percutaneous Endoscopic ApproachProcedureICD-10-PCS08724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS08727DZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS08727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS08728DZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS08728DZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS08728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS08712ZInsertion of Intraluminal Device into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS08114ZZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS08114ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS08114ZZInspection of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0813ZZRepair Trachea, Open ApproachProcedureICD-10-PCS08Q13ZZRepair Tra	0B723DZ	Dilation of Carina with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0B724ZZDilation of Carina, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0B727D2Dilation of Carina with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS0B727Z2Dilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728Z2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728Z2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728Z2Dilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BH722Insertion of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial OpeningProcedureICD-10-PCS0BH1722Insertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BH1822Inspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BJ1822Inspection of Trachea, Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BQ1722Repair Trachea, Open ApproachProcedureICD-10-PCS0BQ1722Repair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BQ1723Repair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0BQ1724Repair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0BQ1725Repair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0BQ1724Repair Trachea, Via Natural or Artificial Openin	0B723ZZ	Dilation of Carina, Percutaneous Approach	Procedure	ICD-10-PCS
08727DZDilation of Carina with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCS08727Z2Dilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS08728DZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS08728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS08H07DZInsertion of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial OpeningProcedureICD-10-PCS0BH17EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BH18EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCS0BQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BQ14ZZRepair Trachea, Open ApproachProcedureICD-10-PCS0BQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BQ14ZZRepair Trachea, Natural or Artificial OpeningProcedureICD-10-PCS0BQ14ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0BQ14ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0BQ14ZZRepair Trachea, Via Natural or Artificial Opening Endoscopic </td <td>0B724DZ</td> <td>Dilation of Carina with Intraluminal Device, Percutaneous Endoscopic Approach</td> <td>Procedure</td> <td>ICD-10-PCS</td>	0B724DZ	Dilation of Carina with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0B727ZZDilation of Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0B728DZDilation of Carina with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0B728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BH07DZInsertion of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial OpeningProcedureICD-10-PCS0BH17EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0BH18EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BJ18ZZRepair Trachea, Open ApproachProcedureICD-10-PCS0BQ13ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BQ13ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0BQ13ZZRepair Trachea, Nercutaneous ApproachProcedureICD-10-PCS0BQ13ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCS0BQ13ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BQ13ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BQ13ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0BQ13ZZRepair Trachea, Via Natural or A	0B724ZZ	Dilation of Carina, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OB728DZDilation of Carina with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOB728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBH07DZInsertion of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial Opening Insertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening Insection of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBH18EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Trachea,	0B727DZ	Dilation of Carina with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
OB728ZZDilation of Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBH07DZInsertion of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial Opening ProcedureICD-10-PCSOBH17EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBH18EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ13ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Nia Natural or Artificial OpeningProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Carina, Open Appro	0B727ZZ	Dilation of Carina, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
OBH07DZInsertion of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial Opening ProcedureICD-10-PCSOBH17EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBH18EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ13ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0B728DZ	Dilation of Carina with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OBH17EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBH18EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ13ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0B728ZZ	Dilation of Carina, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OBH18EZInsertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBJ18ZZInspection of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ13ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0BH07DZ	Insertion of Intraluminal Device into Tracheobronchial Tree, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
OBJ14ZZInspection of Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBJ18ZZInspection of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ13ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	OBH17EZ	Insertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
OBJ18ZZInspection of Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ13ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	OBH18EZ	Insertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OBQ10ZZRepair Trachea, Open ApproachProcedureICD-10-PCSOBQ13ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0BJ14ZZ	Inspection of Trachea, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OBQ13ZZRepair Trachea, Percutaneous ApproachProcedureICD-10-PCSOBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0BJ18ZZ	Inspection of Trachea, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0BQ10ZZ	Repair Trachea, Open Approach	Procedure	ICD-10-PCS
OBQ14ZZRepair Trachea, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOBQ17ZZRepair Trachea, Via Natural or Artificial OpeningProcedureICD-10-PCSOBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0BQ13ZZ	Repair Trachea, Percutaneous Approach	Procedure	ICD-10-PCS
OBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0BQ14ZZ		Procedure	ICD-10-PCS
OBQ18ZZRepair Trachea, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOBQ20ZZRepair Carina, Open ApproachProcedureICD-10-PCS	0BQ17ZZ	Repair Trachea, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
		Repair Trachea, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	0BQ20ZZ	Repair Carina, Open Approach	Procedure	ICD-10-PCS



Appendix C. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Outcome in this Request

0BQ24ZZ Repair Carina, Via Natural or Artificial Opening Procedure ICD-10-PCS   0BQ27ZZ Repair Carina, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS   0CHY7BZ Insertion of Airway into Mouth and Throat, Via Natural or Artificial Opening Procedure ICD-10-PCS   0CHY7BZ Insertion of Airway into Mouth and Throat, Via Natural or Artificial Opening Procedure ICD-10-PCS   0CHX8ZZ Inspection of Larynx, Percutaneous Endoscopic Approach Procedure ICD-10-PCS   0CHSZZ Inspection of Larynx, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS   0DHS5BZ Insertion of Airway into Esophagus, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS   0DHS5BZ Coclusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Procedure ICD-10-PCS   0DL5BZ Coclusion of Sophagus with Intraluminal Device, Via Natural or Artificial Opening Procedure ICD-10-PCS   11 Tracheostomy Procedure ICD-10-PCS ICD-9-CM   12.1 Tracheostomy Procedure ICD-9-CM ICD-9-CM   12.2 Tracheostomy <t< th=""><th></th><th></th><th>Code</th><th></th></t<>			Code	
08027222Repair Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0802822Repair Carina, Via Natural or Artificial OpeningProcedureICD-10-PCS0802822Insertion of Airway into Mouth and Throat, Via Natural or Artificial OpeningProcedureICD-10-PCS0CU5422Inspection of Larynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0CU5425Inspection of Larynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0CU5425Insertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0DU5526Insertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0DU5520Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopProcedureICD-10-PCS0015372Insertion of Other Device into Respiratory Tract, Via Natural or Artificial Opening EndoscopProcedureICD-9-CM11.1TracheostomyProcedureICD-9-CMICD-9-CM11.2TracheostomyProcedureICD-9-CM11.3TracheostomyProcedureICD-9-CM11.4LaryngoscopyProcedureICD-9-CM11.2TracheostomyProcedureCPT-411.3TracheostomyProcedureCPT-411.4TarcheostomyProcedureCPT-411.5LaryngoscopyProcedureCPT-411.5LaryngoscopyProcedureCPT-411.5LaryngoscopyProcedu	Code	Description	Category	Code Type
BBQ28ZZRepair Carina, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSC0CHY78ZInsertion of Airway into Mouth and Throat, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSC0CHY8ZZInspection of Larynx, Percutaneous Endoscopic ApproachProcedureICD-10-PCSC0CHS2ZInspection of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSD0H578ZInsertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSD0H578ZInsertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSD0H578ZOcclusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSD0H577ZInsertion of Other Device into Respiratory Tract, Via Natural or Artificial Opening EndoscopProcedureICD-10-PCS31.1TracheostomyProcedureICD-9-CMICD-9-CM31.2TracheostomyProcedureICD-9-CMICD-9-CM31.3TracheostomyProcedureICD-9-CMICD-9-CM31.42LaryngoscopyProcedureCPT-4ICD-9-CM31.52IntubationProcedureCPT-4ICD-9-CM31.52LaryngoscopyProcedureCPT-4ICD-9-CM31.52LaryngoscopyProcedureCPT-4ICD-9-CM31.52LaryngoscopyProcedureCPT-4ICD-9-CM31.52LaryngoscopyProcedureCPT-4ICD-9-CM31.5	0BQ24ZZ	Repair Carina, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OCHY78ZInsertion of Airway into Mouth and Throat, Via Natural or Artificial OpeningProcedureICD-10-PCSOCHY88ZInsertion of Airway into Mouth and Throat, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOCISZZInspection of Larynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOCISZZInsertion of Airway into Esophagus, Via Natural or Artificial OpeningProcedureICD-10-PCSODIS78ZInsertion of Airway into Esophagus, Via Natural or Artificial OpeningProcedureICD-10-PCSODIS78ZOcclusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSODIS78ZOcclusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSOWHQ77ZInsertion of Other Device into Respiratory Tract, Via Natural or Artificial OpeningProcedureICD-9-CM31.2TracheostomyProcedureICD-9-CMICD-9-CM31.21TracheostomyProcedureICD-9-CM31.22TracheostomyProcedureICD-9-CM31.23TracheostomyProcedureICD-9-CM31.24LaryngoscopyProcedureCPT-431.25LaryngoscopyProcedureCPT-431.26LaryngoscopyProcedureCPT-431.27LaryngoscopyProcedureCPT-431.28LaryngoscopyProcedureCPT-431.25LaryngoscopyProcedureCPT-431.25LaryngoscopyProcedureCPT-4<	0BQ27ZZ	Repair Carina, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
OCHY88ZInsertion of Airway into Mouth and Throat, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOCISAZZInspection of Larynx, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOCISAZZInsertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSODIST8ZInsertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSODIST7ZOcclusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSODIST8ZInsertion of Other Device into Respiratory Tract, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0015232Caclusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCS0015231TracheostomyProcedureICD-9-CMICD-9-CM11.1TracheostomyProcedureICD-9-CM12.21TracheostomyProcedureICD-9-CM13.24TracheostomyProcedureCP-413.25LaryngoscopyProcedureCP-413.26IaryngoscopyProcedureCP-413.25LaryngoscopyProcedureCP-413.26LaryngoscopyProcedureCP-413.27LaryngoscopyProcedureCP-413.28LaryngoscopyProcedureCP-413.24LaryngoscopyProcedureCP-413.25LaryngoscopyProcedureCP-4 <trr>13.26Laryngo</trr>	0BQ28ZZ	Repair Carina, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OCIS4ZZInspection of Larynx, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOCIS8ZZInspection of Larynx, Via Natural or Artificial OpeningProcedureICD-10-PCSODH57BZInsertion of Airway into Esophagus, Via Natural or Artificial OpeningProcedureICD-10-PCSODH58DZCoclusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSODUS50DZOcclusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSMUNQ7YInsertion of Other Device into Respiratory Tract, Via Natural or Artificial OpeningProcedureICD-9-CM31.1TracheostomyProcedureICD-9-CMICD-9-CM31.21TracheostomyProcedureICD-9-CM31.42LaryngoscopyProcedureICD-9-CM31.43TracheostomyProcedureICD-9-CM31.44LaryngoscopyProcedureICD-9-CM31.55LaryngoscopyProcedureCPT-431.50IntubationProcedureCPT-431.55LaryngoscopyProcedureCPT-431.55LaryngoscopyProcedureCPT-431.55LaryngoscopyProcedureCPT-431.54LaryngoscopyProcedureCPT-431.55LaryngoscopyProcedureCPT-431.55LaryngoscopyProcedureCPT-431.55LaryngoscopyProcedureCPT-431.55LaryngoscopyProcedureCPT-431.54 <t< td=""><td>OCHY7BZ</td><td>Insertion of Airway into Mouth and Throat, Via Natural or Artificial Opening</td><td>Procedure</td><td>ICD-10-PCS</td></t<>	OCHY7BZ	Insertion of Airway into Mouth and Throat, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
OCUS8ZZInspection of Larynx, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSDDH578ZInsertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSDD1578DOcclusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSDD1570Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSDD1570Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-90-PCSD01570Occlusion of Other Device into Respiratory Tract, Via Natural or Artificial OpeningProcedureICD-90-M31.1TracheostomyProcedureICD-90-MICD-90-M31.21TracheostomyProcedureICD-90-M31.22TracheostomyProcedureICD-90-M31.31TracheostomyProcedureICD-90-M31.42LaryngoscopyProcedureICD-90-M31.52LaryngoscopyProcedureCPT-431550LaryngoscopyProcedureCPT-431551LaryngoscopyProcedureCPT-431552LaryngoscopyProcedureCPT-431554LaryngoscopyProcedureCPT-431555LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431572LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProc	OCHY8BZ	Insertion of Airway into Mouth and Throat, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
DDH57B2Insertion of Airway into Esophagus, Via Natural or Artificial OpeningProcedureICD-10-PCSDDH58B2Insertion of Airway into Esophagus, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSDDL57D2Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopProcedureICD-10-PCSDDL58D2Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopProcedureICD-10-PCS00L52D2Coclusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopProcedureICD-10-PCS31.1TracheostomyProcedureICD-9-CMICD-9-CM31.21TracheostomyProcedureICD-9-CM31.42LaryngoscopyProcedureICD-9-CM31.42LaryngoscopyProcedureICD-9-CM31.50IntubationProcedureCPT-431502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525 <td< td=""><td>0CJS4ZZ</td><td>Inspection of Larynx, Percutaneous Endoscopic Approach</td><td>Procedure</td><td>ICD-10-PCS</td></td<>	0CJS4ZZ	Inspection of Larynx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
DDH58B2Insertion of Airway into Esophagus, Via Natural or Artificial OpeningProcedureICD-10-PCSDDL57D2Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSDDL58D2Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSDUL57D2Insertion of Other Device into Respiratory Tract, Via Natural or Artificial OpeningProcedureICD-10-PCS31.1TracheostomyProcedureICD-9-CMICD-9-CM31.2TracheostomyProcedureICD-9-CM31.21TracheostomyProcedureICD-9-CM31.29TracheostomyProcedureICD-9-CM31.29IntubationProcedureICD-9-CM31201LaryngoscopyProcedureCPT-431502LaryngoscopyProcedureCPT-431505LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431540LaryngoscopyProcedureCPT-431551Laryngoscopy <td< td=""><td>OCJS8ZZ</td><td>Inspection of Larynx, Via Natural or Artificial Opening Endoscopic</td><td>Procedure</td><td>ICD-10-PCS</td></td<>	OCJS8ZZ	Inspection of Larynx, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
ODL57D2Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial OpeningProcedureICD-10-PCSODL58D2Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopProcedureICD-10-PCSOWHQ7V2Insertion of Other Device into Respiratory Tract, Via Natural or Artificial OpeningProcedureICD-10-PCS31.1TracheostomyProcedureICD-9-CM31.2TracheostomyProcedureICD-9-CM31.4TracheostomyProcedureICD-9-CM31.9IntubationProcedureICD-9-CM31.99IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431600TracheostomyProcedureCPT-431601TracheostomyProcedureCPT-431602TracheostomyProcedureCPT-431603TracheostomyProcedureCPT-431604TracheostomyProcedureCPT-431605TracheostomyPr	0DH57BZ	Insertion of Airway into Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
DDLS8D2Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening EndoscopProcedureICD-10-PCS0WHQ7V2Insertion of Other Device into Respiratory Tract, Via Natural or Artificial OpeningProcedureICD-10-PCS31.1TracheostomyProcedureICD-9-CM31.2TracheostomyProcedureICD-9-CM31.21TracheostomyProcedureICD-9-CM31.22TracheostomyProcedureICD-9-CM31.23TracheostomyProcedureICD-9-CM31.24LaryngoscopyProcedureICD-9-CM31.25LaryngoscopyProcedureCPT-431502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431531LaryngoscopyProcedureCPT-431541LaryngoscopyProcedureCPT-431552LaryngoscopyProcedureCPT-431551LaryngoscopyProcedureCPT-431561TracheostomyProcedureCPT-431605Tracheostomy </td <td>0DH58BZ</td> <td>Insertion of Airway into Esophagus, Via Natural or Artificial Opening Endoscopic</td> <td>Procedure</td> <td>ICD-10-PCS</td>	0DH58BZ	Insertion of Airway into Esophagus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OWHQ7VZInsertion of Other Device into Respiratory Tract, Via Natural or Artificial OpeningProcedureICD-10-PCS31.1TracheostomyProcedureICD-9-CM31.2TracheostomyProcedureICD-9-CM31.21TracheostomyProcedureICD-9-CM31.22TracheostomyProcedureICD-9-CM31.24LaryngoscopyProcedureICD-9-CM31.25LaryngoscopyProcedureICD-9-CM31.20IntubationProcedureCPT-431502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431505LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521TracheostomyProcedureCPT-431525LaryngoscopyProce	0DL57DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
31.1TracheostomyProcedureICD-9-CM31.2TracheostomyProcedureICD-9-CM31.21TracheostomyProcedureICD-9-CM31.22TracheostomyProcedureICD-9-CM31.24LaryngoscopyProcedureICD-9-CM31.25IntubationProcedureICD-9-CM31.21LaryngoscopyProcedureICD-9-CM31.22IntubationProcedureICD-9-CM31.23LaryngoscopyProcedureCPT-431505LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431540LaryngoscopyProcedureCPT-431551LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561TracheostomyProcedureCPT-431561TracheostomyProcedureCPT-431561TracheostomyP	0DL58DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscop	Procedure	ICD-10-PCS
31.2TracheostomyProcedureICD-9-CM31.21TracheostomyProcedureICD-9-CM31.22TracheostomyProcedureICD-9-CM31.42LaryngoscopyProcedureICD-9-CM31.99IntubationProcedureICD-9-CM31.91LaryngoscopyProcedureICD-9-CM31.92IntubationProcedureICD-9-CM31.93IntubationProcedureICD-9-CM31.94LaryngoscopyProcedureICD-9-CM31.95LaryngoscopyProcedureCPT-431.50LaryngoscopyProcedureCPT-431.52LaryngoscopyProcedureCPT-431.52LaryngoscopyProcedureCPT-431.52LaryngoscopyProcedureCPT-431.52LaryngoscopyProcedureCPT-431.52LaryngoscopyProcedureCPT-431.53LaryngoscopyProcedureCPT-431.54LaryngoscopyProcedureCPT-431.55LaryngoscopyProcedureCPT-431.56LaryngoscopyProcedureCPT-431.51LaryngoscopyProcedureCPT-431.51LaryngoscopyProcedureCPT-431.51LaryngoscopyProcedureCPT-431.51LaryngoscopyProcedureCPT-431.51LaryngoscopyProcedureCPT-431.51LaryngoscopyProcedureCPT-431.51Tracheostomy <td< td=""><td>0WHQ7YZ</td><td>Insertion of Other Device into Respiratory Tract, Via Natural or Artificial Opening</td><td>Procedure</td><td>ICD-10-PCS</td></td<>	0WHQ7YZ	Insertion of Other Device into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
31.21TracheostomyProcedureICD-9-CM31.29TracheostomyProcedureICD-9-CM31.42LaryngoscopyProcedureICD-9-CM31.90IntubationProcedureICD-9-CM31231LaryngoscopyProcedureCPT-431502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431505LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520TracheostomyProcedureCPT-431521TracheostomyProcedureCPT-431525TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431614TracheostomyProcedure </td <td>31.1</td> <td>Tracheostomy</td> <td>Procedure</td> <td>ICD-9-CM</td>	31.1	Tracheostomy	Procedure	ICD-9-CM
31.29TracheostomyProcedureICD-9-CM31.42LaryngoscopyProcedureICD-9-CM31.90IntubationProcedureICD-9-CM31.21LaryngoscopyProcedureCPT-431502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431505LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431614TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedure	31.2	Tracheostomy	Procedure	ICD-9-CM
31.42LaryngoscopyProcedureICD-9-CM31.99IntubationProcedureICD-9-CM31231LaryngoscopyProcedureCPT-431502IntubationProcedureCPT-431503LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431531LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431614TracheostomyProcedureCPT-431615TracheostomyProcedure <td< td=""><td>31.21</td><td>Tracheostomy</td><td>Procedure</td><td>ICD-9-CM</td></td<>	31.21	Tracheostomy	Procedure	ICD-9-CM
31.99IntubitionProcedureICD-9-CM31231LaryngoscopyProcedureCPT-431502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431614TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431616TracheostomyProcedureCPT-431617TracheostomyProcedureCPT-431618TracheostomyProcedureCP	31.29	Tracheostomy	Procedure	ICD-9-CM
31231LaryngoscopyProcedureCPT-431502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyCPT-4CPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431614TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431616TracheostomyProcedureCPT-431617TracheostomyCPT-4CPT-4<	31.42	Laryngoscopy	Procedure	ICD-9-CM
31502IntubationProcedureCPT-431505LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561IaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-4316110TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureICD-10-PCS3117822Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedure3117825Respiratory Ventilation, Seatent than	31.99	Intubation	Procedure	ICD-9-CM
31505LaryngoscopyProcedureCPT-431525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening InProcedureCD-10-PCS311782Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening InProcedureCD-10-PCS311782Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS314955Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureCPT-49000IntubationProcedureCPT-4ICD-10-PCS314955IntubationProcedureCPT-4ICD-10-PCS314956IntubationSepiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PC	31231	Laryngoscopy	Procedure	CPT-4
31525LaryngoscopyProcedureCPT-431526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431521LaryngoscopyProcedureCPT-431531LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431614TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyIcb-10-PCS <td>31502</td> <td>Intubation</td> <td>Procedure</td> <td>CPT-4</td>	31502	Intubation	Procedure	CPT-4
31526LaryngoscopyProcedureCPT-431527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431614TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureC	31505	Laryngoscopy	Procedure	CPT-4
31527LaryngoscopyProcedureCPT-431528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431520LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431605TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431616TracheostomyProcedureCPT-431617TracheostomyProcedureCPT-431618TracheostomyProcedureCPT-431619TracheostomyCPT-4Procedure31615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureICD-10-PCS3161782Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening En ProcedureICD-10-PCS319352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS319352Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS319353IntubationProcedureCPT-496Intubat	31525	Laryngoscopy	Procedure	CPT-4
31528LaryngoscopyProcedureCPT-431529LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431605TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431616TracheostomyProcedureCPT-431617TracheostomyCPT-4Procedure31618TracheostomyCPT-4Procedure31619TracheostomyCPT-4Procedure31615TracheostomyCPT-4Procedure31615TracheostomyCPT-4Procedure31615TracheostomyCPT-4Procedure31615TracheostomyCPT-4Procedure31615TracheostomyCPT-4Procedure31615TracheostomyCPT-4Procedure31615TracheostomyCPT-4Procedure31617TracheostomyCPT-4Procedure316182Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedure319352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS319353Respiratory Ventilation, Greater than 96 Consecutive HoursProc	31526	Laryngoscopy	Procedure	CPT-4
31529LaryngoscopyProcedureCPT-431560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431605TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCD-10-PCS31615TracheostomyProcedureICD-10-PCS31615StapaszRespiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS319352Respiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS319352Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS31900IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31527	Laryngoscopy	Procedure	CPT-4
1560LaryngoscopyProcedureCPT-431561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431605TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431611TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial OpeningProcedureICD-10-PCS317882Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS319352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS319352Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS319353Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS319354Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS319355Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS319354Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS319355Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS319355Respiratory Ventilation, Greater th	31528	Laryngoscopy	Procedure	CPT-4
31561LaryngoscopyProcedureCPT-431603TracheostomyProcedureCPT-431605TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS3E1F782Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS3E1F882Irrigation of Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A19552Respiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A19552Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31529	Laryngoscopy	Procedure	CPT-4
31603TracheostomyProcedureCPT-431605TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureICD-10-PCS31615Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening En ProcedureICD-10-PCS5A19352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A19552Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31560	Laryngoscopy	Procedure	CPT-4
31605TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431610TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureICD-10-PCS31615Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS31615Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS319352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS319452Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS31000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31561	Laryngoscopy	Procedure	CPT-4
31610TracheostomyProcedureCPT-431612TracheostomyProcedureCPT-431613TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS3E1F882Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS5A19352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A19452Respiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A19552Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31603	Tracheostomy	Procedure	CPT-4
31612TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-431615TracheostomyProcedureCPT-43E1F782Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS3E1F882Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS5A19352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A19452Respiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A19552Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31605	Tracheostomy	Procedure	CPT-4
31615TracheostomyProcedureCPT-4321615Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial OpeningProcedureICD-10-PCS321F782Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS321F882Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening EnProcedureICD-10-PCS3419352Respiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A19452Respiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A19552Respiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31610	Tracheostomy	Procedure	CPT-4
3E1F78ZIrrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial OpeningProcedureICD-10-PCS3E1F88ZIrrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening En ProcedureICD-10-PCS5A1935ZRespiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A1945ZRespiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A1955ZRespiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31612	Tracheostomy	Procedure	CPT-4
3E1F88ZIrrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening En ProcedureICD-10-PCS5A1935ZRespiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A1945ZRespiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A1955ZRespiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	31615	Tracheostomy	Procedure	CPT-4
5A1935ZRespiratory Ventilation, Less than 24 Consecutive HoursProcedureICD-10-PCS5A1945ZRespiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A1955ZRespiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	3E1F78Z	Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
5A1945ZRespiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A1955ZRespiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	3E1F88Z	Irrigation of Respiratory Tract using Irrigating Substance, Via Natural or Artificial Opening En	Procedure	ICD-10-PCS
5A1945ZRespiratory Ventilation, 24-96 Consecutive HoursProcedureICD-10-PCS5A1955ZRespiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	5A1935Z	Respiratory Ventilation, Less than 24 Consecutive Hours	Procedure	ICD-10-PCS
5A1955ZRespiratory Ventilation, Greater than 96 Consecutive HoursProcedureICD-10-PCS91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	5A1945Z			ICD-10-PCS
91000IntubationProcedureCPT-496IntubationProcedureICD-9-CM	5A1955Z			ICD-10-PCS
96 Intubation Procedure ICD-9-CM	91000			
	96			
	96.0			



Appendix C. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Outcome in this Request

		Code	
Code	Description	Category	Code Type
96.01	Intubation	Procedure	ICD-9-CM
96.02	Intubation	Procedure	ICD-9-CM
96.03	Intubation	Procedure	ICD-9-CM
96.04	Intubation	Procedure	ICD-9-CM
96.05	Intubation	Procedure	ICD-9-CM
96.06	Intubation	Procedure	ICD-9-CM
96.56	Intubation	Procedure	ICD-9-CM
96.7	Intubation	Procedure	ICD-9-CM
96.70	Intubation	Procedure	ICD-9-CM
96.71	Intubation	Procedure	ICD-9-CM
96.72	Intubation	Procedure	ICD-9-CM
99220	ICU Admission	Procedure	CPT-4
99221	ICU Admission	Procedure	CPT-4
99222	ICU Admission	Procedure	CPT-4
99223	ICU Admission	Procedure	CPT-4
99224	ICU Admission	Procedure	CPT-4
99225	ICU Admission	Procedure	CPT-4
99226	ICU Admission	Procedure	CPT-4
99291	ICU Admission	Procedure	CPT-4
99292	ICU Admission	Procedure	CPT-4
A0396	Intubation	Procedure	HCPCS
V44.0	Tracheostomy	Diagnosis	ICD-9-CM
V55.0	Tracheostomy	Diagnosis	ICD-9-CM
Z43.0	Encounter for Attention to Tracheostomy	Diagnosis	ICD-10-CM
Z93.0	Tracheostomy Status	Diagnosis	ICD-10-CM
	Angioedema		
995.1	Angioedema	Diagnosis	ICD-9-CM
ΤΤΟΟΥΥΛ	Angioedema	Diagnosis	ICD-10-CM


Appendix D. Generic and Brand Names of Medical Products Used to Define Exposure Incidence and Exclusion Criteria in this Request

Generic Name	Brand Name
Angiotensin-Convertin	g Enzyme Inhibitors (ACEI)
AMLODIPINE BESYLATE/BENAZEPRIL HCL	Lotrel
AMLODIPINE BESYLATE/BENAZEPRIL HCL	amlodipine-benazepril
BENAZEPRIL HCL	Lotensin
BENAZEPRIL HCL	benazepril
BENAZEPRIL HCL/HYDROCHLOROTHIAZIDE	Lotensin HCT
BENAZEPRIL HCL/HYDROCHLOROTHIAZIDE	benazepril-hydrochlorothiazide
CAPTOPRIL	captopril
CAPTOPRIL/HYDROCHLOROTHIAZIDE	captopril-hydrochlorothiazide
ENALAPRIL MALEATE	Epaned
ENALAPRIL MALEATE	Vasotec
ENALAPRIL MALEATE	enalapril maleate
ENALAPRIL MALEATE/HYDROCHLOROTHIAZIDE	Vaseretic
ENALAPRIL MALEATE/HYDROCHLOROTHIAZIDE	enalapril-hydrochlorothiazide
FOSINOPRIL SODIUM	fosinopril
FOSINOPRIL SODIUM/HYDROCHLOROTHIAZIDE	fosinopril-hydrochlorothiazide
LISINOPRIL	Prinivil
LISINOPRIL	Qbrelis
LISINOPRIL	Zestril
LISINOPRIL	lisinopril
LISINOPRIL/HYDROCHLOROTHIAZIDE	Zestoretic
LISINOPRIL/HYDROCHLOROTHIAZIDE	lisinopril-hydrochlorothiazide
MOEXIPRIL HCL	Univasc
MOEXIPRIL HCL	moexipril
MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE	Uniretic
MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE	moexipril-hydrochlorothiazide
PERINDOPRIL ARGININE/AMLODIPINE BESYLATE	Prestalia
PERINDOPRIL ERBUMINE	Aceon
PERINDOPRIL ERBUMINE	perindopril erbumine
QUINAPRIL HCL	Accupril
QUINAPRIL HCL	quinapril
QUINAPRIL HCL/HYDROCHLOROTHIAZIDE	Accuretic
QUINAPRIL HCL/HYDROCHLOROTHIAZIDE	quinapril-hydrochlorothiazide
RAMIPRIL	Altace
RAMIPRIL	ramipril
TRANDOLAPRIL	Mavik
TRANDOLAPRIL	trandolapril
TRANDOLAPRIL/VERAPAMIL HCL	Tarka
TRANDOLAPRIL/VERAPAMIL HCL	trandolapril-verapamil
amlodipine besylate/benazepril HCl	amlodipine-benazepril
benazepril HCl	Lotensin
benazepril HCl	benazepril
captopril	captopril
enalapril maleate	enalapril maleate



Appendix D. Generic and Brand Names of Medical Products Used to Define Exposure Incidence and Exclusion Criteria in this Request

Generic Name	Brand Name
lisinopril	lisinopril
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
quinapril HCl	quinapril
ramipril	ramipril
trandolapril	trandolapril
Angiotensin II Recept	tor Blockers (ARB)
AMLODIPINE BESYLATE/OLMESARTAN MEDOXOMIL	Azor
AMLODIPINE BESYLATE/OLMESARTAN MEDOXOMIL	amlodipine-olmesartan
AMLODIPINE BESYLATE/VALSARTAN	Exforge
AMLODIPINE BESYLATE/VALSARTAN	amlodipine-valsartan
AMLODIPINE BESYLATE/VALSARTAN/HYDROCHLOROTHIAZIDE	Exforge HCT
AMLODIPINE BESYLATE/VALSARTAN/HYDROCHLOROTHIAZIDE	amlodipine-valsartan-hcthiazid
AZILSARTAN MEDOXOMIL	Edarbi
AZILSARTAN MEDOXOMIL/CHLORTHALIDONE	Edarbyclor
CANDESARTAN CILEXETIL	Atacand
CANDESARTAN CILEXETIL	candesartan
CANDESARTAN CILEXETIL/HYDROCHLOROTHIAZIDE	Atacand HCT
CANDESARTAN CILEXETIL/HYDROCHLOROTHIAZIDE	candesartan-hydrochlorothiazid
EPROSARTAN MESYLATE	Teveten
EPROSARTAN MESYLATE	eprosartan
EPROSARTAN MESYLATE/HYDROCHLOROTHIAZIDE	Teveten HCT
IRBESARTAN	Avapro
IRBESARTAN	irbesartan
IRBESARTAN/HYDROCHLOROTHIAZIDE	Avalide
IRBESARTAN/HYDROCHLOROTHIAZIDE	irbesartan-hydrochlorothiazide
LOSARTAN POTASSIUM	Cozaar
LOSARTAN POTASSIUM LOSARTAN	losartan
POTASSIUM/HYDROCHLOROTHIAZIDE	Hyzaar
LOSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE	, losartan-hydrochlorothiazide
NEBIVOLOL HCL/VALSARTAN	Byvalson
OLMESARTAN MEDOXOMIL	Benicar
OLMESARTAN MEDOXOMIL	olmesartan
OLMESARTAN MEDOXOMIL/AMLODIPINE	
BESYLATE/HYDROCHLOROTHIAZIDE	Tribenzor
OLMESARTAN MEDOXOMIL/AMLODIPINE	
BESYLATE/HYDROCHLOROTHIAZIDE	olmesartan-amlodipin-hcthiazid
OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE	Benicar HCT
OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE	olmesartan-hydrochlorothiazide
TELMISARTAN	Micardis
TELMISARTAN	telmisartan
TELMISARTAN/AMLODIPINE BESYLATE	Twynsta
TELMISARTAN/AMLODIPINE BESYLATE	telmisartan-amlodipine
TELMISARTAN/HYDROCHLOROTHIAZIDE	Micardis HCT



Appendix D. Generic and Brand Names of Medical Products Used to Define Exposure Incidence and Exclusion Criteria in this Request

Generic Name	Brand Name
TELMISARTAN/HYDROCHLOROTHIAZIDE	telmisartan-hydrochlorothiazid
VALSARTAN	Diovan
VALSARTAN	valsartan
VALSARTAN/HYDROCHLOROTHIAZIDE	Diovan HCT
VALSARTAN/HYDROCHLOROTHIAZIDE	valsartan-hydrochlorothiazide
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
candesartan cilexetil	Atacand
candesartan cilexetil	candesartan
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
irbesartan	irbesartan
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
losartan potassium	losartan
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
olmesartan medoxomil	Benicar
olmesartan medoxomil	olmesartan
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
telmisartan	telmisartan
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
valsartan	valsartan
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide



Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request

		Code	
Code	Description	Category	Code Type
402.01	Heart failure	Diamaria	
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic	Diagnosis	ICD-9-CM
404.11	kidney disease stage I through stage IV, or unspecified		
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with	Diagnosis	ICD-9-CM
404.91	chronic kidney disease stage I through stage IV, or unspecified		
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428	Heart failure	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.2	Systolic heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.3	Diastolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.4	Combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
111.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage	-	ICD-10-CM
113.0	4 chronic kidney disease, or unspecified chronic kidney disease	-	
113.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
150	Heart failure	Diagnosis	ICD-10-CM
150.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM



Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Inclusion Criteria in this Request

		Code	
Code	Description	Category	Code Type
150.2	Systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.3	Diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.4	Combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
150.811	Acute right heart failure	Diagnosis	ICD-10-CM
150.812	Chronic right heart failure	Diagnosis	ICD-10-CM
150.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
150.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
150.82	Biventricular heart failure	Diagnosis	ICD-10-CM
150.83	High output heart failure	Diagnosis	ICD-10-CM
150.84	End stage heart failure	Diagnosis	ICD-10-CM
150.89	Other heart failure	Diagnosis	ICD-10-CM
150.9	Heart failure, unspecified	Diagnosis	ICD-10-CM



CodeDescriptionCategoryCode TypeAllergic472.0Chronic rhinitisDiagnosisICD-9-CM477.1Allergic rhinitis due to pollenDiagnosisICD-9-CM477.1Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM477.2Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM477.8Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM477.9Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM477.8Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM691.0Diaper or napkin rashrelated conditionsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to alvegrastDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to solventsDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.7Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.7Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.7Contact dermatitis and other eczema due to suburnDiagnosisICD-9-CM692.7Contact dermatitis and other eczema due to suburnDiagnosisICD-9-C			Code	
472.0Chronic rhinitisDiagnosisICD-9-CM477.0Allergic rhinitis due to pollenDiagnosisICD-9-CM477.1Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM477.2Allergic rhinitis due to other allergenDiagnosisICD-9-CM477.3Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM477.4Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM478.8Other atopic dermatitis and related conditionsDiagnosisICD-9-CM691.0Diagnor or apkin rashDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to detergentsDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to olis and greasesDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to olrug and medicines in contact with skinDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to olru contact with skinDiagnosisICD-9-CM692.70Unspecified dermatitis and other eczema due to olar contact with skinDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to suburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic prokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisI	Code	Description	Category	Code Type
477.0Allergic rhinitis due to pollenDiagnosisICD-9-CM477.1Allergic rhinitis, due to foodDiagnosisICD-9-CM477.2Allergic rhinitis, due to other allergenDiagnosisICD-9-CM477.8Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM477.9Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM691.0Diagnosi and colitis, allergicDiagnosisICD-9-CM692.0Contact dermattis and related conditionsDiagnosisICD-9-CM692.1Contact dermattis and other eczema due to olls and greasesDiagnosisICD-9-CM692.2Contact dermattitis and other eczema due to odrugs and medicines in contact with skinDiagnosisICD-9-CM692.3Contact dermattitis and other eczema due to ford un contact with skinDiagnosisICD-9-CM692.4Contact dermattitis and other eczema due to ford in contact with skinDiagnosisICD-9-CM692.7Cuntact dermattitis and other eczema due to sunburnDiagnosisICD-9-CM692.7.1Contact dermattitis and other eczema due to sunburnDiagnosisICD-9-CM692.7.2Actine retroiloid and actinic granulomaDiagnosisICD-9-CM692.7.4Cother chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.7.5Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.7.6Contact dermattitis due to solar r		Allergies		
477.1Allergic rhinitis, due to foodDiagnosisICD-9-CM477.2Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM477.8Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM477.9Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM478.8Other atopic dermatitis and colitis, allergicDiagnosisICD-9-CM691.0Diaper or napkin rashDiagnosisICD-9-CM692.1Contact dermatitis and other eccema due to als and greasesDiagnosisICD-9-CM692.2Contact dermatitis and other eccema due to solventsDiagnosisICD-9-CM692.3Contact dermatitis and other eccema due to olary and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eccema due to olar (secept food)DiagnosisICD-9-CM692.5Contact dermatitis and other eccema due to olar (secept food)DiagnosisICD-9-CM692.7Contact dermatitis and other eccema due to solventsDiagnosisICD-9-CM692.7Contact dermat	472.0	Chronic rhinitis	Diagnosis	ICD-9-CM
477.2Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-9-CM477.8Allergic rhinitis due to other allergenDiagnosisICD-9-CM477.9Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM58.3Gastroenteritis and colitis, allergicDiagnosisICD-9-CM691.0Diaper or napkin rashDiagnosisICD-9-CM692.0Contact dermatitis and related conditionsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to olis and greasesDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to olrug and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to ofool in contact with skinDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.6Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.71Contact dermatitis due to sun radiationDiagnosisICD-9-CM692.72Diseminated superficial actinic granulomaDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Sunburn of second degreeDiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisI	477.0	Allergic rhinitis due to pollen	Diagnosis	ICD-9-CM
477.8Allergic rhinitis due to other allergenDiagnosisICD-9-CM477.9Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM58.3Gastroenteritis and collits, allergicDiagnosisICD-9-CM691.0Diaper or napkin rashDiagnosisICD-9-CM692.0Contact dermatitis and other eczema due to detergentsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to oslventsDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to oslventsDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to oslventsDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic retriculoid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisI	477.1	Allergic rhinitis, due to food	Diagnosis	ICD-9-CM
477.9Allergic rhinitis, cause unspecifiedDiagnosisICD-9-CM478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM558.3Gastroenteritis and colitis, allergicDiagnosisICD-9-CM691.0Diaper or napkin rashDiagnosisICD-9-CM692.1Contact dermatitis and there eczema due to detergentsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to olis and greasesDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to oly and greasesDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to orbug and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to orbug and medicines in contact with skinDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to orbug and medicines in contact with skinDiagnosisICD-9-CM692.6Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.71Contact dermatitis due to sunDiagnosisICD-9-CM692.72Actue dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chonic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Sunburn of second degreeDiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of second degree<	477.2	Allergic rhinitis due to animal (cat) (dog) hair and dander	Diagnosis	ICD-9-CM
478.8Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-9-CM558.3Gastroenteritis and colitis, allergicDiagnosisICD-9-CM691.0Diaper or napkin rashDiagnosisICD-9-CM692.0Contact dermatitis and other eczema due to detergentsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to oils and greasesDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to oils and greasesDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to orug and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to orug and medicines in contact with skinDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Sunburn of second degreeDiagnosisICD-9-CM692.75Diseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.74Sunburn of third degreeDiagnosisICD-9-CM692.75Diseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of third degree	477.8	Allergic rhinitis due to other allergen	Diagnosis	ICD-9-CM
558.3Gastroenteritis and colitis, allergicDiagnosisICD-9-CM691.0Diaper or napkin rashDiagnosisICD-9-CM691.3Other atopic dermatitis and related conditionsDiagnosisICD-9-CM692.0Contact dermatitis and other eczema due to detergentsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to olis and greasesDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to olys and medicines in contact with skinDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.79Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to other radiationDiagnosisICD-9-CM692.79Other dermatitis due to othe	477.9	Allergic rhinitis, cause unspecified	Diagnosis	ICD-9-CM
691.0Diaper or napkin rashDiagnosisICD-9-CM691.8Other atopic dermatitis and related conditionsDiagnosisICD-9-CM692.0Contact dermatitis and other eczema due to detergentsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to solventsDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis due to sunDiagnosisICD-9-CM692.72Acute dermatitis due to sunDiagnosisICD-9-CM692.73Contact dermatitis due to solar radiationDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of third degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.78Dermatitis due to colar radiationDiagnosisICD-9-CM692.79Other dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.78<	478.8	Upper respiratory tract hypersensitivity reaction, site unspecified	Diagnosis	ICD-9-CM
691.8Other atopic dermatitis and related conditionsDiagnosisICD-9-CM692.0Contact dermatitis and other eczema due to detergentsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to oils and greasesDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to oils and greasesDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to drugs and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to ofod in contact with skinDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to sunDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of second degreeDiagnosisICD-9-CM692.78Dermatitis due to other radiationDiagnosisICD-9-CM692.79Other dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.81Dermatitis due to other radiation	558.3	Gastroenteritis and colitis, allergic	Diagnosis	ICD-9-CM
692.0Contact dermatitis and other eczema due to detergentsDiagnosisICD-9-CM692.1Contact dermatitis and other eczema due to solventsDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to solventsDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to solventsDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.6Contact dermatitis and other eczema due to suburnDiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to suburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.78Dermatitis due to cosmeticsDiagnosisICD-9-CM692.79Other dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.81Dermatitis due to other radiationDiagnosisICD-9-CM	691.0	Diaper or napkin rash	Diagnosis	ICD-9-CM
692.1Contact dermatitis and other eczema due to oils and greasesDiagnosisICD-9-CM692.2Contact dermatitis and other eczema due to solventsDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to drugs and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.6Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic retriculoid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.78Dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.80Dermatitis due to other radiationDiagnosisICD-9-CM692.81Dermatitis d	691.8	Other atopic dermatitis and related conditions	Diagnosis	ICD-9-CM
692.2Contact dermatitis and other eczema due to solventsDiagnosisICD-9-CM692.3Contact dermatitis and other eczema due to drugs and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.78Dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.80Contact dermatitis and other eczema due to animal (cat) (dog) dander <t< td=""><td>692.0</td><td>Contact dermatitis and other eczema due to detergents</td><td>Diagnosis</td><td>ICD-9-CM</td></t<>	692.0	Contact dermatitis and other eczema due to detergents	Diagnosis	ICD-9-CM
692.3Contact dermatitis and other eczema due to drugs and medicines in contact with skinDiagnosisICD-9-CM692.4Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.6Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to other radiationDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to othe	692.1	Contact dermatitis and other eczema due to oils and greases	Diagnosis	ICD-9-CM
692.4Contact dermatitis and other eczema due to other chemical productsDiagnosisICD-9-CM692.5Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.6Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.78Dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosher radiationDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to other radiationDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM <td< td=""><td>692.2</td><td>Contact dermatitis and other eczema due to solvents</td><td>Diagnosis</td><td>ICD-9-CM</td></td<>	692.2	Contact dermatitis and other eczema due to solvents	Diagnosis	ICD-9-CM
692.5Contact dermatitis and other eczema due to food in contact with skinDiagnosisICD-9-CM692.6Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis due to sunDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to other radiationDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.99Contact dermatitis and other eczema due to unspecified agentDiagnosisICD-9-CM692.99Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.80Dermatitis due to other specified auseDiagnosisICD-9-CM692.99	692.3	Contact dermatitis and other eczema due to drugs and medicines in contact with skin	Diagnosis	ICD-9-CM
692.6Contact dermatitis and other eczema due to plants (except food)DiagnosisICD-9-CM692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.99Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM693.00Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.10Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM <t< td=""><td>692.4</td><td>Contact dermatitis and other eczema due to other chemical products</td><td>Diagnosis</td><td>ICD-9-CM</td></t<>	692.4	Contact dermatitis and other eczema due to other chemical products	Diagnosis	ICD-9-CM
692.70Unspecified dermatitis due to sunDiagnosisICD-9-CM692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to metalsDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.95Contact dermatitis and other eczema due to unspecified agentDiagnosisICD-9-CM693.0Dermatitis due to food taken internallyDiagnosisICD-9-CM693.1Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.3Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.4Dermatitis due to other specified sub	692.5	Contact dermatitis and other eczema due to food in contact with skin	Diagnosis	ICD-9-CM
692.71Contact dermatitis and other eczema due to sunburnDiagnosisICD-9-CM692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to other radiationDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.90Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.01Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.10Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.30Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.40Dermatitis due to other specified substance taken internallyDiagnosis<	692.6	Contact dermatitis and other eczema due to plants (except food)	Diagnosis	ICD-9-CM
692.72Acute dermatitis due to solar radiationDiagnosisICD-9-CM692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to other radiationDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.99Contact dermatitis and other eczema, due to unspecified agentDiagnosisICD-9-CM693.0Dermatitis due to food taken internallyDiagnosisICD-9-CM693.1Dermatitis due to other specified causeDiagnosisICD-9-CM693.3Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.4Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.	692.70	Unspecified dermatitis due to sun	Diagnosis	ICD-9-CM
692.73Actinic reticuloid and actinic granulomaDiagnosisICD-9-CM692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to other radiationDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM693.00Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.11Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.29Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.30Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.40Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.51Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.61Dermatitis due to unspecified substance taken int	692.71	Contact dermatitis and other eczema due to sunburn	Diagnosis	ICD-9-CM
692.74Other chronic dermatitis due to solar radiationDiagnosisICD-9-CM692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to other radiationDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.99Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.91Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.01Dermatitis due to other specified causeDiagnosisICD-9-CM693.11Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.29Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.40Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.71Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.81Dermatitis due to unspecified substances taken internallyDiagnosisICD-9-CM693.93Dermatitis due to unspecified substance taken internal	692.72	Acute dermatitis due to solar radiation	Diagnosis	ICD-9-CM
692.75Disseminated superficial actinic porokeratosis (DSAP)DiagnosisICD-9-CM692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to other radiationDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.91Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.02Dermatitis due to other specified causeDiagnosisICD-9-CM693.1Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.29Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.30Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.42Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.93Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.94Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.93Dermatitis due to unspecified substance taken i	692.73	Actinic reticuloid and actinic granuloma	Diagnosis	ICD-9-CM
692.76Sunburn of second degreeDiagnosisICD-9-CM692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to metalsDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.90Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.00Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.3Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.0Allergic urticariaDiagnosisICD-9-CM693.1Idiopathic urticariaDiagnosisICD-9-CM693.2Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.1Idiopathic urticariaDiagnosisICD-9-CM693.2Dermatitis due to unspecifi	692.74	Other chronic dermatitis due to solar radiation	Diagnosis	ICD-9-CM
692.77Sunburn of third degreeDiagnosisICD-9-CM692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to metalsDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.90Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.00Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.11Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.0Allergic urticariaDiagnosisICD-9-CM693.1Idiopathic urticariaDiagnosisICD-9-CM693.1Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.1Idiopathic urticariaDiagnosisICD-9-CM693.2Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.	692.75	Disseminated superficial actinic porokeratosis (DSAP)	Diagnosis	ICD-9-CM
692.79Other dermatitis due to solar radiationDiagnosisICD-9-CM692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to metalsDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.0Allergic urticariaDiagnosisICD-9-CM693.1Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.0Allergic urticariaDiagnosisICD-9-CM693.1Idopathic urticariaDiagnosisICD-9-CM693.1Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9	692.76	Sunburn of second degree	Diagnosis	ICD-9-CM
692.81Dermatitis due to cosmeticsDiagnosisICD-9-CM692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to metalsDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.0Allergic urticariaDiagnosisICD-9-CM693.1Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM693.9Dermatitis due to other specified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.77	Sunburn of third degree	Diagnosis	ICD-9-CM
692.82Dermatitis due to other radiationDiagnosisICD-9-CM692.83Dermatitis due to metalsDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.79	Other dermatitis due to solar radiation	Diagnosis	ICD-9-CM
692.83Dermatitis due to metalsDiagnosisICD-9-CM692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.81	Dermatitis due to cosmetics	Diagnosis	ICD-9-CM
692.84Contact dermatitis and other eczema due to animal (cat) (dog) danderDiagnosisICD-9-CM692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.82	Dermatitis due to other radiation	Diagnosis	ICD-9-CM
692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.83	Dermatitis due to metals	Diagnosis	ICD-9-CM
692.89Contact dermatitis and other eczema due to other specified agentDiagnosisICD-9-CM692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.84	Contact dermatitis and other eczema due to animal (cat) (dog) dander	Diagnosis	ICD-9-CM
692.9Contact dermatitis and other eczema, due to unspecified causeDiagnosisICD-9-CM693.0Dermatitis due to drugs and medicines taken internallyDiagnosisICD-9-CM693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.89			ICD-9-CM
693.1Dermatitis due to food taken internallyDiagnosisICD-9-CM693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	692.9	Contact dermatitis and other eczema, due to unspecified cause		ICD-9-CM
693.8Dermatitis due to other specified substances taken internallyDiagnosisICD-9-CM693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	693.0	Dermatitis due to drugs and medicines taken internally	Diagnosis	ICD-9-CM
693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	693.1	Dermatitis due to food taken internally	Diagnosis	ICD-9-CM
693.9Dermatitis due to unspecified substance taken internallyDiagnosisICD-9-CM708.0Allergic urticariaDiagnosisICD-9-CM708.1Idiopathic urticariaDiagnosisICD-9-CM	693.8	Dermatitis due to other specified substances taken internally	Diagnosis	ICD-9-CM
708.1Idiopathic urticariaDiagnosisICD-9-CM	693.9	Dermatitis due to unspecified substance taken internally	Diagnosis	ICD-9-CM
708.1Idiopathic urticariaDiagnosisICD-9-CM			-	
		-	-	
	708.2	Urticaria due to cold and heat	Diagnosis	ICD-9-CM
708.3 Dermatographic urticaria Diagnosis ICD-9-CM			-	
708.4 Vibratory urticaria Diagnosis ICD-9-CM			-	



CodeDescriptionCategoryCode Type708.5Chalmergic urticariaDiagnosisICD-9-CM708.8Unspecified urticariaDiagnosisICD-9-CM708.9Unspecified urticariaDiagnosisICD-9-CM708.50Other anaphylactic reactionDiagnosisICD-9-CM708.70Other drug allergyDiagnosisICD-9-CM708.71Other adverse food reactions, not elsewhere classifiedDiagnosisICD-9-CM708.72Other adverse food reactions, not elsewhere classifiedDiagnosisICD-10-CM708.73Allergic rhinitisDiagnosisICD-10-CM708.74Other adverse food reactions, not elsewhere classifiedDiagnosisICD-10-CM708.74Allergic rhinitisdue to foodDiagnosisICD-10-CM708.75Other adverse food reactions, rot elsewhere classifiedDiagnosisICD-10-CM708.74Allergic rhinitisdue to foodDiagnosisICD-10-CM708.75Allergic rhinitisdue to foodDiagnosisICD-10-CM708.74Allergic rhinitisDiagnosisICD-10-CM708.74HoldrichDiagnosisICD-10-CM708.74Food protein-induced enterocalitis syndromeDiagnosisICD-10-CM708.72Food protein-induced enteropathyDiagnosisICD-10-CM708.74Holgric and dietetic gastroenteritis and colitisDiagnosisICD-10-CM708.74Holgric and dietetic gastroenteritis and colitisDiagnosisICD-10-CM708.			Code	
708.8Other specified urticariaDiagnosisICD-9CM708.9Unspecified urticariaDiagnosisICD-9CM995.0Other anaphylatic reactionDiagnosisICD-9CM995.27Other anaphylatic reactionDiagnosisICD-9CM995.37Other adverse food reactions, not elsewhere classifiedDiagnosisICD-9CM130.0Vasomotor rhinitisDiagnosisICD-9CM130.1Allergic rhinitis due to pollenDiagnosisICD-10CM130.2Other seasonal allergic rhinitisDiagnosisICD-10CM130.3Allergic rhinitis due to foodDiagnosisICD-10CM130.4Allergic rhinitis due to foodDiagnosisICD-10CM130.5Allergic rhinitisDiagnosisICD-10CM130.8Other allergic rhinitisDiagnosisICD-10CM130.9Allergic rhinitis, unspecifiedDiagnosisICD-10CM130.9Allergic rhinitis, unspecifiedDiagnosisICD-10CM130.9Allergic rhinitisDiagnosisICD-10CM130.9Allergic rhinitisDiagnosisICD-10CM130.9Allergic rhiniticDiagnosisICD-10CM130.9Allergic rhinitisDiagnosisICD-10CM130.9Allergic rhiniticDiagnosisICD-10CM130.9Allergic rhinitisDiagnosisICD-10CM130.9Allergic rhinitisDiagnosisICD-10CM130.9Allergic rhinitisDiagnosisICD-10CM130.9Allergic rhinitis </th <th>Code</th> <th>Description</th> <th>Category</th> <th>Code Type</th>	Code	Description	Category	Code Type
708.9Unspecified urticariaDiagnosisICD-9CM995.0Other anaphylactic reactionDiagnosisICD-9CM995.7Other drug allergyDiagnosisICD-9CM995.7Other drug allergyDiagnosisICD-9CM995.7Other drug allergyDiagnosisICD-9CM995.7Other adverse food reactions, not elsewhere classifiedDiagnosisICD-10-CM130.0Vasomotor rhinitisdue to pollenDiagnosisICD-10-CM130.2Other seasonal allergic rhinitisdue to foodDiagnosisICD-10-CM130.5Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CM130.8Other allergic rhinitisdue to animal (cat) (dog) hair and danderDiagnosisICD-10-CM130.9Allergic rhinitisdue to animal (cat) (dog) hair and danderDiagnosisICD-10-CM130.9Allergic rhinitisdue to animal (cat) (dog) hair and banderDiagnosisICD-10-CM130.9Allergic rhinitis <td>708.5</td> <td>Cholinergic urticaria</td> <td>Diagnosis</td> <td>ICD-9-CM</td>	708.5	Cholinergic urticaria	Diagnosis	ICD-9-CM
995.0Other anaphylactic reactionDiagnosisICD-9CM995.7Other drug allergyDiagnosisICD-9CM995.7Other adverse food reactions, not elsewhere classifiedDiagnosisICD-9CM995.7Other adverse food reactions, not elsewhere classifiedDiagnosisICD-9CM130.0Vasomotor rhinitisDiagnosisICD-10CM130.1Allergic rhinitis due to pollenDiagnosisICD-10CM130.2Other seasonal allergic rhinitisDiagnosisICD-10CM130.3Allergic rhinitis due to foodDiagnosisICD-10CM130.4Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10CM130.9Other allergic rhinitisDiagnosisICD-10CM130.9Other allergic rhinitisDiagnosisICD-10CM130.9Other allergic rhinitisDiagnosisICD-10CM130.9Other allergic and direttic gastroenteritis and colitisDiagnosisICD-10CM131.0Chronic rhinitisDiagnosisICD-10CM132.2Food protein-induced enterocolitis syndromeDiagnosisICD-10CM120.2Food protein-induced enterocolitis syndromeDiagnosisICD-10CM120.4Atopic neurodermatitisDiagnosisICD-10CM120.4Hatrinsic (allergic) ezemaDiagnosisICD-10CM120.4Hatrinsic (allergic) ezemaDiagnosisICD-10CM120.4Intrinsic (allergic) ezemaDiagnosisICD-10CM120.4Hatrinsic (allergic) ezema<	708.8	Other specified urticaria	Diagnosis	ICD-9-CM
995.27Other drug allergyDiagnosisICD-9CM995.3Allergy, unspecified not elsewhere classifiedDiagnosisICD-9CM995.7Other adverse food reactions, not elsewhere classifiedDiagnosisICD-9CM995.7Other adverse food reactions, not elsewhere classifiedDiagnosisICD-10-CM130.0Vasomotor rhinitisDiagnosisICD-10-CM130.1Allergic rhinitis due to pollenDiagnosisICD-10-CM130.5Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CM130.81Allergic rhinitis, unspecifiedDiagnosisICD-10-CM130.9Other allergic rhinitisDiagnosisICD-10-CM130.9Other gic rhinitisDiagnosisICD-10-CM131.0Chronic rhinitisDiagnosisICD-10-CM132.2Food protein-induced enterocolitis syndromeDiagnosisICD-10-CM132.2Food protein-induced enterocolitis syndromeDiagnosisICD-10-CM120.8Atopic neurodermatitisDiagnosisICD-10-CM120.8Atopic neurodermatitisDiagnosisICD-10-CM120.8Flexural eczemaDiagnosisICD-10-CM120.8Atopic neurodermatitisDiagnosisICD-10-CM120.8Atopic dermatitisDiagnosisICD-10-CM120.8Atlergic contact dermatitis due to metalsDiagnosisICD-10-CM120.8Atlergic contact dermatitis due to metalsDiagnosisICD-10-CM120.8Atlergic contact dermatitis	708.9	Unspecified urticaria	Diagnosis	ICD-9-CM
995.3Allergy, unspecified not elsewhere classifiedDiagnosisICD-9-CM995.7Other adverse food reactions, not elsewhere classifiedDiagnosisICD-9-CM130.0Vasomotor rhinitisDiagnosisICD-10-CM130.1Allergic rhinitis due to pollenDiagnosisICD-10-CM130.2Other seasonal allergic rhinitisDiagnosisICD-10-CM130.3Allergic rhinitis due to foodDiagnosisICD-10-CM130.4Diagre in thitisDiagnosisICD-10-CM130.5Allergic rhinitis, unspecifiedDiagnosisICD-10-CM130.9Other allergic rhinitisDiagnosisICD-10-CM130.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CM130.9Allergic rhinitisDiagnosisICD-10-CM130.1Chronic rhinitisDiagnosisICD-10-CM130.2Food protein-induced enterocolitis syndromeDiagnosisICD-10-CM152.2Food protein-induced enteropathyDiagnosisICD-10-CM120.2Food protein-induced enteropathyDiagnosisICD-10-CM120.3Altopic neurodermatitisDiagnosisICD-10-CM120.4Atopic neurodermatitisDiagnosisICD-10-CM120.8Intrinsic (allergic) eczemaDiagnosisICD-10-CM120.8Intrinsic (allergic) eczemaDiagnosisICD-10-CM120.4Allergic contact dermatitis due to admetisDiagnosisICD-10-CM120.4Allergic contact dermatitis due to admetisDiagnosis	995.0	Other anaphylactic reaction	Diagnosis	ICD-9-CM
995.7Other adverse food reactions, not elsewhere classifiedDiagnosisICD-9CM130.0Vasomotor rhinitisDiagnosisICD-10-CM130.1Allergic rhinitis due to pollenDiagnosisICD-10-CM130.2Other seasonal allergic rhinitisDiagnosisICD-10-CM130.3Allergic rhinitis due to foodDiagnosisICD-10-CM130.8Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CM130.8Other allergic rhinitisDiagnosisICD-10-CM130.9Allergic rhinitisDiagnosisICD-10-CM130.9Allergic rhinitisDiagnosisICD-10-CM130.9Allergic rhinitisDiagnosisICD-10-CM130.9Allergic rhinitisDiagnosisICD-10-CM130.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CM130.2.0Resnier's prurigoDiagnosisICD-10-CM120.2Food protein-induced enteropathyDiagnosisICD-10-CM120.8Ithrinis (allergic) ezemaDiagnosisICD-10-CM120.8Ithrinis (allergic) ezemaDiagnosisICD-10-CM120.8Ithrinis (allergic) ezemaDiagnosisICD-10-CM120.8Other atopic dermatitis due to ometalsDiagnosisICD-10-CM120.8Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CM120.8Ithrinis (allergic) ezemaDiagnosisICD-10-CM120.8Allergic contact dermatitis due to odhesives	995.27	Other drug allergy	Diagnosis	ICD-9-CM
J30.0Vasomotor rhinitisDiagnosisICD-10-CMJ30.1Allergic rhinitis due to pollenDiagnosisICD-10-CMJ30.2Other seasonal allergic rhinitisDiagnosisICD-10-CMJ30.5Allergic rhinitis due to foodDiagnosisICD-10-CMJ30.81Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CMJ30.89Other allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ20.29Food protein-induced enterocolitis syndromeDiagnosisICD-10-CML20.80Fiexural eczemaDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Fiexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic)Diagnosis<	995.3	Allergy, unspecified not elsewhere classified	Diagnosis	ICD-9-CM
J30.1Allergic rhinitis due to pollenDiagnosisICD-10-CMJ30.2Other seasonal allergic rhinitisDiagnosisICD-10-CMJ30.5Allergic rhinitis due to foodDiagnosisICD-10-CMJ30.81Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CMJ30.82Other allergic rhinitisDiagnosisICD-10-CMJ30.83Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMJ52.22Food protein-induced entercopathyDiagnosisICD-10-CML52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.8Exural eczemaDiagnosisICD-10-CML20.8Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.8Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.9Atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis due to metalsDiagnosisICD-10-CML20.10DiagnosisICD-10-CMDiagnosisICD-10-CML20.24Interinsic (allergic) eczemaDiagnosisICD-10-CML20.30Allergic contact dermatitis due to metalsDiagnosisICD-10-CML20.41Intrinsic (allergic) eczem	995.7	Other adverse food reactions, not elsewhere classified	Diagnosis	ICD-9-CM
J30.2Other seasonal allergic rhinitisDiagnosisICD-10-CMJ30.5Allergic rhinitis due to foodDiagnosisICD-10-CMJ30.81Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CMJ30.89Other allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMK52.21Food protein-induced entercoolitis syndromeDiagnosisICD-10-CMK52.22Food protein-induced entercoolitis syndromeDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.12Piter atopic neurodermatitisDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.83Atopic neurodermatitisDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.85Other atopic dermatitisDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.85Allergic contact dermatitis due to metalsDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.95Allergic contact dermatitis due t	J30.0	Vasomotor rhinitis	Diagnosis	ICD-10-CM
J30.5Allergic rhinitis due to foodDiagnosisICD-10-CMJ30.81Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CMJ30.89Other allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ31.0Chronic rhinitisDiagnosisICD-10-CMJ32.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMK52.21Food protein-induced entercoolitis syndromeDiagnosisICD-10-CMK52.22Food protein-induced entercoolitis syndromeDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis due to metalsDiagnosisICD-10-CML23.0Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to oflagsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to oflagsDiagnosisICD-10-CML23.2Allergic contact dermatitis due to adhesives<	J30.1	Allergic rhinitis due to pollen	Diagnosis	ICD-10-CM
J30.81Allergic rhinitis due to animal (cat) (dog) hair and danderDiagnosisICD-10-CMJ30.89Other allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitisDiagnosisICD-10-CMJ30.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMK52.21Food protein-induced enterocolitis syndromeDiagnosisICD-10-CMK52.22Food protein-induced enteropathyDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.80Besnier's purigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis due to metalsDiagnosisICD-10-CML23.0Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.1Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to drug in contact with skinDiagnosisICD-10-CML23.5Allergic contact dermatitis due to drug in contact with skinDiagnosisICD-10-CML23.6Allergic conta	J30.2	Other seasonal allergic rhinitis	Diagnosis	ICD-10-CM
J30.89Other allergic rhinitisDiagnosisICD-10-CMJ30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ31.0Chronic rhinitisDiagnosisICD-10-CMJ39.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMK52.21Food protein-induced enterocolitis syndromeDiagnosisICD-10-CMK52.22Food protein-induced enteropathyDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.80Atopic dermatitisDiagnosisICD-10-CML20.81Atopic dermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.85Atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitisdue to adhesivesDiagnosisICD-10-CML23.0Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.1Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact derma	J30.5	Allergic rhinitis due to food	Diagnosis	ICD-10-CM
J30.9Allergic rhinitis, unspecifiedDiagnosisICD-10-CMJ31.0Chronic rhinitisDiagnosisICD-10-CMJ39.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMK52.21Food protein-induced enteropathyDiagnosisICD-10-CMK52.22Food protein-induced enteropathyDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.83Other atopic dermatitisDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.80Other atopic dermatitisDiagnosisICD-10-CML20.91Atopic dermatitis due to adhesivesDiagnosisICD-10-CML23.0Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.3Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.4Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-C	J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander	Diagnosis	ICD-10-CM
J31.0Chronic rhinitisDiagnosisICD-10-CMJ39.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMK52.21Food protein-induced enterocolitis syndromeDiagnosisICD-10-CMK52.22Food protein-induced enteropathyDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.80Other atopic dermatitisDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.83Other atopic dermatitisDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis due to metalsDiagnosisICD-10-CML23.0Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.1Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.3Allergic contact dermatitis due to odyesDiagnosisICD-10-CML23.4Allergic contact dermatitis due to odyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to odyesDiagnosisICD-10-CML33.4 </td <td>J30.89</td> <td>Other allergic rhinitis</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	J30.89	Other allergic rhinitis	Diagnosis	ICD-10-CM
J39.3Upper respiratory tract hypersensitivity reaction, site unspecifiedDiagnosisICD-10-CMK52.21Food protein-induced enteropathyDiagnosisICD-10-CMK52.22Food protein-induced enteropathyDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.83Other atopic dermatitisDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.90Atopic dermatitisDiagnosisICD-10-CML20.91Atopic dermatitisDiagnosisICD-10-CML20.92Diaper dermatitisDiagnosisICD-10-CML20.93Atopic dermatitisDiagnosisICD-10-CML20.94Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.05Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.1Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.5Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.75Allergic contact dermatitis due to animal (cat) (dog) dan	J30.9	Allergic rhinitis, unspecified	Diagnosis	ICD-10-CM
K52.21Food protein-induced enterocolitis syndromeDiagnosisICD-10-CMK52.22Food protein-induced enteropathyDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to osmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.6Allergic contact dermatitis due to ofool in contact with skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML33.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CM <td>J31.0</td> <td>Chronic rhinitis</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	J31.0	Chronic rhinitis	Diagnosis	ICD-10-CM
K52.22Food protein-induced enteropathyDiagnosisICD-10-CMK52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.99Atopic dermatitis, unspecifiedDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.5Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.6Allergic contact dermatitis due to ofol in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to ofol in contact with the skinDiagnosisICD-10-CML23.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.4Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML33.4Allergic cont	J39.3	Upper respiratory tract hypersensitivity reaction, site unspecified	Diagnosis	ICD-10-CM
K52.29Other allergic and dietetic gastroenteritis and colitisDiagnosisICD-10-CML20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML20.10Diagno dermatitisDiagnosisICD-10-CML20.11Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.10Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.8Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.8Allergic contact dermatitis due to animal (cat) (dog) danderDiagn	K52.21	Food protein-induced enterocolitis syndrome	Diagnosis	ICD-10-CM
L20.0Besnier's prurigoDiagnosisICD-10-CML20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML21.0Diaper dermatitisDiagnosisICD-10-CML22.0Diaper dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.7Allergic contact dermatitis due to alants, except foodDiagnosisICD-10-CML23.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML33.7Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML	K52.22	Food protein-induced enteropathy	Diagnosis	ICD-10-CM
L20.81Atopic neurodermatitisDiagnosisICD-10-CML20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML22Diaper dermatitisDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.6Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.7Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.6Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.7Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML33.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML33.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML33.8Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML33.9	K52.29	Other allergic and dietetic gastroenteritis and colitis	Diagnosis	ICD-10-CM
L20.82Flexural eczemaDiagnosisICD-10-CML20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML22Diaper dermatitisDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.5Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.6Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.7Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.8Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML3.89Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML3.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML3.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML3.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML3.89	L20.0	Besnier's prurigo	Diagnosis	ICD-10-CM
L20.84Intrinsic (allergic) eczemaDiagnosisICD-10-CML20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML22Diaper dermatitisDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.6Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.7Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.81Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.0Irritant contact	L20.81	Atopic neurodermatitis	Diagnosis	ICD-10-CM
L20.89Other atopic dermatitisDiagnosisICD-10-CML20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML22Diaper dermatitisDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML24.0Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oslventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to oslventsDiagnosisICD-10-CM	L20.82	Flexural eczema	Diagnosis	ICD-10-CM
L20.9Atopic dermatitis, unspecifiedDiagnosisICD-10-CML22Diaper dermatitisDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML24.0Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to oslventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L20.84	Intrinsic (allergic) eczema	Diagnosis	ICD-10-CM
L22Diaper dermatitisDiagnosisICD-10-CML23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML24.0Irritant contact dermatitis due to other agentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnos	L20.89	Other atopic dermatitis	Diagnosis	ICD-10-CM
L23.0Allergic contact dermatitis due to metalsDiagnosisICD-10-CML23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.0Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.3Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L20.9	Atopic dermatitis, unspecified	Diagnosis	ICD-10-CM
L23.1Allergic contact dermatitis due to adhesivesDiagnosisICD-10-CML23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to drugsDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.9Allergic contact dermatitis, unspecified causeDiagnosisICD-10-CML24.0Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.3Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L22	Diaper dermatitis	Diagnosis	ICD-10-CM
L23.2Allergic contact dermatitis due to cosmeticsDiagnosisICD-10-CML23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.3Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CM	L23.0	Allergic contact dermatitis due to metals	Diagnosis	ICD-10-CM
L23.3Allergic contact dermatitis due to drugs in contact with skinDiagnosisICD-10-CML23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.9Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.3Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.1	Allergic contact dermatitis due to adhesives	Diagnosis	ICD-10-CM
L23.4Allergic contact dermatitis due to dyesDiagnosisICD-10-CML23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis due to detergentsDiagnosisICD-10-CML24.0Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.2	Allergic contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L23.5Allergic contact dermatitis due to other chemical productsDiagnosisICD-10-CML23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis, unspecified causeDiagnosisICD-10-CML24.0Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.3	Allergic contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L23.6Allergic contact dermatitis due to food in contact with the skinDiagnosisICD-10-CML23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis, unspecified causeDiagnosisICD-10-CML24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.4	Allergic contact dermatitis due to dyes	Diagnosis	ICD-10-CM
L23.7Allergic contact dermatitis due to plants, except foodDiagnosisICD-10-CML23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis, unspecified causeDiagnosisICD-10-CML24.0Irritant contact dermatitis due to other agentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.5	Allergic contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis, unspecified causeDiagnosisICD-10-CML24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.6	Allergic contact dermatitis due to food in contact with the skin	Diagnosis	ICD-10-CM
L23.81Allergic contact dermatitis due to animal (cat) (dog) danderDiagnosisICD-10-CML23.89Allergic contact dermatitis due to other agentsDiagnosisICD-10-CML23.9Allergic contact dermatitis, unspecified causeDiagnosisICD-10-CML24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.7	Allergic contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L23.9Allergic contact dermatitis, unspecified causeDiagnosisICD-10-CML24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.81		Diagnosis	ICD-10-CM
L24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.89	Allergic contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L24.0Irritant contact dermatitis due to detergentsDiagnosisICD-10-CML24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L23.9			ICD-10-CM
L24.1Irritant contact dermatitis due to oils and greasesDiagnosisICD-10-CML24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L24.0		-	ICD-10-CM
L24.2Irritant contact dermatitis due to solventsDiagnosisICD-10-CML24.3Irritant contact dermatitis due to cosmeticsDiagnosisICD-10-CM	L24.1	Irritant contact dermatitis due to oils and greases	-	ICD-10-CM
L24.3 Irritant contact dermatitis due to cosmetics Diagnosis ICD-10-CM	L24.2	_	-	ICD-10-CM
-				
		Irritant contact dermatitis due to drugs in contact with skin	-	



		Code	
Code	Description	Category	Code Type
L24.5	Irritant contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L24.6	Irritant contact dermatitis due to food in contact with skin	Diagnosis	ICD-10-CM
L24.7	Irritant contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L24.81	Irritant contact dermatitis due to metals	Diagnosis	ICD-10-CM
L24.89	Irritant contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L24.9	Irritant contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L25.0	Unspecified contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L25.1	Unspecified contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L25.2	Unspecified contact dermatitis due to dyes	Diagnosis	ICD-10-CM
L25.3	Unspecified contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L25.4	Unspecified contact dermatitis due to food in contact with skin	Diagnosis	ICD-10-CM
L25.5	Unspecified contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L25.8	Unspecified contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L25.9	Unspecified contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L27.0	Generalized skin eruption due to drugs and medicaments taken internally	Diagnosis	ICD-10-CM
L27.1	Localized skin eruption due to drugs and medicaments taken internally	Diagnosis	ICD-10-CM
L27.2	Dermatitis due to ingested food	Diagnosis	ICD-10-CM
L27.8	Dermatitis due to other substances taken internally	Diagnosis	ICD-10-CM
L27.9	Dermatitis due to unspecified substance taken internally	Diagnosis	ICD-10-CM
L50.0	Allergic urticaria	Diagnosis	ICD-10-CM
L50.1	Idiopathic urticaria	Diagnosis	ICD-10-CM
L50.2	Urticaria due to cold and heat	Diagnosis	ICD-10-CM
L50.3	Dermatographic urticaria	Diagnosis	ICD-10-CM
L50.4	Vibratory urticaria	Diagnosis	ICD-10-CM
L50.5	Cholinergic urticaria	Diagnosis	ICD-10-CM
L50.6	Contact urticaria	Diagnosis	ICD-10-CM
L50.8	Other urticaria	Diagnosis	ICD-10-CM
L50.9	Urticaria, unspecified	Diagnosis	ICD-10-CM
L55.0	Sunburn of first degree	Diagnosis	ICD-10-CM
L55.1	Sunburn of second degree	Diagnosis	ICD-10-CM
L55.2	Sunburn of third degree	Diagnosis	ICD-10-CM
L55.9	Sunburn, unspecified	Diagnosis	ICD-10-CM
L56.0	Drug phototoxic response	Diagnosis	ICD-10-CM
L56.1	Drug photoallergic response	Diagnosis	ICD-10-CM
L56.2	Photocontact dermatitis [berloque dermatitis]	Diagnosis	ICD-10-CM
L56.3	Solar urticaria	Diagnosis	ICD-10-CM
L56.4	Polymorphous light eruption	Diagnosis	ICD-10-CM
L56.5	Disseminated superficial actinic porokeratosis (DSAP)	Diagnosis	ICD-10-CM
L56.8	Other specified acute skin changes due to ultraviolet radiation	Diagnosis	ICD-10-CM
L56.9	Acute skin change due to ultraviolet radiation, unspecified	Diagnosis	ICD-10-CM
L57.1	Actinic reticuloid	Diagnosis	ICD-10-CM
L57.5	Actinic granuloma	Diagnosis	ICD-10-CM



Code -57.8 -57.9 -58.0 -58.1 -58.9 -50.995A	Description Other skin changes due to chronic exposure to nonionizing radiation Skin changes due to chronic exposure to nonionizing radiation, unspecified	Category Diagnosis	Code Type
.57.9 .58.0 .58.1 .58.9	Skin changes due to chronic exposure to nonionizing radiation, unspecified		ICD-10-CM
-58.0 -58.1 -58.9			
.58.1 .58.9		Diagnosis	ICD-10-CM
.58.9	Acute radiodermatitis	Diagnosis	ICD-10-CM
	Chronic radiodermatitis	Diagnosis	ICD-10-CM
-20 005 0	Radiodermatitis, unspecified	Diagnosis	ICD-10-CM
JU.33JA	Adverse effect of other drugs, medicaments and biological substances, initial encounter	Diagnosis	ICD-10-CM
78.0	Anaphylactic reaction due to food	Diagnosis	ICD-10-CM
78.00	Anaphylactic reaction due to unspecified food	Diagnosis	ICD-10-CM
78.00XA	Anaphylactic reaction due to unspecified food, initial encounter	Diagnosis	ICD-10-CM
78.00XD	Anaphylactic reaction due to unspecified food, subsequent encounter	Diagnosis	ICD-10-CM
78.00XS	Anaphylactic reaction due to unspecified food, sequela	Diagnosis	ICD-10-CM
78.01	Anaphylactic reaction due to peanuts	Diagnosis	ICD-10-CM
78.01XA	Anaphylactic reaction due to peanuts, initial encounter	Diagnosis	ICD-10-CM
78.01XD	Anaphylactic reaction due to peanuts, subsequent encounter	Diagnosis	ICD-10-CM
78.01XS	Anaphylactic reaction due to peanuts, sequela	Diagnosis	ICD-10-CM
78.02	Anaphylactic reaction due to shellfish (crustaceans)	Diagnosis	ICD-10-CM
78.02XA	Anaphylactic reaction due to shellfish (crustaceans), initial encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to shellfish (crustaceans), sequela	Diagnosis	ICD-10-CM
78.03	Anaphylactic reaction due to other fish	Diagnosis	ICD-10-CM
78.03XA		Diagnosis	ICD-10-CM
78.03XD	Anaphylactic reaction due to other fish, subsequent encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to other fish, sequela	Diagnosis	ICD-10-CM
78.04	Anaphylactic reaction due to fruits and vegetables	Diagnosis	ICD-10-CM
78.04XA	Anaphylactic reaction due to fruits and vegetables, initial encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to fruits and vegetables, subsequent encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to fruits and vegetables, sequela	Diagnosis	ICD-10-CM
78.05	Anaphylactic reaction due to tree nuts and seeds	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to tree nuts and seeds, initial encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to tree nuts and seeds, subsequent encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to tree nuts and seeds, sequela	Diagnosis	ICD-10-CM
78.06	Anaphylactic reaction due to food additives	Diagnosis	ICD-10-CM
78.06XA	Anaphylactic reaction due to food additives, initial encounter	Diagnosis	ICD-10-CM
78.06XD	Anaphylactic reaction due to food additives, subsequent encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to food additives, sequela	Diagnosis	ICD-10-CM
78.07	Anaphylactic reaction due to milk and dairy products	Diagnosis	ICD-10-CM
78.07XA	Anaphylactic reaction due to milk and dairy products, initial encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to milk and dairy products, subsequent encounter	Diagnosis	ICD-10-CM
78.07XS	Anaphylactic reaction due to milk and dairy products, subsequent encounter	Diagnosis	ICD-10-CM
78.08	Anaphylactic reaction due to eggs	Diagnosis	ICD-10-CM
78.08 78.08XA	Anaphylactic reaction due to eggs, initial encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to eggs, subsequent encounter	Diagnosis	ICD-10-CIVI



T78.08X5     Anaphylactic reaction due to eggs, sequela     Diagnosis     ICD-10-CN       T78.09X     Anaphylactic reaction due to other food products, initial encounter     Diagnosis     ICD-10-CN       T78.09XA     Anaphylactic reaction due to other food products, subsequent encounter     Diagnosis     ICD-10-CN       T78.09XA     Anaphylactic reaction due to other food products, sequela     Diagnosis     ICD-10-CN       T78.09XA     Anaphylactic reaction due to other food products, sequela     Diagnosis     ICD-10-CN       T78.1XXA     Other adverse food reactions, not elsewhere classified, initial encounter     Diagnosis     ICD-10-CN       T78.2XXA     Anaphylactic shock, unspecified, sequela     Diagnosis     ICD-10-CN       T78.2XXA     Anaphylactic shock, unspecified, sequela     Diagnosis     ICD-10-CN       T78.4XXA     Alergy, unspecified, sequela     Diagnosis     ICD-10-CN       T78.4XXA     Alergy, unspecified, sequela     Diagnosis     ICD-10-CN       T78.4XXA     Alergy, unspecified, subsequent encounter     Diagnosis     ICD-10-CN       T80.51			Code	
T78.09Anaphylactic reaction due to other food products, initial encounterDiagnosisICD-10-CMT78.09XAnaphylactic reaction due to other food products, subsequent encounterDiagnosisICD-10-CMT78.09XAnaphylactic reaction due to other food products, sequelaDiagnosisICD-10-CMT78.12Anaphylactic reaction due to other food products, sequelaDiagnosisICD-10-CMT78.2Anaphylactic shock, unspecified, initial encounterDiagnosisICD-10-CMT78.2XAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.2XXAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.2XXAnaphylactic shock, unspecified, sequelaDiagnosisICD-10-CMT78.40XAllergy, unspecified, subsequent encounterDiagnosisICD-10-CMT78.40XXAllergy, unspecified, subsequent encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.40XAAnaphylactic reaction	Code	Description	Category	Code Type
T78.09XAAnaphylactic reaction due to other food products, initial encounterDiagnosisICD-10-CMT78.09XAAnaphylactic reaction due to other food products, subsequent encounterDiagnosisICD-10-CMT78.09XAAnaphylactic reaction due to other food products, subsequent encounterDiagnosisICD-10-CMT78.1XXAOther adverse food reactions, not elsewhere classified, initial encounterDiagnosisICD-10-CMT78.2XXAAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.2XXAAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.4XXAAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.4XXAAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.4XXAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.4XXAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.4XXAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.4XXAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.4XXAAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to vaccination of blood and blood products, subsequentDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.52XAAnaphylactic reacti	T78.08XS	Anaphylactic reaction due to eggs, sequela	Diagnosis	ICD-10-CM
T78.09XDAnaphylactic reaction due to other food products, subsequent encounterDiagnosisICD-10-CMT78.09XDAnaphylactic reaction due to other food products, sequelaDiagnosisICD-10-CMT78.1XXAOther adverse food reactions, not elsewhere classified, initial encounterDiagnosisICD-10-CMT78.2XXAAnaphylactic shock, unspecified, initial encounterDiagnosisICD-10-CMT78.2XXAAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.2XXAAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.4XXAAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.40XAAnaphylactic reaction due to serumDiagnosisICD-10-CMT80.51Anaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CMT80.52XAnaphylactic reaction due to vaccination, nitial encounterDiagnosisICD-10-CMT80.52XAnaphylactic reaction due to vaccination, nitial encounter </td <td>T78.09</td> <td>Anaphylactic reaction due to other food products</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	T78.09	Anaphylactic reaction due to other food products	Diagnosis	ICD-10-CM
T78.09XSAnaphylactic reaction due to other food products, sequelaDiagnosisICD-10-CNT78.1XAOther adverse food reactions, not elsewhere classified, initial encounterDiagnosisICD-10-CNT78.2Anaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CNT78.2XXAAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CNT78.2XXAAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CNT78.4XXAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.4XXAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.4XXAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.4XXAAllergy, unspecified, sequelaDiagnosisICD-10-CNT78.4XXAAllergy, unspecified, sequelaDiagnosisICD-10-CNT78.4XXAAllergy, unspecified, sequelaDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XAAnaph	T78.09XA	Anaphylactic reaction due to other food products, initial encounter	Diagnosis	ICD-10-CM
T78.1XXOther adverse food reactions, not elsewhere classified, initial encounterDiagnosisICD-10-CNT78.2Anaphylactic shock, unspecified, initial encounterDiagnosisICD-10-CNT78.2XXAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CNT78.2XXAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAllergy, unspecified, initial encounterDiagnosisICD-10-CNT78.40XAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.50XAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.52XAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAnaphylactic reactio	T78.09XD	Anaphylactic reaction due to other food products, subsequent encounter	Diagnosis	ICD-10-CM
T78.2Anaphylactic shock, unspecified, initial encounterDiagnosisICD-10-CMT78.2XXAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.2XXAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CMT78.2XXAnaphylactic shock, unspecified, sequelaDiagnosisICD-10-CMT78.4XXAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CMT78.40X3Allergy, unspecified, sequelaDiagnosisICD-10-CMT78.40X3Allergy, unspecified, sequelaDiagnosisICD-10-CMT78.40X3Allergy, unspecified, sequelaDiagnosisICD-10-CMT78.40X3Allergy, unspecified, sequelaDiagnosisICD-10-CMT78.40X3Anaphylactic reaction due to serumDiagnosisICD-10-CMT80.51X4Anaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CMT80.51X5Anaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CMT80.51X6Anaphylactic reaction due to vaccinationDiagnosisICD-10-CMICD-10-CMT80.52X6Anaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CM <td>T78.09XS</td> <td>Anaphylactic reaction due to other food products, sequela</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	T78.09XS	Anaphylactic reaction due to other food products, sequela	Diagnosis	ICD-10-CM
T78.2XXAAnaphylactic shock, unspecified, initial encounterDiagnosisICD-10-CMT78.2XXSAnaphylactic shock, unspecified, seugelaDiagnosisICD-10-CMT78.40XAllergy, unspecifiedDiagnosisICD-10-CMT78.40XAAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, seugelaDiagnosisICD-10-CMT78.40XAAllergy, unspecified, seugelaDiagnosisICD-10-CMT78.40XAAllergy, unspecified, seugelaDiagnosisICD-10-CMT78.40XAOther allergy, initial encounterDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to serumDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to other serumDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD	T78.1XXA	Other adverse food reactions, not elsewhere classified, initial encounter	Diagnosis	ICD-10-CM
T78.2XXDAnaphylactic shock, unspecified, subsequent encounterDiagnosisICD-10-CNT78.2XXAAnaphylactic shock, unspecified, sequelaDiagnosisICD-10-CNT78.40XAAllergy, unspecified, initial encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CNT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, action due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CNT80.52	T78.2	Anaphylactic shock, unspecified	Diagnosis	ICD-10-CM
T78.2XXAnaphylactic shock, unspecified, sequelaDiagnosisICD-10-CNT78.40XAllergy, unspecified, initial encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CNT78.40XAOther allergy, initial encounterDiagnosisICD-10-CNT80.51Anaphylactic reaction due to serumDiagnosisICD-10-CNT80.51Anaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to vaccinationDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to other serumDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.53XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.53XAAnaphylactic reaction due to	T78.2XXA	Anaphylactic shock, unspecified, initial encounter	Diagnosis	ICD-10-CM
T78.40Allergy, unspecifiedDiagnosisICD-10-CMT78.40XAAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, subsequent encounterDiagnosisICD-10-CMT78.40XAOther allergy, unspecified, sequelaDiagnosisICD-10-CMT78.40XAOther allergy, initial encounterDiagnosisICD-10-CMT80.51Anaphylactic reaction due to administration of blood and blood productsDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CMT80.51XDAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CMT80.51XSAnaphylactic reaction due to vaccinationDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.53XAAnaphylactic reaction due to other serumDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serumDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction	T78.2XXD	Anaphylactic shock, unspecified, subsequent encounter	Diagnosis	ICD-10-CM
T78.40XAAllergy, unspecified, initial encounterDiagnosisICD-10-CMT78.40XDAllergy, unspecified, subsequent encounterDiagnosisICD-10-CMT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CMT78.40XAAllergy, unspecified, sequelaDiagnosisICD-10-CMT88.50XAnaphylactic reaction due to serumDiagnosisICD-10-CMT80.51XAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CMT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CMT80.51XDAnaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CMT80.51XSAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52XSAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, sequelaDiagnosis<	T78.2XXS	Anaphylactic shock, unspecified, sequela	Diagnosis	ICD-10-CM
T78.40X0Allergy, unspecified, subsequent encounterDiagnosisICD-10-CMT78.40X5Allergy, unspecified, sequelaDiagnosisICD-10-CMT78.40X5Allergy, initial encounterDiagnosisICD-10-CMT80.51Anaphylactic reaction due to serumDiagnosisICD-10-CMT80.51Anaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CMT80.51X5Anaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CMT80.51X5Anaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CMT80.51X5Anaphylactic reaction due to administration of blood and blood products, sequela encounterDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.53X7Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.53X7Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.53X8Anaphylactic reaction due	T78.40	Allergy, unspecified	Diagnosis	ICD-10-CM
T78.40X3Allergy, unspecified, sequelaDiagnosisICD-10-CMT78.49X4Other allergy, initial encounterDiagnosisICD-10-CMT80.5Anaphylactic reaction due to serumDiadnosisICD-10-CMT80.51Anaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CMT80.51X4Anaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CMT80.51X5Anaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CMT80.51X5Anaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CMT80.51X5Anaphylactic reaction due to vaccinationDiagnosisICD-10-CMT80.52X5Anaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52X6Anaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52X7Anaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.52X8Anaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.53X8Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59X8Anaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT80.59X8Anaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT80.59X8Anaphylactic reaction due to adverse effect of c	T78.40XA	Allergy, unspecified, initial encounter	Diagnosis	ICD-10-CM
T78.49XAOther allergy, initial encounterDiagnosisICD-10-CNT80.5Anaphylactic reaction due to serumDiagnosisICD-10-CNT80.51Anaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XDAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XDAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to other serumDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to ad	T78.40XD	Allergy, unspecified, subsequent encounter	Diagnosis	ICD-10-CM
T80.5Anaphylactic reaction due to serumDiagnosisICD-10-CNT80.51Anaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XDAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to vaccinationDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.53XAAnaphylactic reaction due to other serumDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosi	T78.40XS	Allergy, unspecified, sequela	Diagnosis	ICD-10-CM
T80.51Anaphylactic reaction due to administration of blood and blood productsDiagnosisICD-10-CNT80.51XAAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XDAnaphylactic reaction due to administration of blood and blood products, subsequentDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to vaccinationDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serumDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosisICD-10-CNadministered, initial encounterDiagnosisICD-10-CNadministered, initial encounterDiagnosisICD-10-CNT88.6XXDAnaphylactic reaction due to adverse effect of correct drug or medicament properly <td>T78.49XA</td> <td>Other allergy, initial encounter</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	T78.49XA	Other allergy, initial encounter	Diagnosis	ICD-10-CM
T80.51XAAnaphylactic reaction due to administration of blood and blood products, initial encounterDiagnosisICD-10-CNT80.51XDAnaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to vaccination initial encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XSAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XSAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properlyDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to	T80.5	Anaphylactic reaction due to serum	Diagnosis	ICD-10-CM
T80.51XDAnaphylactic reaction due to administration of blood and blood products, subsequent encounterDiagnosisICD-10-CNT80.51XSAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CNT80.52Anaphylactic reaction due to vaccinationDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XDAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XDAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.52XSAnaphylactic reaction due to other serumDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CNT80.59X5Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.59X5Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.59X5Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.59X5Anaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XX5Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XX5	T80.51	Anaphylactic reaction due to administration of blood and blood products	Diagnosis	ICD-10-CM
encounterT80.51XSAnaphylactic reaction due to administration of blood and blood products, sequelaDiagnosisICD-10-CNT80.52Anaphylactic reaction due to vaccinationDiagnosisICD-10-CNT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CNT80.52XDAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CNT80.52XSAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CNT80.52XSAnaphylactic reaction due to other serumDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CNT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CNT88.6	T80.51XA	Anaphylactic reaction due to administration of blood and blood products, initial encounter	Diagnosis	ICD-10-CM
T80.52Anaphylactic reaction due to vaccinationDiagnosisICD-10-CMT80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52XDAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52XSAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.59XAnaphylactic reaction due to other serumDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXXAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXXAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CM	T80.51XD		Diagnosis	ICD-10-CM
T80.52XAAnaphylactic reaction due to vaccination, initial encounterDiagnosisICD-10-CMT80.52XDAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52XSAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.52XSAnaphylactic reaction due to other serumDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug	T80.51XS	Anaphylactic reaction due to administration of blood and blood products, sequela	Diagnosis	ICD-10-CM
T80.52XDAnaphylactic reaction due to vaccination, subsequent encounterDiagnosisICD-10-CMT80.52XSAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.59Anaphylactic reaction due to other serumDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.59XDAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXAAnaphylactic reacti	T80.52	Anaphylactic reaction due to vaccination	Diagnosis	ICD-10-CM
T80.52XSAnaphylactic reaction due to vaccination, sequelaDiagnosisICD-10-CMT80.59Anaphylactic reaction due to other serumDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.59X5Anaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59X6Anaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT80.59X7Anaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT80.59X8Anaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CMT88.6XX8Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XX8Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XX8Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XX8Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XX8Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT07.1	T80.52XA	Anaphylactic reaction due to vaccination, initial encounter	Diagnosis	ICD-10-CM
T80.59Anaphylactic reaction due to other serumDiagnosisICD-10-CMT80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.59XDAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XSAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT88.6Anaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction d	T80.52XD	Anaphylactic reaction due to vaccination, subsequent encounter	Diagnosis	ICD-10-CM
T80.59XAAnaphylactic reaction due to other serum, initial encounterDiagnosisICD-10-CMT80.59XDAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XSAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT88.6Anaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CMT88.6XXDAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosis<	T80.52XS	Anaphylactic reaction due to vaccination, sequela	Diagnosis	ICD-10-CM
T80.59XDAnaphylactic reaction due to other serum, subsequent encounterDiagnosisICD-10-CMT80.59XSAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CMT88.6Anaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CMT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered,	T80.59	Anaphylactic reaction due to other serum	Diagnosis	ICD-10-CM
T80.59XSAnaphylactic reaction due to other serum, sequelaDiagnosisICD-10-CNT88.6Anaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CNT88.6XXDAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CNV07.1Need for desensitization to allergensDiagnosisICD-9-CMV13.81Personal history of anaphylaxisDiagnosisICD-9-CM	T80.59XA	Anaphylactic reaction due to other serum, initial encounter	Diagnosis	ICD-10-CM
T88.6Anaphylactic reaction due to adverse effect of correct drug or medicament properly administeredDiagnosisICD-10-CNT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CNT88.6XXDAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CNV07.1Need for desensitization to allergensDiagnosisICD-9-CMV13.81Personal history of anaphylaxisDiagnosisICD-9-CM	T80.59XD	Anaphylactic reaction due to other serum, subsequent encounter	Diagnosis	ICD-10-CM
administeredT88.6XXAAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounterDiagnosisICD-10-CNT88.6XXDAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CNV07.1Need for desensitization to allergensDiagnosisICD-9-CMV13.81Personal history of anaphylaxisDiagnosisICD-9-CM	T80.59XS	Anaphylactic reaction due to other serum, sequela	Diagnosis	ICD-10-CM
administered, initial encounterT88.6XXDAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CMT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CMV07.1Need for desensitization to allergensDiagnosisICD-9-CMV13.81Personal history of anaphylaxisDiagnosisICD-9-CM	T88.6		Diagnosis	ICD-10-CM
T88.6XXDAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounterDiagnosisICD-10-CNT88.6XXSAnaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequelaDiagnosisICD-10-CNV07.1Need for desensitization to allergensDiagnosisICD-9-CMV13.81Personal history of anaphylaxisDiagnosisICD-9-CM	T88.6XXA		Diagnosis	ICD-10-CM
administered, sequelaV07.1Need for desensitization to allergensDiagnosisICD-9-CMV13.81Personal history of anaphylaxisDiagnosisICD-9-CM	T88.6XXD	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent	Diagnosis	ICD-10-CM
V07.1Need for desensitization to allergensDiagnosisICD-9-CMV13.81Personal history of anaphylaxisDiagnosisICD-9-CM	T88.6XXS		Diagnosis	ICD-10-CM
V13.81 Personal history of anaphylaxis Diagnosis ICD-9-CM	V07.1		Diagnosis	ICD-9-CM
		-	•	
	V14.0	Personal history of allergy to penicillin	Diagnosis	ICD-9-CM



		Code	
Code	Description	Category	Code Type
V14.1	Personal history of allergy to other antibiotic agent	Diagnosis	ICD-9-CM
V14.2	Personal history of allergy to sulfonamides	Diagnosis	ICD-9-CM
V14.3	Personal history of allergy to other anti-infective agent	Diagnosis	ICD-9-CM
V14.4	Personal history of allergy to anesthetic agent	Diagnosis	ICD-9-CM
V14.5	Personal history of allergy to narcotic agent	Diagnosis	ICD-9-CM
V14.6	Personal history of allergy to analgesic agent	Diagnosis	ICD-9-CM
V14.7	Personal history of allergy to serum or vaccine	Diagnosis	ICD-9-CM
V14.8	Personal history of allergy to other specified medicinal agents	Diagnosis	ICD-9-CM
V14.9	Personal history of allergy to unspecified medicinal agent	Diagnosis	ICD-9-CM
V15.09	Personal history of other allergy, other than to medicinal agents	Diagnosis	ICD-9-CM
V72.7	Diagnostic skin and sensitization tests	Diagnosis	ICD-9-CM
Z01.82	Encounter for allergy testing	Diagnosis	ICD-10-CM
Z01.89	Encounter for other specified special examinations	Diagnosis	ICD-10-CM
Z51.6	Encounter for desensitization to allergens	Diagnosis	ICD-10-CM
Z87.892	Personal history of anaphylaxis	Diagnosis	ICD-10-CM
Z88.0	Allergy status to penicillin	Diagnosis	ICD-10-CM
Z88.1	Allergy status to other antibiotic agents status	Diagnosis	ICD-10-CM
Z88.2	Allergy status to sulfonamides status	Diagnosis	ICD-10-CM
Z88.3	Allergy status to other anti-infective agents status	Diagnosis	ICD-10-CM
Z88.4	Allergy status to anesthetic agent status	Diagnosis	ICD-10-CM
Z88.5	Allergy status to narcotic agent status	Diagnosis	ICD-10-CM
Z88.6	Allergy status to analgesic agent status	Diagnosis	ICD-10-CM
Z88.7	Allergy status to serum and vaccine status	Diagnosis	ICD-10-CM
Z88.8	Allergy status to other drugs, medicaments and biological substances status	Diagnosis	ICD-10-CM
Z88.9	Allergy status to unspecified drugs, medicaments and biological substances status	Diagnosis	ICD-10-CM
Z91.0	Allergy status, other than to drugs and biological substances	Diagnosis	ICD-10-CM
Z91.01	Food allergy status	Diagnosis	ICD-10-CM
Z91.010	Allergy to peanuts	Diagnosis	ICD-10-CM
Z91.011	Allergy to milk products	Diagnosis	ICD-10-CM
Z91.012	Allergy to eggs	Diagnosis	ICD-10-CM
Z91.013	Allergy to seafood	Diagnosis	ICD-10-CM
Z91.018	Allergy to other foods	Diagnosis	ICD-10-CM
Z91.02	Food additives allergy status	Diagnosis	ICD-10-CM
Z91.03	Insect allergy status	Diagnosis	ICD-10-CM
Z91.030	Bee allergy status	Diagnosis	ICD-10-CM
Z91.038	Other insect allergy status	Diagnosis	ICD-10-CM
Z91.04	Nonmedicinal substance allergy status	Diagnosis	ICD-10-CM
Z91.040	Latex allergy status	Diagnosis	ICD-10-CM
Z91.041	Radiographic dye allergy status	Diagnosis	ICD-10-CM
Z91.048	Other nonmedicinal substance allergy status	Diagnosis	ICD-10-CM
Z91.09	Other allergy status, other than to drugs and biological substances	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
	Angioedema	0-1	
995.1	Angioedema	Diagnosis	ICD-9-CM
T783XXA	Angioedema	Diagnosis	ICD-10-CM
T783XXD	Angioneurotic edema, sequela	Diagnosis	ICD-10-CM
T783XXS	Angioneurotic edema, subsequent encounter	Diagnosis	ICD-10-CM
	Diabetes		
250	Diabetes mellitus	Diagnosis	ICD-9-CM
250.0	Diabetes mellitus without mention of complication	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.1	Diabetes with ketoacidosis	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.2	Diabetes with hyperosmolarity	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.3	Diabetes with other coma	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.4	Diabetes with renal manifestations	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.5	Diabetes with ophthalmic manifestations	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM



		Code	
Code	Description	Category	Code Type
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.6	Diabetes with neurological manifestations	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.7	Diabetes with peripheral circulatory disorders	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.8	Diabetes with other specified manifestations	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.9	Diabetes with unspecified complication	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
A5500	For diabetics only, fitting (including follow-up), custom preparation and supply of off-the- shelf depth-inlay shoe manufactured to accommodate multidensity insert(s), per shoe	Procedure	HCPCS
A5501	For diabetics only, fitting (including follow-up), custom preparation and supply of shoe molded from cast(s) of patient's foot (custom molded shoe), per shoe	Procedure	HCPCS
A5503	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with roller or rigid rocker bottom, per shoe	Procedure	HCPCS
A5504	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with wedge(s), per shoe	Procedure	HCPCS
A5505	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with metatarsal bar, per shoe	Procedure	HCPCS
A5506	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with off-set heel(s), per shoe	Procedure	HCPCS



Code	Description	Code Category	Code Type
A5507	For diabetics only, not otherwise specified modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe, per shoe	Procedure	HCPCS
A5508	For diabetics only, deluxe feature of off-the-shelf depth-inlay shoe or custom molded shoe, per shoe	Procedure	HCPCS
A5510	For diabetics only, direct formed, compression molded to patient's foot without external heat source, multiple-density insert(s) prefabricated, per shoe	Procedure	HCPCS
A5512	For diabetics only, multiple density insert, direct formed, molded to foot after external heat source of 230 degrees Fahrenheit or higher, total contact with patient's foot, including arch, base layer minimum of 1/4 inch material of Shore A 35 durometer or 3/16 inch material of Shore A 40 durometer (or higher), prefabricated, each	Procedure	HCPCS
A5513	For diabetics only, multiple density insert, custom molded from model of patient's foot, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of Shore A 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each	Procedure	HCPCS
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic- hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM



	Description	Code	
Code	Description	Category	Code Type
E11.3211	edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412		Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3491		Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM



E11.3542         Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction         Diagnosis         ICD-10-CM           E11.3543         Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction         Diagnosis         ICD-10-CM           E11.3543         Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction         Diagnosis         ICD-10-CM           E11.3549         Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction         Diagnosis         ICD-10-CM           E11.3551         Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eve         Diagnosis         ICD-10-CM           E11.3555         Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, upper version         Diagnosis         ICD-10-CM           E11.3559         Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, upper version         Diagnosis         ICD-10-CM           E11.3553         Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eve         Diagnosis         ICD-10-CM           E11.3593         Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosis         ICD-10-CM           Inspecified eve         Diagnosis         ICD-10-CM         ICD-10-CM           Inspe 2 diabetes mellitus with proliferative diabetic retinopathy wit			Code	
retinal detachment and rhegmatogenous retinal detachment, left eye E11.3543 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral E11.3549 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye E11.3553 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, light eye E11.3554 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, light eye E11.3555 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unperfede eye E11.3559 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unperfede eye E11.3591 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, lign eye E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with diabetic cataract E11.3593 Type 2 diabetes mellitus with diabetic cataract E11.37X1 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, efft bilateral E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, reye 2 diabetes mellitus with diabetic macular edema, resolved following treatment, eye 2 diabetes mellitus with diabetic macular edema, resolved following treatment, eye 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilagnosis ICD-10-CM eye 2 diabetes mellitus wit	Code	Description	Category	Code Type
rhegmatogenous retinal detachment, left eye       Diagnosis       ICD-10-CM         E11.3543       Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye       Diagnosis       ICD-10-CM         E11.3554       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye       Diagnosis       ICD-10-CM         E11.3555       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye       Diagnosis       ICD-10-CM         E11.3555       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye       Diagnosis       ICD-10-CM         E11.3555       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye       Diagnosis       ICD-10-CM         E11.3551       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with diabetic macular edema, re	E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E11.3543       Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment, bilateral       Diagnosis       ICD-10-CM         E11.3549       Type 2 diabetes mellitus with proliferative diabetic retinopathy, with combined traction retinal detachment, unspecified eye       Diagnosis       ICD-10-CM         E11.3551       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye       Diagnosis       ICD-10-CM         E11.3552       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye       Diagnosis       ICD-10-CM         E11.3559       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosis       ICD-10-CM         E11.3559       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosis       ICD-10-CM         E11.359       Type 2 diabetes mellitus with diabetic catract       Diagnosis       ICD-10-CM         E11.357       Type 2 diabetes mellitus with diabeti		retinal detachment and		
retinal detachment and rhegmatogenous retinal detachment, bilateral E11.3549 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye E11.3555 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye Diagnosis ICD-10-CM E11.3555 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye E11.3559 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye Diagnosis ICD-10-CM E11.3559 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye E11.3591 Type 2 diabetes mellitus with proliferative diabetic retinopathy, unspecified eye E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with diabetic cataract E11.3593 Type 2 diabetes mellitus with diabetic cataract E11.35742 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye E11.37X9 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral E11.37X9 Type 2 diabetes mellitus with diabetic computer etama, resolved following treatment, bilateral E11.37X9 Type 2 diabetes mellitus with diabetic componenty E11.337 Type 2 diabetes mellitus with diabetic compathy E11.337 Type 2 diabetes mellitus with diabetic compathy E11.337 Type 2 diabetes mellitus with diabetic componenty E11.34 Type 2 diabetes mellitus with diabetic componenty E11.35 Type 2 diabetes mellitus with diabetic com		rhegmatogenous retinal detachment, left eye		
rhegmatogenous retinal detachment, bilateral         E11.3549       Type 2 diabetes mellitus with proliferative diabetic retinopathy, with combined traction retinal detachment and retinal detachment, unspecified eye       Diagnosis       ICD-10-CM         E11.3551       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye       Diagnosis       ICD-10-CM         E11.3552       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, without macular edema, rego and red a	E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
E11.3549       Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye       Diagnosis       ICD-10-CM         E11.3551       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye       Diagnosis       ICD-10-CM         E11.3552       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral       Diagnosis       ICD-10-CM         E11.3553       Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, prospecified eye       Diagnosis       ICD-10-CM         E11.3552       Type 2 diabetes mellitus with abole proliferative diabetic retinopathy, unspecified eye       Diagnosis       ICD-10-CM         E11.3591       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilagnosis       ICD-10-CM         E11.3593       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilagnosis       ICD-10-CM         E11.3593       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilagnosis       ICD-10-CM         E11.3594       Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilagnosis       ICD-10-CM         E11.3594       Type 2 diabetes mellitus with diabetic cataract       Diagnosis       ICD-10-CM         E11.3714       Type 2 diabetes mellitus with diabetic macular edema, resolve				
retinal detachment and rhegmatogenous retinal detachment, unspecified eye E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye E11.3552 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye E11.3553 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye E11.3559 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye E11.3591 Type 2 diabetes mellitus with proliferative diabetic retinopathy, unspecified eye E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye E11.37X1 Type 2 diabetes mellitus with diabetic cataract E11.37X2 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateral E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral E11.37X3 Type 2 diabetes mellitus with diabetic neurolar edema, resolved following treatment, bilateral E11.37X3 Type 2 diabetes mellitus with diabetic neuropathy, unspecified eye E11.37X3 Type 2 diabetes mellitus with diabetic neuropathy, unspecified E11.37X3 Type 2 diabetes mellitus with diabetic neuropathy E11.337X3 Type 2 diabetes mellitus with diabetic neuropathy unspecified eye E11.337X3 Type 2 diabetes mellitus with diabetic neuropathy E11.337X3 Type 2 diabetes mellitus with d		rhegmatogenous retinal detachment, bilateral		
rhegmatogenous retinal detachment, unspecified eyeDiagnosisICD-10-CME11.3551Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eyeDiagnosisICD-10-CME11.3552Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, libiteralDiagnosisICD-10-CME11.3553Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eyeDiagnosisICD-10-CME11.3591Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, biagnosisICD-10-CME11.3593Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosis <td>E11.3549</td> <td></td> <td>Diagnosis</td> <td>ICD-10-CM</td>	E11.3549		Diagnosis	ICD-10-CM
E11.3551Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eyeDiagnosisICD-10-CME11.3552Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateralDiagnosisICD-10-CME11.3553Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eyeDiagnosisICD-10-CME11.3559Type 2 diabetes mellitus with proliferative diabetic retinopathy, unspecified eyeDiagnosisICD-10-CME11.3559Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateralDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, uspecified eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, uspecified eyeDiagnosisICD-10-CME11.3514Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X4Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic nononeuropathyDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic mononeuropathyDiagnosisICD-10-CME11				
E11.3552Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eyeDiagnosisICD-10-CME11.3553Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eyeDiagnosisICD-10-CME11.3591Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eyeDiagnosisICD-10-CME11.3592Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.3594Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right with 2DiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic cophthalmic complicationDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic nononeuropathy				
E11.3553Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateralDiagnosisICD-10-CME11.3554Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eyeDiagnosisICD-10-CME11.3557Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eyeDiagnosisICD-10-CME11.3559Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.3594Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.3717Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.3724Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left unspecified eyeDiagnosisICD-10-CME11.3725Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.3735Type 2 diabetes mellitus with diabetic ophthalmic complicationDiagnosisICD-10-CME11.3737Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.3737Type 2 diabetes mellitus with diabetic ophthalmic complicationDiagnosisICD-10-C	E11.3551		-	
E11.3559Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eyeDiagnosisICD-10-CME11.3591Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eyeDiagnosisICD-10-CME11.3592Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateralDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateralDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.3594Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right with augencified eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.37X4Type 2 diabetes mellitus with diabetic ophthalmic complicationDiagnosisICD-10-CME11.37X4Type 2 diabetes mellitus with diabetic neuropathyDiagnos			-	
E11.3591Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eyeDiagnosisICD-10-CME11.3592Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateralDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.3594Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.3712Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right bilateralDiagnosisICD-10-CME11.3723Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateralDiagnosisICD-10-CME11.3724Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.3735Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.3735Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.3744Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.3755Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.374Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.4			-	
right eye E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, liagnosis ICD-10-CM unspecified eye E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, liagnosis ICD-10-CM unspecified eye E11.365 Type 2 diabetes mellitus with diabetic cataract Diagnosis ICD-10-CM E11.37X1 Type 2 diabetes mellitus with diabetic cataract Diagnosis ICD-10-CM eye E11.37X2 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right Diagnosis ICD-10-CM eye E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left Diagnosis ICD-10-CM bilateral E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, Diagnosis ICD-10-CM eye E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, Diagnosis ICD-10-CM bilateral E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, Diagnosis ICD-10-CM bilateral E11.37X3 Type 2 diabetes mellitus with diabetic complication Diagnosis ICD-10-CM E11.40 Type 2 diabetes mellitus with diabetic neuropathy, unspecified Diagnosis ICD-10-CM E11.41 Type 2 diabetes mellitus with diabetic polyneuropathy Diagnosis ICD-10-CM E11.42 Type 2 diabetes mellitus with diabetic curonoreuropathy Diagnosis ICD-10-CM E11.43 Type 2 diabetes mellitus with diabetic curonoreuropathy Diagnosis ICD-10-CM E11.44 Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy Diagnosis ICD-10-CM E11.45 Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy Diagnosis ICD-10-CM E11.45 Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy Diagnosis ICD-10-CM E11.45 Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene Diagnosis ICD-10-CM E11.55 Type 2 diabetes mellitus with diabetic peripheral angiop			-	
E11.3592Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eyeDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateralDiagnosisICD-10-CME11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.367Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37Type 2 diabetes mellitus with diabetic nacular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic ophthalmic complicationDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes me	E11.3591		Diagnosis	ICD-10-CM
left eyeE11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateralDiagnosisICD-10-CME11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.36Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.437Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic ophyneuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neuropathyDiagno				
E11.3593Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateralDiagnosisICD-10-CME11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.36Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37X4Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic neuropathyDiagnosisICD-10-CM	E11.3592		Diagnosis	ICD-10-CM
bilateralE11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.36Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic caturact edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37Type 2 diabetes mellitus with diabetic neuropathy, unspecified DiagnosisDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecified DiagnosisDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic ophyneuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic catonomic (poly)neuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neuropagical complicationDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with	544 2502		<b>.</b> .	
E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eyeDiagnosisICD-10-CME11.36Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.37Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.39Type 2 diabetes mellitus with diabetic nacular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecified DiagnosisDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic nononeuropathy DiagnosisDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic oplyneuropathy DiagnosisDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy DiagnosisDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy DiagnosisDiagnosisICD-10-CME1	E11.3593		Diagnosis	ICD-10-CM
unspecified eyeE11.36Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic nononeuropathy, unspecified eyeDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic nononeuropathy LiagnosisDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathy LiagnosisDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic oploneuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.45	F11 2F00		Diagnasia	
E11.36Type 2 diabetes mellitus with diabetic cataractDiagnosisICD-10-CME11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eyeDiagnosisICD-10-CME11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathy, unspecified 17ye 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	E11.3599		Diagnosis	ICD-10-CIVI
E11.37X1Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, rightDiagnosisICD-10-CMeyeE11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic nononeuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic nononeuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.51Type 2 diabetes mel	F11 36		Diagnosis	
eyeE11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.53Type 2 diabetes mellitus with diab			-	
E11.37X2Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eyeDiagnosisICD-10-CME11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic anyotrophyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic periphe	L11.57/1		Diagnosis	
eyeE11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.45Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.51Type 2 diabetes melli	F11.37X2		Diagnosis	ICD-10-CM
E11.37X3Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateralDiagnosisICD-10-CME11.37X9Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.50Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with other circulatory complications<			21080.0000	
bilateralE11.37X9Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eyeDiagnosisICD-10-CME11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.37X3		Diagnosis	ICD-10-CM
unspecified eyeE11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic mononeuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM			.0	
unspecified eyeE11.39Type 2 diabetes mellitus with other diabetic ophthalmic complicationDiagnosisICD-10-CME11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic mononeuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,	Diagnosis	ICD-10-CM
E11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic mononeuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM			•	
E11.40Type 2 diabetes mellitus with diabetic neuropathy, unspecifiedDiagnosisICD-10-CME11.41Type 2 diabetes mellitus with diabetic mononeuropathyDiagnosisICD-10-CME11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.42Type 2 diabetes mellitus with diabetic polyneuropathyDiagnosisICD-10-CME11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with other diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified		ICD-10-CM
E11.43Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathyDiagnosisICD-10-CME11.44Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with other diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.44Type 2 diabetes mellitus with diabetic amyotrophyDiagnosisICD-10-CME11.49Type 2 diabetes mellitus with other diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.49Type 2 diabetes mellitus with other diabetic neurological complicationDiagnosisICD-10-CME11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.51Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangreneDiagnosisICD-10-CME11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.52Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangreneDiagnosisICD-10-CME11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.59Type 2 diabetes mellitus with other circulatory complicationsDiagnosisICD-10-CME11.610Type 2 diabetes mellitus with diabetic neuropathic arthropathyDiagnosisICD-10-CM	E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.610 Type 2 diabetes mellitus with diabetic neuropathic arthropathy Diagnosis ICD-10-CM	E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
	E11.59		Diagnosis	
E11.618Type 2 diabetes mellitus with other diabetic arthropathyDiagnosisICD-10-CM	E11.610		-	
	E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic- hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular	Diagnosis	ICD-10-CM
2101011	edema	Blaghoolo	
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
E13.37X2		Diagnosis	ICD-10-CM
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	Procedure	HCPCS
G0109	Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes	Procedure	HCPCS



Code	Description	Code Category	Code Type
	Initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS) which must include: (1) the diagnosis of LOPS, (2) a patient history, (3) a physical examination that consists of at least the following elements: (a) visual inspection of the forefoot, hindfoot, and toe web spaces, (b) evaluation of a protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (4) patient education	Procedure	HCPCS
	Follow-up physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS) to include at least the following: (1) a patient history, (2) a physical examination that includes: (a) visual inspection of the forefoot, hindfoot, and toe web spaces, (b) evaluation of protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (3) patient education	Procedure	HCPCS
G0247	Routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS) to include the local care of superficial wounds (i.e., superficial to muscle and fascia) and at least the following, if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails	Procedure	HCPCS
G8015	Diabetic patient with most recent hemoglobin A1c level (within the last 6 months) documented as greater than 9%	Procedure	HCPCS
G8016	Diabetic patient with most recent hemoglobin A1c level (within the last 6 months) documented as less than or equal to 9%	Procedure	HCPCS
G8017	Clinician documented that diabetic patient was not eligible candidate for hemoglobin A1c measure	Procedure	HCPCS
G8018	Clinician has not provided care for the diabetic patient for the required time for hemoglobin A1c measure (6 months)	Procedure	HCPCS
G8019	Diabetic patient with most recent low-density lipoprotein (within the last 12 months) documented as greater than or equal to 100 mg/dl	Procedure	HCPCS
G8020	Diabetic patient with most recent low-density lipoprotein (within the last 12 months) documented as less than 100 mg/dl	Procedure	HCPCS
G8021	Clinician documented that diabetic patient was not eligible candidate for low-density lipoprotein measure	Procedure	HCPCS
G8022	Clinician has not provided care for the diabetic patient for the required time for low- density lipoprotein measure (12 months)	Procedure	HCPCS
G8023	Diabetic patient with most recent blood pressure (within the last 6 months) documented as equal to or greater than 140 systolic or equal to or greater than 80 mm Hg diastolic	Procedure	HCPCS
G8024	Diabetic patient with most recent blood pressure (within the last 6 months) documented as less than 140 systolic and less than 80 diastolic	Procedure	HCPCS
G8025	Clinician documented that the diabetic patient was not eligible candidate for blood pressure measure	Procedure	HCPCS



Code	Description	Code Category	Code Type
G8026	Clinician has not provided care for the diabetic patient for the required time for blood pressure measure (within the last 6 months)	Procedure	HCPCS
G8332	Clinician has not provided care for the diabetic retinopathy patient for the required time for macular edema and retinopathy measurement	Procedure	HCPCS
G8333	Patient documented to have had findings of macular or fundus exam communicated to the physician managing the diabetes care	Procedure	HCPCS
G8334	Documentation of findings of macular or fundus exam not communicated to the physician managing the patient's ongoing diabetes care	Procedure	HCPCS
G8335	Clinician documentation that patient was not an eligible candidate for the findings of their macular or fundus exam being communicated to the physician managing their diabetes care during the reporting year	Procedure	HCPCS
G8336	Clinician has not provided care for the diabetic retinopathy patient for the required time for physician communication measurement	Procedure	HCPCS
G8385	Diabetic patients with no documentation of hemoglobin A1c level (within the last 12 months)	Procedure	HCPCS
G8386	Diabetic patients with no documentation of low-density lipoprotein (within the last 12 months)	Procedure	HCPCS
G8390	Diabetic patients with no documentation of blood pressure measurement (within the last 12 months)	Procedure	HCPCS

Ischemic Heart Dis
--------------------

411	Other acute and subacute forms of ischemic heart disease	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.8	Other acute and subacute forms of ischemic heart disease	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
413	Angina pectoris	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414	Other forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.0	Coronary atherosclerosis	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.1	Aneurysm and dissection of heart	Diagnosis	ICD-9-CM



codeDescriptionCategoryCode type414.10Aneurysm of heartDiagnosisICD-9-CM414.11Aneurysm of coronary vesselsDiagnosisICD-9-CM414.12Dissection of coronary vesselsDiagnosisICD-9-CM414.12Other aneurysm of heartDiagnosisICD-9-CM414.13Other aneurysm of heartDiagnosisICD-9-CM414.14Coronary atherosclerosis due to lipid rich plaqueDiagnosisICD-9-CM414.3Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.4Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.9Unspecified driftowscular diseaseDiagnosisICD-9-CM414.9Unspecified driftowscular diseaseDiagnosisICD-9-CM429.5Rupture of chordae tendineaeDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.7Acquired cardiac septal defectDiagnosisICD-9-CM429.9Unbercertain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.9Unbercertain sequelae of myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Coronary artery disease patient documented to be on antiplatelet therapy			Code	
414.11Aneurysm of coronary vesselsDiagnosisICD-9-CM414.12Dissection of coronary arteryDiagnosisICD-9-CM414.2Chronic total occlusion of coronary arteryDiagnosisICD-9-CM414.3Coronary atherosclerosis due to lipid rich plaqueDiagnosisICD-9-CM414.4Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.4Other specified forms of chronic ischemic heart diseaseDiagnosisICD-9-CM414.9Unspecified chronic ischemic heart diseaseDiagnosisICD-9-CM429.1Unspecified romacsular diseaseDiagnosisICD-9-CM429.2Unspecified romacsular diseaseDiagnosisICD-9-CM429.3Rupture of chordae tendineaeDiagnosisICD-9-CM429.4Cardiac septal defectDiagnosisICD-9-CM429.7Cetain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM68034Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient mot documented to be greaterProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelt therapyProcedureHCPCS	Code	Description	Category	Code Type
414.12Dissection of coronary arteryDiagnosisICD-9-CM414.13Other aneurysm of heartDiagnosisICD-9-CM414.2Chronic total occlusion of coronary arteryDiagnosisICD-9-CM414.3Coronary atherosclerosis due to lipid rich plaqueDiagnosisICD-9-CM414.4Chronic total occlusion of coronary artery diseaseDiagnosisICD-9-CM414.4Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.9Unspecified chronic ischemic heart diseaseDiagnosisICD-9-CM429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.5Rupture of chronic tachemic heart diseaseDiagnosisICD-9-CM429.6Rupture of papillary muscleDiagnosisICD-9-CM429.7Acquired cardiac septal defectDiagnosisICD-9-CM429.70Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.70Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Unspecified heart diseaseDiagnosisICD-9-CMICD-9-CM429.79Other certain sequelae of myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient was not eligible candidate for blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient was not	414.10	Aneurysm of heart	Diagnosis	ICD-9-CM
414.19Other aneurysm of heartDiagnosisICD-9-CM414.2Chronic total occlusion of coronary arteryDiagnosisICD-9-CM414.3Coronary atherosclerosis due to lipid rich plaqueDiagnosisICD-9-CM414.4Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.4Other specified forms of chronic ischemic heart diseaseDiagnosisICD-9-CM414.9Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.5Rupture of chordae tendineaeDiagnosisICD-9-CM429.7Cardian sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.7Acquired cardia septal defectDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM429.9Vinspecified heart diseaseDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM68034Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient was not eligible candidate for not eligible candidate for antiplatelet therapyProcedureHCPCS68036Coronary artery disease patient with low-density lipoprotein documented to be greater r quant y disease patient with low-density lipoprotein do	414.11	Aneurysm of coronary vessels	Diagnosis	ICD-9-CM
414.2Chronic total occlusion of coronary arteryDiagnosisICD-9-CM414.3Coronary atherosclerosis due to lipid rich plaqueDiagnosisICO-9-CM414.4Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.8Other specified forms of chronic ischemic heart diseaseDiagnosisICD-9-CM414.9Unspecified chronic ischemic heart diseaseDiagnosisICD-9-CM429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.5Rupture of chordae tendineaeDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.71Acquired cardiac septial defectDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68036Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be on beta- not eligible candidate for backer therapyProcedureHCPCS68037Coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68038Clinician documented that coronary artery di	414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.3Coronary atherosclerosis due to lipid rich plaqueDiagnosisICD-9-CM414.4Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.8Other specified chromic ischemic heart diseaseDiagnosisICD-9-CM412.9Unspecified chronic ischemic heart diseaseDiagnosisICD-9-CM429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.5Rupture of chorabe tendineaeDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Unspecified heart diseaseDiagnosisICD-9-CM429.79Unspecified heart diseaseDiagnosisICD-9-CM68034Prior myocardial infarction, coronary artery disease patient documented to be on betablocker therapyProcedureHCPCS86035Clinician documented that prior myocardial infarction, coronary artery disease patient was not eligible candidate for beta-blocker therapy measureProcedureHCPCS68036Coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68037Coronary artery disease patient documented to be on antiplatelet therapyProcedureHCPCS68038Clinician documented that coronary artery disease patient was not eligible candidate for or equal	414.19	Other aneurysm of heart	Diagnosis	ICD-9-CM
414.4Coronary atherosclerosis due to calcified coronary lesionDiagnosisICD-9-CM414.8Other specified forms of chronic ischemic heart diseaseDiagnosisICD-9-CM414.9Unspecified chronic ischemic heart diseaseDiagnosisICD-9-CM429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.3Rupture of chordae tendineaeDiagnosisICD-9-CM429.4Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CMHCPCS68034Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapyProcedureHCPCS68036Clinician documented that coronary artery disease patient was not eligible candidate for beta-blocker therapy measureProcedureHCPCS68037Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlP	414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.8Other specified forms of chronic ischemic heart diseaseDiagnosisICD-9-CM414.9Unspecified chronic ischemic heart diseaseDiagnosisICD-9-CM429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.6Rupture of chordae tendineaeDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.70Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.71Acquired cardiac septal defetDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, coronary artery disease patient documented to be on beta-ProcedureHCPCS68033Prior myocardial infarction, coronary artery disease patient not documented to be on beta-ProcedureHCPCS68034Coronary artery disease patient documented to be on antiplatelet therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be greaterProcedureHCPCS68036Coronary artery disease patient not documented to be greaterProcedureHCPCS68037Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68040 <td>414.3</td> <td>Coronary atherosclerosis due to lipid rich plaque</td> <td>Diagnosis</td> <td>ICD-9-CM</td>	414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.9Unspecified chronic ischemic heart diseaseDiagnosisICD-9-CM429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.5Rupture of chordae tendineaeDiagnosisICD-9-CM429.6Rupture of papillary muscleDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.71Acquired cardiac septial defectDiagnosisICD-9-CM429.72Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapyProcedureHCPCS68038Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be greater r equal to 100 mg/dlProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documen	414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
429.2Unspecified cardiovascular diseaseDiagnosisICD-9-CM429.5Rupture of chordae tendineaeDiagnosisICD-9-CM429.6Rupture of papillary muscleDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Unspecified heart diseaseDiagnosisICD-9-CM68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient not documented therapyProcedureHCPCS68036Coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68037Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68040Cincican documented that coronary arte	414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
429.5Rupture of chordae tendineaeDiagnosisICD-9-CM429.6Rupture of papillary muscleDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.71Acquired cardiac septal defectDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CMHCPCS68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68036Coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68037Coronary artery disease patient not documented to be greater than 100 mg/dIProcedureHCPCS68038Cinician documented that coronary artery disease patient was not eligible candidate for neasureProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dIProcedureHCPCS68041Clinician documente	414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
429.6Rupture of papillary muscleDiagnosisICD-9-CM429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.71Acquired cardiac septal defectDiagnosisICD-9-CM429.72Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be on antiplatelet therapy antiplatelet therapyProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCS68037Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlHCPCSHCPCS68040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoproteinProcedureHCPCS68041Clinician doc	429.2	Unspecified cardiovascular disease	Diagnosis	ICD-9-CM
429.7Certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.71Acquired cardiac septal defectDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient not documented to be on beta- beta-blocker therapyProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapy eta-blocker therapy measureProcedureHCPCS68037Cinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCS68038Cinician documented that coronary artery disease patient documented to be greater or equal to 100 mg/dlProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for neasureProcedure<	429.5	Rupture of chordae tendineae	Diagnosis	ICD-9-CM
429.71Acquired cardiac septal defectDiagnosisICD-9-CM429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CM68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient was beta-blocker therapyProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapyProcedureHCPCS68037Coronary artery disease patient not documented to be on antiplatelet therapyProcedureHCPCS68038Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be greaterProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documented for low-density lipoproteinProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoproteinProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documented to be less than low-density lipoprotein measureProcedureHCPCS68041Clinician docu	429.6	Rupture of papillary muscle	Diagnosis	ICD-9-CM
429.79Other certain sequelae of myocardial infarction, not elsewhere classifiedDiagnosisICD-9-CM429.9Unspecified heart diseaseDiagnosisICD-9-CMProcedureHCPCS68033Prior myocardial infarction, coronary artery disease patient documented to be on betablocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on betablocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient was beta-blocker therapy measureProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapy entiplatelet therapyProcedureHCPCS68037Coronary artery disease patient not documented to be on antiplatelet therapy entiplatelet therapy measureProcedureHCPCS68038Clinician documented that coronary artery disease patient was not eligible candidate for beta-100 mg/dlProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for measureDiagnosisICD-10-CM120.0Unstable angina measureDiagnosisICD-10-CM120.1Angina pectoris, unspecifiedDiagnosisICD-10-CM120.3Other forms of angi	429.7	Certain sequelae of myocardial infarction, not elsewhere classified	Diagnosis	ICD-9-CM
429.9Unspecified heart diseaseDiagnosisICD-9-CM68033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient was not eligible candidate for beta-blocker therapy measureProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCS68037Coronary artery disease patient documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCS68038Clinician documented that coronary artery disease patient was not eligible candidate for nor equal to 100 mg/dlProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be greater or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for neasureProcedureHCPCS120.0Unstable anginaDiagnosisICD-10-CM120.1Angina pectoris with documented spasmDiagnosisICD-10-CM120.3Other forms of angina pectorisDiagnosisICD-10-CM123.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	429.71	Acquired cardiac septal defect	Diagnosis	ICD-9-CM
G8033Prior myocardial infarction, coronary artery disease patient documented to be on beta- blocker therapyProcedureHCPCSG8034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyProcedureHCPCSG8035Clinician documented that prior myocardial infarction, coronary artery disease patient was beta-blocker therapy measureProcedureHCPCSG8036Coronary artery disease patient documented to be on antiplatelet therapy or coronary artery disease patient not documented to be on antiplatelet therapy ProcedureProcedureHCPCSG8037Coronary artery disease patient not documented to be on antiplatelet therapy ProcedureProcedureHCPCSG8038Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCSG8039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCSG8041Clinician documented that coronary artery disease patient was not eligible candidate for or equal to 100 mg/dlProcedureHCPCSG8041Clinician documented that coronary artery disease patient was not eligible candidate for neasureProcedureHCPCSI20.0Unstable anginaDiagnosisICD-10-CMI20.1Angina pectoris with documented spasmDiagnosisICD-10-CMI20.3Angina pectoris, unspecifiedDiagnosisICD-10-CMI20.4Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CM	429.79	Other certain sequelae of myocardial infarction, not elsewhere classified	Diagnosis	ICD-9-CM
blocker therapyHCPCS68034Prior myocardial infarction, coronary artery disease patient not documented to be on beta- blocker therapyHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient was beta-blocker therapy measureProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapy or coronary artery disease patient not documented to be on antiplatelet therapy ProcedureProcedureHCPCS68037Coronary artery disease patient not documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCS68038Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for or equal to 100 mg/dlProcedureHCPCS68042Clinician documented that coronary artery disease patient was not eligible candidate for neasureProcedureHCPCS120.0Unstable anginaDiagnosisICD-10-CMI120.1Angina pectoris with documented spasmDiagnosisICD-10-CMI120.3Other forms of angina pectorisDiagnosisICD-10-CMI123.0Hemopericardilum as current complication following acute m	429.9	Unspecified heart disease	Diagnosis	ICD-9-CM
blocker therapyHCPCS68035Clinician documented that prior myocardial infarction, coronary artery disease patient was beta-blocker therapy measureProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapy Coronary artery disease patient not documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCS68036Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for measureProcedureHCPCS120.0Unstable anginaDiagnosisICD-10-CM120.1Angina pectoris with documented spasmDiagnosisICD-10-CM120.9Angina pectoris, unspecifiedDiagnosisICD-10-CM123.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CM123.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8033		Procedure	HCPCS
not eligible candidate for beta-blocker therapy measureProcedureHCPCS68036Coronary artery disease patient documented to be on antiplatelet therapy Coronary artery disease patient not documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCS68037Coronary artery disease patient not documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCS68039Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCS68039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCS68040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCS68041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoprotein measureProcedureHCPCS120.0Unstable anginaDiagnosisICD-10-CM120.1Angina pectoris with documented spasmDiagnosisICD-10-CM120.2Angina pectoris, unspecifiedDiagnosisICD-10-CM123.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CM123.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8034		Procedure	HCPCS
G8037Coronary artery disease patient not documented to be on antiplatelet therapy antiplatelet therapy measureProcedureHCPCSG8038Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCSG8039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCSG8040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCSG8041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoprotein measureProcedureHCPCSI20.0Unstable anginaDiagnosisICD-10-CMI20.1Angina pectoris with documented spasmDiagnosisICD-10-CMI20.9Angina pectoris, unspecifiedDiagnosisICD-10-CMI23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8035	not eligible candidate for	Procedure	HCPCS
G8038Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measureProcedureHCPCSG8039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCSG8040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCSG8041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoprotein measureProcedureHCPCSI20.0Unstable anginaDiagnosisICD-10-CMI20.1Angina pectoris with documented spasmDiagnosisICD-10-CMI20.9Angina pectoris, unspecifiedDiolowing acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8036	Coronary artery disease patient documented to be on antiplatelet therapy	Procedure	HCPCS
antiplatelet therapy measureProcedureHCPCSG8039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCSG8040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCSG8041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoprotein measureProcedureHCPCSI20.0Unstable anginaDiagnosisICD-10-CMI20.1Angina pectoris with documented spasmDiagnosisICD-10-CMI20.9Angina pectoris, unspecifiedDilagnosisICD-10-CMI23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8037	Coronary artery disease patient not documented to be on antiplatelet therapy	Procedure	HCPCS
G8039Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dlProcedureHCPCSG8040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCSG8041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoprotein measureProcedureHCPCSI20.0Unstable anginaDiagnosisICD-10-CMI20.1Angina pectoris with documented spasmDiagnosisICD-10-CMI20.2Other forms of angina pectorisDiagnosisICD-10-CMI20.9Angina pectoris, unspecifiedDiagnosisICD-10-CMI23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8038		Procedure	HCPCS
G8040Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dlProcedureHCPCSG8041Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoprotein measureProcedureHCPCS120.0Unstable anginaDiagnosisICD-10-CM120.1Angina pectoris with documented spasmDiagnosisICD-10-CM120.8Other forms of angina pectorisDiagnosisICD-10-CM120.9Angina pectoris, unspecifiedDiagnosisICD-10-CM123.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CM123.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8039	Coronary artery disease patient with low-density lipoprotein documented to be greater	Procedure	HCPCS
Iow-density lipoprotein measureIow-density lipoprotein measure120.0Unstable anginaDiagnosisICD-10-CM120.1Angina pectoris with documented spasmDiagnosisICD-10-CM120.8Other forms of angina pectorisDiagnosisICD-10-CM120.9Angina pectoris, unspecifiedDiagnosisICD-10-CM123.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CM123.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8040		Procedure	HCPCS
I20.1Angina pectoris with documented spasmDiagnosisICD-10-CMI20.8Other forms of angina pectorisDiagnosisICD-10-CMI20.9Angina pectoris, unspecifiedDiagnosisICD-10-CMI23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	G8041	low-density lipoprotein	Procedure	HCPCS
I20.1Angina pectoris with documented spasmDiagnosisICD-10-CMI20.8Other forms of angina pectorisDiagnosisICD-10-CMI20.9Angina pectoris, unspecifiedDiagnosisICD-10-CMI23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM	120.0		Diagnosis	ICD-10-CM
I20.8Other forms of angina pectorisDiagnosisICD-10-CMI20.9Angina pectoris, unspecifiedDiagnosisICD-10-CMI23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM		-	-	
I20.9Angina pectoris, unspecifiedDiagnosisICD-10-CMI23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM			-	
I23.0Hemopericardium as current complication following acute myocardial infarctionDiagnosisICD-10-CMI23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM			-	
I23.1Atrial septal defect as current complication following acute myocardial infarctionDiagnosisICD-10-CM			-	
			-	



		Code	
Code	Description	Category	Code Type
123.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
123.7	Postinfarction angina	Diagnosis	ICD-10-CM
123.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
124.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
124.1	Dressler's syndrome	Diagnosis	ICD-10-CM
124.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
124.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
125.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
125.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
125.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.3	Aneurysm of heart	Diagnosis	ICD-10-CM
125.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
125.42	Coronary artery dissection	Diagnosis	ICD-10-CM
125.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
125.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
125.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
125.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
125.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
125.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
125.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
125.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
125.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
125.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
125.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
125.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
125.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
125.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
151.0	Cardiac septal defect, acquired	Diagnosis	ICD-10-CM
151.1	Rupture of chordae tendineae, not elsewhere classified	Diagnosis	ICD-10-CM
151.2	Rupture of papillary muscle, not elsewhere classified	Diagnosis	ICD-10-CM
151.9	Heart disease, unspecified	Diagnosis	ICD-10-CM
152	Other heart disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
	Renal Disorders		
584	Acute kidney failure	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585	Chronic kidney disease (CKD)	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM



Generic Name	Brand Name
	y Treatments
Chlorpheniramine Maleate/Codeine	Cotabflu
Phosphate/Acetaminophen	
DIPHENHYDRAMINE HCL	Dicopanol
acetaminophen/dextromethorphan HBr	Child Cough and Sore Throat
aclidinium bromide	Tudorza Pressair
albuterol sulfate	ProAir HFA
albuterol sulfate	ProAir RespiClick
albuterol sulfate	Proventil HFA
albuterol sulfate	Ventolin HFA
albuterol sulfate	Vospire ER
albuterol sulfate	albuterol sulfate
alcaftadine	Lastacaft
aldosterone	aldosterone (bulk)
aminophylline	aminophylline
aminophylline	aminophylline (bulk)
arformoterol tartrate	Brovana
azelastine HCl	Astelin
azelastine HCl	Astepro
azelastine HCl	Optivar
azelastine HCl	azelastine
azelastine HCl/fluticasone propionate	Dymista
azelastine/fluticasone/sodium chloride/sodium	Ticalast
bicarbonate	
beclomethasone dipropionate	Beconase AQ
beclomethasone dipropionate	QNASL
beclomethasone dipropionate	Qvar
beclomethasone dipropionate	Qvar RediHaler
benralizumab	Fasenra
bepotastine besilate	Bepreve
betamethasone acetate and sodium phos in sterile water/PF	betameth ac,sodphos(PF)-water
betamethasone acetate and sodium	Betaloan SUIK
phosph/norflurane/HFC 245fa	
betamethasone acetate and sodium	Pod-Care 100CG
phosph/norflurane/HFC 245fa	
betamethasone acetate/betamethasone sodium	Beta-1
phosphate	Dela-T
betamethasone acetate/betamethasone sodium	Celestone Soluspan
phosphate	
betamethasone acetate/betamethasone sodium	Pod-Care 100C
phosphate	
betamethasone acetate/betamethasone sodium	ReadySharp Betamethasone
phosphate	Readyonally becamethasone
phosphate	



Generic Name	Brand Name
betamethasone acetate/betamethasone sodium	betamethasone acet, sod phos
phosphate	
betamethasone acetate/betamethasone sodium	betamethasone ace,sodphos-wtr
phosphate/water	
betamethasone sodium phosph in sterile water for	betamethasone sodphosph-water
injection	
brompheniramine maleate	J-TAN PD
brompheniramine maleate	brompheniramine maleate(bulk)
brompheniramine maleate/phenylephrine HCl	Children's Cold-Allergy (PE)
brompheniramine maleate/phenylephrine HCl	Dimaphen (PE)
brompheniramine maleate/phenylephrine HCl	Glenmax PEB
brompheniramine maleate/phenylephrine HCl	Relhist BP
brompheniramine maleate/phenylephrine	Trexbrom
HCl/chlophedianol HCl	
brompheniramine maleate/phenylephrine	M-END PE
HCl/codeine phosphate	
brompheniramine maleate/phenylephrine	Poly-Tussin AC
HCI/codeine phosphate	
brompheniramine maleate/phenylephrine	AP-Hist DM
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	Ala-Hist DM
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	Altipres-B
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	Bio T Pres-B
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	BroveX PEB DM
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	Children's Cold and Cough(PE)
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine	Children's Cold and CoughDM
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	Children's Dibromm DMCold-Cou
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine	Cold and Cough DM
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine	Cold and Cough Elixir
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine	Dimaphen DM
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine	Dimetapp DM Cold-Cough(PE)
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	EndaCof - DM
HCI/dextromethorphan	



Generic Name	Brand Name
brompheniramine maleate/phenylephrine	Glenmax PEB DM
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine	Glenmax PEB DM Forte
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	LoHist PEB DM
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine	LoHist-DM
HCI/dextromethorphan	
brompheniramine maleate/phenylephrine HCl/dextromethorphan	M-Hist DM
	Niva-Hist DM
brompheniramine maleate/phenylephrine HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	Drocgon B
HCl/dextromethorphan	Presgen B
brompheniramine maleate/phenylephrine	RelCof DM
HCl/dextromethorphan	Reicol Divi
brompheniramine maleate/phenylephrine	Runov DM
HCl/dextromethorphan	Rynex DM
brompheniramine maleate/phenylephrine	Tussi Pres-B
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	Wal-tap DM
HCl/dextromethorphan	
brompheniramine maleate/phenylephrine	brompheniramin-phenylephrin-DM
HCl/dextromethorphan	
brompheniramine maleate/pseudoephedrine	Atuss DA
HCl/chlophedianol	
brompheniramine maleate/pseudoephedrine	brompheniramine-pseudoeph-DM
HCl/dextromethorphan	
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	Rhinocort Allergy
budesonide	Rhinocort Aqua
budesonide	budesonide
budesonide, micronized	budesonide, micronized (bulk)
budesonide/formoterol fumarate	Symbicort
carbinoxamine maleate	Arbinoxa
carbinoxamine maleate	Karbinal ER
carbinoxamine maleate	PALGIC
carbinoxamine maleate	RyVent
carbinoxamine maleate	carbinoxamine maleate
cetirizine HCl	24Hour Allergy
cetirizine HCl	All Day Allergy (cetirizine)
cetirizine HCl	All Day Allergy Relief(cetir)
cetirizine HCl	Aller-Tec
cetirizine HCl	Allergy Relief (cetirizine)



Generic Name	Brand Name
cetirizine HCl	Child Allergy Relf(cetirizine)
cetirizine HCl	Child's All Day Allergy(cetir)
cetirizine HCl	Children's Aller-Tec
cetirizine HCl	Children's Allergy Complete
cetirizine HCl	Children's Allergy(cetirizine)
cetirizine HCl	Children's Cetirizine
cetirizine HCl	Children's Wal-Zyr
cetirizine HCl	Children's Zyrtec Allergy
cetirizine HCl	Wal-Zyr (cetirizine)
cetirizine HCl	Zyrtec
cetirizine HCl	cetirizine
cetirizine HCl/pseudoephedrine HCl	All Day Allergy-D
cetirizine HCl/pseudoephedrine HCl	Aller-Tec D
cetirizine HCI/pseudoephedrine HCI	Allergy Complete-D
cetirizine HCI/pseudoephedrine HCI	Allergy D-12
cetirizine HCI/pseudoephedrine HCI	Allergy Relief-D (cetirizine)
cetirizine HCI/pseudoephedrine HCI	Allergy-Congest Relief-D (cet)
cetirizine HCI/pseudoephedrine HCI	Cetiri-D
cetirizine HCI/pseudoephedrine HCI	Wal-Zyr D
cetirizine HCI/pseudoephedrine HCI	Zyrtec-D
cetirizine HCI/pseudoephedrine HCI	cetirizine-pseudoephedrine
chlophedianol HCl/guaifenesin	Chlo Tuss EX
chlophedianol HCl/guaifenesin	Vanacof G
chlophedianol HCl/guaifenesin	chlophedianol-guaifenesin
chlorcyclizine HCl	Ahist (chlorcyclizine)
chlorcyclizine HCl/codeine phosphate	Poly-Tussin
chlorcyclizine HCl/phenylephrine HCl	Dallergy (chlorcyclizine-PE)
chlorcyclizine HCl/pseudoephedrine HCl	Nasopen
chlorcyclizine HCl/pseudoephedrine HCl	Stahist AD
chlorcyclizine HCl/pseudoephedrine	Biclora-D
HCI/chlophedianol HCl	
chlorcyclizine HCl/pseudoephedrine HCl/codeine phosphate	Poly-Tussin D
chlorcyclizine hydrochloride/chlophedianol hydrochloride	Biclora
chlorpheniram/phenyleph/dextromethorphn /acetaminophen/guaifn	Cold-Flu M-SymptomDay-Night
chlorpheniram/phenyleph/dextromethorphn /acetaminophen/guaifn	Tylenol Cold-Flu SevereDay-Nt
chlorpheniramine maleate	Aller-Chlor
chlorpheniramine maleate	Allergy (chlorpheniramine)
chlorpheniramine maleate	Allergy 4-Hour
chlorpheniramine maleate	Allergy Relief(chlorpheniramn)
chlorpheniramine maleate	Allergy-Time
chlorpheniramine maleate	Chlor-Trimeton
chlorpheniramine maleate	Chlorphen SR



Generic Name	Brand Name
chlorpheniramine maleate	ED Chlorped Jr
chlorpheniramine maleate	Ed-ChlorPed
chlorpheniramine maleate	Ed-Chlortan
chlorpheniramine maleate	Pharbechlor
chlorpheniramine maleate	Wal-Finate
chlorpheniramine maleate	chlorpheniramine maleate
chlorpheniramine maleate/codeine phosphate	Codar AR
chlorpheniramine maleate/codeine phosphate	EndaCof-C
chlorpheniramine maleate/codeine phosphate	Tuxarin ER
chlorpheniramine maleate/codeine phosphate	Z-Tuss AC
chlorpheniramine maleate/codeine phosphate	Zodryl AC 25
chlorpheniramine maleate/codeine phosphate	Zodryl AC 30
chlorpheniramine maleate/codeine phosphate	Zodryl AC 35
chlorpheniramine maleate/codeine phosphate	Zodryl AC 40
chlorpheniramine maleate/codeine phosphate	Zodryl AC 50
chlorpheniramine maleate/codeine phosphate	Zodryl AC 60
chlorpheniramine maleate/codeine phosphate	Zodryl AC 80
chlorpheniramine maleate/dextromethorphan HBr	Chld Robitussin Night CoughDM
chlorpheniramine maleate/dextromethorphan HBr	Cough and Cold(chlorphen-DM)
chlorpheniramine maleate/dextromethorphan HBr	Cough-Cold Relief HBP
chlorpheniramine maleate/dextromethorphan HBr	Maxi-TussDM(chlorpheniramine)
chlorpheniramine maleate/dextromethorphan HBr	Scot-Tussin DM
chlorpheniramine maleate/phenylephrine HCl	Cold and Allergy
chlorpheniramine maleate/phenylephrine HCl	Sinus and Allergy PE
chlorpheniramine maleate/phenylephrine HCl	Sinus-Allergy (phenylephrine)
chlorpheniramine maleate/phenylephrine	Carbaphen CH
HCl/chlophedianol HCl	
chlorpheniramine maleate/phenylephrine	Carbaphen Ped CH
HCl/chlophedianol HCl	
chlorpheniramine maleate/phenylephrine	ExaPhen CH
HCl/chlophedianol HCl	
chlorpheniramine maleate/phenylephrine	Phenagil CH
HCl/chlophedianol HCl	
chlorpheniramine maleate/phenylephrine	CapCof
HCI/codeine phosphate	
chlorpheniramine maleate/phenylephrine	Maxi-Tuss CD
HCI/codeine phosphate	
chlorpheniramine maleate/phenylephrine	Bio-Rytuss
HCI/dextromethorphan	
chlorpheniramine maleate/phenylephrine	Maxichlor PEH DM
HCI/dextromethorphan	
chlorpheniramine maleate/phenylephrine	Advil Allergy-Congestion Rlf
HCI/ibuprofen	
chlorpheniramine maleate/phenylephrine	Cold Relief
bitartrate/aspirin	


Generic Name	Brand Name
chlorpheniramine maleate/phenylephrine	Cold Relief Plus
bitartrate/aspirin	
chlorpheniramine maleate/pseudoephedrine	Tricode AR
HCI/codeine	
chlorpheniramine maleate/pseudoephedrine	Zodryl DAC 25
HCI/codeine	
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl DAC 30
chlorpheniramine maleate/pseudoephedrine	Zodryl DAC 35
HCl/codeine	
chlorpheniramine maleate/pseudoephedrine	Zodryl DAC 40
HCI/codeine	
chlorpheniramine maleate/pseudoephedrine	Zodryl DAC 50
HCI/codeine	
chlorpheniramine maleate/pseudoephedrine	Zodryl DAC 60
HCI/codeine	
chlorpheniramine maleate/pseudoephedrine	Zodryl DAC 80
HCI/codeine	A de la Allemana Cincer
chlorpheniramine maleate/pseudoephedrine	Advil Allergy Sinus
HCI/ibuprofen	A humana
ciclesonide	Alvesco
ciclesonide	Omnaris Zatanna
ciclesonide	Zetonna
clemastine fumarate	Allergy Relief (clemastine)
clemastine fumarate	Allerhist (clemastine) Allerhist-1
clemastine fumarate	
clemastine fumarate clemastine fumarate	Dayhist Allergy Tavist-1
clemastine fumarate	clemastine
clemizole HCl	clemizole HCl (bulk)
codeine phosphate/guaifenesin	G Tussin AC
codeine phosphate/guaifenesin	Robafen AC
codeine phosphate/guaifenesin	Virtussin AC
codeine phosphate/guaifenesin	codeine-guaifenesin
codeine phosphate/guarenesin codeine phosphate/pyrilamine maleate	Pro-Clear AC
codeine polistirex/chlorpheniramine polistirex	Tuzistra XR
cortisone acetate	cortisone
cromolyn sodium	Nasal Allergy SymptomControl
cromolyn sodium	cromolyn
cyproheptadine HCl	cyproheptadine
cyproheptadine HCl	cyproheptadine (bulk)
deflazacort	Emflaza
desloratadine	Clarinex
desloratadine	desloratadine
desloratadine/pseudoephedrine sulfate	Clarinex-D 12 HOUR



Generic Name	Brand Name
desloratadine/pseudoephedrine sulfate	Clarinex-D 24 HOUR
desoxycorticosterone acetate	desoxycorticosterone ac(bulk)
dexamethasone	Decadron
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dexamethasone Intensol
dexamethasone	Dxevo
dexamethasone	HiDex
dexamethasone	LoCort
dexamethasone	TaperDex
dexamethasone	ZoDex
dexamethasone	ZonaCort
dexamethasone	dexamethasone
dexamethasone acetate and sodium phosphate in	dexamethasone ac, sodph-water
sterile water	
dexamethasone acetate in sodium chloride,	dexamethasoneace-NaCl, iso-osm
iso-osmotic	
dexamethasone acetate, micronized	dexamethasone ac, micro(bulk)
dexamethasone sodium phosphate	Dexonto
dexamethasone sodium phosphate	dexamethasone sod phos(bulk)
dexamethasone sodium phosphate in 0.9 %	dexamethasone-0.9 % sod.chlor
sodium chloride	
dexamethasone sodium phosphate/PF	Active Injection Kit D (PF)
dexamethasone sodium phosphate/PF	DoubleDex (PF)
dexamethasone sodium phosphate/PF	MAS Care-Pak (PF)
dexamethasone sodium phosphate/PF	dexamethasone sodium phos(PF)
dexamethasone sodium phosphate/lidocaine HCl	Lidocidex-I
dexamethasone, micronized	dexamethasone,micronized(bulk)
dexamethasone/PF/norflurane/pentafluoropropane	DMT SUIK
(HFC 245fa)	
dexbromphen-pseudoephedrine	M-End DMX
-dextromethorphan	
dexbrompheniramine maleate	Ala-Hist IR
dexbrompheniramine maleate	Pediavent
dexbrompheniramine maleate/chlophedianol HCl	Chlo Hist
dexbrompheniramine maleate/phenylephrine HCl	Ala-Hist PE
dexbrompheniramine maleate/phenylephrine HCl	Dallergy(dexbrompheniramn-PE)
dexbrompheniramine maleate/phenylephrine HCl	dexbrompheniramine-phenyleph
dexbrompheniramine maleate/pseudoephedrine	Acticon (dexbromph-pse)
HCI	·
dexbrompheniramine maleate/pseudoephedrine	M-End Max D
HCl/codeine phos	
dexchlorpheniramine maleate	Ryclora
dexchlorpheniramine maleate	dexchlorpheniramine maleate



Generic Name	Brand Name
dexchlorpheniramine maleate/phenylephrine HCl	Rymed(dexchlorpheniramine-PE)
dexchlorpheniramine maleate/phenylephrine HCl	Stahist (dexchlorpheniramine)
dexchlorpheniramine maleate/phenylephrine	Pro-Red AC (w/dexchlorphenir)
HCl/codeine	
dexchlorpheniramine	Polytussin DM
maleate/phenylephrine/dextromethorphan	
dextromethorphan	Child Plus Cough and Runny Nose
HBr/acetaminophen/chlorpheniramine maleate	
dextromethorphan	Child's TylenolplusCough,RNos
HBr/acetaminophen/chlorpheniramine maleate	
dextromethorphan	Coricidin HBP Flu
HBr/acetaminophen/chlorpheniramine maleate	
dextromethorphan	Flu BP
HBr/acetaminophen/chlorpheniramine maleate	
dextromethorphan	Flu HBP
HBr/acetaminophen/chlorpheniramine maleate	
dextromethorphan	Maximum Strength Flu
HBr/acetaminophen/chlorpheniramine maleate	
dextromethorphan	Vicks NyQuil Cold/Flu (cpm)
HBr/acetaminophen/chlorpheniramine maleate	
dextromethorphan	Diabetic Tussin Night Time
HBr/acetaminophen/diphenhydramine HCl	
dextromethorphan	All-Nite Cold-Flu
HBr/acetaminophen/doxylamine	
dextromethorphan	Cold-Flu Relief
HBr/acetaminophen/doxylamine	
dextromethorphan	Contac Cold-Flu Night
HBr/acetaminophen/doxylamine	
dextromethorphan	Coricidin HBP Cold-MultiSympt
HBr/acetaminophen/doxylamine	
dextromethorphan	Cough-Sore Throat Night
HBr/acetaminophen/doxylamine	
dextromethorphan	Night Time
HBr/acetaminophen/doxylamine	
dextromethorphan	Night Time Cold
HBr/acetaminophen/doxylamine	
dextromethorphan	Night Time Cold and FluRelief
HBr/acetaminophen/doxylamine	
dextromethorphan	Night Time Cold-Flu
HBr/acetaminophen/doxylamine	
dextromethorphan	Night Time Cold-Flu Relief
HBr/acetaminophen/doxylamine	-
dextromethorphan	Nighttime Cold-Flu
HBr/acetaminophen/doxylamine	5



Generic Name	Brand Name
dextromethorphan	Nighttime Cold-Flu Relief
IBr/acetaminophen/doxylamine	
dextromethorphan	Nite Time Cold-Flu
HBr/acetaminophen/doxylamine	
dextromethorphan	Nite Time Cold-Flu Relief
HBr/acetaminophen/doxylamine	
dextromethorphan	Nite-Time Cold-Flu
HBr/acetaminophen/doxylamine	
dextromethorphan	Nitetime Multi-Symptom
IBr/acetaminophen/doxylamine	
dextromethorphan	Robitussin Cold-Flu Night
IBr/acetaminophen/doxylamine	
dextromethorphan	Vicks Nature Fusion Cold-Flu
HBr/acetaminophen/doxylamine	
dextromethorphan	Vicks NyQuil Cold/FluLiquicap
HBr/acetaminophen/doxylamine	
dextromethorphan	Vicks Nyquil Nighttime Relief
IBr/acetaminophen/doxylamine	
lextromethorphan HBr/doxylamine succinate	Daytime-Nighttime Cough
lextromethorphan HBr/doxylamine succinate	NightTime Cough
lextromethorphan HBr/doxylamine succinate	Nite Time Cough
lextromethorphan HBr/doxylamine succinate	Nitetime Cough
lextromethorphan HBr/doxylamine succinate	Robitussin Nighttime CoughDM
lextromethorphan HBr/doxylamine succinate	SafeTussin PM
lextromethorphan HBr/doxylamine succinate	Tussin Nighttime Cough DM
lextromethorphan HBr/doxylamine succinate	Vicks NyQuil Cough
dextromethorphan HBr/phenylephrine HCl	Children's Cold-CoughDaytime
dextromethorphan HBr/phenylephrine HCl	Children's Sudafed PE Cough
lextromethorphan HBr/phenylephrine HCl	Cold and Cough (pe-dm)
dextromethorphan HBr/phenylephrine HCl	Triaminic Cold and Cough(PE)
dextromethorphan HBr/phenylephrine	Cold Head CongestionDaytime
HCI/acetaminophen	
dextromethorphan HBr/phenylephrine	Cold Multi-Symptom
HCI/acetaminophen	
dextromethorphan HBr/phenylephrine	Cold-Flu Relief
ICI/acetaminophen	
dextromethorphan HBr/phenylephrine	Day Multi-Symp Flu-SevereCold
ICI/acetaminophen	
lextromethorphan HBr/phenylephrine	Day Time PE
ICI/acetaminophen	
lextromethorphan HBr/phenylephrine	DayTime
HCI/acetaminophen	
lextromethorphan HBr/phenylephrine	Daytime Cold
HCI/acetaminophen	



Generic Name	Brand Name
dextromethorphan HBr/phenylephrine	Daytime Cold-Flu
HCl/acetaminophen	Doutime Cold Elu Poliof (PC)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Daytime Cold-Flu Relief (PE)
dextromethorphan HBr/phenylephrine	Flu Relief Therapy Daytime
HCl/acetaminophen	The Neller Therapy Daytime
dextromethorphan HBr/phenylephrine	Flu-Severe Cold-CoughDaytime
HCl/acetaminophen	
dextromethorphan HBr/phenylephrine	HerbioMed Body Aches-SinusM-S
HCl/acetaminophen	,
dextromethorphan HBr/phenylephrine	Mapap Cold Formula
HCI/acetaminophen	
dextromethorphan HBr/phenylephrine	Mucinex Fast-MaxCongest-Head
HCl/acetaminophen	
dextromethorphan HBr/phenylephrine	Mucinex Fast-MaxSevCold-Sinus
HCl/acetaminophen	
dextromethorphan HBr/phenylephrine	Robitussin Cold-Flu Day
HCI/acetaminophen	
dextromethorphan HBr/phenylephrine	Sudafed PEPressure-Pain-Cough
HCI/acetaminophen	
dextromethorphan HBr/phenylephrine	Theraflu ExpressMax ColdDay
HCI/acetaminophen	
dextromethorphan HBr/phenylephrine	Theraflu Multi-Symptom Cold
HCI/acetaminophen	Tulanal Cald May Dav
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Tylenol Cold Max Day
dextromethorphan HBr/phenylephrine	Tulanal Cald Multi Symptom Day
HCl/acetaminophen	Tylenol Cold Multi-SymptomDay
dextromethorphan HBr/phenylephrine	Vicks DayQuil Cold-Flu Relief
HCl/acetaminophen	
dextromethorphan HBr/phenylephrine	Vicks Nature Fusion
HCl/acetaminophen	
dextromethorphan HBr/phenylephrine	Wal-Flu Severe Cold-Cough
HCl/acetaminophen	Ŭ
dextromethorphan HBr/phenylephrine	Alahist CF
HCl/dexbrompheniramine	
dextromethorphan HBr/phenylephrine	Alahist DM
HCl/dexbrompheniramine	
dextromethorphan HBr/phenylephrine	Bionatuss DXP
HCI/dexbrompheniramine	
dextromethorphan HBr/phenylephrine	G-P-Tuss DXP
HCI/dexbrompheniramine	
dextromethorphan HBr/phenylephrine	Supress A
HCI/dexbrompheniramine	



Conoria Nomo	Brand Nama
Generic Name	Brand Name
dextromethorphan	Alka-Seltzer PlusSin-Allg-Cgh
HBr/phenylephrine/acetaminophen/doxylamine	Cold Markin Computer and Line 1
dextromethorphan	Cold Multi-SymptomNightTime
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Cold and Flu Relief Plus (D/N)
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Cold-Flu Relief, Day/Night
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Daytime-Nighttime
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Daytime-Nighttime Cold-Flu
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Mucinex Fast-Max Nite (doxyl)
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Nite Time Cold-Flu Relief (PE)
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Severe Cold and FluNighttime
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Severe Sinus CongestAlrgy-Cgh
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Tylenol Cold Max Night
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Tylenol Cold Multi-SymptNight
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan	Vicks NyQuil Severe Cold-Flu
HBr/phenylephrine/acetaminophen/doxylamine	
dextromethorphan HBr/pseudoephedrine	DAY-TIME
HCI/acetaminophen	
dextromethorphan HBr/pseudoephedrine	Daytime Cold and Flu Relief
HCI/acetaminophen	
dextromethorphan/phenylephrine/acetaminophen	HerbioMed Deep Cold-FluNight
/diphenhydramine	
dextromethorphan/phenylephrine/acetaminophen	Multi-Symptom SevereCold-Nt
/diphenhydramine	
dextromethorphan/pseudoephrine	Alka-Seltzer Plus Cold+Flu
HCl/acetaminophen/doxylamine	
dextromethorphan/pseudoephrine	Night Time Cold Medicine
HCl/acetaminophen/doxylamine	
dextromethorphan/pseudoephrine	Night Time Cold-Flu
HCl/acetaminophen/doxylamine	
dextromethorphan/pseudoephrine	Night Time Cold-Flu Relief
HCl/acetaminophen/doxylamine	
dextromethorphan/pseudoephrine	Nite Time
HCl/acetaminophen/doxylamine	
diclofenac sodium	diclofenac sodium



diphenhydramine HCl         Alka-Settzer Plus Allergy           diphenhydramine HCl         Aller-G-Time           diphenhydramine HCl         Allergy (diphenhydramine)           diphenhydramine HCl         Allergy Medicine           diphenhydramine HCl         Allergy Medicine           diphenhydramine HCl         Allergy Medicine           diphenhydramine HCl         Allergy Medicine           diphenhydramine HCl         Banophen           diphenhydramine HCl         Banophen           diphenhydramine HCl         Benadryl           diphenhydramine HCl         Child Allergy Relief (diphenhydramine)           diphenhydramine HCl         Children's Allergy (diphenhydramine)           diphenhydramine HCl         Children's Allergy (diphenhydramine)           diphenhydramine HCl         Children's Allergy Medicine           diphenhydramine HCl         Children's Wal-Dryl Allergy           diphenhydramine HCl         Complete Allergy Medicine           diphenhydramine HCl         Diphedryl           diphenhydramine HCl </th <th>Generic Name</th> <th>Brand Name</th>	Generic Name	Brand Name
diphenhydramine HClAllergydiphenhydramine HClAllergy (diphenhydramine)diphenhydramine HClAllergy Medicationdiphenhydramine HClAllergy Medicationdiphenhydramine HClBanophendiphenhydramine HClBanophen Allergydiphenhydramine HClBenadryldiphenhydramine HClBenadryl Allergydiphenhydramine HClChild Allergy Relief (diphen)diphenhydramine HClChild Carls' Allergy (diphenhyd)diphenhydramine HClChild Carls' Allergy Medicinediphenhydramine HClChildran's Allergy Medicinediphenhydramine HClChildran's Allergy Medicinediphenhydramine HClChildran's Diphenhydraminediphenhydramine HClChildran's Benadryl Allergydiphenhydramine HClComplete Allergy Medicinediphenhydramine HClComplete Allergydiphenhydramine HClComplete Allergydiphenhydramine HClDiphendiphenhydramine HClDiphendiphenhydramine HClDiphendiphenhydramine HClDiphendiphenhydramine HClDiphendiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryl	diphenhydramine HCl	Alka-Seltzer Plus Allergy
diphenhydramine HCIAllergy (diphenhydramine)diphenhydramine HCIAllergy Medicinediphenhydramine HCIBanophendiphenhydramine HCIBanophen Allergydiphenhydramine HCIBanophen Allergydiphenhydramine HCIBenadryldiphenhydramine HCIBenadryldiphenhydramine HCIChild Allergy Relief (diphen)diphenhydramine HCIChild Carl's Allergy (diphenhyd)diphenhydramine HCIChild Carl's Allergy (diphenhyd)diphenhydramine HCIChild Carl's Allergy (diphenhyd)diphenhydramine HCIChild Carl's Sheph Medicinediphenhydramine HCIChild Carl's Sheph Medicinediphenhydramine HCIChild Carl's Sheph Medicinediphenhydramine HCIChild Carl's Sheph Medicinediphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIDiphenhydraminediphenhydramine HCIDiphenhydraminediphenhydramine HCIComplete Allergydiphenhydramine HCIMedi-Phedryldiphenhydramine HCIMedi-Phedryldi	diphenhydramine HCl	Aller-G-Time
diphenhydramine HCIAllergy Medicationdiphenhydramine HCIAllergy Medicinediphenhydramine HCIBanophendiphenhydramine HCIBanophendiphenhydramine HCIBanophendiphenhydramine HCIBenadryl Allergydiphenhydramine HCIChildren's Allergy (diphenhydramine HCIdiphenhydramine HCIChildren's Allergy (diphenhydramine HCIdiphenhydramine HCIChildren's Allergy (diphenhydramine HCIdiphenhydramine HCIChildren's Allergy (diphenhydramine HCIdiphenhydramine HCIChildren's Allergy Medicinediphenhydramine HCIChildren's Diphenhydraminediphenhydramine HCIChildren's Diphenhydraminediphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIDiphendiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIBarentydiphenhydramine HCIBarentydiphenhydramine HCIBarentydiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCIQuealindiphenhydramine HCIQuealindiphenhydramine HCIQuealindiphenhydramine HCIQuealindiphenhydramine HCIQuealindiphenhydr	diphenhydramine HCl	Allergy
diphenhydramine HCIAllergy Relicf(diphenhydramin)diphenhydramine HCIBanophendiphenhydramine HCIBanophen Allergydiphenhydramine HCIBenadryldiphenhydramine HCIBenadryl Allergydiphenhydramine HCIChildren's Allergy Medicinediphenhydramine HCIChildren's Malergy Medicinediphenhydramine HCIChildren's Malergy Medicinediphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIDiphendiphenhydramine HCIDiphendiphenhydramine HCIDiphenhitdiphenhydramine HCIMaramindiphenhydramine HCIMaramin	diphenhydramine HCl	Allergy (diphenhydramine)
diphenhydramine HClAllergyRelief(diphenhydramin)diphenhydramine HClBanophen Allergydiphenhydramine HClBenadryldiphenhydramine HClChildren's Allergy (diphenhydldiphenhydramine HClChildren's Allergy (diphenhydl)diphenhydramine HClChildren's Allergy (diphenhydl)diphenhydramine HClChildren's Allergy Medicinediphenhydramine HClChildren's Allergy Medicinediphenhydramine HClChildren's Diphenhydraminediphenhydramine HClChildren's Val-Dryl Allergydiphenhydramine HClComplete Allergy Medicinediphenhydramine HClComplete Allergydiphenhydramine HClComplete Allergy Medicinediphenhydramine HClDiphedryldiphenhydramine HClDiphedryldiphenhydramine HClDiphedryldiphenhydramine HClDiphedryldiphenhydramine HClDiphedryldiphenhydramine HClDiphedryldiphenhydramine HClBeriter Nettorediphenhydramine HClBeriter Nettorediphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine	diphenhydramine HCl	Allergy Medication
diphenhydramine HClBanophendiphenhydramine HClBenadryldiphenhydramine HClBenadryl Allergydiphenhydramine HClChild Allergy Relief (diphen)diphenhydramine HClChildren's Sallergy Medicinediphenhydramine HClChildren's Allergy Medicinediphenhydramine HClChildren's Allergy Medicinediphenhydramine HClChildren's Sallergy Medicinediphenhydramine HClChildren's Diphenhydraminediphenhydramine HClChildren's Diphenhydraminediphenhydramine HClComplete Allergydiphenhydramine HClComplete Allergy Medicinediphenhydramine HClComplete Allergy Medicinediphenhydramine HClCompozdiphenhydramine HClDiphedryldiphenhydramine HClDiphenhyldiphenhydramine HClDiphenhyldiphenhydramine HClDiphenhyldiphenhydramine HClDiphenhyldiphenhydramine HClDiphenhyldiphenhydramine HClDiphenhyldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClGuenalindiphenhydramine HClGuenalindiphenhydramine HClGue	diphenhydramine HCl	Allergy Medicine
diphenhydramine HClBanophen Allergydiphenhydramine HClBenadryl Allergydiphenhydramine HClChild Allergy Relief (diphen)diphenhydramine HClChild Allergy Relief (diphen)diphenhydramine HClChildren's Allergy (diphenhyd)diphenhydramine HClChildren's Diphenhydraminediphenhydramine HClChildren's Sul-Cryl Allergydiphenhydramine HClComplet Allergydiphenhydramine HClCompotdiphenhydramine HClDiphenhydraminediphenhydramine HClDiphenhydraminediphenhydramine HClSelep Allergydiphenhydramine HClSelep Allergydiphenhydramine HClNarmindiphenhydramine HClNarmindiphenhydramine HClNarmindiphenhydramine HClNightTime Sleep Ald (diphen)diphenhydramine HClOrmirdiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClSelep Ald Mas Str(diphenhydramine HCldiphenhydramine HClSleep Ald Mas Str(diphenhydramine HCldiphenhydramine HClSleep Ald Mas Str	diphenhydramine HCl	AllergyRelief(diphenhydramin)
diphenhydramine HClBenadryl Allergydiphenhydramine HClBenadryl Allergy Relief (diphen)diphenhydramine HClChildren's Allergy Melicinediphenhydramine HClChildren's Allergy Melicinediphenhydramine HClChildren's Diphenhydraminediphenhydramine HClChildren's Diphenhydraminediphenhydramine HClChildren's Diphenhydraminediphenhydramine HClComplete Allergydiphenhydramine HClComplete Allergy Medicinediphenhydramine HClComplete Allergy Medicinediphenhydramine HClComplete Allergy Medicinediphenhydramine HClComplete Allergydiphenhydramine HClDiphenhydraminediphenhydramine HClSeperationdiphenhydramine HClSeperationdiphenhydramine HClBiphenhydramine HCldiphenhydramine HClSeperationdiphenhydramine HClSeperationdiphenhydramine HClNarmindiphenhydramine HClNarmindiphenhydramine HClNarmindiphenhydramine HClNightTime Sleep Ad (diphen)diphenhydramine HClOrmirdiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClSep Simply NightTime Sleep Addiphenhydramine HClSleep Today Sadiphenhydramine HClSleep Ad Max Str(diphenhydramine HCldiphenhydra	diphenhydramine HCl	Banophen
diphenhydramine HCIBenadryl Allergydiphenhydramine HCIChild Allergy Relief (diphenh)diphenhydramine HCIChildren's Allergy Medicinediphenhydramine HCIChildren's Benadryl Allergydiphenhydramine HCIChildren's Benadryl Allergydiphenhydramine HCIChildren's Diphenhydraminediphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIDiphendiphenhydramine HCIBiphendiphenhydramine HCIDiphedryldiphenhydramine HCIBiphendiphenhydramine HCIBiphendiphenhydramine HCIBiphendiphenhydramine HCIMedi-Phedryldiphenhydramine HCIMedi-Phedryldiphenhydramine HCINightTime Sleep Ald (diphen)diphenhydramine HCINightTime Sleep Ald (diphen)diphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCISiladry Sadiphenhydramine HCISiladry Sadiphenhydramine HCISiladry Sadiphenhydramine HCISiladry Sadiphenhydramine HCISiladry Sadiphenhydramine HCISiladry Sadiphenhydramine HCISiladry Sadi	diphenhydramine HCl	Banophen Allergy
diphenhydramine HCIChild Ailergy Relief (diphen)diphenhydramine HCIChildren's Allergy (diphenhyd)diphenhydramine HCIChildren's Allergy (bedicinediphenhydramine HCIChildren's Benadryl Allergydiphenhydramine HCIChildren's Wal-Dryl Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIBiphenhydramine HCIdiphenhydramine HCIBiphenhydramine HCIdiphenhydramine HCIMedi-Phedryldiphenhydramine HCIMedi-Phedryldiphenhydramine HCINaramindiphenhydramine HCINightTime Sleep Aid (diphen)diphenhydramine HCIOrmirdiphenhydramine HCIOrmirdiphenhydramine HCIOrmirdiphenhydramine HCIOrmirdiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCISleep Coughdiphenhydramine HCISleep Coughdiphenhydramine HCISleep Coughdiphenhydramine HCISleep Coughdiphenhydramine HCISleep Coughdiphenhydramine HCISleep Coughdiphenhydramine HCISleep All (diphenhydramine HCIdiphenhydramine HCISleep	diphenhydramine HCl	Benadryl
diphenhydramine HCIChildren's Allergy (diphenhyd)diphenhydramine HCIChildren's Allergy Medicinediphenhydramine HCIChildren's Diphenhydraminediphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIBiphenhydramine HCIdiphenhydramine HCIGerl-Dryldiphenhydramine HCINaramindiphenhydramine HCINightTime Sleep Aid (diphen)diphenhydramine HCINightTime Sleep Aid (diphen)diphenhydramine HCIOrmirdiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCISiladryl Sleepdiphenhydramine HCISiladryl Sleep <trr></trr>	diphenhydramine HCl	Benadryl Allergy
diphenhydramine HCIChildren's Allergy Medicinediphenhydramine HCIChildren's Benadryl Allergydiphenhydramine HCIChildren's Wal-Dryl Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIDiphedryldiphenhydramine HCIDiphenfyldiphenhydramine HCIDiphenhydramine HCIdiphenhydramine HCIDiphenhydramine HCIdiphenhydramine HCIDiphenhydramine HCIdiphenhydramine HCIBiphenhydramine HCIdiphenhydramine HCIGeri-Dryldiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINightTime Sleep Ald (diphen)diphenhydramine HCINightTime Sleep Ald (diphen)diphenhydramine HCIOrmirdiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCISliadryl SAdiphenhydramine HCISliadryl SAdiphenhydramine HCISliadryl SAdiphenhydramine HCISliadryl SAdiphenhydramine HCISliadryl SAdiphenhydramine HCISliadryl SAdiphenhydramine HCISleepdiphenhydramine HCISleepdiphenhydramine HCISleepdiphenhydramine HCISleepdiphenhydramine HCISleepdiphenhydr	diphenhydramine HCl	Child Allergy Relief (diphen)
diphenhydramine HCIChildren's Benadryl Allergydiphenhydramine HCIChildren's Diphenhydraminediphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIComplete Allergydiphenhydramine HCIDiphedryldiphenhydramine HCIDiphedryldiphenhydramine HCIDiphenhyldiphenhydramine HCIDiphenhyldiphenhydramine HCIDiphenhyldiphenhydramine HCIBiphenhyldiphenhydramine HCIBiphenhyldiphenhydramine HCIBiphenhyldiphenhydramine HCIMedi-Phedryldiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCISiladryl Sadiphenhydramine HCISiladryl Sa<	diphenhydramine HCl	Children's Allergy (diphenhyd)
diphenhydramine HCIChildren's Diphenhydraminediphenhydramine HCIComplete Allergy Medicinediphenhydramine HCIComplete Allergy Medicinediphenhydramine HCICompozediphenhydramine HCIDiphenhydramine HCIdiphenhydramine HCIDiphenhistdiphenhydramine HCIDiphenhistdiphenhydramine HCIEZ Nite Sleepdiphenhydramine HCIGeri-Dryldiphenhydramine HCIMedi-Phedryldiphenhydramine HCIMedi-Phedryldiphenhydramine HCIMarinediphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCINaramindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCISlady ISAdiphenhydramine HCISleep Aid (diphenhydramine)diphenhydramine HCISleep Aid (diphenhydramine)diphenhydramine HCISleep Aid (diphenhydramine)diphenhydramine HCISleep Aid (diphenhydramine)diphenhydramine HCISleep Aid (di	diphenhydramine HCl	Children's Allergy Medicine
diphenhydramine HClChildren's Wal-Dryl Allergydiphenhydramine HClComplete Allergydiphenhydramine HClComplete Allergy Medicinediphenhydramine HClDiphedryldiphenhydramine HClDiphedryldiphenhydramine HClDiphenhistdiphenhydramine HClEX Nite Sleepdiphenhydramine HClGeri-Dryldiphenhydramine HClMedi-Phedryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClNaramindiphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Ald (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQornyldiphenhydramine HClQornyldiphenhydramine HClSleep Ald (diphen)diphenhydramine HClSleep Ald (diphenhydramine)diphenhydramine HClSleep Tabsdiphenhydramine HClSleep Tabs	diphenhydramine HCl	Children's Benadryl Allergy
diphenhydramine HClComplete Allergydiphenhydramine HClCompozdiphenhydramine HClDiphedryldiphenhydramine HClDiphenhydramine HCldiphenhydramine HClDiphenhistdiphenhydramine HClEZ Nite Sleepdiphenhydramine HClGeri-Dryldiphenhydramine HClGeri-Dryldiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClSiladryl SAdiphenhydramine HCl <td>diphenhydramine HCl</td> <td>Children's Diphenhydramine</td>	diphenhydramine HCl	Children's Diphenhydramine
diphenhydramine HCIComplete Allergy Medicinediphenhydramine HCICompozdiphenhydramine HCIDiphenlydiphenhydramine HCIDiphenhistdiphenhydramine HCIEZ Nite Sleepdiphenhydramine HCIGeri-Dryldiphenhydramine HCIMedi-Phedryldiphenhydramine HCINaramindiphenhydramine HCINightTime Sleep Aid (diphen)diphenhydramine HCINightTime Sleep Aid (diphen)diphenhydramine HCIOrmirdiphenhydramine HCIQormirdiphenhydramine HCIQormirdiphenhydramine HCIQormirdiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCISilbyl Nighttime Sleepdiphenhydramine HCISilbyl Night Sleepdiphenhydramine HCISilbyl Night Sleepdiphenhydramine HCISleep Aid (diphenhydramine)diphenhydramine HCISleep Aid Max Str(diphenhydramine)diphenhydramine HCISleep Aid Max Str(diphenhydramine)diphenhydramine HCISleep Timediphenhydramine HCISleep Timediphenhydramine HCISleep Timediphenhydramine HCISleep Timediphenhydramine HCISleep Timediphen	diphenhydramine HCl	Children's Wal-Dryl Allergy
diphenhydramine HClCompozdiphenhydramine HClDiphedryldiphenhydramine HClDiphenhistdiphenhydramine HClEZ Nite Sleepdiphenhydramine HClGeri-Dryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClNightTime Allergy Reliefdiphenhydramine HClOrmirdiphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClSleep Aid (diphen)diphenhydramine HClSleep Aid (diphen)diphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClSleep Aid (diphen)diphenhydramine HClSleep Aid (diphen)diphenhydramine HClSleep Aid (diphen)diphenhydramine HClSleep Aid (diphen)diphenhydramine HClSiladryl SAdiphenhydramine HClSiladryl SAdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timedi	diphenhydramine HCl	Complete Allergy
diphenhydramine HClDiphedryldiphenhydramine HClDiphendiphenhydramine HClDiphenhistdiphenhydramine HClEZ Nite Sleepdiphenhydramine HClGeri-Dryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhyd	diphenhydramine HCl	Complete Allergy Medicine
diphenhydramine HClDiphendiphenhydramine HClDiphenhistdiphenhydramine HClEZ Nite Sleepdiphenhydramine HClGeri-Dryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQuenalinediphenhydramine HClQuenalinediphenhydramine HClQuenalinediphenhydramine HClSleep Aid (diphen)diphenhydramine HClSiladryl SAdiphenhydramine HClSleep Idiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydramine)diphenhydramine HClSleep I IIdiphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenh	diphenhydramine HCl	Compoz
diphenhydramine HClDiphenhistdiphenhydramine HClEZ Nite Sleepdiphenhydramine HClGeri-Dryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQuenlindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSiladryl SAdiphenhydramine HClSiladryl SAdiphenhydramine HClSilepen Coughdiphenhydramine HClSilepen Coughdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSl	diphenhydramine HCl	Diphedryl
diphenhydramine HClEZ Nite Sleepdiphenhydramine HClGeri-Dryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClSiladryl SAdiphenhydramine HClSiladryl SAdiphenhydramine HClSilepen Coughdiphenhydramine HClSleep Aid (diphenhydramine HCldiphenhydramine HClSilep Coughdiphenhydramine HClSilep Coughdiphenhydramine HClSilep Coughdiphenhydramine HClSleep Aid (diphenhydramine HCldiphenhydramine HClSleep Aid (diphenhydramine HCldiphenhydramine HClSleep Aid (diphenhydramine HCldiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine	diphenhydramine HCl	Diphen
diphenhydramine HClGeri-Dryldiphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClSildaryl SAdiphenhydramine HClSileep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydram	diphenhydramine HCl	Diphenhist
diphenhydramine HClMedi-Phedryldiphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClOrmirdiphenhydramine HClOrmirdiphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (Max Str(diphenhydr)diphenhydramine HClSleep Timediphenhydramine HClSleep T	diphenhydramine HCl	EZ Nite Sleep
diphenhydramine HClNaramindiphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClNighttime Allergy Reliefdiphenhydramine HClOrmirdiphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSiladryl SAdiphenhydramine HClSilphen Coughdiphenhydramine HClSilphen Coughdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Time<	diphenhydramine HCl	Geri-Dryl
diphenhydramine HClNightTime Sleep Aid (diphen)diphenhydramine HClNighttime Allergy Reliefdiphenhydramine HClOrmirdiphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSiladryl SAdiphenhydramine HClSimply Sleepdiphenhydramine HClSimply Sleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (Max Str(diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Time </td <td>diphenhydramine HCl</td> <td>Medi-Phedryl</td>	diphenhydramine HCl	Medi-Phedryl
diphenhydramine HCINighttime Allergy Reliefdiphenhydramine HCIOrmirdiphenhydramine HCIPharbedryldiphenhydramine HCIQuenalindiphenhydramine HCIQuenalindiphenhydramine HCIRest Simply Nighttime Sleepdiphenhydramine HCISiladryl SAdiphenhydramine HCISiladryl SAdiphenhydramine HCISilphen Coughdiphenhydramine HCISilepdiphenhydramine HCISleepdiphenhydramine HCISleepdiphenhydramine HCISleepdiphenhydramine HCISleepdiphenhydramine HCISleep Aid (diphenhydramine)diphenhydramine HCISleep Aid (diphenhydramine)diphenhydramine HCISleep IIdiphenhydramine HCISleep Timediphenhydramine HCISleep Timediphenhydramine HCISleep Timediphenhydramine HCISleep Timediphenhydramine HCISleep Time	diphenhydramine HCl	Naramin
diphenhydramine HClOrmirdiphenhydramine HClPharbedryldiphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClRestfully Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSimply Sleepdiphenhydramine HClSimply Sleepdiphenhydramine HClSimply Sleepdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Tabsdiphenhydramine HClSleep Tabs	diphenhydramine HCl	NightTime Sleep Aid (diphen)
diphenhydramine HClPharbedryldiphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClSildryl Sleepdiphenhydramine HClSildryl SAdiphenhydramine HClSilphen Coughdiphenhydramine HClSimply Sleepdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Time	diphenhydramine HCl	Nighttime Allergy Relief
diphenhydramine HClQ-Dryldiphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClRestfully Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSilphen Coughdiphenhydramine HClSimply Sleepdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Time	diphenhydramine HCl	Ormir
diphenhydramine HClQuenalindiphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClRestfully Sleepdiphenhydramine HClSilddryl SAdiphenhydramine HClSilphen Coughdiphenhydramine HClSimply Sleepdiphenhydramine HClSleepdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep Time	diphenhydramine HCl	Pharbedryl
diphenhydramine HClRest Simply Nighttime Sleepdiphenhydramine HClRestfully Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSimply Sleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Timediphenhydramine HClSleep Time	diphenhydramine HCl	Q-Dryl
diphenhydramine HClRestfully Sleepdiphenhydramine HClSiladryl SAdiphenhydramine HClSilphen Coughdiphenhydramine HClSimply Sleepdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Tabsdiphenhydramine HClSleep Tabs	diphenhydramine HCl	Quenalin
diphenhydramine HClSiladryl SAdiphenhydramine HClSilphen Coughdiphenhydramine HClSimply Sleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep Time	diphenhydramine HCl	Rest Simply Nighttime Sleep
diphenhydramine HClSilphen Coughdiphenhydramine HClSimply Sleepdiphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep Time	diphenhydramine HCl	Restfully Sleep
diphenhydramine HClSimply Sleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep Time	diphenhydramine HCl	Siladryl SA
diphenhydramine HClSleepdiphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Timediphenhydramine HClSleep Tabsdiphenhydramine HClSleep Tabs	diphenhydramine HCl	Silphen Cough
diphenhydramine HClSleep Aid (diphenhydramine)diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep-Tabsdiphenhydramine HClSleeping	diphenhydramine HCl	Simply Sleep
diphenhydramine HClSleep Aid Max Str(diphenhydr)diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep-Tabsdiphenhydramine HClSleeping	diphenhydramine HCl	Sleep
diphenhydramine HClSleep IIdiphenhydramine HClSleep Timediphenhydramine HClSleep-Tabsdiphenhydramine HClSleeping	diphenhydramine HCl	Sleep Aid (diphenhydramine)
diphenhydramine HClSleep Timediphenhydramine HClSleep-Tabsdiphenhydramine HClSleeping	diphenhydramine HCl	Sleep Aid Max Str(diphenhydr)
diphenhydramine HClSleep-Tabsdiphenhydramine HClSleeping	diphenhydramine HCl	Sleep II
diphenhydramine HCl Sleeping	diphenhydramine HCl	Sleep Time
	diphenhydramine HCl	Sleep-Tabs
diphenhydramine HCl Total Allergy Medicine	diphenhydramine HCl	Sleeping
	diphenhydramine HCl	Total Allergy Medicine



Generic Name	Brand Name
diphenhydramine HCl	Unisom SleepGels
diphenhydramine HCl	Unisom SleepMelts
diphenhydramine HCl	Valu-Dryl Allergy
diphenhydramine HCl	Vanamine PD
diphenhydramine HCl	Vicks QlearQuil Nighttime Rlf
diphenhydramine HCl	Wal-Dryl Allergy
diphenhydramine HCl	Wal-Sleep Z
diphenhydramine HCl	Wal-Som (diphenhydramine)
diphenhydramine HCl	Z-Sleep
diphenhydramine HCl	ZzzQuil
diphenhydramine HCl	diphenhydramine HCl
diphenhydramine HCl in 0.9 % sodium chloride	diphenhydramine-0.9 %sod.chlr
diphenhydramine HCl/hydrocortisone	HC Derma-Pax
diphenhydramine HCl/phenylephrine	Adult Robitussin Night M-SCld
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Allergy M-S Nighttime
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Allergy Plus Severe Sinus HA
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Allergy Sinus Headache (PE)
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Allergy and Cold PE
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Child Delsym Cough+Cold
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Children Dimetapp M-SCold-Flu
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Children's Mucinex NightTime
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Cold and FluRelief(diphen-pe)
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Cough and Severe Cold
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Delsym Cough-ColdNightTime
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Flu Relief Therapy Nighttime
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Flu and Sore Throat Relief
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Flu-Severe Cold-Cough Night
HCI/acetaminophen	Use de la mais de Alla verse Calific de
diphenhydramine HCl/phenylephrine	Herbiomed Allergy Cold-Sinus
HCI/acetaminophen	Musiney Fast May NiteCold Fly
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Fast-Max NiteCold-Flu
i cyacetallillopileli	



Generic Name	Brand Name
diphenhydramine HCl/phenylephrine	Mucinex Sinus-Max NiteCongest
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Severe Allergy-SinusHeadache
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Severe Cold Cough-Flu
HCl/acetaminophen	-
diphenhydramine HCl/phenylephrine	Severe Cold PE
HCl/acetaminophen	
diphenhydramine HCI/phenylephrine	Theraflu ExpressMax ColdNight
HCl/acetaminophen	
diphenhydramine HCl/phenylephrine	Theraflu Night SevereCold-Cgh
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Theraflu Nighttime PowerPod
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Wal-Dryl Severe Allergy-Sinus
HCI/acetaminophen	
diphenhydramine HCl/phenylephrine	Wal-Flu Severe Cold andCough
HCI/acetaminophen	Wal abod BE Sovera Cald
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-phed PE Severe Cold
diphenhydramine HCl/phenylephrine	Child Cold-Cough Day-Night
HCI/dextromethorphan HBr	child cold-cough bay Night
diphenhydramine	Sinus Relief Max StrDay-Night
HCl/phenylephrine/acetaminophen/guaifenesin	
diphenhydramine/phenylephrin/dextromethorph	Children's M-S ColdDay-Night
/acetaminophen/GG	, 3
diphenhydramine/phenylephrin/dextromethorph	Daytime-ColdNighttime-Cld-Flu
/acetaminophen/GG	
diphenhydramine/phenylephrin/dextromethorph	Mucinex Fast-Max Day-NiteCold
/acetaminophen/GG	
diphenhydramine/phenylephrin/dextromethorph	Mucinex Fast-Max Day-NiteCong
/acetaminophen/GG	
doxylamine succ/pseudoephedrine	Glentuss
HCl/dextromethorphan Hbr	
doxylamine succ/pseudoephedrine	Lortuss DM
HCI/dextromethorphan Hbr	
doxylamine succinate/phenylephrine HCl	Poly Hist Forte
doxylamine succinate/phenylephrine HCl	Poly Hist Forte (doxylamine)
doxylamine succinate/phenylephrine HCl	doxylamine-phenylephrine
doxylamine succinate/pseudoephedrine HCl	Lortuss LQ
doxylamine/phenylephrine/dextromethorphan /acetaminophen/GG	Day-Nite Severe Cold-Flu
doxylamine/phenylephrine/dextromethorphan	Mucinex Fast-MaxDay-Nt(doxyl)
/acetaminophen/GG	ινιασητέλ τα στηνιαλισαγηνιζιασλύμ



ieneric Name	Brand Name	
oxylamine/phenylephrine/dextromethorphan	Mucinex Sinus-Max Dy-Nt(dxyl)	
acetaminophen/GG		
oxylamine/phenylephrine/dextromethorphan	Severe Cold andFlu(Day/Night)	
acetaminophen/GG		
upilumab	Dupixent	
yphylline	Lufyllin	
yphylline	dyphylline (bulk)	
medastine difumarate	Emadine	
phedrine sulfate	ephedrine sulfate	
phedrine sulfate/guaifenesin	Bronkaid Dual Action	
pinastine HCl	Elestat	
pinastine HCl	epinastine	
pinephrine	Adrenaclick	
pinephrine	Adrenalin	
pinephrine	Adyphren	
pinephrine	Adyphren Amp	
pinephrine	Adyphren Amp II	
pinephrine	Adyphren II	
pinephrine	Auvi-Q	
pinephrine	Bronchial Mist	
pinephrine	Bronchial Mist Refill	
pinephrine	EPIsnap	
pinephrine	EpiPen	
pinephrine	EpiPen 2-Pak	
pinephrine	EpiPen Jr	
pinephrine	EpiPen Jr 2-Pak	
pinephrine	EpinephrineSnap-EMS	
pinephrine	EpinephrineSnap-V	
pinephrine	Epy	
pinephrine	Primatene Mist	
pinephrine	Symjepi	
pinephrine	epinephrine	
pinephrine HCl/PF	epinephrine HCl (PF)	
exofenadine HCl	Allegra Allergy	
exofenadine HCl	Aller-Fex	
exofenadine HCl	Aller-ease	
exofenadine HCl	Allergy Relief (fexofenadine)	
exofenadine HCl	Children's Allegra Allergy	
exofenadine HCl	Children's Allergy Relief(fex)	
exofenadine HCl	Children's Wal-Fex	
exofenadine HCl	Mucinex Allergy	
exofenadine HCl	Wal-Fex Allergy	
exofenadine HCl	fexofenadine	
exofenadine HCl	fexofenadine (bulk)	
exofenadine HCl/pseudoephedrine HCl	Allegra-D 12 Hour	



Generic Name	Brand Name
fexofenadine HCl/pseudoephedrine HCl	Allergy Relief D
fexofenadine HCl/pseudoephedrine HCl	Allergy Relief-D(fexofenadine)
fexofenadine HCl/pseudoephedrine HCl	Allergy-CongestRelief-D(fexo)
fexofenadine HCl/pseudoephedrine HCl	Wal-Fex D 12 Hour
fexofenadine HCl/pseudoephedrine HCl	Wal-Fex D 24 Hour
fexofenadine HCI/pseudoephedrine HCI	fexofenadine-pseudoephedrine
fludrocortisone acetate	fludrocortisone
flunisolide	Aerospan
flunisolide	flunisolide
fluocinolone acetonide/emollient combination	Synalar Cream Kit
no.65	
fluocinolone acetonide/emollient combination	Synalar Ointment Kit
no.65	
fluocinolone acetonide/skin cleanser comb no.28	Synalar TS
fluocinolone acetonide/skin cleanser	Xilapak
no.10/silicone, tape	
fluocinolone acetonide/urea/silicone, adhesive	Noxipak
flurbiprofen	flurbiprofen
fluticasone furoate	Arnuity Ellipta
fluticasone furoate	Children's Flonase Sensimist
fluticasone furoate	Flonase Sensimist
fluticasone furoate	Veramyst
fluticasone furoate/umeclidinium bromide/vilanterol trifenat	Trelegy Ellipta
fluticasone furoate/vilanterol trifenatate	Breo Ellipta
fluticasone propionate	24 Hour Allergy Relief
fluticasone propionate	Aller-Flo
fluticasone propionate	Allergy Relief (fluticasone)
fluticasone propionate	ArmonAir RespiClick
fluticasone propionate	Children's Flonase Allergy Rlf
fluticasone propionate	Childrens 24 Hr Allergy Relief
fluticasone propionate	ClariSpray
fluticasone propionate	Flonase
fluticasone propionate	Flonase Allergy Relief
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA
fluticasone propionate	Xhance
fluticasone propionate	fluticasone propionate fluticasone propionate (bulk)
fluticasone propionate	fluticasone prop, micro (bulk)
fluticasone propionate, micronized fluticasone propionate/emollient combination	Beser Kit
no.65	
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Advair HFA
fluticasone propionate/salmeterol xinafoate	AirDuo RespiClick
fluticasone propionate/salmeterol xinafoate	Wixela Inhub



Generic Name	Brand Name
luticasone propionate/salmeterol xinafoate	fluticasone propion-salmeterol
luticasone propionate/sodium chloride/sodium	Ticanase
picarbonate	
luticasone propionate/sodium chloride/sodium	Ticaspray
picarbonate	
ormoterol fumarate	Foradil Aerolizer
ormoterol fumarate	Perforomist
ormoterol fumarate	formoterol fumarate (bulk)
ormoterol fumarate dihydrate, micronized	formoterol fum dihyd,mic(bulk)
glycopyrrolate	Seebri Neohaler
glycopyrrolate/formoterol fumarate	Bevespi Aerosphere
glycopyrrolate/nebulizer accessories	Lonhala Magnair Refill
glycopyrrolate/nebulizer and accessories	Lonhala Magnair Starter
guaifenesin/acetaminophen	Chest Congestion
guaifenesin/dextromethorphan HBr	Adt Robitussin Peak Cld DMMax
guaifenesin/dextromethorphan HBr	Adult Cough Formula DM Max
guaifenesin/dextromethorphan HBr	Adult Robitussin Peak ColdDM
guaifenesin/dextromethorphan HBr	Adult Tussin Cough CongestDM
guaifenesin/dextromethorphan HBr	Adult Tussin DM
guaifenesin/dextromethorphan HBr	Adult Wal-Tussin DM Max
guaifenesin/dextromethorphan HBr	Allfen DM
guaifenesin/dextromethorphan HBr	Biocotron
guaifenesin/dextromethorphan HBr	Biospec DMX
guaifenesin/dextromethorphan HBr	Chest Congestion Relief DM
guaifenesin/dextromethorphan HBr	Chest Congestion-CoughRelief
guaifenesin/dextromethorphan HBr	Child ChestCongestion-Cough
guaifenesin/dextromethorphan HBr	Child Cough-Chest CongestDM
guaifenesin/dextromethorphan HBr	Child Delsym Cough+ChestDM
guaifenesin/dextromethorphan HBr	Child Mucinex CoughMini-Melts
guaifenesin/dextromethorphan HBr	Child Mucus Relief Cough
guaifenesin/dextromethorphan HBr	Child TriaminicCough-Congest
guaifenesin/dextromethorphan HBr	Children's Cough
guaifenesin/dextromethorphan HBr	Children's Mucinex Cough
guaifenesin/dextromethorphan HBr	Chld Robitussin Cough-ChestDM
guaifenesin/dextromethorphan HBr	Coricidin HBP ChestCong-Cough
guaifenesin/dextromethorphan HBr	Cough Control DM
guaifenesin/dextromethorphan HBr	Cough Control DM Max
guaifenesin/dextromethorphan HBr	CoughSuppressant-Expectorant
guaifenesin/dextromethorphan HBr	Cough Syrup DM
guaifenesin/dextromethorphan HBr	Cough-Chest Congestion DM
guaifenesin/dextromethorphan HBr	DM Max
guaifenesin/dextromethorphan HBr	Daytime Mucus Relief DM
guaifenesin/dextromethorphan HBr	Delsym Cough-ChestCongest DM
guaifenesin/dextromethorphan HBr	Diabetic Siltussin-DM
guaifenesin/dextromethorphan HBr	Diabetic Siltussin-DM Max Str
guaifenesin/dextromethorphan HBr	Diabetic Tussin DM



Generic Name	Brand Name
guaifenesin/dextromethorphan HBr	Diabetic Tussin Max St
guaifenesin/dextromethorphan HBr	Double-Tussin DM
guaifenesin/dextromethorphan HBr	Expectorant DM
guaifenesin/dextromethorphan HBr	Fenesin DM IR
guaifenesin/dextromethorphan HBr	G-Fenesin DM
guaifenesin/dextromethorphan HBr	G-Tron
guaifenesin/dextromethorphan HBr	G-Zyncof
guaifenesin/dextromethorphan HBr	Geri-Tussin DM
guaifenesin/dextromethorphan HBr	Guaiasorb DM
guaifenesin/dextromethorphan HBr	Guaicon DMS
guaifenesin/dextromethorphan HBr	Guaifenesin-DM
guaifenesin/dextromethorphan HBr	Intense Cough
guaifenesin/dextromethorphan HBr	Intense Cough Reliever
guaifenesin/dextromethorphan HBr	lophen DM-NR
guaifenesin/dextromethorphan HBr	Medi-Tussin DM
guaifenesin/dextromethorphan HBr	Medi-Tussin DM Diabetic
guaifenesin/dextromethorphan HBr	Mucinex DM
guaifenesin/dextromethorphan HBr	Mucinex Fast-Max DM Max
guaifenesin/dextromethorphan HBr	Mucosa DM
guaifenesin/dextromethorphan HBr	Mucus DM
uaifenesin/dextromethorphan HBr	Mucus DM Max ER
guaifenesin/dextromethorphan HBr	Mucus Relief Cough
guaifenesin/dextromethorphan HBr	Mucus Relief DM
guaifenesin/dextromethorphan HBr	Mucus Relief DM Cough
guaifenesin/dextromethorphan HBr	Mucus Relief DM Max
guaifenesin/dextromethorphan HBr	Mucus Relief ER DM-MAX
guaifenesin/dextromethorphan HBr	Mucus and Cough Relief
guaifenesin/dextromethorphan HBr	Neo-Tuss
guaifenesin/dextromethorphan HBr	Q-Tussin DM
guaifenesin/dextromethorphan HBr	Refenesen DM
guaifenesin/dextromethorphan HBr	Ri-Tussin DM
guaifenesin/dextromethorphan HBr	Robafen DM
guaifenesin/dextromethorphan HBr	Robafen DM Cough
guaifenesin/dextromethorphan HBr	Robafen DM Cough-ChestCongest
guaifenesin/dextromethorphan HBr	Robitussin Cough-ChestCong DM
guaifenesin/dextromethorphan HBr	Safe Tussin DM
guaifenesin/dextromethorphan HBr	Scot-Tussin Senior
guaifenesin/dextromethorphan HBr	Siltussin DM DAS
guaifenesin/dextromethorphan HBr	Siltussin-DM
guaifenesin/dextromethorphan HBr	Sorbugen NR
guaifenesin/dextromethorphan HBr	Supress DM
guaifenesin/dextromethorphan HBr	TRISPEC DMX
guaifenesin/dextromethorphan HBr	Tab Tussin DM
guaifenesin/dextromethorphan HBr	Tusnel Diabetic
guaifenesin/dextromethorphan HBr	Tussin Cough DM
guaifenesin/dextromethorphan HBr	Tussin Cough-ChestCongestion



Generic Name	Brand Name
guaifenesin/dextromethorphan HBr	Tussin DM
guaifenesin/dextromethorphan HBr	Tussin DM Clear
guaifenesin/dextromethorphan HBr	Tussin DM Cough
guaifenesin/dextromethorphan HBr	Tussin DM Cough and Chest
guaifenesin/dextromethorphan HBr	Tussin DM Max
guaifenesin/dextromethorphan HBr	Ultra DM Free and Clear
guaifenesin/dextromethorphan HBr	Ultra Tuss Safe
guaifenesin/dextromethorphan HBr	Wal-Tussin DM
guaifenesin/dextromethorphan HBr	Zyncof
guaifenesin/dextromethorphan HBr	dextromethorphan-guaifenesin
guaifenesin/dextromethorphan HBr/phenylephrine	Actidom DMX
guaifenesin/dextromethorphan HBr/phenylephrine	Adult Robitussin M-S Cold
guaifenesin/dextromethorphan HBr/phenylephrine	Adult Robitussin Peak ColdM-S
guaifenesin/dextromethorphan HBr/phenylephrine	Adult Tussin Multi-Symp Cold
guaifenesin/dextromethorphan HBr/phenylephrine	Altipres
guaifenesin/dextromethorphan HBr/phenylephrine	Altipres Pediatric
guaifenesin/dextromethorphan HBr/phenylephrine	Aquanaz
guaifenesin/dextromethorphan HBr/phenylephrine	Bio T Pres
guaifenesin/dextromethorphan HBr/phenylephrine	Bio T Pres Pediatric
guaifenesin/dextromethorphan HBr/phenylephrine	Bio-S-Pres Dx
guaifenesin/dextromethorphan HBr/phenylephrine	BioGtuss NF
guaifenesin/dextromethorphan HBr/phenylephrine	Biobron DX
guaifenesin/dextromethorphan HBr/phenylephrine	Biobron SF
guaifenesin/dextromethorphan HBr/phenylephrine	Biocotron-D
guaifenesin/dextromethorphan HBr/phenylephrine	Biodesp DM
guaifenesin/dextromethorphan HBr/phenylephrine	Biogil
guaifenesin/dextromethorphan HBr/phenylephrine	Broncotron PED
guaifenesin/dextromethorphan HBr/phenylephrine	Brontuss SF
guaifenesin/dextromethorphan HBr/phenylephrine	Child MucinexCongestion-Cough
guaifenesin/dextromethorphan HBr/phenylephrine	Child Multi-SymptomCold/Cough
guaifenesin/dextromethorphan HBr/phenylephrine	Child's Mucus Relief M-S Cold
guaifenesin/dextromethorphan HBr/phenylephrine	Children's MucinexMulti-Symp
guaifenesin/dextromethorphan HBr/phenylephrine	Cough Control CF (PE)
guaifenesin/dextromethorphan HBr/phenylephrine	Cough and Cold
guaifenesin/dextromethorphan HBr/phenylephrine	Cough and Cold Mucus ReliefCF
guaifenesin/dextromethorphan HBr/phenylephrine	Deconex DMX
guaifenesin/dextromethorphan HBr/phenylephrine	Desgen
guaifenesin/dextromethorphan HBr/phenylephrine	Desgen DM
guaifenesin/dextromethorphan HBr/phenylephrine	Despec DM-G
guaifenesin/dextromethorphan HBr/phenylephrine	Despec EDA Cough-ColdDrops
guaifenesin/dextromethorphan HBr/phenylephrine guaifenesin/dextromethorphan HBr/phenylephrine	Despec-DM(phenyleph-DM-guaif) Dometuss-DMX
guaifenesin/dextromethorphan HBr/phenylephrine	Duravent DM
guaifenesin/dextromethorphan HBr/phenylephine	Endacon
guaifenesin/dextromethorphan HBr/phenylephrine	Exactuss
guaifenesin/dextromethorphan HBr/phenylephrine	Exactuss TR
guarrenesin/ uextrometrior priari nor/prieriyiepinine	LAGUUSS IN



**Brand Name** 

Fast Mucus RlfCongest-Cough

#### **Generic Name**

guaifenesin/dextromethorphan HBr/phenylephrine guaifenesin/dextromethorphan HBr/potassium citrate

guaifenesin/dextromethorphan HBr/pseudoephedrine HCl guaifenesin/dextromethorphan HBr/pseudoephedrine HCl guaifenesin/dextromethorphan HBr/pseudoephedrine HCl guaifenesin/dextromethorphan HBr/pseudoephedrine HCl

**G-Supress DX G-Tron PED** G-Tusicof Giltuss **Giltuss Cough-Cold Giltuss Pediatric** Giltuss TR Maxiphen DM Mucinex Fast-MaxCongest-Cough Mucus ReliefCongestion-Cough NeoTuss-D (ImprovedFormula) Nivanex DMX Pres Gen Pres Gen Pediatric **Relhist DMX** Robafen CF (phenylephrine) Robitussin Cough and ColdCF Robitussin M-S Cold CF Max Severe Congestion and Cough Max Supress DX Tusicof **Tusnel DM** Tusnel DMPediatric(phenyleph) **Tussi-Pres Tussi-Pres Pediatric** Tussin CF (PE-DM-guaif) **Tussin CF Cough-Cold Tussin CF MAX** Tusslin VanaTab DM Vanacof DM Wal-Tussin Cough and ColdCF phenylephrine-DM-guaifenesin Sorbutuss Actinel

Ambi 40PSE-400GFN-20DM

**Actinel Pediatric** 

Bionel



Generic Name	Brand Name
guaifenesin/dextromethorphan	Bionel Pediatric
HBr/pseudoephedrine HCl	Constant DM
guaifenesin/dextromethorphan	Capmist DM
HBr/pseudoephedrine HCl	Descrete DM(seconds and seconds and seconds)
guaifenesin/dextromethorphan	Desgen DM(pseudoephedrine)
HBr/pseudoephedrine HCl	Decree DM(neeudeenh DM quait)
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Despec-DM(pseudoeph-DM-guaif)
guaifenesin/dextromethorphan	Entex PAC
HBr/pseudoephedrine HCl	Ellex PAC
guaifenesin/dextromethorphan	Entre-Cough
HBr/pseudoephedrine HCl	Little-Cough
guaifenesin/dextromethorphan	ExeFen DMX
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	Pecgen PSE
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	Poly-Vent DM
HBr/pseudoephedrine HCl	,
guaifenesin/dextromethorphan	Robafen CF
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	TRISPEC PSE
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	Tusnel DMPediatric(pseudoeph)
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	Tusnel New Formula
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	Tusnel Pediatric
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	Tussin CF
HBr/pseudoephedrine HCl	
guaifenesin/dextromethorphan	Z-Cof 12 DM
HBr/pseudoephedrine HCl	
guaifenesin/dyphylline	Difil-G 400
guaifenesin/ephedrine HCl	Primatene Asthma
guaifenesin/hydrocodone bitartrate	Flowtuss
guaifenesin/hydrocodone bitartrate	Obredon hydrogodono gyzifanosin
guaifenesin/hydrocodone bitartrate	hydrocodone-guaifenesin
guaifenesin/phenylephrine HCl guaifenesin/phenylephrine HCl	Chest Congestion Relief PE Chest-Sinus CongestionRelief
guaifenesin/phenylephrine HCl	Child Mucinex StuffyNose-Chst
guaifenesin/phenylephrine HCl	Child Mucinex StuffyNose-Cold
guaifenesin/phenylephrine HCl	Children's Stuffy Nose-Cold
guaifenesin/phenylephrine HCl	Congest-Eze PE
guaifenesin/phenylephrine HCl	Deconex IR
guaifenesin/phenylephrine HCl	Despec
0 /r - /-r	1 <sup>- 1</sup>



Generic Name	Brand Name
guaifenesin/phenylephrine HCl	Duravent PE
guaifenesin/phenylephrine HCl	ED Bron GP
guaifenesin/phenylephrine HCl	Entex LQ
guaifenesin/phenylephrine HCl	ExaPhex TR
guaifenesin/phenylephrine HCl	Fenesin PE IR
guaifenesin/phenylephrine HCl	Gilphex TR
guaifenesin/phenylephrine HCl	J-MAX
guaifenesin/phenylephrine HCl	Liquibid D-R
guaifenesin/phenylephrine HCl	Liquibid PD-R
guaifenesin/phenylephrine HCl	Maxiphen
guaifenesin/phenylephrine HCl	MucaphEd
guaifenesin/phenylephrine HCl	Mucus Relief D(phenylephrine)
guaifenesin/phenylephrine HCl	Mucus Relief PE
guaifenesin/phenylephrine HCl	Mucus Relief Sinus
guaifenesin/phenylephrine HCl	Refenesen PE
guaifenesin/phenylephrine HCl	RelCof IR
guaifenesin/phenylephrine HCl	Rescon-GG
guaifenesin/phenylephrine HCl	Supress-PE
guaifenesin/phenylephrine HCl	TL-DMX
guaifenesin/phenylephrine HCl/acetaminophen	Cold HeadCongest(gg-pe-acetm)
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Cold and Sinus
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Fast-Max Cold-Sinus
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Sinus-MaxPressur-Pain
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max SevCongestn
guaifenesin/phenylephrine HCl/acetaminophen	Mucus Relief Cold and Sinus
guaifenesin/phenylephrine HCl/acetaminophen	Mucus ReliefSinusPressur-Pain
guaifenesin/phenylephrine HCl/acetaminophen	Mucus Rlf Severe SinusCongest
guaifenesin/phenylephrine HCl/acetaminophen	Pressure-Pain PE Plus Mucus
guaifenesin/phenylephrine HCl/acetaminophen	Severe Congestion Relief
guaifenesin/phenylephrine HCl/acetaminophen	Severe Sinus
guaifenesin/phenylephrine HCl/acetaminophen	Sinus Congestion-Pain(guaif)
guaifenesin/phenylephrine HCl/acetaminophen	Sinus Relief Pressure and Pain
guaifenesin/phenylephrine HCl/acetaminophen	Sinus Relief SevereCongestion
guaifenesin/phenylephrine HCl/acetaminophen	Sudafed PEPressure-Pain-Mucus
guaifenesin/phenylephrine HCl/acetaminophen	Tylenol Cold Head CongestSevr
guaifenesin/phenylephrine HCl/acetaminophen	Tylenol Sinus CongestionPain
guaifenesin/phenylephrine HCl/acetaminophen	Tylenol Sinus Severe
guaifenesin/pseudoephedrine HCl	Ambi 60PSE-400GFN
guaifenesin/pseudoephedrine HCl	Chest Congestion Relief D
guaifenesin/pseudoephedrine HCl	Congest-Eze
guaifenesin/pseudoephedrine HCl	Congestac
guaifenesin/pseudoephedrine HCl	Despec-Tab
guaifenesin/pseudoephedrine HCl	Entex T
guaifenesin/pseudoephedrine HCl	ExeFen-IR
guaifenesin/pseudoephedrine HCl	Maxifed
guaifenesin/pseudoephedrine HCl	Mucinex D



Generic Name	Brand Name
guaifenesin/pseudoephedrine HCl	Mucinex D Maximum Strength
guaifenesin/pseudoephedrine HCl	Mucus D
guaifenesin/pseudoephedrine HCl	Mucus Relief D(pseudoephed)
guaifenesin/pseudoephedrine HCl	Poly-Vent IR
guaifenesin/pseudoephedrine HCl	Respaire-30
guaifenesin/pseudoephedrine HCl	Triacting Expectorant
guaifenesin/pseudoephedrine HCl	Tusnel Pediatric
guaifenesin/pseudoephedrine HCl	pseudoephedrine-guaifenesin
halobetasol propionate/ammonium lactate	Halonate
halobetasol propionate/ammonium lactate	Halonate Pac
halobetasol propionate/ammonium lactate	Ultravate PAC
halobetasol propionate/lactic acid	Ultravate X
hydrocodone bitartrate/chlorpheniramine maleate	Vituz
hydrocodone bitartrate/homatropine methylbromide	Hydrocodone Compound
hydrocodone bitartrate/homatropine methylbromide	Hydromet
hydrocodone bitartrate/homatropine methylbromide	Tussigon
hydrocodone bitartrate/homatropine methylbromide	hydrocodone-homatropine
hydrocodone bitartrate/pseudoephedrine HCl/guaifenesin	Hycofenix
hydrocodone polistirex/chlorpheniramine polistirex	TussiCaps
hydrocodone polistirex/chlorpheniramine polistirex	Tussionex Pennkinetic ER
hydrocodone polistirex/chlorpheniramine polistirex	hydrocodone-chlorpheniramine
hydrocortisone	Cortef
hydrocortisone	hydrocortisone
hydrocortisone acetate/aloe vera	Nucort
hydrocortisone acetate/aloe vera	hydrocortisone acet-aloe vera
hydrocortisone acetate/pramoxine HCl	Analpram-HC
hydrocortisone acetate/pramoxine HCl	Epifoam
hydrocortisone acetate/pramoxine HCl	Mezparox-HC
hydrocortisone acetate/pramoxine HCl	Novacort
hydrocortisone acetate/pramoxine HCl	Pramosone
hydrocortisone acetate/pramoxine HCl	hydrocortisone-pramoxine
hydrocortisone acetate/pramoxine HCl/aloe	Novacort (with aloe)
polysaccharide	
hydrocortisone acetate/pramoxine HCl/emollient base	Pramosone E
hydrocortisone acetate/urea	U-Cort
hydrocortisone sod succinate	A-Hydrocort
hydrocortisone sod succinate	Solu-Cortef
hydrocortisone sodium succinate/PF	Solu-Cortef Act-O-Vial (PF)
hydrocortisone/aloe vera	Anti-Itch(hydrocortisone)-Aloe



Generic Name	Brand Name
nydrocortisone/aloe vera	Cortisone with Aloe
nydrocortisone/aloe vera	Cortizone-10 with aloe
nydrocortisone/aloe vera	Hydrocortisone Plus
nydrocortisone/aloe vera	Hydroskin with Aloe
nydrocortisone/aloe vera	hydrocortisone-aloe vera
nydrocortisone/aloe vera/vitamin E	Anti-Itch (HC) with Aloe-Vit E
cetate/vitamins A and D	
nydrocortisone/aloe vera/vitamin E	Anti-Itch Plus
acetate/vitamins A and D	
hydrocortisone/emollient combination no.45	Pediaderm HC
nydrocortisone/mineral oil/petrolatum, white	hydrocortisone-min oil-wht pet
ydrocortisone/skin cleanser combination no.25	Aqua Glycolic HC
ydrocortisone/skin cleanser combination no.35	Dermasorb HC Complete Kit
buprofen	Addaprin
buprofen	Children's Ibu-Drops
buprofen	Children's Ibuprofen
buprofen	Ibuprofen IB
buprofen	Ibuprofen Jr Strength
buprofen	Infant's Ibuprofen
buprofen	Infants Ibu-Drops
buprofen	Medi-Profen
buprofen	Wal-Profen
buprofen	ibuprofen
buprofen/diphenhydramine HCl	lbuprofen PM
buprofen/diphenhydramine HCl	ibuprofen-diphenhydramineHCl
buprofen/diphenhydramine citrate	lbuprofen PM
buprofen/phenylephrine HCl	Advil Congestion Relief
buprofen/phenylephrine HCl	Congestion Relief(ibuprof-PE)
buprofen/pseudoephedrine HCl	Advil Cold and Sinus
puprofen/pseudoephedrine HCl	Cold and Sinus Pain Relief
buprofen/pseudoephedrine HCl	Cold-Sinus Relief
buprofen/pseudoephedrine HCl	Ibuprofen Cold
buprofen/pseudoephedrine HCl	Ibuprofen Cold-Sinus(withPSE)
buprofen/pseudoephedrine HCl	Wal-Profen Cold-Sinus
buprofen/pseudoephedrine HCl	Wal-Profen D Cold and Sinus
ndacaterol maleate	Arcapta Neohaler
ndacaterol maleate/glycopyrrolate	Utibron Neohaler
pratropium bromide	Atrovent HFA
pratropium bromide	ipratropium bromide
pratropium bromide/albuterol sulfate	Combivent Respimat
pratropium bromide/albuterol sulfate	DuoNeb
pratropium bromide/albuterol sulfate	ipratropium-albuterol
ketotifen fumarate	Alaway
xetotifen fumarate	Allergy Eye (ketotifen)
setotifen fumarate	Antihistamine Eye Drops
xetotifen fumarate	Children's Alaway



Conoris Namo	Prond Namo
Generic Name ketotifen fumarate	Brand Name Eye Itch Relief
ketotifen fumarate	-
ketotifen fumarate	ltchy Eye Drops Wal-Zyr (ketotifen)
ketotifen fumarate	Zaditor
ketotifen fumarate	ketotifen fumarate
levalbuterol HCl	Xopenex
levalbuterol HCl	Xopenex Concentrate
levalbuterol HCl	levalbuterol HCl
levalbuterol HCl	levalbuterol HCl (bulk)
levalbuterol tartrate	Xopenex HFA
levalbuterol tartrate	levalbuterol tartrate
levocetirizine dihydrochloride	24HR Allergy Relief
levocetirizine dihydrochloride	Xyzal
levocetirizine dihydrochloride	levocetirizine
levocetirizine dihydrochloride	levocetirizine (bulk)
lodoxamide tromethamine	Alomide
loratadine	Alavert
loratadine	Allerclear
loratadine	Allergy Relief (loratadine)
loratadine	Children's Allergy Relief(lor)
loratadine	Children's Claritin
loratadine	Children's Loratadine
loratadine	Claritin
loratadine	Claritin Liqui-Gel
loratadine	Claritin RediTabs
loratadine	Loradamed
loratadine	Non-Drowsy Allergy
loratadine	Vicks QlearQuil Allergy
loratadine	Wal-itin
loratadine	loratadine
loratadine	loratadine (bulk)
loratadine, micronized	loratadine, micronized (bulk)
loratadine/pseudoephedrine sulfate	Alavert D-12 Allergy-Sinus
loratadine/pseudoephedrine sulfate	AllerClear D-12hr
loratadine/pseudoephedrine sulfate	AllerClear D-24hr
loratadine/pseudoephedrine sulfate	Allergy Relief D-24hr
loratadine/pseudoephedrine sulfate	Allergy Relief D12
loratadine/pseudoephedrine sulfate	Allergy Relief, Nasal Decongest
loratadine/pseudoephedrine sulfate	Allergy Relief-D (loratadine)
loratadine/pseudoephedrine sulfate	Allergy and Congestion Relief
loratadine/pseudoephedrine sulfate	Allergy-Congestion Relief-D
loratadine/pseudoephedrine sulfate	Claritin-D 12 Hour
loratadine/pseudoephedrine sulfate	Claritin-D 24 Hour
loratadine/pseudoephedrine sulfate	Lorata-D
loratadine/pseudoephedrine sulfate	Loratadine-D
loratadine/pseudoephedrine sulfate	Wal-Itin D 12 Hour



Generic Name	Brand Name
oratadine/pseudoephedrine sulfate	Wal-itin D
oratadine/pseudoephedrine sulfate	lorata-dine D
oratadine/pseudoephedrine sulfate	loratadine-pseudoephedrine
neloxicam	Mobic
neloxicam	meloxicam
nepolizumab	Nucala
netaproterenol sulfate	metaproterenol
nethylprednisolone	Medrol
nethylprednisolone	Medrol (Pak)
nethylprednisolone	Methylpred DP
nethylprednisolone	methylprednisolone
nethylprednisolone acetate	Depo-Medrol
nethylprednisolone acetate	P-Care D40
nethylprednisolone acetate	P-Care D80
nethylprednisolone acetate	ReadySharpMethylprednisolone
nethylprednisolone acetate	methylprednisolone acetate
nethylprednisolone acetate in sodium	methylpredac(PF)-NaCl, iso-osm
hloride,iso-osmotic/PF	
nethylprednisolone acetate in sterile water for	methylprednisoloneacet-water
njection	
nethylprednisolone acetate/bupivacaine HCl	Physicians EZ Use M-Pred
nethylprednisolone acetate/bupivacaine HCl in	methylprednisolac-bupivac-wat
terile water	
nethylprednisolone acetate/norflurane/HFC 245fa	Medroloan II SUIK
nethylprednisolone acetate/norflurane/HFC 245fa	Medroloan SUIK
nethylprednisolone acetate/norflurane/HFC 245fa	P-Care D40G
nethylprednisolone acetate/norflurane/HFC 245fa	P-Care D80G
nethylprednisolone sodium succinate	Solu-Medrol
nethylprednisolone sodium succinate	methylprednisolone sodiumsucc
nethylprednisolone sodium succinate/PF	Solu-Medrol (PF)
nethylprednisolone, micronized	methylprednisolone, mic(bulk)
nometasone furoate	Asmanex HFA
nometasone furoate	Asmanex Twisthaler
nometasone furoate	Nasonex
nometasone furoate	mometasone
nometasone furoate	mometasone furoate (bulk)
nometasone furoate/ammonium lactate	Momexin
nometasone furoate/formoterol fumarate	Dulera
nontelukast sodium	Singulair
nontelukast sodium	montelukast
nontelukast sodium	montelukast (bulk)
aproxen	naproxen
aproxen sodium	All Day Pain Relief
aproxen sodium	All Day Relief
naproxen sodium	Flanax (naproxen)
haproxen sodium	Midol (naproxen)



Generic Name	Brand Name
naproxen sodium	Wal-Proxen
naproxen sodium	naproxen sodium
naproxen sodium/pseudoephedrine HCl	Aleve Cold and Sinus
naproxen sodium/pseudoephedrine HCl	Aleve Sinus and Headache
naproxen sodium/pseudoephedrine HCl	All Day Pain Relief Sinus,Cold
naproxen sodium/pseudoephedrine HCl	Sinus and Cold-D
nedocromil sodium	Alocril
olodaterol HCl	Striverdi Respimat
olopatadine HCl	Pataday
olopatadine HCl	Patanase
olopatadine HCl	Patanol
olopatadine HCl	Pazeo
olopatadine HCl	olopatadine
omalizumab	Xolair
phenylephrine HCl/acetaminophen	AcetaminophenCongestion-Pain
phenylephrine HCl/acetaminophen	Contac Cold-Flu Day
phenylephrine HCl/acetaminophen	DayTime Sinus
phenylephrine HCl/acetaminophen	Daytime Sinus-Congestion
phenylephrine HCl/acetaminophen	Mapap Sinus Max Strength(PE)
phenylephrine HCl/acetaminophen	Non-Aspirin Sinus
phenylephrine HCl/acetaminophen	Pain Relief Sinus PE
phenylephrine HCl/acetaminophen	Pyrroxate Cold andCongestion
phenylephrine HCl/acetaminophen	Sinus Congestion and Pain
phenylephrine HCl/acetaminophen	Sinus Headache PE
phenylephrine HCl/acetaminophen	Sinus Maximum Strength
phenylephrine HCl/acetaminophen	Sinus Pain-Pressure (PE)
phenylephrine HCl/acetaminophen	Sinus Relief (Non-Drowsy)
phenylephrine HCl/acetaminophen	Sudafed PE Pressure-Pain
phenylephrine HCl/acetaminophen	Suphedrine PE SinusHeadache
phenylephrine HCl/acetaminophen	Tylenol Sinus CongestionPain
phenylephrine HCl/acetaminophen	Vicks Dayquil Sinex
phenylephrine HCl/acetaminophen	Vicks QlearQuil DaytimeSinus
phenylephrine HCl/acetaminophen	Vicks Sinex Daytime
phenylephrine HCl/acetaminophen	Wal-Phed PE SinusHeadache
phenylephrine	Allergy Multi-Symptom
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Allergy Relief Multi-Symptom
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Allergy Relief(chlorphen-acet)
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Allergy Sinus PE
HCI/acetaminophen/chlorpheniramine	
phenylephrine	Contac Cold-Flu Day andNight
HCl/acetaminophen/chlorpheniramine	



Generic Name	Brand Name
phenylephrine	Contac Cold-Flu Max Strength
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Dristan Cold
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Effervescent Cold Relief Plus
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Medicidin-D
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Norel AD
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Sinus Congest-PainDay-Night
HCl/acetaminophen/chlorpheniramine	Sinds confester and ay might
phenylephrine	SinusCongestion-Pain(chlorph)
HCl/acetaminophen/chlorpheniramine	
phenylephrine	Sinutrol PE
HCl/acetaminophen/chlorpheniramine	Sindi OFFE
phenylephrine HCl/acetaminophen/doxylamine	DayTime and NiteTime Sinus
succinate	Bay time and interime sinus
phenylephrine HCl/acetaminophen/doxylamine	NightTime Sinus
succinate	
phenylephrine HCl/acetaminophen/doxylamine	Nighttime Sinus-Congestion
succinate	Montaine Sinds congestion
phenylephrine HCl/acetaminophen/doxylamine	Sinus Daytime-Nightime
succinate	Sinds Daytine Hightine
phenylephrine HCl/acetaminophen/doxylamine	Vicks Nyquil Sinex
succinate	······ ,
phenylephrine HCl/acetaminophen/doxylamine	Vicks QlearQuil NightimeSinus
succinate	
phenylephrine HCl/chlophedianol HCl/guaifenesin	Donatussin Pediatric
phenylephrine HCl/chlophedianol HCl/guaifenesin	Vanacof GPE
phenylephrine HCl/chlophedianol HCl/guaifenesin	phenylephrine-chlophedianol-GG
phenylephrine HCl/codeine	Phenflu CD
phosphate/acetaminophen/guaifen	
phenylephrine HCl/codeine	Phenflu CDX
phosphate/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Children's Cold-Cough-Sore
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Children's MucinexCold-Fever
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Cold Head Congestion SeverDay
HBr/acetaminophen/guaifen	continear confection sever bay
phenylephrine HCl/dextromethorphan	Cold Severe Congestion
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Cold and Flu Severe
HBr/acetaminophen/guaifen	
nor, accommophen, Sudiren	



Generic Name	Brand Name
phenylephrine HCl/dextromethorphan	Cold-Cough Sinus Relief PE
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Decorel Forte Plus
HBr/acetaminophen/guaifen	Decorerrorte rius
phenylephrine HCl/dextromethorphan	Delsym Cough-Cold Daytime
HBr/acetaminophen/guaifen	Deisym Cough-Colu Daytime
phenylephrine HCl/dextromethorphan	Dometuss G
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Fast Mucus Relief SevereCold
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Head Congestion Cold Relief
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Herbiomed Severe Cold-FluM-S
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Mucinex Cold,Flu,Sore Throat
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Mucinex Fast-MaxCold-Flu-Thrt
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Mucinex Fast-Max SevereCold
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Mucinex Sinus-MaxPressure-Cgh
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Mucinex Sinus-Max SevCong(DM)
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Mucus Relief Cold-Flu-SoreThr
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Mucus Relief Plus
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Mucus Relief SevCongest-Cold
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Mucus Relief Severe Cold
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Multi-Symptom Cold (PE)
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Non-Pseudo Cold Relief
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Pain Relief Cold
HBr/acetaminophen/guaifen	
phenylephrine HCI/dextromethorphan	Pressure-Pain PE Plus Cold
HBr/acetaminophen/guaifen	Descente Dain Cald
phenylephrine HCl/dextromethorphan	Pressure-Pain-Cold
HBr/acetaminophen/guaifen	Domno Docho May MultiSumetare
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Rompe Pecho Max MultiSymptoms
nor/acetaninophen/guanen	



Generic Name	Brand Name
phenylephrine HCl/dextromethorphan	Severe Cold
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Severe Cold Multi-Symptom
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Severe Cold and Flu (PE)
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Sudafed PEPressure-Pain-Cold
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Tussin CF Max Severe M-SCold
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Tylenol Cold and Flu Severe
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Vicks DayQuil SevereCold-Flu
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Wal-Phed PE Cold-Cough
HBr/acetaminophen/guaifen	
phenylephrine HCl/dextromethorphan	Wal-Phed PEPressure+Pain+Cold
HBr/acetaminophen/guaifen	
phenylephrine HCl/diphenhydramine HCl	Aldex-CT
phenylephrine HCl/diphenhydramine HCl	Allergy and Sinus Relief
phenylephrine HCl/diphenhydramine HCl	Child Allergy Plus Congestion
phenylephrine HCl/diphenhydramine HCl	Child Benadryl PlusCongestion
phenylephrine HCl/diphenhydramine HCl	Child's Benadryl-D Allergy-Sin
phenylephrine HCl/diphenhydramine HCl	Children Night TimeCold-Cough
phenylephrine HCl/diphenhydramine HCl	Childs Triacting Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Cold and Cough(diphenhydr-pe)
phenylephrine HCl/diphenhydramine HCl	Dimetapp Cold-Congestion
phenylephrine HCl/diphenhydramine HCl	Nighttime Cough-Cold
phenylephrine HCl/diphenhydramine HCl	Triaminic Cold andCoughNT(PE)
phenylephrine HCl/diphenhydramine HCl	diphenhydramine-phenylephrine
phenylephrine HCl/promethazine HCl	Promethazine VC
phenylephrine HCl/promethazine HCl	promethazine-phenylephrine
phenylephrine HCl/pyrilamine maleate	Aldex D
phenylephrine HCl/pyrilamine maleate	Glen PE
phenylephrine HCl/pyrilamine maleate	Poly Hist Forte (pyrilamine)
phenylephrine HCl/pyrilamine maleate	Pyril D
phenylephrine HCl/pyrilamine maleate	Vazotab (pyrilamine)
phenylephrine HCl/pyrilamine maleate	pyrilamine-phenylephrine
phenylephrine HCl/triprolidine HCl	Histex PE
phenylephrine HCl/triprolidine HCl	Sinus Nighttime
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	Prelone
prednisolone	prednisolone
prednisolone acetate	Flo-Pred



Generic Name	Brand Name
prednisolone acetate, micronized	prednisolone ac, micro (bulk)
prednisolone, micronized	prednisolone, micro (bulk)
prednisone	Deltasone
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	prednisone
prednisone micronized	prednisone micronized (bulk)
promethazine HCl	Phenadoz
promethazine HCl	Phenergan
promethazine HCl	Promethegan
promethazine HCl	promethazine
promethazine HCl	promethazine (bulk)
promethazine HCl in 0.9 % sodium chloride	promethazine in 0.9 % NaCl
promethazine HCI/codeine	promethazine-codeine
promethazine HCI/dextromethorphan HBr	promethazine-DM
promethazine/phenylephrine HCl/codeine	Promethazine VC-Codeine
promethazine/phenylephrine HCl/codeine	promethazine-phenyleph-codeine
pseudoephedrine HCl/acetaminophen	Nexafed Sinus Pressure-Pain
pseudoephedrine HCI/acetaminophen	Sinus HeadacheDegongestant
pseudoephedrine	Allergy Sinus-D
HCl/acetaminophen/chlorpheniramine	
pseudoephedrine	Non-Aspirin Allergy Sinus
HCl/acetaminophen/chlorpheniramine	
pseudoephedrine	Non-Aspirin Child's Cold
HCl/acetaminophen/chlorpheniramine	
pseudoephedrine	Pain Reliever Allergy Sinus
HCl/acetaminophen/chlorpheniramine	
pseudoephedrine HCI/acrivastine	Semprex-D
pseudoephedrine HCI/chlophedianol HCI	Rondec-D
pseudoephedrine HCI/chlophedianol	Certuss-D
HCl/guaifenesin	
pseudoephedrine HCI/chlophedianol	Vanacof DX
HCl/guaifenesin	
pseudoephedrine HCI/chlophedianol	Vanatab DX
HCl/guaifenesin	
pseudoephedrine HCl/chlorpheniramine	Respa-AR
maleate/bellad alk	
pseudoephedrine HCI/codeine phosphate	Codar D
pseudoephedrine HCl/codeine	Maxiflu CD
phosphate/acetaminophen/guaifen	
pseudoephedrine HCI/codeine	Maxiflu CDX
phosphate/acetaminophen/guaifen	
pseudoephedrine HCl/codeine	Cheratussin DAC
phosphate/guaifenesin	



Generic Name	Brand Name
pseudoephedrine HCl/codeine	Coditussin DAC
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Guaifenesin DAC
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Lortuss EX
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Phenylhistine
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Tricode GF
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Tusnel C
phosphate/guaifenesin	
pseudoephedrine HCI/codeine	Virtussin DAC
phosphate/guaifenesin	
pseudoephedrine HCI/codeine	Zodryl DEC 25
phosphate/guaifenesin	
pseudoephedrine HCI/codeine	Zodryl DEC 30
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Zodryl DEC 35
phosphate/guaifenesin	
pseudoephedrine HCI/codeine	Zodryl DEC 40
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Zodryl DEC 50
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Zodryl DEC 60
phosphate/guaifenesin	
pseudoephedrine HCl/codeine	Zodryl DEC 80
phosphate/guaifenesin	
pseudoephedrine HCI/codeine/chlorpheniramine	Phenylhistine DH
pseudoephedrine HCI/hydrocodone bitartrate	Rezira
pyrilamine maleate	pyrilamine maleate (bulk)
pyrilamine maleate/chlophedianol HCl	DayClear Allergy Relief
pyrilamine maleate/chlophedianol HCl	Ninjacof
pyrilamine maleate/chlophedianol HCl	VanaCof AC
pyrilamine maleate/chlophedianol HCl	VanaTab AC
pyrilamine maleate/chlophedianol HCl	Vanacof-8
pyrilamine maleate/chlophedianol	Ninjacof-A
HCI/acetaminophen	
pyrilamine maleate/dextromethorphan HBr	Capron DM
pyrilamine maleate/dextromethorphan HBr	Capron DMT
pyrilamine maleate/phenylephrine	Pro-Chlo
HCl/chlophedianol HCl	
pyrilamine maleate/phenylephrine	Codituss DM
HCI/dextromethorphan HBr	



Generic Name	Brand Name						
pyrilamine maleate/pseudoephedrine	Ninjacof-D						
HCI/chlophedianol HCl							
racepinephrine HCl	Asthmanefrin Refill						
racepinephrine HCl	Asthmanefrin Starter Kit						
racepinephrine HCl	S2 Racepinephrine						
racepinephrine HCl	racepinephrine						
racepinephrine HCl	racepinephrine (bulk)						
reslizumab	Cinqair						
revefenacin	Yupelri						
roflumilast	Daliresp						
salmeterol xinafoate	Serevent Diskus						
terbutaline sulfate	terbutaline						
theophylline anhydrous	Elixophyllin						
theophylline anhydrous	Theo-24						
theophylline anhydrous	Theochron						
theophylline anhydrous	theophylline						
thonzylamine HCl/chlophedianol HCl	POLY HIST PD						
thonzylamine HCl/phenylephrine HCl	Nasopen PE						
thonzylamine HCl/phenylephrine	Vanacof APE						
HCI/chlophedianol HCl							
thonzylamine HCl/phenylephrine	Poly-Hist DM (thonzylamine)						
HCI/dextromethorphan HBr							
tiotropium bromide	Spiriva Respimat						
tiotropium bromide	Spiriva with HandiHaler						
tiotropium bromide/olodaterol HCl	Stiolto Respimat						
tranilast	tranilast (bulk)						
triamcinolone acetonide	24 Hour Nasal Allergy						
riamcinolone acetonide	Arze-Ject-A						
triamcinolone acetonide	Children's Nasacort						
triamcinolone acetonide	Kenalog						
triamcinolone acetonide	Kenalog-80						
triamcinolone acetonide	Nasacort						
triamcinolone acetonide	Nasacort AQ						
riamcinolone acetonide	Nasal Allergy						
triamcinolone acetonide	P-Care K40						
triamcinolone acetonide	P-Care K80						
triamcinolone acetonide	Pod-Care 100K						
triamcinolone acetonide	Pro-C-Dure 5						
triamcinolone acetonide	Pro-C-Dure 6						
triamcinolone acetonide	ReadySharp Triamcinolone						
triamcinolone acetonide	Zilretta						
triamcinolone acetonide	triamcinolone acetonide						
triamcinolone acetonide	triamcinolone acetonide (bulk)						
triamcinolone acetonide in 0.9 % sodium chloride	triamcinolone aceton-0.9%NaCl						
triamcinolone acetonide/0.9% sodium chloride/PF	triamcinol ac (PF) in0.9%NaCl						
triamcinolone acetonide/dimethicone	Ellzia Pak						



Generic NameBrand Nametriamcinolone acetonide/dimethicone/silicone, adhesiveDermaSilkRx SDSadhesiveDermaWerx SDSadhesiveDermaCinRx SilaPakadhesiveDermacinRx SilaPakadhesiveTriamcinolone acetonide/dimethicone/silicone, adhesiveDermacinRx SilaPakadhesiveSanaDermRxadhesiveTriamcinolone acetonide/dimethicone/silicone, adhesiveSanaDermRxadhesiveSure Result Tac PakadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-SilaadhesiveTri-Silatriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm TDPakadhesiveTriamcinolone acetonide/dimethicone/silicone, triamcinolone acetonide/dimethicone/silicone, triamcinolone acetonide/idemeticone/silicone, triamcinolone acetonide/ideciane HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/ideciane HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone diacetate in 0
adhesive triamcinolone acetonide/dimethicone/silicone, triamcinolone acetonide/imethicone/silicone, triamcinolone diacetate in 0.9 % sodium choride triamcinolone dia
triamcinolone acetonide/dimethicone/silicone,DermaWerx SDSadhesive
adhesive triamcinolone acetonide/dimethicone/silicone, triamcinolone acetonide/formeticone/silicone, triamcinolone diacetate in 0.9 % sodium chloride triamcinolone diacetate in 0.9 % sodium chloride triamcinolone diacetate in 0.9 % sodi
triamcinolone acetonide/dimethicone/silicone, DermacinRx SilaPak adhesive adhesive arbitriamcinolone acetonide/dimethicone/silicone, SanaDermRx adhesive arbitriamcinolone acetonide/dimethicone/silicone, SanaDermRx adhesive arbitriamcinolone acetonide/dimethicone/silicone, Sure Result Tac Pak adhesive arbitriamcinolone acetonide/dimethicone/silicone, Tri-Sila adhesive arbitriamcinolone acetonide/filocaline Arbitriamcinolone acetonide/lidocaline HCI arbitriamcinolone tilacetate in 0.9 % sodium chloride triamcinolone diacetate in 0.9 % sodium chloride
adhesive triamcinolone acetonide/dimethicone/silicone, adhesive triamcinolone acetonide/mollient combination no.45 triamcinolone acetonide/lidocaine HCl EZ Use Joint-Tunnel-Trigger triamcinolone acetonide/lidocaine HCl Lidocilone I triamcinolone diacetate in 0.9 % sodium chloride triamcinolone hexacetonide triamcinolone hexacetonide triamcinolone hex
triamcinolone acetonide/dimethicone/silicone, adhesiveNuTriaRxtriamcinolone acetonide/dimethicone/silicone, adhesiveSanaDermRxadhesiveSure Result Tac Pakadhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveSure Result Tac Pakadhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveTri-Silaadhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm TDPakadhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm TIPaktriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm TAtriamcinolone acetonide/dimethicone/silicone, adhesivePediaderm TAtriamcinolone acetonide/dimethicone/silicone, adhesiveDermasorb TA Complete Kittriamcinolone acetonide/dimethicone/silicone, adhesiveLidocilone Itriamcinolone acetonide/dimethicone/silicone, adhesiveDermasorb TA Complete Kittriamcinolone acetonide/idocaine HCILidocilone Itriamcinolone acetonide/idocaine HCILidocilone Itriamcinolone acetonide/idocaine HCILidocilone Itriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diaceto.95%NaCItriamcinolone diacetate in 0.9 % sodium chlorideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexacetonidetriamcinolone hexacetonide, micronizedtriamcinolone hexacetonide, micronizedtriamcinolone hexacetonide, micronizedtriamcinolone hexacetonide, micronizedtriamcinolone hexa
adhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveSanaDermRxadhesiveSure Result Tac Paktriamcinolone acetonide/dimethicone/silicone, adhesiveTri-Silatriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm TDPakadhesiveTri-Silatriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm Trilasil PakadhesiveTriamcinolone acetonide/dimethicone/silicone, adhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm Trilasil PakadhesiveTriamcinolone acetonide/dimethicone/silicone, adhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm Trilasil PakadhesiveTriamcinolone acetonide/dimethicone/silicone, adhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveDermacinz Paktriamcinolone acetonide/dimethicone/silicone, adhesiveDermacinz Paktriamcinolone acetonide/dimethicone/silicone, boxenDermacinz Paktriamcinolone acetonide/emollient combination no.86Dermacinz Paktriamcinolone acetonide/lidocaine HClEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine/prilocaineDermacinz Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodium chlorideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideTriamcinolone hexacetonidetriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)
adhesivetriamcinolone acetonide/dimethicone/silicone,Sure Result Tac PakadhesiveTri-Silatriamcinolone acetonide/dimethicone/silicone,Tri-SilaadhesiveTriamcinolone acetonide/dimethicone/silicone,Whytederm TDPakadhesiveTriamcinolone acetonide/dimethicone/silicone,Whytederm TDPakadhesiveTriamcinolone acetonide/dimethicone/silicone,Whytederm Trilasil PakadhesiveTriamcinolone acetonide/emollient combinationPediaderm TAao.45Triamcinolone acetonide/emollient combinationDermasorb TA Complete Kitno.86Triamcinolone acetonide/lidocaine HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine HCIDermasorb TA Complete Kittriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCItriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexacetonidetriamcinolone hexacetonide, micronizedtriamcinolone hexacetoni(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacetoni(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacetoni(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacetoni(bulk)triamcinolon
triamcinolone acetonide/dimethicone/silicone, Sure Result Tac Pak adhesive Triamcinolone acetonide/dimethicone/silicone, Tri-Sila adhesive Triamcinolone acetonide/dimethicone/silicone, Whytederm TDPak adhesive Triamcinolone acetonide/dimethicone/silicone, Whytederm Trilasil Pak adhesive Triamcinolone acetonide/dimethicone/silicone, Whytederm Trilasil Pak adhesive Triamcinolone acetonide/dimethicone/silicone, Pediaderm TA Tac Pak adhesive Triamcinolone acetonide/dimethicone/silicone, Triamcinolone acetonide/dimethicone/silicone, Triamcinolone acetonide/emollient combination Pediaderm TA Tac Pak adhesive Triamcinolone acetonide/emollient combination Pediaderm TA Tac Pak Tac Pak Pediaderm TA Tac Pak Pak Pediaderm TA Tac Pak Pediaderm TA Tac Pak Pediaderm TA Tac Pak Pediaderm TA Tac Pak Pediaderm TA Pak Ped
adhesive triamcinolone acetonide/dimethicone/silicone, Tri-Sila adhesive triamcinolone acetonide/dimethicone/silicone, Whytederm TDPak adhesive triamcinolone acetonide/dimethicone/silicone, Whytederm Trilasil Pak adhesive triamcinolone acetonide/dimethicone/silicone, Whytederm Trilasil Pak adhesive triamcinolone acetonide/dimethicone/silicone, Dermasorb TA Complete Kit no.45 triamcinolone acetonide/lidocaine HCl EZ Use Joint-Tunnel-Trigger triamcinolone acetonide/lidocaine HCl Lidocilone I triamcinolone diacetate in 0.9 % sodium chloride triamcinolone diacetate in 0.9 % sodium chloride triamcinolone diacetate in 0.9 % sodium chloride triamcinolone diacetonide/ FF triamcinolone hexacetonide MCl Aristospan Intra-Articular triamcinolone hexacetonide triamcinolone hexace
triamcinolone acetonide/dimethicone/silicone, Tri-Sila adhesive triamcinolone acetonide/dimethicone/silicone, Whytederm TDPak adhesive triamcinolone acetonide/dimethicone/silicone, Whytederm Trilasil Pak adhesive triamcinolone acetonide/dimethicone/silicone, Pediaderm TA adhesive triamcinolone acetonide/emollient combination Pediaderm TA no.45 triamcinolone acetonide/emollient combination Dermasorb TA Complete Kit no.86 triamcinolone acetonide/lidocaine HCl EZ Use Joint-Tunnel-Trigger triamcinolone acetonide/lidocaine HCl Lidocilone I triamcinolone acetonide/lidocaine HCl Lidocilone I triamcinolone acetonide/lidocaine/prilocaine triamcinolone diacetate in 0.9 % sodium chloride triamcinolone diacetate in 0.9 % sodium chloride triamcinolone diacetate in 0.9 % sodium chloride triamcinolone hexacetonide triamcinolone hexacetonide, micronized triamcinolone hexacetonide
adhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm TDPaktriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm Trilasil Pakadhesivetriamcinolone acetonide/emollient combination no.45Pediaderm TAtriamcinolone acetonide/emollient combination no.86Dermasorb TA Complete Kittriamcinolone acetonide/idocaine HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine HCIDermacinRx Cinlone-I CPItriamcinolone dacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCItriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexacetonide, micronizedtriamcinolone hexacetonideTriamcinolone hexacetonide, micronizedtriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideTriamcinolone hexaceton(bulk)triamcinolone hexacetonideTriamcinolone hexaceton(bulk)triamcinolone hexacetonideTriamcinolone hexacetonideTriamcin
triamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm TDPaktriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm Trilasil PakadhesivePediaderm TAtriamcinolone acetonide/emollient combination no.45Pediaderm TAtriamcinolone acetonide/emollient combination no.86Dermasorb TA Complete Kittriamcinolone acetonide/lidocaine HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)triamcinolone/norflurane
adhesivetriamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm Trilasil PakadhesivePediaderm TAno.45riamcinolone acetonide/emollient combination no.45Permasorb TA Complete Kittriamcinolone acetonide/emollient combination no.86Dermasorb TA Complete Kittriamcinolone acetonide/lidocaine HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCItriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexacetonidetriamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)F
triamcinolone acetonide/dimethicone/silicone, adhesiveWhytederm Trilasil Paktriamcinolone acetonide/emollient combination no.45Pediaderm TAtriamcinolone acetonide/emollient combination no.86Dermasorb TA Complete Kittriamcinolone acetonide/lidocaine HCIEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HCILidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone acetonide/lidocaine/prilocaineTriamcinolone diaceta-0.9%NaCItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCItriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonide, micronizedtriamcinolone hexacetonidulk)triamcinolone hexacetonideTriamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)F
adhesivetriamcinolone acetonide/emollient combinationPediaderm TAno.45triamcinolone acetonide/emollient combinationDermasorb TA Complete Kitno.86triamcinolone acetonide/lidocaine HClEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HClLidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9% sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9% sodiumtriamcinolone diacet-0.9%NaCltriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)
triamcinolone acetonide/emollient combination no.45Pediaderm TAtriamcinolone acetonide/emollient combination no.86Dermasorb TA Complete Kittriamcinolone acetonide/lidocaine HClEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HClLidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodiumtriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodiumtriamcinolone diacet-0.9%NaCltriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)T
no.45triamcinolone acetonide/emollient combination no.86Dermasorb TA Complete Kittriamcinolone acetonide/lidocaine HClEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HClLidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)HEC
triamcinolone acetonide/emollient combination no.86Dermasorb TA Complete Kittriamcinolone acetonide/lidocaine HClEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HClLidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodium chloridetriamcinolonedia(PF)-0.9%NaCltriamcinolone diacetate in 0.9 % sodiumtriamcinolonedia(PF)-0.9%NaCltriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexacetonidetriamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)triamcinolone
no.86triamcinolone acetonide/lidocaine HClEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HClLidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodiumtriamcinolone diacet-0.9%NaCltriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)HEC 245fa)
triamcinolone acetonide/lidocaine HClEZ Use Joint-Tunnel-Triggertriamcinolone acetonide/lidocaine HClLidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaClchloride/PFtriamcinolone hexacetonidetriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexacetonidetriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcin hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)Her State St
triamcinolone acetonide/lidocaine HClLidocilone Itriamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodiumtriamcinolone diacet-0.9%NaCltriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)U
triamcinolone acetonide/lidocaine/prilocaineDermacinRx Cinlone-I CPItriamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodiumtriamcinolonedia(PF)-0.9%NaClchloride/PFtriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)
triamcinolone diacetate in 0.9 % sodium chloridetriamcinolone diacet-0.9%NaCltriamcinolone diacetate in 0.9 % sodiumtriamcinolonedia(PF)-0.9%NaClchloride/PFtriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcinolone hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)
triamcinolone diacetate in 0.9 % sodiumtriamcinolonedia(PF)-0.9%NaClchloride/PFAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonide, micronizedtriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcin hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)triamcinolone/norflurane and pentafluoropropane
chloride/PFtriamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcin hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)triamcinolone hexaceton(bulk)
triamcinolone hexacetonideAristospan Intra-Articulartriamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcin hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)Kara Kara Kara Kara Kara Kara Kara Kara
triamcinolone hexacetonideAristospan Intralesionaltriamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcin hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)Kara Kara Kara Kara Kara Kara Kara Kara
triamcinolone hexacetonidetriamcinolone hexaceton(bulk)triamcinolone hexacetonide, micronizedtriamcin hexacet, micro (bulk)triamcinolone/norflurane and pentafluoropropaneP-Care K40G(HFC 245fa)
triamcinolone/norflurane and pentafluoropropane P-Care K40G (HFC 245fa)
(HFC 245fa)
triamcinolone/norflurane and pentafluoropropane P-Care K80G
(HFC 245fa)
triamcinolone/norflurane and pentafluoropropane Pod-Care 100KG
(HFC 245fa)
triamcinolone/norflurane and pentafluoropropane Triloan II SUIK
(HFC 245fa)
triamcinolone/norflurane and pentafluoropropane Triloan SUIK
(HFC 245fa)
trimeprazine tartrate trimeprazine tartrate (bulk)
tripelennamine HCl tripelennamine (bulk)
triprolidine HCl Histex (triprolidine)



Generic Name	Brand Name						
triprolidine HCl	Histex PD						
triprolidine HCl	Histex PDX						
triprolidine HCl	M-Hist PD						
triprolidine HCl	VanaClear PD						
triprolidine HCl	Vanahist PD						
triprolidine HCl	triprolidine HCl						
triprolidine HCl	triprolidine HCl (bulk)						
triprolidine HCl/phenylephrine HCl/codeine	Histex-AC						
phosphate							
triprolidine HCl/phenylephrine	Histex DM						
HCI/dextromethorphan HBr							
triprolidine HCl/pseudoephedrine HCl	Aprodine						
triprolidine HCl/pseudoephedrine	Trymine CD						
HCI/chlophedianol HCI							
umeclidinium bromide	Incruse Ellipta						
umeclidinium bromide/vilanterol trifenatate	Anoro Ellipta						
zafirlukast	Accolate						
zafirlukast	zafirlukast						
zileuton	Zyflo						
zileuton	Zyflo CR						
zileuton	zileuton						
Nonsteroidal Anti-Infl	ammatory Drugs						
	Advil Allergy-Congestion Rlf						
CHLORPHENIRAMINE	Advil Allergy-Congestion Rlf						
CHLORPHENIRAMINE MALEATE/PHENYLEPHRINE HCL/IBUPROFEN	Advil Allergy-Congestion Rlf						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE	Advil Allergy-Congestion Rlf Advil Allergy Sinus						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE							
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN	Advil Allergy Sinus						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN	Advil Allergy Sinus Ibudone						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN	Advil Allergy Sinus Ibudone Reprexain						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN	Advil Allergy Sinus Ibudone Reprexain Vicoprofen						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen-oxycodone						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/OXYCODONE HCL IBUPROFEN/PHENYLEPHRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen advil Congestion Relief						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen ibuprofen. Advil Congestion Relief Congestion Relief(ibuprof-PE)						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen-oxycodone Advil Congestion Relief Congestion Relief(ibuprof-PE) Advil Cold and Sinus						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen-oxycodone Advil Congestion Relief Congestion Relief(ibuprof-PE) Advil Cold and Sinus Cold and Sinus Pain Relief						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen ibuprofen-oxycodone Advil Congestion Relief Congestion Relief(ibuprof-PE) Advil Cold and Sinus Cold and Sinus Pain Relief Cold-Sinus Relief						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/DXYCODONE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen-oxycodone Advil Congestion Relief Congestion Relief Congestion Relief(ibuprof-PE) Advil Cold and Sinus Cold and Sinus Pain Relief Cold-Sinus Relief Ibuprofen Cold						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/DXYCODONE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen ibuprofen-oxycodone Advil Congestion Relief Congestion Relief(ibuprof-PE) Advil Cold and Sinus Cold and Sinus Pain Relief Cold-Sinus Relief Ibuprofen Cold Ibuprofen Cold-Sinus(withPSE)						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen-oxycodone Advil Congestion Relief Congestion Relief(ibuprof-PE) Advil Cold and Sinus Cold and Sinus Pain Relief Cold-Sinus Relief Ibuprofen Cold Ibuprofen Cold-Sinus(withPSE) Wal-Profen Cold-Sinus						
MALEATE/PHENYLEPHRINE HCL/IBUPROFEN CHLORPHENIRAMINE MALEATE/PSEUDOEPHEDRINE HCL/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN HYDROCODONE/IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN IBUPROFEN/DXYCODONE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PHENYLEPHRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL IBUPROFEN/PSEUDOEPHEDRINE HCL	Advil Allergy Sinus Ibudone Reprexain Vicoprofen Xylon 10 hydrocodone-ibuprofen Children's Ibuprofen ibuprofen ibuprofen ibuprofen-oxycodone Advil Congestion Relief Congestion Relief(ibuprof-PE) Advil Cold and Sinus Cold and Sinus Pain Relief Cold-Sinus Relief Ibuprofen Cold Ibuprofen Cold-Sinus(withPSE)						



NARROXEN SODIUM         naproxen sodium           NARROXEN SODIUM/PSEUDOEPHEDRINE         Aleve Cold and Sinus           HCL         NARROXEN SODIUM/PSEUDOEPHEDRINE         Aleve Cold and Sinus and Headache           HCL         NARROXEN SODIUM/PSEUDOEPHEDRINE         Aleve-D Sinus and Cold-D           HCL         NARROXEN SODIUM/PSEUDOEPHEDRINE         Aleve-D Sinus and Cold-D           HCL         OXAPROXEN SODIUM/PSEUDOEPHEDRINE         Sinus and Cold-D           HCL         OXAPROXEN SODIUM/PSEUDOEPHEDRINE         Sinus and Cold-D           VGL         OXAPROXEN SODIUM/PSEUDOEPHEDRINE         Sinus and Cold-D           HCL         OXAPROXEN SODIUM/PSEUDOEPHEDRINE         Sinus and Cold-D           VGL         OXAPROXEN         Treximet           SODIUM         celecoxib         Celebrex           celecoxib         Celecoxib         Celecoxib           diclofenac potassium         Clafafam           diclofenac potassium         Clafafam           diclofenac sodium/misoprostol         Arthrotec 50      <	Generic Name	Brand Name					
NAPROXEN SODIUM/PSEUDOEPHEDRINEAleve Cold and SinusHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and ColdHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and HeadacheHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and HeadacheHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus,ColdHCLNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLVarPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLVarPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLVarPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLSinus and Cold-DSinus and Cold-DCledorac polasiumCatafamSinus and Cold-DSODIUMSinus and Cold-DSinus and Cold-DSODIUMSinus and Cold-DSinus and Cold-DSODIUMSinus and Cold-DSinus and Cold-DSolichare polasiumCatafamSinus and Cold-DSolichare polasiumCatafamSinus and Cold-DSolichare polasiumCatafamSinus and Cold-DSolichare polasium/misoprostolCathare xRSolichare polasium/misoprostolSin							
HCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve Sinus and HeadacheHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and ColdHCLHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and HeadacheHCLHCLHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus,ColdHCLHCLHCLOXAPROZEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLHCLHCLOXAPROZEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLHCLHCLOXAPROZINpiroxicamSODIUMEdecoxibCelecoxibCelecoxibGledofaca potassiumCelecoxibGledofaca potassiumCelecoxibGledofaca potassiumCelecoxibGledofaca potassiumCiclofanac potassiumGledofaca pota							
HCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and ColdHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and HeadacheHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus,ColdHCLNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLUNATROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLVisuand Cold-DSinus and Cold-DHCLVisuand Cold-DSinus and Cold-DCXAPROZINoxaprozinSinus and Cold-DPIROXICAMpiroxicamSinus and Cold-DVISUATRIFITAN SUCCINATE/NAPROXENcelecoxinSinus and Cold-DSUMATRIFITAN SUCCINATE/NAPROXENCelecoxinCelecoxindiclofenac potassiumCataflamCataflamdiclofenac potassiumGatofana potassiumCataflamdiclofenac potassiumGatofana potassiumGatofana potassiumdiclofenac potassiumGatofana potassiumGatofana potassiumdiclofenac sodium/misoprostolGitclefenac potassiumdiclofenac sodium/misoprostolGitclefenac insioprostoldiclofenac sodium/misoprostolGatinediclofenac sodium/misoprostolSorole ketodolacEnorthofenoprofen calciumNafonfenoprofen calciumAdvil Iugui-Geilfenoprofen calciumAdvil Iugui-Geilfenoprofen calciumAdvil Iugui-Geilfenoprofen calciumAdvil Iugui-Geilfenoprofen calciumChildren's Advil Iugui-GeilibuprofenAdvil Iugui-GeilibuprofenChild							
HCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and ColdHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and HeadacheHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus,ColdHCLNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLUNATROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLVisuand Cold-DSinus and Cold-DHCLVisuand Cold-DSinus and Cold-DCXAPROZINoxaprozinSinus and Cold-DPIROXICAMpiroxicamSinus and Cold-DVISUATRIPTAN SUCCINATE/NAPROXENcelecoldSinus and Cold-DSUMATRIPTAN SUCCINATE/NAPROXENCelecoldCelecolddiclofenac potassiumCataflamCataflamdiclofenac potassiumCataflamCataflamdiclofenac potassiumGlofenac potassiumCataflamdiclofenac sodium/misoprostolVistran-XRdiclofenac sodium/misoprostolCatofenac potassiumdiclofenac sodium/misoprostolCatofenac Sinusdiclofenac sodium/misoprostolCatofenac Sinusdiclofenac sodium/misoprostolCatofenac Sinusdiclofenac sodium/misoprostolCatofenac Sinusfenoprofen calciumProfenofenoprofen calciumNalfonfenoprofen calciumAdvilfenoprofen calciumAdvilfenoprofen calciumAdvilfenoprofen calciumAdvilfenoprofen calciumCildfenac Sodium/Misoprostolfenoprofen calciumCildfenac Sodiumfenoprofen calcium <td>NAPROXEN SODIUM/PSEUDOEPHEDRINE</td> <td>Aleve Sinus and Headache</td>	NAPROXEN SODIUM/PSEUDOEPHEDRINE	Aleve Sinus and Headache					
HCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and HeadacheHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus,ColdNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLUOXAPROZINoxaprozinPIROXICAMpiroxicamSUMATRIFTAN SUCCINATE/NAPROXENreximetSODIUMcelecoxibcelecoxibcelecoxibcelecoxibcelecoxibdiclofenac potassiumcambiadiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolconvolexdiclofenac sodium/misoprostolcolorediclofenac colacumporvolexfenoprofen calciumporvolexfenoprofen calciumconvolexfenoprofen calciumArthrotec 75fenoprofen calciumprofenofenoprofen calciumprofenofenoprofen calciumprofenofenoprofen calciumArthrotec 75fenoprofen calciumprofenofenoprofen calciumArthrotec 75fenoprofen calciumprofenofenoprofen calciumArthrotec 76fenoprofen calciumArthrotec 75fenoprofen calciumArthrotec 76fenoprofen calciumArthrotec 76fenoprofen calciumArthrotec 76fenoprofen calciumArthrotec 76fenoprofen calciumArthrotec 76fenoprofen calciumArthrotec 76fenopro	-						
NAPROXEN SODIUM/PSEUDOEPHEDRINEAleve-D Sinus and HeadacheHCLNAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus,ColdCUNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLvaprozinOXAPROZINoxaprozinPIROXICAMpiroxicamSUMATRIPTAN SUCCINATE/NAPROXENTreximetSODIUMcelecoxibcelecoxibcelecoxibdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolColdolacdiclofenac sodium/misoprostolColdolacdiclofenac colaciumProvinexfenoprofen calciumFenoprofen calciumfenoprofen calciumArthrotec 75filoprofen calciumSonolacfenoprofen calciumKoldolacfenoprofen calciumKoldolacfenoprofen calciumKoldolacfuoprofen calciumArthrote Celefuoprofen calciumKoldolacfuoprofen calciumKoldolacfuoprofen calciumKoldolacfuoprofen calciumColdolacfuoprofen calciumColdolacfuoprofen calciumColdolacfuoprofen calciumColdolacfuoprofen calciumColdolacfuoprofen calciumColdolacfuoprofen calciumColdolacfuoprofen calciumColdolacfuoprofenColdolac </td <td>NAPROXEN SODIUM/PSEUDOEPHEDRINE</td> <td>Aleve-D Sinus and Cold</td>	NAPROXEN SODIUM/PSEUDOEPHEDRINE	Aleve-D Sinus and Cold					
HCINAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus, ColdHCISinus and Cold-DNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCIUVXAPROZINproxicamPIROXICAMpiroxicamSUMATRIPTAN SUCCINATE/NAPROXENTeximetSODIUMCelebrexcelecoxibCelebrexdiclofena potassiumCathalamdiclofena potassiumCathalamdiclofena potassiumCathalamdiclofena potassiumCathalamdiclofena cotassiumCathalamdiclofena cotassiumCathalamdiclofena cotassiumCathalamdiclofena cotassiumCathalamdiclofena cotassiumCathalamdiclofena codium/misoprostolArthrotes 50diclofena sodium/misoprostolCathalamdiclofena codium/misoprostolCathalamdiclofena codium/misoprostolCathalamdiclofena codium/misoprostolCathalamdiclofena codium/misoprostolCathalamdiclofena codium/misoprostolCathalamfenoprofen calciumFenoprofenfenoprofen calciumFenoprofenfenoprofen calciumArthrote 75fenoprofen calciumArthrote 75fenoprofen calciumFenoprofenfurbiprofenArthrote 75fenoprofen calciumFenoprofenfenoprofen calciumFenoprofenfurbiprofenArthrote 75fenoprofen calciumKathalamfurbiprofenArthrote 75fenoprofen ca	HCL						
NAPROXEN SODIUM/PSEUDOEPHEDRINEAll Day Pain Relief Sinus,ColdHCLNAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLOXAPROZINoxaprozinDIXARDApiroxicanSUMATRIFXAN SUCCINATE/NAPROXENreximetSODIUMcelecoxibCelebrexcelecoxibcelecoxibdiclofenac potassiumCathflamdiclofenac potassiumCathflamdiclofenac potassiumCathflamdiclofenac potassiumCathflamdiclofenac potassiumCathflamdiclofenac potassiumCathflamdiclofenac potassiumCathflamdiclofenac potassiumCathflamdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostolGatinediclofenac sodium/misoprostolGatinefenoprofen calciumFenorthofenoprofen calciumFenorthofenoprofen calciumProfenofenoprofen calciumProfenofubprofenAdvil Itqui-GelibuprofenAdvil MigraineibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's MotrinibuprofenChildren's Motrin	NAPROXEN SODIUM/PSEUDOEPHEDRINE	Aleve-D Sinus and Headache					
HCLNAPROXEN SODIUM/PSEUDOEPHEDRINESius and Cold-DHCLCOXAPROZINoxaprozinPIROXICAMpiroxicamSUMATRIPTAN SUCCINATE/NAPROXENpiroxicamSODIUMcelecoxibCelebrexcelecoxibCelebrexdiclofenac potassiumCambiadiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumVoltaren-XRdiclofenac potassiumVoltaren-XRdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac codium/misoprostolLodineetodolacErovolexfenoprofen calciumProFenofurporfen calciumAnsaidfurporfen calciumAnsaidibuprofenAdvil Liqui-GelibuprofenAdvil KigraineibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's MotrinibuprofenChildren's Motrin	HCL						
NAPROXEN SODIUM/PSEUDOEPHEDRINESinus and Cold-DHCLvaprozinOXAPROZINoxaprozinPIROXICAMpiroxicamSUMATRIPTAN SUCCINATE/NAPROXENTreximetSODIUMcelecoxibcelecoxibcelecoxibdiclofenac potassiumCelebrexdiclofenac potassiumCatafiamdiclofenac potassiumZipsordiclofenac potassiumCatafiamdiclofenac potassiumCatafiamdiclofenac potassiumCatafiamdiclofenac potassiumCatafiamdiclofenac potassiumCatafiamdiclofenac potassiumCatafiamdiclofenac sodium/misoprostolArthrote 50diclofenac sodium/misoprostolCorolex-misoprostoldiclofenac sodium/misoprostolCorolexdiclofenac sodium/misoprostolCorolexdiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena colium/misoprostolSoliefenac-misoprostoldiclofena coliumSoliefenac-misoprostolfenoprofen calciumFenoprofenfenoprofen calciumAdvilinibuprofenAdvili Gui-Gel	NAPROXEN SODIUM/PSEUDOEPHEDRINE	All Day Pain Relief Sinus,Cold					
HCLOXARDZINoxarozinPIROXICAMpiroxicamPIROXICAMreximetSODIUMTreximetcelecoxibcelecoxibcelecoxibcelecoxibdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumZipsordiclofenac sodium/misoprostolVoltaren-XRdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolCaroladiclofenac sodium/misoprostolCorolexdiclofenac sodium/misoprostolCorolexetodolacLodineetodolacSorolexfenoprofen calciumFenorthofenoprofen calciumAnsaidibuprofenAnsaidibuprofenAdvil liqui-GelibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Motrinibuprofen<	HCL						
OXAPROZINoxaprozinPIROXICAMpiroxicamSUMATRIPTAN SUCCINATE/NAPROXENTreximetSODIUMresimetcelecoxibCelebrexcelecoxibcelecoxibdiclofenac potassiumCataflamdiclofenac potassiumZipsordiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumValran-XRdiclofenac sodium/misoprostolArthrote 50diclofenac sodium/misoprostolArthrote 75diclofenac sodium/misoprostolColeineadiclofena colacum/misoprostolColeineadiclofena colum/misoprostolColeineadiclofena colum/misoprostolColeineadiclofena colum/misoprostolColeineadiclofena colum/misoprostolColeineadiclofena colum/misoprostolColeineadiclofena colum/misoprostolColeineadiclofena colum/misoprostolColeineadiclofena columPioprofenfenoprofen calciumFenorthofenoprofen calciumPioprofenfenoprofen calciumAnsaidibuprofenAdvil Iqui-GelibuprofenAdvil Iqui-GelibuprofenChild IbuprofenibuprofenChildren's AdviiibuprofenChildren's Profen IBibuprofenChildren's Profen IB	NAPROXEN SODIUM/PSEUDOEPHEDRINE	Sinus and Cold-D					
PIROXICAMpiroxicamSUMATRIPTAN SUCCINATE/NAPROXENTreximetSODIUMcelecoxibCelebrexcelecoxibcelecoxibdiclofenac potassiumCambiadiclofenac potassiumCataflamdiclofenac potassiumdiclofenac sodium/misoprostoldiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostolArthrotec 75diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostolNalfonfenoprofen calciumFenorthofenoprofen calciumFenorthofenoprofen calciumFenorthofenoprofen calciumAdvilibuprofenAdvilibuprofenAdvilibuprofenAdvilibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's ProfenibuprofenChildren's Profen IBibuprofenChildren's Profen IB	HCL						
SUMATRIPTAN SUCCINATE/NAPROXENTreximetSODIUMCelecoxibcelecoxibCelecoxibcelecoxibcelecoxibdiclofenac potassiumCarbiadiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac sodium/misoprostolVoltaren-XRdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolCorvolexdiclofenac sodium/misoprostolLodinediclofenac sodium/misoprostolCorvolexdiclofenac sodium/misoprostolLodinediclofenac sodium/misoprostolLodinefenoprofen calciumFenoprofenfenoprofen calciumMolingrineibuprofenAdvil Liqui-Gelibuprofen <td>OXAPROZIN</td> <td>oxaprozin</td>	OXAPROZIN	oxaprozin					
SODIUMcelecoxibCelebrexcelecoxibcelecoxibdiclofenac potassiumCambiadiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumCataflamdiclofenac potassiumdiclofenac potassiumdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolArthrotec 75diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostolLodinediclofenac sodium/misoprostolCorvolexetodolacetodolacetodolacetodolacfenoprofen calciumFenoprofenfenoprofen calciumFenoprofenfurbiprofenAdvilliubprofenAdvillibuprofenAdvillibuprofenChildren's AdvilibuprofenChildren's MotrinibuprofenChildren's NotrinibuprofenChildren's Profen IB	PIROXICAM	piroxicam					
celecoxibCelebrexcelecoxibcelecoxibdiclofenac potassiumCambiadiclofenac potassiumCataflamdiclofenac potassiumZipsordiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac potassiumdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac submicronizedZorvolexetodolacetodolacetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumFenorthofenoprofen calciumAdvilfubrjorefnAdvil Iqui-GelibuprofenAdvil Iqui-GelibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Porfen IBibuprofenChildren's Porfen IB		Treximet					
celecoxib celeco							
diclofenac potassiumCambiadiclofenac potassiumCataflamdiclofenac potassiumZipsordiclofenac potassiumdiclofenac potassiumdiclofenac sodiumVoltaren-XRdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolArthrotec 75diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostolCorvolexdiclofenac submicronizedEdodlacetodolacLodineetodolacEnorthofenoprofen calciumFenorthofenoprofen calciumFenorthofenoprofen calciumAdvilfurbiprofenAdvillibuprofenAdvil NigrainelibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's AdviriibuprofenChildren's AdviriibuprofenChildren's MotrinibuprofenChildren's Motrin							
diclofenac potassiumCataflamdiclofenac potassiumZipsordiclofenac potassiumdiclofenac potassiumdiclofenac sodium/misoprostolVoltaren-XRdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolCatorenac soprostoldiclofenac sodium/misoprostolCatorenac soprostoldiclofenac sodium/misoprostolCorvolexetodolacLodineetodolacetodolacetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumProFenofenoprofen calciumAdvilibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Nedi-ProfenibuprofenChildren's Nedi-Profen							
diclofenac potassiumZipsordiclofenac potassiumdiclofenac potassiumdiclofenac sodium/misoprostolVoltaren-XRdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac submicronizedZorvolexetodolacLodineetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumProFenofenoprofen calciumfenoprofenfenoprofen calciumAntariaibuprofenAntariaibuprofenAdvilibuprofenAdvilibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's MotrinibuprofenChildren's MotrinibuprofenChildren's Motrin	-						
diclofenac potassiumdiclofenac potassiumdiclofenac sodiumVoltaren-XRdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolArthrotec 75diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac sodium/misoprostolCorvolexdiclofenac submicronizedLodineetodolacetodolacetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumProFenofenoprofen calciumfenoprofenfurbiprofenAdvilibuprofenAdvil liqui-GelibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-Profen IBibuprofenChildren's Profen IB							
diclofenac sodiumVoltaren-XRdiclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolArthrotec 75diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac submicronizedZorvolexetodolacetodolacetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumProFenofenoprofen calciumfenoprofen calciumfenoprofen calciumfenoprofenfenoprofen calciumAdvilibuprofenAdvilibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenChildren's AdvilibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's MetrinibuprofenChildren's Metrin<	-	-					
diclofenac sodium/misoprostolArthrotec 50diclofenac sodium/misoprostolArthrotec 75diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac submicronizedZorvolexetodolacLodineetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumAnsaidibuprofen calciumAnsaidibuprofen calciumAdvilibuprofen calciumAdvilibuprofen calciumAdvilibuprofen calciumAdvilibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's MotrinibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenChildren's Profen IB	-	-					
diclofenac sodium/misoprostolArthrotec 75diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac submicronizedZorvolexetodolacLodineetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumfenoprofenfenoprofen calciumArtsidfenoprofen calciumAdvilfurbiprofenAdvilibuprofenAdvilibuprofenAdvil Iqui-GelibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-Profen IBibuprofenLipurofen IB							
diclofenac sodium/misoprostoldiclofenac-misoprostoldiclofenac submicronizedZorvolexetodolacLodineetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumfenoprofenfenoprofen calciumfenoprofenfenoprofen calciumAnsaidfurbiprofenAdvilibuprofenAdvil Liqui-GelibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenIbuprofen IB							
diclofenac submicronizedZorvolexetodolacLodineetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumfenoprofenfenoprofen calciumAnsaidfurbiprofenAdvilibuprofenAdvil Liqui-GelibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Profen IBibuprofenI-Prin							
etodolacLodineetodolacetodolacfenoprofen calciumFenorthofenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumfenoprofen calciumfenoprofen calciumAnsaidfurbiprofenAdvilibuprofenAdvil Liqui-GelibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenIbuprofen IB		-					
etodolacetodolacfenoprofen calciumFenorthofenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumfenoprofenfenoprofen calciumAnsaidflurbiprofenAdvilibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenChild IbuprofenibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-Profen IBibuprofenIbuprofen IB							
fenoprofen calciumFenorthofenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumfenoprofenflurbiprofenAnsaidibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenIchildren's Profen IBibuprofenIchildren's Profen IB							
fenoprofen calciumNalfonfenoprofen calciumProFenofenoprofen calciumfenoprofenflurbiprofenAnsaidibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-Profen IBibuprofenIbuprofen IB							
fenoprofen calciumProFenofenoprofen calciumfenoprofenflurbiprofenAnsaidibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenIbuprofen IB	•						
fenoprofen calciumfenoprofenflurbiprofenAnsaidibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenIbuprofen IB	•						
flurbiprofenAnsaidibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenI-Prin							
ibuprofenAdvilibuprofenAdvil Liqui-GelibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenI-Prin		-					
ibuprofenAdvil Liqui-GelibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenI-Prin		Advil					
ibuprofenAdvil MigraineibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenI-Prin		Advil Liqui-Gel					
ibuprofenChild IbuprofenibuprofenChildren's AdvilibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenI-Prin	•						
ibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenI-Prin	-	-					
ibuprofenChildren's Medi-ProfenibuprofenChildren's MotrinibuprofenChildren's Profen IBibuprofenI-Prin	ibuprofen	Children's Advil					
ibuprofen Children's Profen IB ibuprofen I-Prin		Children's Medi-Profen					
ibuprofen I-Prin	ibuprofen	Children's Motrin					
	ibuprofen	Children's Profen IB					
ibuprofen IBU	ibuprofen	I-Prin					
	ibuprofen	IBU					



Generic Name	Brand Name						
ibuprofen	IBU-200						
ibuprofen	Ibu-Drops						
ibuprofen	Infant's Advil						
ibuprofen	Infant's Medi-Profen						
ibuprofen	Infant's Motrin						
ibuprofen	Infants ProfenIB						
ibuprofen	Motrin IB						
buprofen	Provil						
buprofen/diphenhydramine HCl	Advil PM Liqui-Gels						
ibuprofen/diphenhydramine citrate	Advil PM						
ibuprofen/diphenhydramine citrate	Motrin PM						
ibuprofen/diphenhydramine citrate	ibuprofen-diphenhydramine cit						
ibuprofen/famotidine	Duexis						
indomethacin	Indocin						
indomethacin	indomethacin						
indomethacin, submicronized	Tivorbex						
ketoprofen	ketoprofen						
ketorolac tromethamine	ketorolac						
meclofenamate sodium	meclofenamate						
mefenamic acid	Ponstel						
mefenamic acid	mefenamic acid						
meloxicam	Qmiiz ODT						
meloxicam, submicronized	Vivlodex						
nabumetone	nabumetone						
naproxen	EC-Naprosyn						
naproxen	EC-Naproxen						
naproxen	Naprosyn						
naproxen sodium	Aleve						
naproxen sodium	Anaprox						
naproxen sodium	Anaprox DS						
naproxen sodium	Mediproxen						
naproxen sodium	Naprelan CR						
naproxen sodium/diphenhydramine HCl	Aleve PM						
naproxen/esomeprazole magnesium	Vimovo						
oxaprozin	Daypro						
oxaprozin	oxaprozin						
piroxicam	Feldene						
piroxicam	piroxicam						
sulindac	sulindac						
tolmetin sodium	tolmetin						
	es, potassium sparing, loop diuretics)						
amiloride HCl	amiloride						
amiloride HCl/hydrochlorothiazide	amiloride-hydrochlorothiazide						
bumetanide	bumetanide						
chlorothiazide	Diuril						
chlorothiazide	chlorothiazide						



Generic Name	Brand Name					
chlorothiazide sodium	Diuril IV					
chlorothiazide sodium	chlorothiazide sodium					
chlorthalidone	chlorthalidone					
eplerenone	Inspra					
eplerenone	eplerenone					
ethacrynate sodium	Sodium Edecrin					
ethacrynate sodium	ethacrynate sodium					
ethacrynic acid	Edecrin					
ethacrynic acid	ethacrynic acid					
furosemide	Lasix					
furosemide	furosemide					
furosemide	furosemide (bulk)					
urosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl					
furosemide/dextrose 5 % in water	furosemide in dextrose 5 %					
hydrochlorothiazide	Microzide					
hydrochlorothiazide	hydrochlorothiazide					
hydrochlorothiazide	hydrochlorothiazide (bulk)					
ndapamide	indapamide					
methyclothiazide	methyclothiazide					
netolazone	Zaroxolyn					
metolazone	metolazone					
spironolactone	Aldactone					
spironolactone	CaroSpir					
spironolactone	spironolactone					
spironolactone	spironolactone (bulk)					
spironolactone, micronized	spironolactone micro (bulk)					
spironolactone/hydrochlorothiazide	Aldactazide					
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz					
torsemide	Demadex					
torsemide	torsemide					
triamterene	Dyrenium					
triamterene	triamterene					
triamterene	triamterene (bulk)					
triamterene/hydrochlorothiazide	Dyazide					
triamterene/hydrochlorothiazide	Maxzide					
triamterene/hydrochlorothiazide	Maxzide-25mg					
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid					
trichlormethiazide	trichlormethiazide (bulk)					
	Everolimus					
everolimus	Afinitor					
everolimus	Afinitor Disperz					
everolimus	Zortress					
	Sirolimus					
sirolimus	Rapamune					
sirolimus	sirolimus					



This request executed the Cohort Identification and Descriptive Analysis (CIDA) and Propensity Score Analysis (PSA) tools, version 9.7.0, to assess the risk for angioedema associated with sacubitril/valsartan (SV) compared to angiotensin-converting enzyme inhibitors (ACEI) or to angiotensin II receptor blockers (ARBs) among heart failure patients in the Sentinel Distributed Database (SDD).

	Query Period: July 7, 2015 - Februrary 29, 2020 Coverage Requirement: Medical and drug coverage Enrollment Requirement: 183 days Enrollment Gap: 45 days Age Groups: 18-44, 45-54, 55-64, 65+ years Output Requested: Attrition table, Kaplan-Meier curves												
	No p	No prior comparator use; angioedema Gap sensitivity analysis No prior comparator use; serious angioedema											
	Compa	rison 1	Compa	rison 2	Compa	rison 3	Compa	arison 4	Compa	arison 5	Compa	rison 6	
Drug/Exposure													
Exposure/ Comparator	Sacubitril/ Valsartan (SV)	Angiotensin- converting enzyme inhibitors (ACEI)	SV	Angiotensin II receptor blockers (ARBs)	SV	ACEI	SV	ARBs	SV	ACEI	sv	ARBs	
Incident with Respect to:	ACEI, A	RBs, SV	ACEI, A	RBs, SV	ACEI, ARBs, SV		ACEI, ARBs, SV		ACEI, ARBs, SV		ACEI, ARBs, SV		
Incidence Assessment	Dispensing o sup	date or days oply	Dispensing date or days supply		Dispensing date or days supply			date or days oply	Dispensing date or days supply		Dispensing date or days supply		
Washout (days)	18	33	18	33	183 183		83	183		183			
Cohort Definition	First valid incident exposure episode		First valid incident exposure episode		First valid incident exposure episode		First valid incident exposure episode		First valid incident exposure episode		First valid incident exposure episode		
Stockpiling overlapping claims	Default		Default		Default		Default		Default		Default		
Episode Gap (days)	14		14		7		7		14		14		
Episode Extension Period (days)	14		14		7		7		14		14		
Maximum Episode Duration (days)	36	55	3(	65	36	65	3	65	365		36	365	



	No prior comparator use; angioedema			No prior comparator use; angioedema Gap sensitivity analysis				No prior comparator use; serious angioedema				
	Comparison 1		Comparison 2		Comparison 3		Comparison 4		Comparison 5		Compa	rison 6
Censor Criteria	ACEI	SV	ARBs	SV	ACEI	SV	ARBs	SV	ACEI	SV	ARBs	SV
	ARBs, end of treatment, outcome occurrence, disenrollment, recorded death, data end date		ACEI, end of treatment, outcome occurrence, disenrollment, recorded death, data end date		ARBs, end of treatment, outcome occurrence, disenrollment, recorded		ACEI, end of treatment, outcome occurrence, disenrollment, recorded		ARBs, end of treatment, outcome occurrence, disenrollment, recorded		ACEI, end of treatment, outcome occurrence, disenrollment, recorded death, data end date	
			ucatil, dat			a end date		a end date		a end date		
Inclusion/Exclusion Pre-Existing Condition	Heart failure		Heart	failure	Heart	Heart failure Heart failure		Heart failure		Heart failure		
Include/Exclude	Incl	ude	Incl	ude	Include		Include		Include		Include	
Lookback Period (days)	-18	3, 0	-18	183, 0 -183, 0		3, 0	-183, 0		-183, 0		-183, 0	
Pre-Existing Condition	ACEI, ARBs	SV, ARBs	ACEI, ARBs	SV, ACEI	ACEI, ARBs	SV, ARBs	ACEI, ARBs	SV, ACEI	ACEI, ARBs	SV, ARBs	ACEI, ARBs	SV, ACEI
Include/Exclude	Exclude	Exclude	Exclude	Exclude	Exclude	Exclude	Exclude	Exclude	Exclude	Exclude	Exclude	Exclude
Care Setting/ Primary Diagnosis	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any
Lookback Period (dyas)	0	0	0	0	0	0	0	0	0	0	0	0
Inclusion Assessment	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date	Dispensing date



	No prior comparator use; angioedema		No prior comparato Gap sensitiv	or use; angioedema vity analysis	No prior comparator use; serious angioedema			
Comparison 1		Comparison 2	Comparison 3	Comparison 4	Comparison 5	Comparison 6		
Event/Outcome								
Event/Outcome	Angioedema	Angioedema	Angioedema	Angioedema	Serious Angioedema	Serious Angioedema		
Care Setting/ Primary Diagnosis	Inpatient, emergency department or outpatient	Inpatient, emergency department or outpatient	Inpatient, emergency department or outpatient	Inpatient, emergency department or outpatient		Inpatient or emergency department (ED) angioedema diagnosis requiring an intensive care unit admission, intubation, tracheostomy, or laryngoscopy occurring within 2 days of the date of hospital admission or ED visit		
Washout (days)	0	0	0	0	0	0		
Blackout Period (days)	0	0	0	0	0	0		
Propensity Score (PS) Matching								
Covariates	See Appendix J	See Appendix J	See Appendix J	See Appendix J	See Appendix J	See Appendix J		
Matching Ratio	1:1	1:1	1:1	1:1	1:1	1:1		
Matching Caliper Settings	0.05	0.05	0.05	0.05	0.05	0.05		
Analysis Type Sensitivity Analysis	Conditional and unconditional PS stratification with deciles	Conditional and unconditional PS stratification with deciles	Conditional and unconditional 	Conditional and unconditional 	Conditional and unconditional 	Conditional and unconditional 		
Subgroup Analyses		with declies						
Stratifying variable	Angioedema	Angioedema			Angioedema	Angioedema		
Evaluation Window (days)	-183, -1	-183, -1			-183, -1	-183, -1		



	No prior comparate	or use; angioedema		or use; angioedema vity analysis	No prior comparator use; serious angioedema			
Comparison 1		Comparison 2	Comparison 3	Comparison 4	Comparison 5	Comparison 6		
Re-matching		Re-matching should be done with the matched cohort	·		Re-matching should be done with the matched cohort	Re-matching should b done with the matche cohort		
Stratifying variable	Angioedema	Angioedema			Angioedema	Angioedema		
Evaluation Window (days)	Pre-index enrollment history, -1	Pre-index enrollment history, -1			Pre-index enrollment history, -1	Pre-index enrollment history, -1		
Re-matching	Re-matching should be done with the matched cohort	Re-matching should be done with the matched cohort			Re-matching should be done with the matched	Re-matching should b done with the matche		
Stratifying variable	Serious allergies	Serious allergies			Serious allergies	Serious allergies		
Evaluation Window (days)	-183, -1	-183, -1			-183, -1	-183, -1		
Re-matching	Re-matching should be done with the matched cohort	Re-matching should be done with the matched cohort			Re-matching should be done with the matched	Re-matching should b done with the matche		
Stratifying variable	Age group	Age group			Age group	Age group		
Re-matching	Re-matching should be done with the matched cohort	Re-matching should be done with the matched cohort			Re-matching should be done with the matched	Re-matching should b done with the matche		
Stratifying variable	Sex	Sex			Sex	Sex		
Re-matching	Re-matching should be done with the matched cohort	Re-matching should be done with the matched cohort			Re-matching should be done with the matched	Re-matching should be done with the matche		
Stratifying variable	Race	Race			Race	Race		
Re-matching	Re-matching should be done with the matched cohort	Re-matching should be done with the matched cohort			Re-matching should be done with the matched	Re-matching should I done with the match		

International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Edition, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) codes are provided by Optum360. National Drug Codes are checked against First Data Bank's "FDB MedKnowledge<sup>®</sup>" database.



Covariate	Covariate Evaluation Window
Demographic Characteristics	
Age (years, continuous)	Index date
Age-group	
18-44 years*	Index date
45-54 years*	Index date
55-64 years*	Index date
≥65 years*	Index date
Sex	
Male	Index date
Female	Index date
Race/ethnicity	
American Indian or Alaska Native	Index date
Asian	Index date
Black or African American	Index date
Native Hawaiian or Other Pacific Islander	Index date
White	Index date
Unknown	Index date
Year	
2015	Index date
2016	Index date
2017	Index date
2018	Index date
Combined comorbidity score	
Combined comorbidity score	-183 to 0
Health Conditions	
Angioedema	-183 to -1
Angioedema*	Ever to -1
Ambulatory allergies or allergy treatment*	-183 to -1
Serious allergies (inpatient hospital stays or emergency department	nt vis -183 to -1
Ambulatory allergies or treatment and not serious allergies	-183 to -1
Diabetes	-183 to 0
Ischemic heart disease	-183 to 0
Renal disorders	-183 to 0
Medications	
Diuretics (thiazides, potassium sparing, loop diuretics)	-183 to 0
Nonsteroidal anti-inflammatory drugs (NSAIDs)	-183 to 0
Sirolimus	-183 to 0
Everolimus	-183 to 0
Health care utilization	
Number of inpatient hospital stays	-183 to 0
Number of emergency department visits	-183 to 0
Numer of institutional stay visits	-183 to 0
Number of ambulatory visits	-183 to 0
Number of other ambulatory visits	-183 to 0

Appendix I. Specifications Defining Parameters for Baseline Covariate Groups in this Request



Appendix I. Specifications Defining Parameters for Baseline Covariate Groups in this Request	
Covariate	Covariate Evaluation Window
Drug utilization	
Number of unique dispensings*	-183 to 0
Number of unique generics dispensed*	-183 to 0
Number of unique drug classes dispensed	-183 to 0

# Appendix I. Specifications Defining Parameters for Baseline Covariate Groups in this Request

\* Covariates followed by an asterisk (\*) were not included in the adjusted Propensity Score (PS) model; only those covariates not followed by an asterisk (\*) were included in the adjusted PS model.